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Abstract
The 2004 outbreak of influenza A H5N1 and the WHO’s recommendation for a 
national influenza pandemic plan has led the Thai Ministry of Public Health to develop 
an influenza vaccination programme for high-risk adults. One approach adopted by this 
programme has focus on implementing influenza vaccination in people with chronic 
medical conditions. However, influenza vaccination uptake rate among this high-risk 
group was relatively low, particularly in Chiang Rai province. Accordingly, the main 
objectives of this research were two-fold. This first objective was to explore beliefs 
about influenza and influenza vaccination, and the social influences on decisions 
whether or not to accept the influenza vaccination in a sample of urban-dwelling Thai 
adults. To reach this objective, a qualitative research approach was adopted. The second 
objective was to test the effect of a Health Action Process Approach (HAPA) based 
leaflet and action planning intervention on influenza vaccination behaviours among 
these high-risk individuals and to evaluate the impact of a HAPA-based leaflet on 
potential mediators of behavioural change. A controlled before and after trial was 
performed to evaluate the intervention effects. As the HAPA model was used as a 
conceptual framework for study two; the model’s predictive utility was, thus, also 
examined. The results of the first study supported the development of the leaflet used 
in study 2.
A qualitative study using in-depth interviews was carried out with 20 high-risk 
individuals who were either (i) aged 65 and over, or (ii) under 65 years with chronic 
diseases that had clinical indications requiring influenza vaccination. Findings indicate 
that most participants had insufficient knowledge about influenza and influenza 
vaccination. Their decisions whether or not to get vaccinated against influenza were 
based on a number of factors, including salience of risk, influence of others, perception 
of the need for preventive health care, and the availability of influenza vaccine. These 
findings underscore the need to consider and understand factors underlying people’s 
vaccination decisions to create an effective influenza vaccination programme.
Subsequently, a controlled before and after trial was conducted to compare the effects of 
a theory-based educational leaflet and action planning intervention with a standard 
government information leaflet on influenza vaccination behaviours among high-risk
urban dwelling Thai adults. Participants in the intervention group (n = 99) received a 
leaflet based on the HAPA and asking them to form an action planning as to where, when 
and how they would seek vaccination. Those in the comparison condition (n = 102) 
received a standard government information leaflet. The intervention had positive effects 
in changing risk perceptions, outcome expectancies, self-efficacy, and intention relative 
to the comparison condition. Stronger intentions to become vaccinated against influenza 
in the intervention group than the comparison group were explained by change in 
outcome expectancies and self-efficacy for arranging time and transportation. No 
significant difference in vaccination rates was observed between two groups. Influenza 
vaccination was predicted by self-efficacy and intention. A theory-based educational 
leaflet may be a useful tool to increase individual’s vaccination intention, but larger trials 
are required to confirm these findings and to examine further the impact of similar 
interventions on influenza vaccination rates.
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Chapter 1: Background and significance of the study
1.1 Introduction
The low influenza vaccination uptake among high-risk Thai adults, especially in 
Chiang Rai province, indicates a need for the development of an effective intervention 
programme to increase uptake in this population. To develop such an intervention 
programme, we first needed to understand how these high-risk people perceived 
influenza and the influenza vaccination and what influenced their decisions whether 
or not to be vaccinated. Factors underlying people’s vaccination decisions need to be 
understood in order to guide the development of an intervention to promote influenza 
vaccination. In other words, knowing what high-risk people think about influenza and 
the influenza immunisation may help us to motivate them to take up immunisation. 
Thus, this thesis consists of two studies. The first study was designed to explore 
qualitatively high-risk Thai adults’ beliefs regarding influenza and influenza 
vaccination, as well as other influences on their decisions. This was then used to 
inform the development of an intervention programme designed to increase 
vaccination rates among these high-risk individuals (study 2). Study 1 did not intend 
to test hypotheses; rather it investigated people’s beliefs regarding influenza and 
influenza vaccination and identified factors underlying their vaccination decisions. A 
qualitative approach was therefore pursued in this study.
Subsequently, a controlled, before and after trial was conducted (study 2) to assess the 
effects of an intervention designed to promote influenza vaccination. This study was a 
pragmatic, randomised trial. The study design permits a precise assessment of the 
cause-and-effects relationships between an intervention programme and outcome, 
allowing the intervention to be modified and improved if necessary. As shown in 
previous studies, a number of factors have been associated with the people’s decision 
of whether or not to get the influenza vaccine (e.g. Sengupta & Strauss, 2004; Bums, 
Ring, & Carroll, 2005; Jimenez-Garcia, Hemandez-Barrera, Carrasco-Garrido et al., 
2006; Chen, Yi, Wu et al., 2007; Evans, Prout, Prior et al., 2007; Lau, Lau, & Lau, 
2009). However, this study focused only cognitive factors influencing decision to 
vaccinate against influenza, as they are assumed to largely mediate the effects of other
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factors and are more open to change than others. Thus, it is important to note that 
other factors, such as social and economic factors that were not assessed in this study, 
may also have a powerful effect on participants’ decisions regarding influenza 
vaccination (Kroneman, Paget, & van Essen, 2003; Takahashi, Noguchi, Rahman et 
al, 2003; Gill, Taylor, & Watson, 20007). This chapter provides the background and 
the significance of the research project. The objectives that directed this research and 
hypotheses (study two) are presented. Finally, the overall structure of the thesis is 
outlined.
1.2 Background to the study
Influenza remains an important worldwide public health problem, although the 
effectiveness of influenza vaccine has been well established. The global burden of 
influenza epidemics in each year is estimated to be 3-5 million cases of severe illness, 
leading to 250,000-500,000 deaths (World Health Organization: WHO, 2003). Most 
cases of serious disease and death occur among high risk people: those over 65 years 
of age or who have chronic medical conditions such as cardiovascular diseases, 
chronic pulmonary diseases, diabetes and cancer (Centers for Disease Control and 
Prevention [CDC], 2007; Rothberg, Haessler, & Brown, 2008). The control and 
prevention of influenza have largely been accomplished through the use of vaccines 
(CDC, 2005, 2006; Kamps, Hoffmann, & Preiser, 2006). Although the effectiveness 
of influenza vaccine against influenza has been demonstrated since the 1940s, 
influenza vaccination coverage has often been suboptimal in most countries, even in 
North America and Europe and especially among older people with chronic disease. 
While influenza is recognised as an important health problem and public health efforts 
are made to increase immunisation rates in western countries (Humair, Buchs, Stalder, 
2002; Zimmerman, Nowalk, Raymund et al., 2003; Bohmer, Jennings, Smith et al., 
2004; CDC, 2006), but little is known about the burden of influenza in developing 
countries such as Thailand. Published data on human influenza in Thailand has been 
limited. This may have resulted from the lack of laboratory confirmation for 
influenza. Most cases have been diagnosed by using clinically diagnosed influenza 
(influenza-like illness).
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However, influenza-associated morbidity and mortality has been a growing concern in 
Thailand since an outbreak of influenza A H5N1 in 2004, with a total of 17 confirmed 
human cases and 12 deaths. In addition, the WHO has strongly recommended that all 
countries develop or update their national influenza preparedness plans to prepare for 
and respond to threats and occurrences of pandemic influenza (Simmerman, 
Thawatsupha, Kingnate et al., 2004; Tiensin, Chaitaweesub, Songserm et al., 2005; 
WHO, 2005a). Together, these drive the need for the development of an influenza 
prevention and control programme in Thailand. One approach adopted by this 
programme has focused on implementing influenza vaccination among high-risk 
people aged over 65 years with chronic diseases and all healthcare workers involved 
in direct patient care (Ministry of Public Health: MOPH, 2008).
Influenza vaccine has been used in Thailand for many years but only in limited 
populations including healthcare workers, Thai pilgrims who attend the Hajj, and 
those who are able to afford for the cost of vaccination (Chunsuttiwat, 2002; 
Simmerman, Thawatsupha, Kingnate et al., 2004). Free influenza vaccine for high- 
risk older people was provided for the first time during the influenza vaccination 
period from 1 May to 30 June 2008. This programme was targeted at high-risk people 
aged over 65 years who had chronic diseases and with a history of inpatient hospital 
admission within the previous 12 months, and it will be expanded to cover more high 
risk Thai people in the coming years. In addition to providing free vaccine, an 
educational leaflet regarding influenza and influenza vaccine was designed and 
distributed to health professionals and high risk individuals. Despite these efforts, the 
overall immunisation rate in high-risk older people for the first year of the project in 
Chiang Rai province was relatively low (37.7 per cent); P. Sriwongpan, personal 
communication, March 6, 2009): insufficient to provide population protection against 
the influenza virus.
Data from a number of studies conducted in the United States and Europe indicate 
that the decisions whether or not to receive influenza vaccination are complex, and 
influenced by many medical and psychosocial factors. Comford and Morgan (1999), 
for example, found that older people recognised that influenza could cause death, but 
few considered themselves to be at risk from it even though they had at least one 
chronic disease that did increase their risk of developing complications or death
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attributable to influenza. As a consequence, many were reluctant to receive the 
influenza vaccination. Similarly, Gosney (2000) demonstrated that beliefs that the 
vaccine was both effective and free from side effects were associated with older 
adults’ vaccination acceptance, while fear of side effects was negatively associated. 
Additionally, Telford and Rogers (2007) found that elderly peoples’ decisions about 
whether to accept or refuse the influenza vaccination were influenced by trust or 
mistrust of modem medicine, prior experience of vaccination, and perceived risk from 
influenza. Other studies have found that the acceptance of influenza vaccination 
among older people was predicted by social influences, from sources such as health 
care providers, family members, and friends (e.g. Takahashi, Noguchi, Rahman, et al., 
2003; Zimmerman, Nowalk, Raymund et al., 2003; Gallagher & Povey, 2006), and 
the costs and convenience of obtaining the vaccination (e.g. CDC, 1993; Nex0e, 
Kraqstrup, & Sogaard, 1999; Kroneman, Paget, & van Essen, 2003; Bums, Ring, & 
Carroll, 2005).
These factors provide a number of targets for any public health programme designed 
to increase uptake of influenza vaccine. Theoretical models also provide target 
variables to be addressed within any behaviour change intervention. They help 
determine the focus and content of any educational programme, and can be utilised 
to explain how interventions work to promote behavioural change (Fishbein & Yzer, 
2003). The Health Action Process Approach (HAPA) (Schwarzer, 2001) provides one 
such explanatory model. This model has been widely applied to different behaviours 
and found to have good predictive utility in understanding health-related intentions 
and behaviours, including those related to nutrition (Schwarzer & Renner, 2000), 
breast self-examination (Luszczynska & Schwarzer, 2003), physical exercise 
(Sniehotta, Scholz, & Schwarzer, 2005; Scholz, Schuz, Ziegelmann et al., 2008), seat 
belt use (Schwarzer, Schuz, Ziegelmann et al., 2007), smoking (Scholz, Nagy, Gohner 
et al., 2009), and food hygiene (Chow & Mullan, 2010).
Crucially, evidence has shown that a theoretical approach to developing an 
intervention is more effective than interventions developed without theoretical basis 
(Abraham, Sheeran, & Johnston, 1998; Dishman & Buckworth, 1996). Using 
behaviour change theory to guide the development of interventions has many benefits. 
Firstly, theory identifies the variables that are hypothesised to cause change in
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behaviour, thereby allowing researchers to target for the developing intervention. 
Secondly, using theory as a conceptual framework facilitates the accumulation of 
empirical evidence of effectiveness across different behaviours and population. 
Thirdly, theory-based intervention facilitates an understanding of the causal 
mechanisms of behaviour change and provides a basis for refining and revising a 
theory (Abraham & Michie, 2008; Michie, Johnston, Francis et al., 2008; Michie & 
Prestwich, 2010).
From the above, it can be concluded that developing effective interventions to 
maximise the uptake of influenza vaccination should be based on an understanding 
of the factors underlying people’s vaccination decisions, and that behaviour change 
theory should be used to inform the design and development of any influenza 
vaccination programme. However, in Thailand where large-scale influenza 
vaccination programmes have yet to be undertaken, to date there is no available 
information on the theoretical basis of any intervention, and how to maximise the 
uptake of vaccine by the Thai population. Thus, this research is beginning to address 
this knowledge gap; it serves as a starting point for understanding Thai older people’ 
beliefs about influenza and influenza vaccination (study 1), and for the development 
of an intervention to promote influenza vaccination among individuals with chronic 
disease, a group of people who are at risk of serious complication from influenza 
(study 2).
1.3 Significance of the study
This research is significant because it examines factors that influence high-risk Thai 
adults’ decisions whether or not to receive influenza vaccine. It explores their beliefs 
about influenza and influenza vaccination, as well as other influences on their 
decision. The findings from this research can be used to guide the public health staff 
or other health professionals in developing tailored interventions to encourage 
influenza vaccination for such individuals. In addition, this research is also considered 
to be of value in providing a starting point for public health staff to develop a theory- 
based intervention to improve uptake of influenza vaccination. The findings of this 
research suggest that a relatively brief and simple intervention based on the HAPA 
model is effective in enhancing individual’s vaccination intention, and has the
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potential to change behaviour. The HAPA-based leaflet is inexpensive to reproduce; 
thus, it will be sustainable in routine practice. Accordingly, this research project 
provides one practical way to promote influenza vaccination in high-risk Thai adults 
living in the community, although other approaches are needed in primary care to 
raise influenza vaccination rate of this vulnerable group of people.
1.4 Aims of the research
As indicated above, this thesis reported on two research studies. The objective of the 
first study was to explore people’s beliefs about influenza and influenza vaccination, 
and to investigate factors that affected the vaccination decision of a sample of urban- 
dwelling Thai adults. Study 2 was conducted with the objective of testing the effect of 
a HAPA-based educational leaflet and action planning intervention on influenza 
vaccination behaviours among these high-risk individuals, and evaluating the impact 
of this on potential mediators of behavioural change. In addition to assessing the 
intervention effects, this study also provided an opportunity to examine the predictive 
utility of the HAPA model in relation to both intention and subsequent vaccination 
behaviour in a certain high risk group in Thailand. The hypotheses for study two were 
as follows:
1. The implementation of a HAPA-based leaflet would lead to changes in key 
mediator variables (knowledge, risk perception, self-efficacy, outcome expectancies, 
and intention to seek vaccination), as well as higher rates of influenza immunisation 
than in a control group who received a standard information leaflet.
2. Risk perception, outcome expectancies, self-efficacy would predict the 
strength of intentions to obtain influenza vaccine.
3. Action planning, self-efficacy, and intention would significantly predict 
influenza vaccination in a sample of high-risk Thai adults.
1.5 Structure of the thesis
This thesis is organised into eight chapters.
Chapter two summarises issues relevant to influenza infection. The structure of the 
influenza virus is first presented. The chapter then describes how influenza virus 
changes every year (antigenic drift and shift). It also provides information about
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pathology of influenza virus, clinical symptoms, complications of influenza, and 
mode of transmission. Finally, the chapter outlines the disease burden and cost.
Chapter three describes the influenza vaccine development process, type of vaccine, 
and the efficacy and safety of vaccination. A summary of immune responses to 
inactivated and live, attenuated influenza vaccines is also presented. Finally, 
recommendations for the use of seasonal influenza vaccine are outlined.
Chapter four reviews lay beliefs about influenza, influenza vaccine, and factors 
influencing the decision to be vaccinated against influenza among high-risk adults. 
The first part of this chapter presents the issues related to lay beliefs about influenza 
and influenza vaccine. It then focuses on the six categories of factors related to 
influenza vaccination: socio-demographic factors, health conditions, accessibility, 
knowledge and attitudes towards influenza vaccination, influence of others, and health 
beliefs and behaviour.
Chapter five presents a qualitative study of factors that influence high-risk urban- 
dwelling Thai adults’decisions whether or not to receive influenza vaccine. Study 1 
findings are reported. Reported findings encompass participants’ beliefs and their 
knowledge about influenza and influenza vaccination. It then presents four main 
themes that emerged from the data. This chapter finally draws out implications for 
clinical practice.
Chapter six details social cognition models, the Health Action Process Approach 
(HAPA) model which is used as a theoretical framework for this research (study 2), 
and the application of the HAPA model to health-related behaviours. This chapter 
further presents the formation of “if-then” plans (implementation intentions) and their 
effectiveness in changing health behaviour.
Chapter seven outlines the development and implementation of an intervention 
programme to increase influenza vaccine uptake in high-risk Thai individuals. It 
reports the results of a controlled before and after trial investigating the effects 
of a HAPA-based educational leaflet intervention on influenza vaccination. This 
chapter also presents findings on the applicability of the HAPA model in the context
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of vaccination behaviour. It also considers the strengths and limitations of the study. 
Finally, the conclusion of the study is provided in the last section.
Chapter eight summarises the major findings from both studies. Theoretical and 
methodological implications are discussed. It then draws out implications for policy 
and practice. It also outlines the limitations of the research and discusses potential 
areas for future investigation. Finally, the chapter closes with the main conclusion.
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Chapter 2: Influenza infection, epidemiology and burden of 
disease
2.1 Introduction
Few human infections have such a significant impact on hospitalisation, death, social 
disruption and economic cost as influenza. This chapter provides a review of the 
literature on the history and nature of influenza, including the influenza virus, 
antigenic drift, antigenic shift, pathology, clinical symptoms, diagnosis of influenza, 
influenza-related complications, antiviral treatment, mode of transmission, 
seasonality, and the burden of seasonal influenza.
2.2 A history of Influenza
The occurrence of influenza-like disease was described by Hippocrates as early as 412 
BC. The name “influenza” has a Latin root and refers to the ancient belief that the 
disease was caused by supernatural influence; influenza epidemics were attributed to 
the “influence” of the stars. The first outbreak of influenza-like illness was reported in 
1173-1174 (Hirsch, 1883 cited in Potter, 2001). Since then, there have been several 
reports of influenza-like epidemics throughout America and Europe. However, the 
outbreak of influenza which was firstly accepted as a global pandemic occurred in 
1580 (Pyle, 1986, cited in Potter, 2001; Cunha, 2004). During the eighteenth century, 
at least three influenza pandemics (1729-1730, 1732-1733, and 1781-1782) were 
documented (Cunha, 2004). The data on influenza outbreaks has been more reliable 
since the first isolation of the influenza virus by Smith, Andrewes, and Laidlaw in 
1933.
There are three main types of influenza viruses (influenza A, B and C viruses). 
Influenza A viruses can be further categorised into distinct subtypes (Cox & 
Subbarao, 2000). In the last century, there were three global influenza pandemics, 
which occurred in 1918-1919 (Spanish influenza), 1957-1958 (Asian influenza) and 
1968-1969 (Hong Kong influenza) (Cox & Subbarao, 2000; Nguyen-Van-Tam & 
Hampson, 2003; Lemer & Lemer, 2008). The most destructive influenza pandemic in
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human history was the Spanish influenza, with an estimated 40-50 million deaths 
worldwide (Potter, 2001; Lemer & Lemer, 2008; Gatherer, 2009). The vims that 
caused the pandemic was an influenza A H1N1 vims. The unique feature of this 
pandemic was that the vast majority of influenza-related deaths occurred mainly in 
healthy young adults (age range, 20-40 years) (Cox & Subbarao, 2000; Cunha, 2004). 
It was estimated that about ten times as many Americans died of influenza during this 
pandemic than died in the World War I (1914-1918) (Lemer & Lemer, 2008). The 
two subsequent pandemics had less of an impact than the Spanish influenza. The 
Asian influenza pandemic that was caused by influenza A vims subtype H2N2, killed 
approximately one to two million people worldwide (Nguyen-Van-Tam & Hampson, 
2003; Lemer & Lemer, 2008). The Hong Kong influenza which was caused by a 
strain of influenza known as H3N3 was much milder than the previous two 
pandemics. There were an estimated 700,000 deaths worldwide during this pandemic 
(Lemer & Lemer, 2008).
As an influenza pandemic rapidly spreads and affects almost all people around 
the world, monitoring the global circulation of vimses, rapidly identifying new strains 
and timely reporting are essential to implement control measures, and the WHO is 
responsible for these activities. The WHO's Global Influenza Surveillance Network 
set up in 1952 comprises 131 National Influenza Centres in 102 countries working 
closely together with the four WHO collaborating centres: the National Institute for 
Medical Research, Mill Hill, London, United Kingdom, the Centers for Disease 
Control and Prevention, Atlanta, United States; the Commonwealth Serum 
Laboratories, Parkville, Melbourne, Australia, and the National Institute for Infectious 
Disease, Tokyo, Japan. According to the data collected by the network, WHO issues 
biannual recommendation for the vaccine components for the subsequent influenza 
season and related activities (WHO, 2010a). On June 11, 2009, the first influenza 
pandemic of the 21st century was officially declared by the WHO (Chan, 2009). A 
novel influenza A (H1N1) vims was determined the cause of this pandemic. As of 28 
March 2010, the WHO has recorded over 17,483 people deaths in more than 213 
countries as a consequence of the disease (WHO, 2010b).
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2.3 Influenza virus
2.3.1 Structure of the virus
Influenza viruses are members of the Orthomyxoviridae family of RNA (ribonucleic 
acid) viruses, which comprise four genera: influenza virus A, influenza virus B, 
influenza virus C, and thogotovirus (Cox & Subbarao, 1999; Sutherland, 2002).
There are differences in host range and pathogenicity among the three types of 
influenza viruses (Taubenberger & Morens, 2008). All of them can cause disease in 
humans, but influenza A and B are mainly found infecting humans (Cox & Subbarao, 
2000). Occasionally, influenza B causes local outbreaks of influenza. Both influenza 
A and B can cause annual epidemics in many parts of the world; however, only 
influenza A has caused human global pandemics (Zambon, 2001). Influenza A viruses 
are further classified into subtypes based on the antigenicity of two glycoproteins on 
the surface of the virus: haemagglutinin (HA) and neuraminidase (NA). There are 15 
HA (HI-HI5) and 9 NA (N1-N9) subtypes to date (Cox & Subbarao, 2000; Zambon, 
2001; Nicholson, Wood, & Zambon, 2003; Lofgren, Fefferman, Naumov et al., 2007). 
All known subtypes of influenza A have been isolated in aquatic birds. However, only 
three haemagglutinin (HI, H2, H3) and two neuraminidase (N1 and N2) subtypes 
have been found circulating in human populations. Additionally, these subtypes have 
also been linked to epidemics and pandemics in humans since 1918 (Cox & Subbarao, 
1999; Stephenson & Zambon, 2002; Nguyen-Van-Tam & Hampson, 2003; Nicholson, 
Wood, & Zambon, 2003; Bouvier & Palese, 2008).
Unlike influenza A, influenza B and C viruses are not categorised into subtypes. The 
structure of influenza B viruses is similar to influenza A. There are four envelope 
glycoproteins (HA, NA, NB, and BM2) for influenza B viruses. However, influenza C 
viruses have only one major envelope glycoprotein, namely hemagglutinin-esterase- 
fusion (HEF) protein (Whittaker, 2001; Bouvier & Palese, 2008; Taubenberger & 
Morens, 2008). Influenza virus particles are typically spherical, 80-120 nanometres in 
diameter, and they are enveloped RNA viruses. Influenza A and B viruses have two 
different glycoprotein spikes on the surface of a virus: haemagglutinin (HA) and 
neuraminidase (NA) (Sutherland, 2002; Treanor, 2005; Bouvier & Palese, 2008). 
Each virus particle contains approximately 500 molecules of HA and 100 molecules
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of NA on its surface. The HA helps influenza virus penetration into host cells and 
initiates infection, whereas NA facilitates the release of newly produced virus 
particles from the host cell (Gubareva, Kaiser, & Hayden, 2000; Steinhauer & Skehel, 
2002). These two viral proteins are also associated with the virulence of the influenza 
virus. For influenza A viruses (Figure 2.3.1), M2 protein is present at the surface of 
the influenza virion (a single infective viral particle). On the inner side of the 
envelope, the ribonucleoprotein (RNP) complex, which consists of helical segments 
of virion RNA coated with nucleoprotein (NP), Ml protein, and three polymerase 
proteins (PB1, PB2, PA), is responsible for transcription and replication of each virus 
gene. RNPs are surrounded by layer of matrix (Ml) protein. Ml protein is the major 
component of virus particle. Additionally, the non-structural protein 2 (NS 2) is found 
within the virus particle, and it is believed to be involved in virus particle assembly 
and budding (Gubareva, Kaiser, & Hayden, 2000; Whittaker, 2001; Steinhauer & 
Skehel, 2002; Treanor, 2005; Bouvier & Palese, 2008; Taubenberger & Morens, 
2008).
M2
Figure 2.3.1. Schematic representation of influenza A virus 
Source: Gubareva, Kaiser, & Hayden, 2000
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2.3.2 The replication cycle of influenza virus
Figure 2.3.2 illustrates the replication cycle of influenza virus. The cycle consists of 
four distinct phases: virus attachment and entry; synthesis of viral RNA; synthesis of 
viral proteins and assembly of virion; and virus budding and release from host cell 
(Gubareva, Kaiser, & Hayden, 2000; Whittaker, 2001; Bouvier & Palese, 2008). The 
influenza virus initially attaches to specific receptors on the host cell (sialic-acid 
receptors) through the HA protein spikes and penetrates into the host cells. Once 
inside the host cell (cytoplasmic vesicles), influenza virion sheds its envelope, 
resulting in the release of the genetic material of the virus (RNP) into the host cell 
cytoplasm in order to be transcribed and translated. This process is called “uncoating” 
(Gubareva, Kaiser, & Hayden, 2000; Whittaker, 2001; Bouvier & Palese, 2008). The 
M2 protein is thought to function as an ion channel that allows the flow of hydrogen 
ions into the virion to facilitate ribonucleoprotien uncoating (Whittaker, 2001; 
Bouvier & Palese, 2008). The uncoated RNPs are transported to the host cell nucleus 
for replication. In the nucleus, all influenza virus RNAs are synthesized. In addition, 
the viral proteins (NP, M l, NS2 and the polymerases) are brought into the host cell 
nucleus to assist in viral RNA replication and RNP assembly. At this stage, the 
influenza virus takes control over host cell functions, producing many new influenza 
virus copies. Following virus replication, the progeny viruses are assembled and 
budded through the host plasma membrane (Whittaker, 2001; Jennings & Read, 2002; 
Bouvier & Palese, 2008).
Neuramidase (NA) plays a significant role in the release of the new viruses from the 
cell surface by removing the sialic acid both from cellular receptors and from the HA 
spikes. Without this stage, progeny viruses clump at the cell surface, resulting in a 
decreased ability of viruses to spread and infect other cells. Thus, the NA prevents 
the aggregation of the new virus particles and facilitates the release of new virion 
particles from infected cells, allowing them to infect a new host cell (Gubareva, 
Kaiser, & Hayden, 2000; Whittaker, 2001; Steinhauer & Skehel, 2002; Treanor, 2005; 
Bouvier & Palese, 2008).
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Figure 2.3.2 Influenza virus replication cycle 
Source: Gubareva, Kaiser, & Hayden, 2000
2.3.3 Influenza virus nomenclature
Influenza viruses have a standard nomenclature. According to the WHO system 
(WHO, 1980), the full nomenclature for influenza virus isolates includes the host 
of origin, the geographical site, serial number, year of isolation, and then follows 
the year of isolation with the H and N variants in parentheses, for instance 
“A/swine/Iowa/3/70 (H1N1)”. In the case of influenza virus isolated from humans, 
the host of origin is not given, e.g. A/Fujian/411/2002 (H3N2).
2.4 Antigenic drift and shift
There are two types of antigenic variation on envelope glycoproteins (HA and NA) of 
influenza A viruses: antigenic drift and antigenic shift. Such variations make people 
more susceptible to infection with a new virus strain that was not recognised by the 
human immune system. This results in influenza epidemics and pandemics (Cox & 
Subbarao, 2000; Nicholson, Wood, & Zambon, 2003).
“Antigenic drift” refers to the gradual accumulation of point mutations (minor 
changes) in the HA and NA genes of influenza virus that arises during the replication 
of the influenza genome (Cox & Subbarao, 2000; Stephenson & Zambon, 2002; 
Treanor, 2005). These changes in the genes occur because the viral RNA polymerase
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enzyme that copies the viral genome produces an error. This enzyme is involved in 
transcription of the influenza genome, but lacks the ability to correct errors during 
RNA transcription (no proof-reading activity). It is estimated that the RNA 
polymerase of influenza viruses create replication errors in 1/104 bases per replication 
cycle (Zambon, 2001). This genetic variation is considered as part of the evolution of 
influenza viruses and occurs in all three types of influenza viruses (A, B, and C). The 
mutation contributes to amino acid substitutions in the two surface glycoproteins (HA, 
NA) of the influenza virus, enabling the mutated viruses to invade the host immune 
system through neutralizing antibodies (immunoglobulins) and cause infection, 
even though the human population has pre-existing antibodies acquired by previous 
infection (Ferguson, Galvani, & Bush, 2003; Lofgren, Fefferman, Naumov et al.,
2007).
The emergence of new variants is the reason for reassessing the components of 
influenza vaccine every year as part of public health programmes (Boni, 2008). In 
addition, there is evidence that the HA gene of influenza A viruses has a higher 
mutation rate than the HA gene of influenza B viruses (3.60x10'3 nucleotide changes 
per nucleotide site per year and 1.60x10’ nucleotide changes per nucleotide site per 
year, respectively). In other words, there is less antigenic drift in influenza B viruses 
than influenza A viruses. This may partially explain why influenza B outbreaks have 
occurred less frequently than influenza A viruses (Cox & Bender, 1995; Me Cullers, 
1999; Zambon, 2001).
A second type of variation is “antigenic shift”, which has been observed only in 
influenza A viruses. Antigenic shift is a major change in the surface protein(s) of 
influenza viruses (the HA and/or NA) (Cox & Subbarao, 2000; Nguyen-Van-Tam & 
Hampson, 2003; Nicholson, Wood, & Zambon, 2003; Treanor, 2005). Influenza 
pandemic occurs with the emergence of a novel virus with completely new surface or 
internal proteins. The new subtypes of influenza viruses arise as a result of genetic 
reassortment (an exchange of a gene segment) between human and animal influenza 
viruses (Figure 2.4) (Zambon, 2001; Nicholson, Wood, & Zambon, 2003). Influenza 
A viruses infect both human and many animal species (bird, pig, duck, horse), and it 
is believed that wild aquatic birds are the primary natural reservoirs of influenza A 
viruses (Cox & Subbarao, 2000). These animals can be a source of HAs that are novel
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to humans and increase the chance for the emergence of new pandemic viruses 
(Obenauer, Denson, Mehta et al., 2006). There is different receptor binding specificity 
of human and avian influenza viruses. The haemagglutinin of human influenza virus 
preferentially binds to sialic acid molecules with a-2,6-linkages, whereas avian 
influenza viruses favour attachment to sialic acid molecules with a-2,3-linkages. 
However, tracheal epithelium cells of pigs have both types of receptor binding. Thus, 
pigs may serve as “mixing vessels” for the genetic recombination of avian and 
humans influenza A viruses (Cox & Subbarao, 2000; Lofgren, Fefferman, Naumov et 
al., 2007).
Most of antigenic shifts are thought to have originated in China where agricultural 
practices allow people in close proximity to ducks, pigs, and domestic animals, as 
well as the high human population density, thereby facilitating the genetic 
reassortment of avian and human influenza A viruses (Zanbon, 2001; Nicholson, 
Wood, & Zambon, 2003). The segmented nature of the influenza A genome 
containing eight separate gene fragments allows the possibility of genetic 
recombination between influenza A viruses. It is estimated that up to 256 gene 
combinations during co-infection with human and animal viruses (Figure 2.4) 
(Nicholson, Wood, & Zambon, 2003).
Migratory w ater birds
Domestic pig
Domestic birds
Human virus Non-human virus
Respiratory epithelial cell
R easso rtan t virus
Figure 2.4 Origin of antigenic shift and pandemic influenza
Source: Nicholson, Wood, & Zambon, 2003
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Although gene reassortment of two influenza A viruses may produce severe disease, 
stable adaptation to replicate in new host species is essential for new virus variants. 
Thus, influenza A viruses that have undergone antigenic shift have potential to cause 
major global pandemics if they have ability to adapt to human hosts and to spread 
from person to person. In addition, if most of population have little or no immunity 
against the new virus, the global influenza pandemic may occur (Cox & Subbarao, 
2000; Nguyen-Van-Tam & Hampson, 2003; Taubenberger, Morens, & Fauci, 2007).
2.5 Pathology of influenza viruses
The pathogenesis caused by influenza viruses depends on the balance between 
the virulence of the infecting strain and the host’s immune response. Typically, 
in non-fatal influenza infection, the viruses cause inflammation, congestion, and 
epithelial necrosis of the upper respiratory tract of humans (Jennings & Read, 2002; 
Suntherland, 2002; Treanor, 2005; Kuiken & Taubenberger, 2008; Guamer & Falcon- 
Escobedo, 2009). The inhaled virus attaches to ciliated epithelial cells of the trachea, 
bronchi, and bronchioles. After attachment, influenza viruses rapidly penetrate the 
cells, and intracellular replication is initiated. Viruses multiply in 
the epithelial cells of the respiratory tract and destroy the cilia. This causes many 
symptoms that come with infection, such as cough, depressed tracheobronchial 
clearance, and altered pulmonary function. The cell damage triggers an acute 
inflammatory response (Sweet & Smith, 1980; Julkunen, Melen, Nygvist et al., 2001; 
Suntherland, 2002). At this point, the early response of the host cell to pathogen 
invasion is the synthesis and release of two cytokines: interleukin-6 (IL-6) and 
interferon-alpha (IFN-a) (Hayden, Fritz, Lobo et al., 1998; Sutherland, 2002; Collier 
& Oxford, 2006). The damage at the site of viral replication, together with the release 
of cytokines and inflammatory mediators, contribute to the development of the local 
and systemic symptoms of influenza (Eccles, 2005; Hayden, Fritz, Lobo et al., 1998). 
The inflammatory mediators are responsible for the local symptoms of influenza 
(nasal obstruction, cough, sore throat), and cytokines (IL-6 and IFN-a) play a 
significant role in generating the systemic symptoms (headache, fever, chills, 
anorexia, myalgia) (Eccles, 2005; Sutherland, 2002; Collier & Oxford, 2006). Viral 
antigens also induce the B lymphocytes to produce specific antibodies. These
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antibodies made against two glycoproteins (HA, NA) on the surface of a virus. 
Specific antibodies can block binding the host cell receptor, thus inhibit virus 
attachment and penetration. Antibodies can also cause aggregation of virions, thereby 
limiting them spread to new cells and making them more readily phagocytosed 
(Gubareva, Kaiser, & Hayden, 2000; Whittaker, 2001; Treanor, 2005; Bouvier & 
Palese, 2008).
However, in fatal cases of influenza, highly virulent strains (e.g. H5N1) cause 
alveolar damage and severe pneumonia. The main target organs for this high virulent 
of influenza A viruses are the lower respiratory tract and lungs. Co-incident bacterial 
pneumonia frequently occurs and increases the severity of disease (Guamer & Falcon- 
Escobedo, 2009). In addition to bacterial co-infection, other underlying medical 
conditions (e.g. asthma, chronic obstructive pulmonary disease, obesity, and diabetes) 
can contribute to the severe or fatal outcomes among these fatal cases (Taubenberger 
& Morens, 2008; Guamer & Falcon-Escobedo, 2009: Shieh, Blau, Denison et al., 
2010).
2.6 Clinical symptoms
Uncomplicated influenza illness in healthy adults varies in severity from mild to 
severe. It is characterised by the abrupt onset of fever (38-40 °C) or feverishness, 
headache, muscle aches and pain, fatigue, sore throat, and a dry cough. Additional 
symptoms may include loss of appetite, runny or stuffy nose, a clear nasal discharge 
and sneezing (Cox & Subbarao, 1999; Jennings & Read, 2002; Cunha, 2004; Eccles, 
2005; Treanor, 2005). The average duration of fever is three days, but it can last four 
to eight days (Jennings & Read, 2002; Treanor, 2005). Fever and cough have been 
identified as the best predictors of an influenza infection, with a positive predictive 
value of 79 per cent (Monto, Gravenstein, Elliott et al., 2000). Mild to moderate cases 
of uncomplicated influenza typically recover within 7 days. However, other 
symptoms, particularly cough, malaise, and fatigue can persist for weeks after 
recovery from the major clinical symptoms (Jennings & Read, 2002; Cunha, 2004).
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Although most cases of influenza are mild and self-limited illness, more severe illness 
is observed in an elderly and people of any age with chronic medical conditions such 
as asthma, congestive heart failure, chronic obstructive pulmonary disease, diabetes, 
and chronic renal failure. In addition, the risks for complications, hospitalisation and 
death related to influenza are higher among these individuals (Jennings & Read, 2002; 
Hak, Wei, Nordin et al., 2004; Rothberg, Haessler, & Brown, 2008).
2.7 Diagnosis
Early diagnosis of influenza is crucial for antiviral treatment, chemoprophylaxis, and 
institutional outbreak management. Although the presence of high fever and cough 
was found to be the best clinical predictors for influenza infection in adults during 
influenza season, diagnosis of influenza based on clinical symptoms alone was 
imperfect. The study by Boivin, Hardy, Tellier et al. (2000) indicated that the positive 
predictive value (PPV: the percentage of test positive cases who have influenza), 
negative predictive value (NP: the percentage of test negative cases who do not have 
influenza) and the specificity of a clinical diagnosis (fever [temperature >38 °C], and 
cough) were 86.8 per cent, 39.3 per cent and 55.0 per cent, respectively. By contrast, 
the PPV of clinical diagnosis using the same clinical symptoms was found only 44 per 
cent (95% Cl, 30-58 %) in the study conducted in the southern region of the 
Netherlands (Govaert, Dinant, Aretz et al., 1998). However, the clinical diagnosis 
based on the acute onset of high fever and cough was more likely to predict influenza 
during influenza epidemics, with PPV ranging from 79 per cent to 87 per cent and 
NPV ranging from 39 per cent to 75 per cent). Moreover, the likelihood of confirmed 
influenza infection cases increases with higher temperature and acute presentation 
(within 36-48 hours of onset) (Gavin & Thomson, 2003; WHO, 2005b). The accuracy 
of clinical diagnosis of influenza is limited as the influenza symptoms can be 
confounded by symptoms from illness caused by other agents. Furthermore, clinical 
diagnosis of influenza may have been influenced by factors such as the circulating 
virus strain, duration of symptoms at presentation, preceding use of antipyretics, the 
patient’s age, underlying medical conditions, and vaccination status (Gavin & 
Thomson, 2003).
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Laboratory methods to detect influenza virus infection include: (1) virus isolation in 
cell culture; (2) direct antigen detection: direct fluorescent antibody test [DFA] or 
immunofluorescent antibody [IFA] test, and rapid enzyme and optical immunoassays 
for influenza antigen (rapid diagnostic tests); (3) detection of influenza-specific RNA 
by reverse transcriptase-polymerase chain reaction (RT- PCR); and (4) serologic 
diagnosis. These test methods vary in terms of the sensitivity and specificity of the 
assay, the turnaround time for reporting of assay results, and cost (Linde, 2001; Gavin 
& Thomson, 2003; Pachucki, 2005; WHO, 2005b; Petrie, Comanor, & Petti, 2006).
2.7.1 Virus isolation in cell culture
Viral culture is considered to be the gold standard for laboratory diagnosis of 
influenza. There are two different techniques of viral culture: convention culture and 
shell vial culture. For conventional virus culture, the results are generally available 
in four to five days (range, 2-14 days), whereas shell vial culture (rapid culture 
technique) for detection of influenza virus takes one to three days after inoculation 
(Gavin & Thomson, 2003; Talbot & Falsey, 2010). Although shell vial culture 
provides results in less time compared with the conventional technique, it does not 
generate results quickly enough in guiding the clinical management of influenza 
patients (antiviral treatment, infection control, and management of close contacts). 
Nevertheless, this rapid culture technique provides confirmation of the influenza 
diagnosis. The specificity of shell vial culture for the detection of influenza virus is 
100 per cent. Another advantage of virus culture methods is the detection of influenza 
A subtypes and strains. Thus, both conventional and shell vial culture methods can be 
used for monitoring the emergence of new influenza virus strains, and the information 
about the new virus strain circulating will be used to update the formulation of the 
influenza vaccine for the coming year (Steininger, Kundi, Aberle et al., 2002; Gavin 
& Thomson, 2003; WHO, 2005b; Petrie, Comanor, & Petti, 2006; Talbot & Falsey, 
2010).
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2.7.2 Detection of virus antigen
There are two types of diagnostic tests for detection of influenza virus: 1) Direct 
fluorescent antibody tests (DFA) or immunofluorescent antibody (IFA) and 2) rapid 
enzyme/optical immunoassays or assay for NA enzymatic activity.
1) Direct fluorescent antibody tests (DFA) or immunofluorescent 
antibody (IFA)
Generally, the sensitivity of DFA is slightly lower than IF A, but the DFA test can 
provide the results in less time and is thereby more popular than IF A. Previous studies 
(Leonard, Leib, Birkhead et al., 1994; Doing, Jerkofsky, Dow et al., 1998; Chan, 
Maldeis, Pope et al., 2002; Gavin & Thomson, 2003) have shown that DFA is a fast 
and reliable technique for the detection of influenza, as well as relatively accurate 
results (sensitivity, range: 70-100 per cent; specificity, range: 80-100 per cent; PPV, 
range: 85-94 per cent; and NPV, range: 96-100 per cent).
2) Rapid enzyme/optical immunoassays or assay for NA enzymatic 
activity.
There are a number of commercial rapid influenza detection tests, and six of which 
are in general use for detecting influenza virus. Such tests include Directigen 
Influenza A, and Influenza A plus B tests (Becton Dickinson, Franklin Lakes, New 
Jersy), Binax Now Influenza A and B tests (Binax Inc., Portland, Maine), Biostar 
INFLUENZA OIA (Biostar, Inc., Boulder, Colorado), Quidel Quick vue (Quidel San 
Diego, Carifomia), and ZstatFlu test (Zyme Tx, Inc., Oklahoma City, Oklahoma). 
Most of these tests detect influenza viral antigen (viral neucleoprotein antigen). Only 
one diagnostic test (ZstatFlu test) detects influenza virus NA enzyme activity (Gavin 
& Thomson, 2003). Rapid diagnostic tests have been widely used for screening 
influenza A and B virus infections before confirmatory diagnostic testing using viral 
culture or PCR (polymerase chain reaction). These tests vary in terms of test 
complexity, the type of specimen tested, the ability of the test to detect types of 
influenza, and the time needed to produce results (WHO, 2005b). The rapid influenza 
tests can detect: (1) only influenza A virus; (2) both influenza A and B viruses, 
but does not differentiate between the two types; (3) both influenza A and B and
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differentiate between the two types (CDC, 2009a). However, none of the rapid 
diagnostic tests distinguish influenza A virus subtypes. Most diagnostic tests can 
provide the results within 15-30 minutes, which facilitates timely diagnosis, antiviral 
treatment, prevention and outbreak management (CDC, 2009a). Various respiratory 
specimen types can be used for rapid diagnostic tests, including nasal aspirates, nasal 
washes, sputum, nasal pharyngeal swabs, nasal swabs, and throat swabs. Among 
these specimen types, nasal aspirates or washes yield the highest detection rates for 
influenza virus (WHO, 2005b; Hurt, Allexander, Hibbert et al., 2007; Smit, Beynon, 
Murdoch et al., 2007). Nasal aspirate specimens should be transported in sterile 
containers, while nasal or throat swabs should be collected and transported in virus 
transport media.
Most rapid diagnostic tests for the diagnosis of influenza have sensitivity of 70 to 75 
per cent, compared to viral culture or reverse transcription polymerase chain reaction 
(RT-PCR), and their specificity is relatively high (median, 90-95 per cent) (Pachucki, 
2005; WHO, 2005b). A further study (Hurt, Allexander, Hibbert et al., 2007) that 
tested six influenza diagnostic tests found that five of the rapid diagnostic tests (Binax 
Now influenza A & B, Directigen EZflu A+B, Denka Seiken Quick Ex-flu, Fujirebio 
Espline Influenza A&B-N, and Quidel Quick Vue Influenza A+B test) were 61-71 per 
cent sensitive for detecting influenza and 99-100 per cent specific compared with cell 
culture.
Although both the sensitivity and specificity of rapid diagnostic tests are relatively 
high, test results should be considered based on patients’ clinical symptoms and 
epidemiologic information. The rapid influenza tests are most reliable when they are 
performed during periods of high influenza activity (at the height of the influenza 
season) and when samples were collected within four days of illness (high viral load). 
Therefore, when the prevalence of influenza in the community is low (at the 
beginning and end of influenza season), confirmation of rapid influenza test-positive 
by viral culture or RT-PCR may be necessary because a false-positive rapid test result 
is more likely to occur during low influenza activity. In particular, outside of the 
influenza season, positive rapid test results must be interpreted with caution, and 
confirmation of the results by other tests is warranted (Gavin & Thomson, 2003; 
WHO, 2005b; Petrie, Comanor, & Petti, 2006; CDC, 2009a).
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2.7.3 Detection of influenza-specific RNA by reverse transcriptase- 
polymerase chain reaction (RT- PCR)
Reverse transcriptase-polymerase chain reaction (RT-PCR) is the most sensitive and 
specific technique for detecting influenza virus. There are two types of RT-PCR 
methods: conventional RT-PCR and real-time RT-PCR. Reverse transcriptase- 
polymerase chain reaction methods can detect influenza virus, differentiate subtype 
and strains of influenza virus. Previous studies using RT-PCR have more accurately 
detected influenza virus than conventional viral culture (Taubenberger & Layne, 
2001; Steininger, Kundi, Aberle et al., 2002). The study by Steininger, Kundi, Aberle 
et al. (2002) demonstrated that RT-PCR provided a higher detection rate of influenza 
(93 per cent) than virus culture (80 per cent) and antigen enzyme-linked 
immunosorbent assay (ELISA) (62 per cent). The sensitivity of RT-PCR was 103 
times higher than viral culture and 106 to 107 greater than ELISA. However, RT-PCR 
methods for detection influenza virus are expensive and require high technical skills. 
Conventional RT-PCR can provide results in one to two days; however, its turnaround 
time is still limited in guiding clinical management decisions. The real time RT-PCT 
method has been developed as a quick, sensitive and reliable method. Real time RT- 
PCR can provide rapid results within four to five hours (Gavin & Thomson, 2003). 
Two studies by van Elden, Nijhuis, Schipper et al. (2001) and van Elden, van Kraaij, 
Nijhuis et al. (2002) showed that real time RT-PCR had greater sensitivity for 
detection of influenza virus than viral culture methods. Accordingly, real time RT- 
PCR may replace the current gold standard for confirming influenza which is viral 
culture in the future (van Elden, van Kraaij, Nijhuis et al., 2002).
2.7.4 Serologic diagnosis
Serologic diagnosis of influenza is based on the presence of a four-fold or higher 
rise in influenza-specific antibody titres between acute (within one week after 
initial infection) and convalescent serum samples (four to seven weeks after 
infection). Because this diagnostic method is time consuming; thus, its clinical value 
is limited. However, serological tests can be used for detecting influenza virus for 
epidemiological and research studies (Gavin & Thomson, 2003; Petrie, Comanor, & 
Petti, 2006).
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2.8 Complications o f influenza
The complications of influenza may be divided into two categories: pulmonary 
complications and non-pulmonary complications.
2.8.1 Pulmonary complications
The most frequent complication of influenza is pulmonary complications, especially 
pneumonia. There are two clinical presentations of pneumonia associated with 
influenza: primary influenza pneumonia and secondary bacterial pneumonia (Treanor, 
2005; Rothberg, Haessler, & Brown, 2008). Primary viral pneumonia is an 
uncommon complication associated with high mortality rate. However, the study by 
Hers et al. (1958, cited in Nguyen-Van-Tam & Hampson, 2003) found that there was 
a higher incidence rate of primary influenza pneumonia during the 1957-1958 
influenza pandemic. In addition, it was evidenced that this pneumonia caused many 
deaths among young healthy adults in the 1918-1919 influenza pandemic (Treanor, 
2005). The illness starts within 24 hours of the onset of fever with a dry cough, 
followed by a rapid progression of dyspnea, cyanosis, and respiratory failure. No 
significant bacteria were detected in the sputum Gram stain. Patients deteriorate and 
do not respond to antibiotic therapy, with a mortality rate of 80 per cent (Cox & 
Subbarao, 1999; Treanor, 2005; Louria et al., 1959, cited in Rothberg, Haessler, & 
Brown, 2008). At the present time, during the interpandemic periods, primary 
influenza pneumonia occurs predominantly in the people with underlying severe co- 
morbid conditions (cardiac disease, chronic obstructive pulmonary disease, diabetes, 
renal disease and immunosuppression), and the mortality rates are 6 per cent to 29.4 
per cent (Oliverira & Marik, 2001; Murata, Walsh, & Falsey, 2007).
Secondary bacterial pneumonia occurs more frequently than primary viral pneumonia. 
Staphylococcus aureus, Streptococcus pneumoniae, Hemophilus influenza, and other 
Gram-negative bacilli are the most common causative agents of secondary bacterial 
pneumonia in older adults and those with chronic medical conditions. This pneumonia 
occurs in the early convalescent phase of a typical influenza. It is marked by the 
recrudescence of fever, cough, and sputum production. The areas of consolidation can 
be seen on a chest radiograph. A predominance of a bacterial pathogen was seen on
24
Gram’s stain and culture. Most patients with secondary bacterial pneumonia respond 
to antibiotic therapy. During the outbreak of influenza, people may have primary viral 
pneumonia, secondary bacterial pneumonia or mixed viral and bacterial pneumonias. 
The response to antibiotic therapy varies among patient with mixed viral and bacterial 
infections (Cox & Subbarao, 1999; Treanor, 2005).
In addition, influenza virus is also the leading cause of acute exacerbation of chronic 
bronchitis and other chronic pulmonary diseases (e.g. asthma and chronic obstructive 
pulmonary disease: COPD) (Rothberg, Haessler, & Brown, 2008). Influenza viruses 
have been reported to be involved in COPD exacerbations in 25 per cent of cases 
(Rohde, Wiethege, Borg et al., 2003).
2.8.2 Non-pulmonary complications
Although pulmonary complications are common in influenza patients, the viruses 
can cause complication in other organs (influenza-associated extra-respiratory 
complications) such as myositis, myocarditis, and neurologic complications of 
influenza (Fujimoto, Kobayashi, Uemura et al., 1998; Cox & Subbarao, 1999; 
McCullers, Facchini, Chesney et al., 1999; Studahl, 2003; Rothberg, Haessler, & 
Brown, 2008).
Myositis (inflammation of muscle) may occur in both children and adults after being 
infected with influenza, but primarily in children. It has been reported to be associated 
with influenza B infection. The clinical symptoms include transient muscle pain in the 
lower extremities. In most cases, recovery is complete within one week (Cox & 
Subbarao, 1999; Treanor, 2005; Kuiken &Taubenberger, 2008).
Myocarditis—Although influenza infection can cause of exacerbations in patients 
with chronic heart diseases (such as congestive heart failure, ischemic heart disease), 
direct cardiac complications (pericarditis and myocarditis) are considered to be very 
rare (Onitsuka, Imamura, Miyamoto et al., 2001; Treanor, 2005; Rothberg, Haessler, 
& Brown, 2008). However, influenza viral antigen was detected within the 
myocardium of a person with marked myocardial necrosis (Ray, Icenogle, Minnich et 
al., 1989). A combination of the direct cytolytic effect of viral infection and the host
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immune response may play an important role in the pathogenesis of the necrosis and 
inflammation in the myocardium (Kuiken & Taubenberger, 2008).
Neurologic complications of influenza include post influenza encephalitis, 
encephalopathy (Reye’s syndrome), transverse myelitis, and Guillain-Barre syndrome 
(GBS). These complications may occur during influenza attack or after the influenza 
infection. Recently, encephalitis/encephalopathy associated with influenza has been 
increasingly reported in Japan, particularly in children aged younger than five years. 
The major clinical signs include altered or loss of consciousness, convulsion, cough 
and vomiting. Multiple-organ failure can occur in many cases, and the prognosis is 
generally poor (death or severe neurologic sequelae). The pathogenesis of encephalitis 
/encephalopathy associated with influenza has not been elucidated, but is thought to 
occur by direct viral invasion and host immune response. However, influenza virus 
RNA was detected in the cerebrospinal fluid (CSF) of the patients with acute 
encephalopathy associated with influenza-like illness (Fujimoto, Kobayashi, Uemura 
et al., 1998; McCullers, Facchini, Chesney et al., 1999; Morishima, Togashi, Yokota 
et al., 2002; Rothberg, Haessler, & Brown, 2008).
Reye’s syndrome is one of the encephalopathies associated with influenza epidemics. 
It is an acute, non-inflammatory encephalopathy and occurs most often in children or 
adolescents, especially children aged less than 14 years who take or are given aspirin 
to reduce fever due to influenza and other viruses. This disease begins with severe 
vomiting and confusion, and these symptoms can progress to coma due to swelling of 
the brain. On this basis, aspirin use should be avoided in the children with febrile 
illness. In addition, the children and adolescents who require long-term aspirin 
therapy should be vaccinated against influenza every year in order to reduce the risk 
of Reye’s syndrome (Treanor, 2005; Beigel, 2008; Rothberg, Haessler, & Brown,
2008).
Guillain-Barre syndrome is a post-infection autoimmune disorder and a rare disease. 
It has been previously suggested that there is a link between Guillain- Barre syndrome 
and influenza infection, but no definite causal connection has been established 
(Treanor, 2005). Recently, two studies by Tam, O' Brien, & Rodrigues (2006) and 
Sivadon-Tardy, Orlikowski, Porcher et al. (2009) have confirmed this causal
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relationship; a positive association between the incidence of GBS and reported 
influenza illness was observed in both studies. The clinical symptoms of GBS may 
begin as early as 1-3 weeks after infection, and the symptoms include limb muscle 
weakness accompanied by absent or depressed deep tendon reflexes. Complete or 
partial functional recovery may occur over weeks or months (Koningsveld, 
Steyerberg, Moghes et al., 2007; Toovey, 2008).
2.9 Antiviral treatment
Currently, there are two classes of antiviral drugs against influenza: M2 inhibitors 
(amantadine and rimantadine), and neuraminidase inhibitors (zanamivir and 
oseltamivir).
2.9.1 M2 inhibitors or adamantanes (amantadine and rimantadine)
Adamantanes act to block the function of M2 ion channel, leading to prevent viral 
uncoating and the release of viral RNA in to the host cell, thereby inhibiting viral 
replication. Both amantadine and rimantadine are only effective against influenza 
virus A and are administered orally. Treatment of influenza is most effective when 
adamantanes are administered within 48 hours of symptom onset (Moscona, 2008; 
Nayak & Treanor, 2009; Schirmer & Holodniy, 2009). A recent Cochrane review of 
the amantadine and rimantadine regime for influenza A in adults indicated that these 
drugs have been shown to be similarly effective in alleviation of influenza symptoms 
in adults. In addition, neither amantadine nor rimantadine was effective in interrupting 
the spread of influenza. Adverse gastrointestinal effects were reported in both drugs, 
but amantadine can also cause serious side effects on the central nervous system 
(such as insomnia, dizziness, and difficulty in concentrating) (Jefferson, Demicheli, 
Pietrantonj et al., 2009). Similarly, a randomised, double-blind, placebo-controlled 
study comparing rimantadine to acetaminophen therapy in children by Hall, Dolin, 
Gala et al. (1987) found that children in the rimantadine group showed a more rapid 
decrease in fever and influenza symptoms during the first three days after they had 
taken the drug. The study also found that viral shedding was decreased during the first
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two days, but the proportion of patients shedding virus increased in the subsequent 
days of therapy.
Additionally, the incidence of adamantanes resistance among influenza A viruses 
isolated worldwide has increased significantly from 1.8 per cent in 1995-2002 to
12.3 per cent in 2004 (Bright, Medina, Xu et al., 2005). In the United States, the 
incidence of adamantanes-resistance H3N2 was 92.3 per cent during the 2005-2006 
influenza season (Bright, Shay, Shu et al., 2006). Consequently, the use of amantadine 
and rimantadine for the treatment or prophylaxis of influenza has been limited.
2.9.2 Neuraminidase inhibitors (zanamivir and oseltamivir)
Understanding the structure and function of viral neuramidase has yielded information 
that contributed to the development of anti-viral drugs. Recently, two neuramidase 
inhibitors (zanamivir: Relenza®, and oseltamivir: Tamiflu®) have been launched, and 
they are active against both influenza A and B viruses. These antiviral drugs inhibit 
the viral replication at the final stage by blocking the release of budded viruses from 
infected cells (Gubareva, Kaiser, & Hayden, 2000; Moscona, 2005) (Figure 2.9.2).
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Neuraminidase inhibitors, zanamivir and oseltamivir, are effective for both treatment 
and prophylaxis of influenza infection. Because viral replication in respiratory tract 
peaks between 24 and 72 hour after the onset of the illness, the early treatment with 
zanamivir or oseltamivir is more likely to provide benefits of neuraminidase inhibitor 
in prophylaxis and treatment of influenza (Makela, Pauksens, Rostila et al., 2000; 
Treanor, Hayden, Vrooman et al., 2000). The study by Aoki, Macleod, Paggiaro et al., 
(2003) indicated that total duration of illness is shortened by 41 per cent (3.1 days) 
when starting oseltamivir therapy within 12 hours after fever onset. Zanamivir is 
approved for treatment of influenza in persons five years and older, and it is inhaled 
through the mouth using a specific inhaler (Diskhaler). Unlike zanamivir, oseltamivir 
is administered orally and licensed for use in persons aged one year and over 
(Moscona, 2008; Nayak & Treanor, 2009). In randomised, double-blind placebo- 
controlled trials, both drugs have been shown to be effective in reducing the duration 
of illness by 1- 2.5 days compared with the placebo group (Hayden, Osterhaus, 
Treanor et al., 1997; Hedrick, Barzilai, Behre et al., 2000; Makela, Pauksens, Rostila 
et al., 2000; Nicholson, Aoki, Osterhaus et al., 2000; Treanor, Hayden, Vrooman et 
al., 2000; Aoki, Macleod, Paggiaro et al., 2003). Additionally, reduction in the 
severity of major influenza symptoms (such as headache, sore throat, feverishness, 
muscle aches, and weakness) was reported in patients treated with neuraminidase 
inhibitors (zanamivir or oseltamivir) (Hayden, Osterhaus, Treanor et al., 1997; 
Makela, Pauksens, Rostila et al., 2000; Nicholson, Aoki, Osterhaus et al., 2000; Aoki, 
Macleod, Paggiaro et al., 2003).
Early treatment with neuraminidase inhibitors was associated with shorter time to 
return to normal health and activity (Hedrick, Barzilai, Behre et al., 2000; Makela, 
Pauksens, Rostila et al., 2000; Nicholson, Aoki, Osterhaus et al., 2000; Aoki, 
Macleod, Paggiaro et al., 2003). One randomised, placebo-controlled, double-blind 
study evaluating the efficacy and safety of oseltamivir treatment demonstrated that 
oseltamivir-treated patients had a faster return to usual activity by 2-3 days compared 
to placebo-treated patients. Furthermore, oseltamivir has also been shown to reduce 
the secondary complications (bronchitis, sinusitis). Secondary complications were 
more likely to occur in the placebo recipients than the oseltamivir recipients (15 per 
cent vs. 7 per cent; p  = .03) (Treanor, Hayden, Vrooman et al., 2000). The further 
study by Kaiser, Wat, Mills et al. (2003) also demonstrated that oseltamivir decreased
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the incidence of influenza-related lower respiratory tract complications (e.g. 
bronchitis and pneumonia) and hospitalisations, resulting in a reduction in antibiotic 
use by 55 per cent. Similar treatment effects were also found in the high-risk group 
(Makela, Pauksens, Rostila et al., 2000; Lalezari, Campion, Keene et al., 2001). The 
study investigating the efficacy of zanamivir treatment in high-risk patients showed 
that zanamivir reduced the illness duration by 2.5 days, allowing a more rapid return 
to normal activity (3 days). Early treatment with zanamivir in high-risk adults also 
resulted in a 43 per cent reduction in the rates of influenza-associated complications 
compared to the placebo group (Lalezari, Campion, Keene et al., 2001). Additionally, 
a reduction in viral shedding during treatment was observed in patients treated with 
zanamivir or oseltamivir (Hayden, Osterhaus, Treanor et al., 1997; Hayden, Treanor, 
Fritz et al., 1999; Nicholson, Aoki, Osterhaus et al., 2000).
Overall, both zanamivir and oseltamivir were well-tolerated. The reported adverse 
events during treatment with both drugs were nausea, vomiting, diarrhoea and 
abdominal pain. These gastrointestinal events generally occur after starting the drugs 
and resolve spontaneously within 1-2 days (Hayden, Treanor, Fritz et al., 1999; 
Hedrick, Barzilai, Behre et al., 2000; Nicholson, Aoki, Osterhaus et al., 2000; Aoki, 
Macleod, Paggiaro et al., 2003; Treanor, 2005). Acute bronchospasm may rarely 
occur during using zanamivir, particularly in those with chronic obstructive 
pulmonary disease and asthma (Hedrick, Barzilai, Behre et al., 2000; Murphy, 
Eivindson, Pauksens et al., 2000; Treanor, 2005).
Several randomised, double-blind, placebo-controlled trials have shown that both 
oseltamivir and zanamivir are effective in preventing influenza illnesses in healthy 
adults and household contacts, with about 70-90 per cent protective efficacy (Hayden, 
Treanor, Fritz et al., 1999; Monto, Robinson, Herlocher et al., 1999; Monto, 
Pichichero, Blanckenberg et al., 2002). One study conducted in North America and 
Europe (76 centres) showed that the protective efficacy of oseltamivir against 
influenza in individuals and households exposed to influenza-infected index cases was 
89 per cent and 84 per cent, respectively (Welliver, Monto, Carewicz et al, 2001). The 
study evaluating the efficacy of inhaled zanamivir for the prevention of influenza in 
families, also found that in the zanamivir group, the proportion of families in which at
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least one household contact had symptomatic, laboratory-confirmed influenza was 
reduced by 79 per cent (Hayden, Larisa, Monto et al., 2000).
2.10 Mode of transmission
Human influenza is thought to be transmitted primarily via the large droplet 
(particles > 5 microns [pm] in diameter) and contact routes. Virus particles in the 
nasal secretions are expelled when infected person coughing or sneezing. These 
activities produce infectious aerosols of various sizes. The large droplets can travel 
through the air no more than 3 feet (one meter). Thus influenza virus transmission can 
occur within 3 feet of the source of infection (infected person). These large droplets 
deposit in the nose and upper airway of a new host. The viruses attach, invade and 
replicate in the epithelial cells of the upper respiratory tract, which will subsequently 
cause proinflammatory cytokines and necrosis of ciliated epithelial cells. In addition 
to generation of the large particle aerosol, coughing and sneezing can also produce 
small droplet nuclei or airborne particles (< 5 pm) which remain suspended in the air 
for long periods of time because they are small. Therefore, the droplet nuclei can 
spread to people far away from the source of infection and reach the lower respiratory 
tract of a new host. However, the airborne spread of influenza is relatively rare. 
By contrast, contact appears to be an important route of transmission for influenza. 
The influenza virus can be transmitted from person to person either through direct 
skin-to-skin contact with infected persons (e.g. hand shaking) or indirect contact by 
touching a surface or object contaminated with influenza viruses (e.g. door knobs, 
telephone receivers) (Bridges, Kuehnert, & Hall, 2003; Brankston, Gitterman, Hirji et 
al., 2007).
One study revealed that during influenza season, influenza viral RNA was detected on 
23 per cent and 59 per cent of the fomites tested in day-care centres and home, 
respectively (Boone & Gerba, 2005). Influenza viruses enter mucous membranes 
when infected persons touch these contaminated surfaces or objects and then touch 
their eyes or nose. The typical incubation period for influenza virus averages two days 
(range, 1-4 days). Influenza virus shedding occurs before clinical onset, and it usually 
continues for 5 -10 days. However, young children shed virus several days before
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their illness onset, and the viral shedding is detectable for 10 days or more because of 
their relative lack of immunity to influenza (Cox & Subbarao, 1999; Whitley, 
Hayden, Reisinger et al., 2001; Jennings & Read, 2002; Treanor, 2005).
2.11 Seasonality
Influenza infection has a distinctive seasonality in temperate climates. In general, its 
incidence peaks during the winter months. In northern hemisphere, influenza mainly 
occurs from November to April, whereas in the southern hemisphere influenza 
infections are more prevalent between May and September (Simomsen, 1999). By 
contrast, the influenza viruses circulate throughout the year in the tropical and 
subtropical regions, and there is a remarkable increase in influenza cases in these 
regions during rainy seasons. Additionally, biannual pattern of influenza epidemics 
which occur both in spring and autumn have been observed in some subtropical and 
tropical countries (Chew, Doraisingham, Ling et al., 1998; Simonsen, 1999; Dosseh, 
Ndiaye, Spiegel et al., 2000; Shek & Lee., 2003; Simmerman, Thawatsupha, Kingnate 
et al., 2004; Nguyen, Saito, Ngiem et al., 2007; Moura, Perdigao, & Siqueira, 2009).
Many factors other than climate have been assumed to account for the seasonal 
variation of influenza. They include seasonal fluctuations in host immunity (e.g. 
melatonin in relation to the light/dark cycles and vitamin D), seasonal host-behaviour 
changes (e.g. school attendance, air travel, crowding indoors during cold or rainy 
weather), prevalence or virulence of the pathogen, and environment changes 
(temperature, relative humidity, rain, wind) (Dowell, 2001; Brownstein, Wolfe, & 
Mandl, 2006; Lofgren, Fefferman, Naumov et al., 2007; Lowen, Mubareka, Steel et 
al., 2007; Monto, 2008). However, only a few studies have directly examined the 
causal relationship between these factors and the seasonal variation of influenza.
The study by Curwen (1997) has shown the relationship between air temperature 
and the incidence of epidemic influenza and influenza-like illness in the UK; the 
peak incidence of influenza and influenza-like illness occurred at the period of lowest 
average temperature in February (Curwen, 1997, cited in Eccles, 2002). The most 
recent laboratory experiment using the guinea pig as a model host, revealed that
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temperature and relative humidity were contributing factors to variation in influenza 
transmission; the increased viral shedding was more likely to occur at 5 °C, and low 
relative humidities of 20 per cent to 35 per cent were the most efficient transmission 
of influenza viruses among the guinea pigs. The influenza virus was not transmitted 
when the temperature reached 30 °C, and the relative humidity was 80 per cent 
(Lowen, Mubareka, Steel et al., 2007). It has been indicated that cold air exposure 
affects tracheal mucociliary clearance by reducing both ciliary beat frequency and the 
rate of secretion of mucus. In addition, cooling of the nasal mucosa also causes the 
depression of lymphocyte proliferation and other aspects of the immune response. 
This can lead to an increased incidence of upper respiratory tract viral infections in 
the winter, including influenza (Shephard & Shek, 1998; Eccles, 2002).
Relative humidity can have an influence on seasonal virus survival and transmission. 
At a low relative humidity, large droplets containing influenza virus can evaporate to 
become airborne particles (small droplet), promoting the spread of influenza viruses, 
as well as the survival of the virus in the air. In contrast, high relative humidity 
impedes the evaporation of water from exhaled virus droplets; thus these droplets fall 
to the ground more quickly (Lowen, Mubareka, Steel et al., 2007; Lipsitch & Viboud, 
2009). Although the temperature and relative humidity have an effect on the incidence 
of influenza, there are still influenza epidemics in warm tropical climates. It has been 
proposed that the influenza virus transmission in tropical countries is predominantly 
by the contact route, and this transmission route may also reflect the sporadic 
outbreaks without a definite seasonal pattern in these regions (Lowen, Steel, 
Mubareka et al., 2008). In addition, influenza is likely to occur during rainy season in 
tropical countries (Shek & Lee, 2003; Simmerman, Thawatsupha, Kingnate et al.,
2004). Influenza surveillance data covering January 2001-September 2003 from 
Thailand National Institute of Health also showed that peak periods of influenza cases 
were seen from June through October, which was the height of the rainy season 
(Simmerman, Thawatsupha, Kingnate et al., 2004).
2.12 The burden of seasonal influenza
Seasonal influenza causes a significant disease burden and costs in many parts of the 
world each year. However, it has been difficult to quantify the actual burden of
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influenza on physician consultations, hospitalizations and mortality because influenza 
lacks pathognomonic features, and it causes a range of non-specific complication in 
individuals with chronic diseases (such as secondary bacterial infection, exacerbations 
of chronic lung diseases). Many influenza-related deaths occur from these 
complications, and a primary influenza infection may not be recognised. The 
confirmation of influenza infection by laboratory testing has been rarely performed. 
Additionally, influenza often concurrently occurs with other respiratory pathogens 
(e.g. respiratory syncitial virus). As a consequence, this may have underestimated the 
impact of influenza (Nicholson, Wood, & Zambon, 2003; Viboud, Alonso, & 
Simonsen, 2006).
Overall, influenza A outbreaks produced the greater burden of illness than influenza 
B virus. In particular, H3N2 subtype influenza A virus which is the most virulent 
strain of the currently circulating influenza viruses, causes more severe influenza and 
more hospital admissions, as well as influenza related deaths because antigenic drift 
has been found frequently in this strain (Frank, Taber, & Wells, 1985; Wright, 
Thompson, & Karzon, 1980; Simonsen, Fukuda, Schonberger et al., 2000; Thompson, 
Shay, Weintraub et al., 2003). Thus, most people have little or no pre-existing 
immunity to this variant virus, resulting in a more severe clinical course. The study by 
Fleming et al. (2000) using surveillance data covering 1987-1996 from sentinel 
general practice networks in England, Wales and The Netherlands found that the 
H3N2 influenza A epidemics were associated with higher consultation rates than 
influenza B virus, particularly in the age groups 0-4 years and 65 years and older.
2.12.1 Morbidity and mortality associated with influenza among adults in 
temperate countries
Although influenza morbidity varies substantially from year to year depending on the 
strain of virus and the immune status of the population, the average attack rates range 
from 10 to 20 per cent during influenza epidemics. However, these rates can reach as 
high as 40-50 per cent among susceptible individuals, such as elderly and people with 
chronic medical conditions. In addition, the highest attack rates were observed in 
school-age children. Accordingly, the higher occurrence of influenza was also 
reported in household contacts (Longini, Koopman, Monto et al., 1982; LaForce,
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Nichol, & Cox, 1994; Cox & Subbarao, 2000; Treanor, 2005). In order to estimate the 
burden of influenza (influenza-attributable morbidity and mortality), indirect 
statistical modelling methods have been applied to analyse hospital discharge, cause 
of death, and virological surveillance data (Simmerman & Uyeki, 2008).
One retrospective study in USA (Mullooly, Bridges, Thompson et al., 2007) using 
data from four respiratory seasons (1996/1997-1999/2000) found that individuals with 
chronic medical conditions aged 50-64 years had significant excess pneumonia and 
influenza hospitalisations and circulatory and respiratory hospitalisations (123 and 
232 per 100,000 person-periods, respectively). Moreover, persons older than 65 years 
with underlying chronic diseases had substantially higher influenza-associated rates of 
hospitalisations for pneumonia and influenza (556 per 100,000 person-periods) 
compared to healthy elderly persons (187 per 100,000 person-periods). Similarly, 
the study estimating influenza-related hospital admissions in older people from Swiss 
Sentinel Surveillance Network (SSSN) database over a 10-year period (1987-99 to 
1996-97) revealed that the average rates of excess hospitalisations due to influenza 
epidemics each year was substantially higher in the elderly (110 per 100,000 
population) than in those aged 51-65 years (6.56 per 10,000 population). The excess 
for both pneumonia and influenza and other respiratory conditions hospitalisations 
were highest among the oldest age-group (>65 years) (Scuffham, 2004). The 
increased risk for influenza-associated hospitalisations was also demonstrated in 
persons with chronic obstructive pulmonary disease (COPD). The study by Rohde, 
Wiethege, Borg al. (2003) showed that the respiratory viruses were found in 56 per 
cent of the patients with acute exacerbations of chronic obstructive pulmonary disease 
(AE-COPD) and in 19 per cent of the control patients. Influenza viruses accounted for 
25 per cent of AE-COPD cases. Similarly, a longitudinal cohort study of older adults 
with COPD conducted in United States found that 45 per cent of COPD 
hospitalisations between December and March were attributed to respiratory viral 
infections, including influenza infections (Greenberg, Allen, Wilson et al., 2000). 
Another study conducted in Canada also showed a marked increase in physician 
visits, emergency room visits, and admission rates for influenza and pneumonia and 
chronic lung disease over four influenza seasons (1995-96 to 1998-99) among adults 
aged 65 and over (Menec, Black, MacWilliam et al., 2003).
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Influenza infections also have a major impact on mortality, especially in the 
elderly and persons with underlying diseases. Excess mortality from influenza and 
pneumonia (P&I) deaths during influenza season have been considered as the primary 
index for assessing the severity of influenza seasons (Simonsen, Clarke, Williamson 
et al., 1997, Simonsen, 1999). However, excess pneumonia and influenza mortality 
may not reflect the overall picture of disease burden because influenza epidemics 
were also associated with an increase in hospitalisations and deaths in people with 
underlying disease such as COPD, congestive heart failure and secondary bacterial 
infection (Simonsen, 1999; Thompson, Shay, Weintraub et al., 2003). Therefore, the 
excess in mortality due to circulatory and respiratory (C&R) deaths and influenza- 
associated all-cause deaths have been used to estimate the total burden of deaths 
associated with influenza infections in several epidemiological studies (Simonsen, 
Clarke, Williamson et al., 1997; Simonsen, 1999; Thompson, Shay, Weintraub et al., 
2003; Wong, Chan, Hedley et al., 2004; Chow, Ma, Ling et al., 2006).
The number of influenza-related deaths in France between 1980 and 1990 was 
estimated at 11-81 per 100,000 populations. However, this mortality rate was 
underestimated because many deaths attributable to influenza were registered as 
deaths from other causes (e.g. lung disease, heart disease). Final calculations of this 
statistic suggested total estimated death rates ranged from 28 per 100,000 populations 
(1988-89) to 482 per 100,000 populations (1985-86) (Carrat & Valleron, 1995). There 
were an estimated 30,000 excess deaths occurring during the 56 days of one influenza 
epidemic (17 November 1989 -  11 January 1990) in England and Wales (Ashley, 
Smith, & Dunnell, 1991). Additionally, the study conducted in the United States by 
Thompson, Shay, Weintraub et al. (2003) showed that annual estimates of influenza- 
associated deaths from pneumonia and influenza, respiratory and circulatory, and all 
causes increased markedly between 1976-77 and 1998-99. Influenza-associated 
deaths for pneumonia and influenza (P&I), circulatory and respiratory deaths (C&R), 
and all causes in persons aged 65 or older were 22.1, 98.3, and 132.5 per 100,000 
person-years, respectively. Persons aged 65 years or older accounted for 90 per cent 
of deaths attributed to pneumonia and influenza during 1990-1999. Influenza caused 
more deaths than respiratory syncytial virus in all age groups, except for children 
younger than 1 year. Another study conducted in Canada by Menec, Black, 
MacWilliam et al. (2003) showed a similar result; significant excess mortality rates
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due to influenza and pneumonia and chronic lung disease were evident among the 
elderly and nursing home residents. Influenza also posed a serious threat for diabetic 
persons. Excess mortality rates due to pneumonia and influenza were observed among 
these high-risk individuals in southern Wisconsin during 1980-1988 (Moss, Klein, & 
Klein, 1991).
Among pregnant women, there is concern that influenza during pregnancy is 
associated with an increase risk for maternal and foetal complications (Neuzil, Reed, 
Mitchel et al., 1998; Irving, James, Stephenson et al., 2000). Most previous studies 
have assessed the effect of influenza on pregnant women during influenza season. 
However, influenza-related hospitalisations in pregnant women have been measured 
in terms of excess hospitalisations for respiratory illness but not laboratory-confirmed 
influenza hospitalisation. During the influenza season, there was a higher rate of 
outpatient medical services for acute respiratory disease among pregnant women 
relative to non-pregnant women (Mullooly, Barker, & Nolan, 1986). In addition, 
hospitalised pregnant women with respiratory illness had a longer length of stay than 
those without respiratory illness. The average length of hospital stay among pregnant 
women with respiratory illness was 3.88 days for non-delivery and 6.36 days for 
delivery, whereas the average length of stay among those without respiratory illness 
was 2.69 days for non- delivery and 2.45 days for delivery (Cox, Posner, McPheeters 
et al., 2006).
Hospitalisations with respiratory illness among pregnant women were significantly 
higher in seasons when the prominent H3N2 influenza A circulating (Cox, Posner, 
McPheeters et al., 2006). A recent population-based cohort study of 33,775 pregnant 
women conducted over a study period of 13 years has found that the rate of third- 
trimester hospital admissions among pregnant women during influenza season was 
five times higher than the rate during the influenza season in the year before 
pregnancy (Dodds, McNeil, Fell et al., 2007). Moreover, the rate of hospital 
admissions during the third trimester of pregnancy was more than twice as high as 
the rate during the non-influenza season. An estimated 1,210 additional hospital 
admissions in the third trimester per 100,000 pregnant women with co-morbidities 
and 68 per 100,000 pregnant women without co-morbidities during the influenza 
season has been documented (Dodds, McNeil, Fell et al., 2007).
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In a retrospective cohort study among 3975 pregnant women who were consecutively 
delivered at two Nottingham teaching hospitals, Irving, James, Stephenson et al. 
(2000) found significant differences in the pregnancy complications between the cases 
and controls. The pregnant women whose paired ante- and postnatal sera showed a 
rise in anti-influenza titres (cases) had more foetal, medical and obstetric 
complications (e.g. reduced fetal movements, preterm, pneumonia, pulmonary 
embolus, atrial fibrillation, bleeding, post dates induction) than the controls (106/181 
vs. 73/180,/? <0.001). By contrast, another study showed that there was no increased 
risk for adverse perinatal outcomes among pregnant women with respiratory 
hospitalisations during influenza season (Hartert, Neuzil, Shintani et al., 2003). The 
UK study also found a non-significant increased risk for low birth weight, low Apgar 
score and congenital anomalies among newborns of infected mothers with laboratory- 
confirmed influenza during the second and third trimesters of pregnancy (Irving, 
James, Stephenson et al., 2000).
2.12.2 Morbidity and mortality associated with influenza among children 
in temperate countries
Influenza illness is a leading cause of visits to medical practices and emergency 
departments among children younger than five years. A recent study conducted in the 
US. by Poehling, Edwards, & Weinberg (2006) revealed that the estimated rates of 
outpatient and emergency department visits associated with influenza were 50-95, and 
6-27 per 1000 children younger than 5 years, respectively in the two consecutive 
influenza seasons (2002-03 and 2003-04).
A higher rate of outpatient visits or emergency department visits for infectious 
respiratory illness, including influenza among children younger than five years of age 
was also found in other studies (Neuzil, Mellen, Wright et al., 2000; Neuzil, Zhu, 
Griffin, et al., 2002; Bourgeois, Valim, Wei et al., 2006). The excess use of antibiotics 
in children younger than 15 years of age has also been observed during the influenza 
season (Neuzil, Mellen, Wright et al., 2000). In addition, Neuzil, Mellen, Wright et al. 
(2000) found that the rates of influenza-related hospitalisations were higher among 
infant and young children, and the hospital admission rates declined significantly with 
increasing age (104 per 10,000 children younger than 6 months, 50 per 10,000
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children aged 6 months to less than 12 months, 19 per 10,000 children aged 1 year to 
less than 3 years, 9 per 10,000 children age 3 years to less than 5 years, and 4 per
10.000 children aged 5 years to less than 15 years).
Recently, a retrospective cohort study that measured hospitalisation rates for 
laboratory-confirmed influenza over three influenza seasons in children 18 years of 
age and younger provided similar results. The population-based rates of 
hospitalisation ranged from 6.3 to 252.7 per 100,000 children; hospitalisation 
attributable to influenza was highest in children younger than 6 months (252.7 per
100.000 children), and rates decreased in older children (Ampofo, Gesteland, Bender 
et al., 2006). In addition, a four-fold difference in the rate of hospitalisations from 
influenza was found between children aged up to 6 years old with asthma and healthy 
children of the same age (Miller, Griffin, Edwards et al., 2008). However, influenza- 
related deaths are rare among children. It is estimated that the excess number of 
deaths attributable to influenza is 8 per million in children younger than 15 years of 
age (Neuzil, Mellen, Wright et al., 2000).
2.12.3 Morbidity and mortality associated with influenza in tropical and 
subtropical countries
Unlike the temperate countries, the burden of influenza in tropical countries has not 
been well documented. This is partly because these countries are in the process of 
developing an influenza surveillance system, limiting the use of such surveillance data 
to reflect the true picture for influenza disease burden (Simonsen, 1999). Additionally, 
influenza occurs year-round, and seasonality is less defined in tropical country. These 
factors make it difficult to precisely quantify the burden of disease in this region 
because the year-round influenza activity probably prevents the detection of excess 
morbidity and mortality associated with influenza. However, recent studies have 
shown that influenza also causes an increase in hospitalisations and deaths in tropical 
and subtropical countries.
One study conducted in Hong Kong using the Poisson regression method to estimate 
influenza-related mortality found that influenza was responsible for approximately
29.3 additional pneumonia and influenza hospitalisations per 100,000 across all ages 
during 1996-2000 (Wong, Yang, Chan et al., 2006). This was comparable to those
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reported in temperate countries such as the United States. The study by Thompson, 
Shay, Weintraub et al. (2004) using the same method to estimate excess influenza- 
associated hospitalisations during 1979-2001 found that the annual average rate of 
pneumonia and influenza hospitalisations was 36.8 per 100,000 population for all 
ages. Similarly, a retrospective study in a tertiary hospital in the tropics showed that 
influenza was associated with excess hospitalisations for pneumonia, acute 
exacerbations of COPD, and heart failure in persons aged 65 or older. Influenza 
activity accounted for 38.9, 7.5, and 45.6 of the variance in hospital admissions for 
pneumonia, COPD, and heart failure, respectively. The adjusted rates of excess 
influenza-related hospitalizations for these three diagnoses were 585, 200, 292 and 
134 excess hospitalisations per 100,000 elderly persons in 1998, 1999, 2000, and 
2001, respectively (Yap, Ho, Lam et al., 2004).
Ng, Pwee, Niti et al. (2002) assessed the burden of illness in the community in 
Singapore, and found that there were 630,000 cases of influenza-like illness, resulting 
in 520,000 medical visits each year. In Thailand, a prospective, population-based 
surveillance system and laboratory found that children younger than 5 years of age 
and the elderly have the greatest incidence of influenza pneumonia (236 per 100,000 
and 375 per 100,000, respectively). It was estimated that there would be 
approximately 36,413 annual hospitalisations and 322 in-hospital deaths for influenza 
pneumonia in Thailand during 2005-2008 (Simmerman, Chittaganpitch, Levy et al.,
2009).
Influenza-associated mortality rates, especially among elderly people in tropical and 
subtropical climates were higher in Singapore and Hong Kong than in the United 
States. Chow, Ma, Ling, et al. (2006) using a statistical model to estimate influenza- 
associated mortality in Singapore found that influenza-associated deaths for 
pneumonia and influenza (P&I), circulatory and respiratory deaths (C&R), and all 
causes in persons aged 65 or older were 46.9, 155.4, and 167.8 per 100,000 person- 
years, respectively. Moreover, these estimates of influenza-associated deaths were 
higher than those reported in Hong Kong (39.3 pneumonia and influenza deaths per
100.000 persons, 102.0 circulatory and respiratory deaths per 100,000 persons, and
136.1 all-cause deaths per 100,000 persons) and in the United States (22.1 per
100,000 persons from underlying P&I deaths, 98.3 per 100,000 persons from
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underlying circulatory and respiratory deaths, and 132.5 per 100,000 persons from all­
cause deaths) (Thompson, Shay, Weintraub et al., 2003; Wong, Chan, Hedley et al., 
2004; Chow, Ma, Ling et al., 2006).
2.12.4 The costs associated with influenza
Seasonal influenza epidemics can have an economic impact on both society and the 
individual. A number of studies have attempted to assess the full economic impact 
of influenza, which includes direct medical costs and indirect costs, such as lost 
productivity from illness and lost earnings due to loss of life (Meltzer, Cox, & Fukuda 
1999; Akazawa, Sindelar, & Palteil, 2003; Molinari, Ortega-Sanchez, Messonnier et 
al., 2007). A recent study estimating the annual impact of seasonal influenza in the 
US based on 2003 population demographics indicated that there were an estimated 
41,008 deaths (610,660 life-years lost), 3.1 million hospitalised days and 31.4 million 
outpatient visits annually, resulting in direct medical costs of $US 10.4 billion (95% 
confidence interval [C.I.], $US 4.1 - $US 22.2) annually. The total annual economic 
burden of influenza in the United States has been estimated at $US 87.1 billion, 
including $US 10.4 billion in direct medical costs and $US 76.7 billion in indirect 
costs. The indirect costs of influenza were estimated to account for 88 per cent of the 
total economic burden of influenza; the majority of these indirect costs were produced 
as a result of lost productivity (Molinari, Ortega-Sanchez, Messonnier et al., 2007).
The economic burden of influenza was further illustrated in a cost analysis by Newall 
& Scuffham (2008) who found that annual epidemics of seasonal influenza resulted in 
an average of 310,000 general practitioner consultations, and 18,404 hospital 
admissions (95% Cl: 15,918 - 20,889). The cost for the treatment of influenza-related 
illness alone in a typical season in Australia has been estimated at A$ 115 million per 
year (range A$ 72.3-A$ 170.1 million). In Thailand, a recent study that estimated the 
burden of influenza in hospitalised pneumonia and outpatient febrile respiratory 
illness with laboratory confirmed influenza has shown that the total economic costs of 
influenza has been estimated to be between US$ 23.4 and US$ 62.9 million during 
September 2003 and August 2004, and lost productivity accounted for 56 per cent of 
all costs (Simmerman, Lertiendumrong, Dowell et al., 2006).
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Influenza illness also results in work loss. It was estimated that 10-12 per cent 
of all sickness absence from work is attributable to influenza (Keech, Scott, & Ryan,
1998). Moreover, after returning to work, approximately 80 per cent of adults had 
impaired work performance (Adams & Marano, 1994, cited in Keech & Beardworth,
2008). In the United States alone, it was estimated that influenza-like illness 
accounted for more than 79 million working days lost each year (Benson & Marano, 
1998, cited in Keech & Beardworth, 2008). Similarly, a cost-of-illness study based on 
the data from German Sickness Funds indicated that the economic costs of influenza 
epidemic in 1997 was approximately two billion Deutschmarks (DM), and the costs 
were mainly associated with lost work productivity and medical treatment (Szucs,
1999). The indirect costs due to lost productivity from influenza illness were further 
demonstrated by Simmerman, Lertiendumrong, Dowell et al. (2006). This study 
conducted in Thailand and showed that hospitalised influenza pneumonia resulted in 
approximately 118,335 to 941,567 lost workdays. Additionally, a recent study 
quantifying the impact on working days lost due to influenza- like illness indicated 
that the mean number of missed work days after being diagnosed with influenza 
ranged from 3.7 to 5.9 days per episode (Keech & Beardsworth, 2008), and the 
average work loss due to influenza-like illness was estimated at US $137 per person 
(Akazawa, Sindelar, & Palteil, 2003).
With regard to the burden of influenza in children, a retrospective cohort study of 
children aged younger than 21 years who were hospitalised with laboratory-confirmed 
influenza by Keren, Zaoutis, Saddlemire et al. (2006) has shown that the burden of 
influenza-related hospitalisation in children is greater than previously appreciated. 
The mean total cost of hospitalisation attributable to influenza ranges from US$ 7,030 
(interquartile range [IQR]: 3372 - 7309) for patients cared for exclusively on the 
wards to US$ 39,792 (IQR: 10634 - 44942) for those admitted to an ICU. Children 
with chronic disease (such as cardiac disease, neurological or neuromuscular disease) 
had higher mean total costs (US$ 15,269) than those in the low risk group (US$ 
9,107). This retrospective cohort study over three influenza seasons at Primary 
Children’s Medical Centre, Utah, USA also revealed that children aged two years and 
over had higher rates of pneumonia, intensive care stay, and mechanical ventilation 
than younger children, leading to longer hospital stays and higher hospital cost of 
care. The total direct cost attributable to the treatment of influenza over a 3-year
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period (July 2001-June 2004) was US$ 2 million. Children aged two years and older 
were responsible for 55 per cent of the total direct costs. Moreover, forty five per cent 
of these children did not have chronic medical conditions that place them at risk of 
influenza complications (Ampofo, Gesteland, Bender et al., 2006).
The indirect burden of influenza in terms of secondary respiratory illness in families 
of children with influenza, work and school day loss was demonstrated by two 
studies. In Italy, a prospective study comparing clinical and socio-economic impact of 
influenza and respiratory syncytial virus (RSV) infection in children aged 15 years or 
younger who attended an emergency department found that children with influenza 
were absent significantly more than RSV-positive children (median, 12 vs. 5 days). 
Furthermore, secondary attack rates, medical visits, antipyretic use and the number of 
parent days lost from work were significantly higher in families of influenza-positive 
children compared with the families of RSV-positive children (Esposito, Gasparini, 
Bosis et al., 2005).
A recent study by Tsolia, Logotheti, Papadopoulos et al. (2006) also demonstrated an 
impact of influenza in healthy children and their families. Secondary respiratory 
illness was more prevalent in family members of influenza-positive children; the 
estimated secondary infection rate was 17 per cent. Parents lost an average of 1.34 
workdays for taking care of sick children and 0.36 days for their own illness.
2.13 Conclusion
This chapter aimed to provide a greater understanding of influenza infection and its 
impact on health and society. It revealed that influenza is a highly contagious 
respiratory disease caused by the influenza virus and occurs globally, though is more 
prevalent in temperate countries during the winter months. Influenza epidemics pose a 
substantial burden on healthcare systems around the world. Influenza can affect 
people of all ages. However, older people and vulnerable populations can suffer more 
severe illness and a more rapid deterioration. Influenza infection is characterised by 
an abrupt onset of fever, muscles ache and pain, headache, fatigue, sore throat, and a 
dry cough. Influenza can be difficult to diagnose based on clinical features alone 
because its symptoms are similar to those of other upper respiratory conditions, such 
as a common cold. There are several laboratory methods for the detection of influenza
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infection. These include virus isolation in cell culture, direct antigen detection, 
detection of influenza-specific RNA by reverse transcriptase-polymerase chain 
reaction (RT-PCR), and serologic diagnosis. The choice among these diagnostic tests 
depends on the turnaround time for reporting of the results and cost. Currently, there 
are four antiviral drugs (amantadine, rimantadine, oseltamivir, and zanamivir) 
available for the treatment and prophylaxis of influenza. The influenza vaccine is the 
best means of preventing influenza and its complications. More details about the 
vaccine development process, type of vaccine, and the efficacy and safety of influenza 
vaccination will be presented in the next chapter.
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Chapter 3: Influenza vaccine
3.1 Introduction
Influenza viruses have long-been with humankind for centuries, causing seasonal 
epidemics every year and pandemics every few decades. It is generally accepted that 
“Influenza vaccine is the most effective preventive measure available” (WHO, 
2005a). The vaccine has been proven to be safe and effective in preventing influenza 
and its serious complications across all age groups (Gross, Hermogenes, Sacks et al., 
1995; Nichol, 2001, 2003; Hak, Buskens, van Essen et al., 2005; Looijmans-Van den 
akker, 2006; Poole, Chacko, Wood-Baker et al., 2006).
3.2 History of vaccine
The term “vaccination” is originally derived from Latin word “vacca” meaning cow, 
and it was first used in 1796 by Edward Jenner, who demonstrated the scientific 
principles of smallpox prevention by using cowpox virus to vaccinate people against 
the disease. Influenza vaccine successfully developed by the scientists in the 1940s, 
and was first used by the U.S military during the Second World War (Smith, 
Andrewes, & Laidlaw, 1933; Francis & Magill, 1937; Hilleman, 1998; Hilleman, 
2000; Kamps, Hoffmann, & Preiser, 2006). Since then, significant progress has been 
made to develop a safe and effective influenza vaccine. At present, almost 300 million 
doses of trivalent influenza vaccines are distributed worldwide each year. Most of 
these vaccines are produced in nine countries: the United Kingdom, the United States, 
Germany, Canada, France, Italy, Netherlands, and Japan. Sixty two per cent of the 
influenza vaccines are also used in these countries. According to the current global 
vaccine-production capacity, it could be possible to produce around 900 million doses 
of pandemic vaccines (monovalent vaccine which contains only the pandemic 
influenza virus strain) when the next influenza pandemic occurs (Gerdill, 2003; van 
Essen, Palache, Forleo et al., 2003; WHO, 2004; Fedson, 2005; MIV study group,
2005).
3.3 The vaccine development process
The production of a new influenza vaccine is a complex process that involves several 
sequential steps and generally takes around six months. As two surface glycoproteins, 
HA and NA, of the influenza virus continually change by mutation, the WHO
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coordinates the international surveillance network to monitor the global 
epidemiological situation. Biannually, the WHO announces the virus strains which are 
likely to be circulating in the forthcoming influenza season to aid the production of a 
matched vaccine. Influenza vaccine contains one influenza A (H3N2) virus, one 
influenza A (H1N1) virus, and one influenza B virus. The recommendation for 
influenza vaccine composition for use in the forthcoming influenza season will be 
made by the WHO in February for influenza vaccines for use in the northern 
hemisphere. Likewise, the recommended composition of influenza virus vaccines for 
use in the southern hemisphere will be issued in September.
As the circulation of influenza and seasonal pattern are less defined in equatorial 
regions, epidemiological considerations will influence which recommendations 
(February or September) are appropriate for vaccine used in these regions. Through 
this process, the influenza vaccine for use in the 2010-2011 Northern hemisphere 
winter will contain the following influenza viruses: A/Califomia/7/2009(HlNl); 
A/Perth/ 16/2009 (H3N2); and B/Brisbane/60/2008. As the 2009 pandemic influenza 
A (H1N1) is expected to continue to occur during the 2010-11 influenza season, 
influenza A (H1N1) 2009 is included in the upcoming influenza vaccine, as well as 
the H3N2 influenza A component has been changed from A/Brisbane/10/2007 
(H3N2) in the 2009-2010 to A/Perth/16/2009 (H3N2) in the 2010-2011 formulation. 
The influenza B virus strain used in this composition is the same strain used in the 
2009 seasonal influenza vaccine. This recommendation was based on surveillance 
data related to epidemiology and antigenic characteristics of influenza virus strains 
circulating in the next year (WHO, 2010c; CDC, 2010a).
Once the recommendations for influenza vaccine composition for the forthcoming 
season have been issued, the preparation of vaccine virus needs to be done by the 
WHO in order to make the vaccine virus less dangerous and also safety. The seasonal 
influenza virus strain is mixed with an A/PR8/34 (a standard laboratory virus strain 
which is attenuated and unable to replicate in humans), and these viruses grow 
together, allowing the production of high-growth reassortants. These hybrid viruses 
contain both components of the laboratory strain and the seasonal influenza virus 
strain. The hybrid viruses are tested to make sure that they produce surface proteins 
(HA and NA) of the seasonal influenza virus and grow well in hen’s eggs. After
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verification of the vaccine strain, the hybrid vaccine viruses are then distributed to 
vaccine manufacturers for use in vaccine production. In parallel, the WHO 
collaborating centres produce official reference reagents (standardized substances) 
that are provided to all vaccine manufacturers. The reference reagents will be used to 
verify the antigenic content and the immunogenetic capacity of the commercial 
vaccines. The new vaccine viruses are injected into thousands of eggs which are 
incubated for two to three days to allow the virus to multiply. These viruses are then 
harvested, separated from the egg white, inactivated using formaldehyde or p- 
propiolactone and disrupted with detergent. The surface proteins of viruses (subunit 
hemagglutinin and neuraminidase) are subsequently purified, resulting in production 
of thousands of litres of purified virus protein for use as antigen which is the active 
ingredient in the influenza vaccine. In order to control quality, each lot of vaccine 
antigen is tested and verified with the WHO reference reagents. Finally the bulk 
vaccine is diluted to the desired concentration, packed, labelled and delivered. The 
summary of the influenza vaccine manufacturing process is shown in figure 3.3 
(Gerdil, 2003; Treanor, 2004; Kamps, Hoffmann, & Preiser, 2006; WHO, 2009; CDC, 
2 0 1 0 a).
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Figure 3.3 The process of development and manufacturing of influenza vaccines. 
Source: Treanor, 2004
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3.4 Type of influenza vaccine
At present, there are two types of influenza vaccines available: trivalent inactivated 
influenza vaccine (TIV) and live, attenuated influenza vaccine (LAIV). Inactivated 
can be further divided into intact (whole virus), split/subvirion, and sub-unit (purified 
surface antigen) influenza vaccines. Sub-unit vaccines contain highly purified 
antigens (HA and NA) instead of the whole virus, and therefore have less potential for 
adverse reactions, especially fever. Split and sub-unit influenza vaccines are as 
immunogenic as whole virion vaccine (Stephenson & Nicholson, 2001; Treanor, 
2005). In inter-pandemic years, influenza vaccines contain two influenza A subtypes 
(H1N1 and H3N2), and one influenza B strain (trivalent inactivated influenza 
vaccine), whereas during the influenza pandemic, vaccine may contain only a strain 
that causes the influenza outbreak (monovalent vaccine). Although both types of 
influenza vaccines, TIV and LAIV, are effective against the influenza virus, the 
vaccines have several important differences (LaForce, Nichol, & Cox 1994; Nichol, 
2001, 2003; Stephenson & Nicholson, 2001; CDC, 2009b).
3.4.1 Trivalent inactivated influenza vaccine
Trivalent inactivated influenza vaccines (TIV) are made from killed viruses. 
Therefore, the vaccines can provide protection against seasonal influenza but do not 
cause influenza illness. TIV is approved for use in any persons aged six months or 
older, including healthy people and those with chronic medical conditions (LaForce, 
Nichol, & Cox 1994; Treanor, 2005; CDC, 2008, 2009b). Each 0.5 mL dose of the 
2009-10 trivalent inactivated influenza vaccine contains 15 pg of hemagglutinin from 
each of the following strains: A/Brisbane/59/2007 (HlNl)-like, A/Brisbane/10/2007 
(H3N2)-like, and B/Brisbane 60/2008-likes. Preservatives (e.g. thimerosal) are added 
in multi-dose vials to prevent microbial growth. Inactivated, thimerosal preservative- 
free 0.5 mL, single dose vial or pre-filled syringes are also available (CDC, 2009b; 
WHO, 2009). TIV should be stored in a refrigerator between 2-8°C. Vaccine that is 
exposed to freezing temperatures must not be used (CDC, 2009b).
As the whole virus vaccine is associated with febrile reactions, only split-virus 
vaccine is recommended for children 12 years of age or younger (Campos-Outcalt,
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2004). Accordingly, at present the whole virus vaccines are less frequently used than 
split or subunit vaccines and unlicensed in many countries (Stephenson & Nicholson,
2001). TIV is administered by intramuscular injection. The deltoid muscle is the 
recommended site of vaccination, and the needle should be one inch or more in length 
(> 25 mm) for adolescents and adults immunisations, as this length allows for 
penetration to reach in the muscle tissue. For infants and young children, the 
anterolateral aspect of the thigh is the preferred site for vaccination. A needle length 
of 7/8-1 inch should be used for children younger than 12 months of age. The dosage 
recommendations vary according to age groups (see Table 3.4.1). Children aged less 
than nine years need two doses of influenza vaccines for full immunity in the first 
year, and these should be separated by four weeks. If these children received only one 
dose of vaccine in their first year, they should receive two doses in the following year 
(Campos-Outcalt, 2004; CDC, 2009b).
Table 3.4.1 Influenza vaccine dosage, by age of patient
Age group Producta Dosage Number of 
doses
Route
6-35 months Split virus only 0.25 mL 1 or 2 b Intramuscular
3-8 years Split virus only 0.50 mL 1 o r2 b Intramuscular
9-12 years Split virus only 0.50 mL 1 Intramuscular
Over 12 years Whole or split virus 0.50 mL 1 Intramuscular
Note’. a Because of the lower potential for causing febrile reactions, only split-virus vaccines 
should be used in children. They may be labelled as “split”, “subvirion”, or “purified- 
surface- antigen” vaccine. Immunogenicity and side-effects of split-virus and whole-virus 
vaccines are similar in adults when vaccines are used at the recommended dosage. 
b Two doses are recommended for children younger than 9 years of age who are receiving 
influenza vaccine for the first time.
Source: Campos-Outcalt, 2004; CDC, 2009b
3.4.1.1 Immune response
After influenza infection or immunisation with trivalent inactivated influenza vaccine, 
the protection against influenza virus is mainly connected with an increasing of 
haemagglutination-inhibiting (HAI) antibody in serum, which inhibits influenza virus
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attachment to respiratory epithelial cells and neutralise virus infectivity (Kilboume, 
Laver, Schulman et al., 1968; Clements, Betts, Tierney et al., 1986; Brydak & 
Machala, 2000; Brydak, Machala, Mysliwska et al., 2003). Haemagglutination- 
inhibiting antibody is first detectable between four and seven days after infection or 
immunisation, and peak titres were found at 14 - 21 days (Potter & Oxford, 1979; 
Gross, Russo, Dran et al., 1997). This HAI antibody in serum could persist for several 
months (or even years). Haemagglutination-inhibiting antibody titres of 
approximately 1:30 - 1:40 are considered positive for antibody against influenza 
infection and its complications (Potter & Oxford, 1979; Brydak & Machala, 2000; 
Stephenson & Nicholson, 2001; Hannoun, Megas, & Piercy, 2004). The presence of 
HAI antibody has also been found to reduce the severity of influenza illness (Morris 
et al., 1966 cited in Potter & Oxford, 1979; Brydak & Machala, 2000; Couch, 2000; 
Hannoun, Megas, & Piercy, 2004).
Additionally, antibody to the virus neuraminidase has been detected following 
immunisation with influenza vaccine and contributes to immunity against influenza 
virus infection (Kilboume, Laver, Schulman et al., 1968; Kilboume, Couch, Kasel et 
al., 1995; Brydak, Machala, Mysliwska et al., 2003). Unlike the HAI antibody, the 
neuraminidase inhibiting (NI) is non-neutralising antibody and plays a major role in 
limiting the spread of vims from infected cells; thus the NI antibody does not prevent 
infection, but helps to reduce the severity and duration of influenza infection 
(Kilboume, Laver, Schulman et al., 1968; Kilboume, Couch, Kasel et al., 1995; 
Brydak & Machala, 2000; Brydak, Machala, Mysliwska et al., 2003). This NI 
antibody has also been found to stimulate the immune response to subsequent 
influenza infection (Potter & Oxford, 1979). A lower incidence of influenza A 
infections which are caused by the influenza A/Hong Kong/6 8  (H3N2) containing a 
new haemagglutinin antigen (H3) but the same neuraminidase antigen (N2), was 
observed in individuals with NI antibody acquired by previous infection with 
influenza A H2N2 compared with those without NI antibody (Monto & Kendal, 
1973).
In addition to producing the serum HAI and NI antibodies, local antibodies (e.g. IgA 
antibody to influenza haemagglutinin) can be produced following immunisation with 
inactivated influenza vaccine (Ruben, Potter, & Stuart-Harris, 1975; Potter & Oxford,
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1979; Clements, Betts, Tierney et al., 1986). Local antibodies are detectable in nasal 
washing between four and seven days after infection or immunisation with influenza 
vaccine, reach their peak at two to three weeks and do not provide a long duration of 
immunity against influenza infection (Potter & Oxford, 1979; Couch & Kasel, 1983). 
Immunsation with inactivated influenza vaccine has also been reported to stimulate 
cytotoxic T-lymphocyte or cellular immune responses among individuals primed by 
previous influenza infection (Ennis, Yi-Hua, & Schild, 1982). T-cells might be 
important in recovery from influenza symptoms or reducing viral shedding, although 
they cannot prevent host cells from influenza infection (Yap & Ada, 1978; Ennis, Yi- 
Hua, & Schild, 1982; Bernstein, Kaye, Abrutyn et al., 1999). However, the 
importance of the local antibodies and cell-mediated immunity is probably less than 
that of specific humoral IgG antibody response to viral haemagglutinin (Ruben, 
Potter, & Stuart-Harris, 1975; Potter & Oxford, 1979; Clements, Betts, Tierney et al., 
1986).
There is currently no estimate on a protective level of anti-neuraminidase antibody. 
Accordingly, most previous studies evaluating serological responses to influenza 
vaccination were more focused on the immunological response to haemagglutinin 
(Brydak & Machala, 2000; Brydak, Machala, Mysliwska et al., 2003). A number of 
studies have been shown a converse correlation between the level of HI antibody 
titres and the susceptibility to influenza infection (Dowdle, Coleman, Mostow et al., 
1973; Masurel & Laufer, 1984; Brydak & Machala, 2000). The higher post­
vaccination HI antibody titres (120-160) are associated with the lower risk of 
influenza infection (Masurel & Laufer, 1984; Hannoun, Megas, & Piercy, 2004). 
Dowdle, Coleman, Mostow et al. (1973) examined an association of post vaccine 
serum haemagglutination-inhibition and neuraminidase inhibition titres to protect 
against Hong Kong influenza infections during the influenza epidemic of 1968-1969. 
In this study, assessment of attack rate among influenza vaccinees using fever as an 
index of disease, the results showed that the influenza attack rate which caused by 
influenza A/Hong Kong/6 8  (H3N2) among volunteers without HAI and NI antibodies 
was 45 per cent, whereas in the volunteers with presence of NI antibody, the attack 
rate was reduced to 24 per cent. Those with both HAI and NI antibodies in serum 
(titres equal to or greater than 160) experienced an attack rate of 7 per cent.
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The majority of healthy children and young adults develop high HAI antibody titres 
against influenza viruses after vaccination (Bridges, Thompson, Meltzer et al., 2000; 
Neuzil, Dupont, Wright et al., 2001; Demicheli, Pietrantonj, Jefferson et al., 2007). 
However, the influenza vaccine is less immunogenic in older people, individuals on 
immunosuppressive therapy and those with chronic diseases such as renal disease, 
diabetes mellitus, cancer and haemophilia (Ershler, 1988; Brydak & Machala, 2000; 
Treanor, 2005). Beyer (1989) reviewed thirty studies measuring the humoral immune 
response following vaccination, and the results showed a decreased humoral immune 
response with age in ten studies. In addition, there is evidence that the use of higher 
doses of influenza vaccine and administration of a booster dose one month after the 
first dose of vaccine have not been demonstrated to enhance immune response in the 
elderly (Gross, Weksler, Quinnan et al., 1987; Levine, Beattie, & Mclean 1987; 
Gravenstein, Miller, & Drinka, 1992).
3.4.1.2 The efficacy and effectiveness of trivalent inactivated influenza vaccine
The protective effect of inactivated influenza immunisation is influenced by a number 
of factors, including the degree of similarity between vaccine viruses and those in 
circulation, how the vaccine is administered, and the characteristics of the target 
population (e.g. age, co-morbidity, use of concurrent medications, prior influenza 
vaccination, and pre-vaccination HI antibody titres) (Demicheli, Jefferson, Rivetti et 
al., 2000; Hannoun, Megas, & Piercy (2004). The ability of a vaccine to elicit 
protective immunity can be assessed by considering the vaccine efficacy (the percent 
reduction in the incidence of influenza illness among vaccinated and unvaccinated 
persons in controlled trials) and vaccine effectiveness (the level of vaccine protection 
under ordinary field conditions). Thus, the effectiveness of a vaccine depends not only 
on its efficacy, but also on the conditions of its intended use and the characteristics of 
the target population (Comstock, 1994).
There are a number of multiple possible outcome measures that have been used 
to assess the efficacy and effectiveness of influenza vaccine in the previous studies 
such as the prevention of medically attended acute respiratory illness (MAART), 
prevention of lab-confirmed influenza infection and prevention of influenza-related 
to hospitalisations or deaths (CDC, 2008). Among these measures, lab-confirmed
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influenza infection is considered “the gold standard” for many studies assessing 
vaccine efficacy, as it provides more specific outcome information than others 
(Nichol & Treanor, 2006; CDC, 2008).
A single dose of trivalent inactivated influenza vaccine injection has been found to 
elicit protective immune responses against influenza virus among healthy adults aged 
younger than 65 years of age. The trivalent inactivated influenza vaccine has been 
shown to be 70-90 per cent effective in preventing influenza infection among healthy 
adults in randomised controlled trials when the vaccine viruses are well matched to 
the circulating strains (Nichol, Lind, Margolis et al., 1995; Cambell & Rumley, 1997; 
Bridges, Thompson, Meltzer et al., 2000; Demicheli, Pietrantonj, Jefferson et al., 
2007). In addition, vaccination has been shown to reduce absenteeism and the cost of 
influenza-like illness in healthy, working adults when there is well-match between 
vaccine and circulating viruses (Demicheli, Pietrantonj, Jefferson et al., 2007; 
Maciosek, Solberg, Coffield et al., 2006; Campbell & Rumley, 1997; Nichol, Lind, 
Margolis et al., 1995). A prospective study conducted in North Carolina workers 
showed that vaccinated employees were significantly less likely to report an 
influenza-like illness than unvaccinated employees (20 per cent vs. 49 per cent). This 
resulted in a substantial reduction in lost work days among vaccinated employees (43 
and 93 lost work days in vaccinated and unvaccinated employees). The cost savings 
were estimated to be $22 per saved lost workday (Campbell & Rumley, 1997).
Similarly, a double-blind, placebo-controlled trial by Nichol, Lind, Margolis et al. 
(1995) found that vaccination against influenza in healthy adults in the workplace 
resulted in decreased absenteeism from work and physician visits by 43 per cent and 
44 per cent, respectively. The potential cost-savings was also reported, and it was 
estimated to be $46.85 per person vaccinated (Nichol, Lind, Margolis et al., 1995). 
The ability of vaccine to reduce influenza-like illness and physician visits and work 
absenteeism was further demonstrated by Bridges, Thompson, Meltzer et al. (2000) 
who conducted a double-blind, randomised, placebo-controlled trial during two 
influenza seasons. Their results showed that significant lower rates of reported 
influenza-like illness, physician visits, and work absenteeism were reported among 
vaccine recipients. In addition, influenza vaccination of healthy working adults was 
shown to provide societal economic benefits in the year in which vaccine strains were
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antigenically similar to the circulating viruses (Bridges, Thompson, Meltzer et al., 
2000). In addition to conferring protection against influenza infection, the influenza 
vaccine was reported to decrease viral shedding by 38.8 per cent (Keitel, Cate, Couch 
1997). This helps to reduce the risk of spreading the influenza virus to other people.
The vaccine's effectiveness appears substantially lower when vaccine viruses are not 
closely related antigenically to epidemic strains. A case-control study assessing the 
influenza vaccine effectiveness among people aged 50-64 years which was conducted 
in a season with suboptimal antigenic match, found that vaccine effectiveness was 
60 per cent and 48 per cent (compared to 70-90 per cent immunity conferred by more 
closely matched vaccines) among individuals without and with high-risk medical 
chronic conditions, respectively (Herrera, Iwane, Cortese et al., 2007). A double­
blind, randomised, placebo-controlled trial by Bridges, Thompson, Meltzer et al. 
(2000) also illustrated that vaccine efficacy was 50 per cent when there was a poor 
match between vaccine and the predominant circulating viruses.
A recent randomised, double-blind, placebo-controlled trial conducted in Michigan 
during the 2004-2005 influenza season, when vaccine viruses were antigenically 
dissimilar to the majority of circulating strains, indicated that the absolute efficacy of 
the inactivated influenza vaccine ranged from 67 per cent (95% Cl, 16-87) to 77 per 
cent (95% Cl, 37 to 92) in preventing laboratory-confirmed influenza in healthy 
adults, depending on the laboratory method for measurement of influenza antigen and 
antibody; the inactivated influenza vaccine had 77 per cent efficacy against 
laboratory-confirmed influenza for influenza cases diagnosed using isolating the virus 
in cell culture, 75 per cent efficacy for influenza cases diagnosed using either by 
isolating virus or real-time PCR and 67 per cent efficacy for influenza cases 
diagnosed using either by isolating virus or observing a rise in the serum antibody 
titre (Ohmit, Victor, Rotthoff et al, 2006).
Previous studies have reported conflicting results regarding the effectiveness of 
influenza vaccine in the high-risk populations. Several studies found that influenza 
vaccine offered less protection against influenza in older people and those with 
chronic medical conditions than healthy adults (e. g. pulmonary disease, renal disease, 
diabetes mellitus, heart disease, and cancer) (Keren, Segev, Morag et al., 1988;
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Govaert, Thijs, Masurel et al., 1994; Beyer, Palache, Baljet et al, 1989; Brydak, 
Machala, Centkowski et al., 2006), while others have documented the effectiveness of 
inactivated influenza vaccine in these high-risk individuals, particularly its 
effectiveness in reducing hospitalisations and deaths among elderly people and those 
under age of 65 years with chronic medical conditions (Gross, Hermogenes, Sacks et 
al., 1995; Dorrell, Hassan, Marshall et al., 1997; Nichol, Wuorenma, & Sternberg, 
1998; Plusa, Brydak, Jahnz-Rozyk, et al., 2004; Hak, Buskens, van Essen et al., 2005; 
Looijmans-Van den akker, Nichol, Verheij, et al., 2006; Poole, Chacko, Wood-Baker 
et al., 2006).
In Argentina, a randomised control study conducted by Gurfinkel, Leon de la Fuente, 
and Mendiz (2004) showed that in acute coronary patients, vaccination against 
influenza caused significantly lower incidence of cardiovascular deaths at one year in 
the vaccine recipients compared with unvaccinated groups (6  per cent vs. 17 per cent, 
hazard ratio 0.34; 95% Cl, 0.17 to 0.71). Similarly, a more recent randomised, double­
blind, placebo-controlled study conducted in Poland, during the 2004-2005 season in 
658 coronary artery disease patients by Ciszewski, Bilinska, Brydak et al. (2008) 
found that vaccinated persons had a lower rate of coronary ischaemic events (major 
adverse cardiac events: MACE or hospitalisation for myocardial ischaemia) during 
the 12-month follow up compared to the placebo group (6.02 per cent vs. 9.97 per 
cent, hazard ratio 0.54; 95% Cl, 029-0.99, p  = 0.047).
However, at the moment, influenza vaccination has already been recommended for 
populations at high risk of influenza-related complications regardless of their age, it is 
unethical to conduct placebo-controlled trials. Accordingly, cohort or case control 
studies are used for the most recent research related to the assessment of efficacy, 
effectiveness of the influenza vaccine in the high-risk groups, including the elderly 
and persons with chronic diseases (CDC, 2008). Numerous observational studies of 
influenza vaccine have demonstrated substantial benefits of influenza vaccination 
among high-risk persons (Nichol, Wuorenma, & Sternberg, 1998; Hak, Buskens, van 
Essen et al., 2005; Looijmans-Van den akker, Nichol, Verheij, et al., 2006; Poole, 
Chacko, Wood-Baker et al., 2006). A case-control study of the clinical effectiveness 
of influenza vaccine conducted in the Netherlands during the 1999-2000 influenza 
season by Hak, Buskens, van Essen et al. (2005) found that influenza vaccination was
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associated with a 87 per cent reduction in hospitalisation for acute respiratory disease 
or cardiopulmonary disease and a 78 per cent reduction in deaths attributable to any 
cause among adults aged 18-64 years with chronic medical conditions.
Similar results were observed by Looijmans-Van den akker, Nichol, Verheij, et al. 
(2006) who investigated the clinical effectiveness of influenza vaccination in adult 
and elderly diabetic patients in the Netherlands. A considerable reduction in the 
incidence of the combined outcome of a hospitalisation or death (reduction of 56 per 
cent), hospitalisation (reduction of 54 per cent), and death from any cause (reduction 
of 58 per cent) in patients with diabetes was reported. A case-control conducted in 
Leicestershire, England also demonstrated that influenza vaccination prevented 79 per 
cent (95% Cl, 19-95%) of hospitalisations for people with diabetes (Colquhoun, 
Nichol, Botha et al., 1997). In the Unites States, Herrera, Iwane, Cortese, et al. (2007) 
indicated that the vaccine effectiveness was 36 per cent (95% Cl, 0-63%) in 
preventing influenza-related hospitalisation among older adults aged 50-64 years with 
high-risk conditions, although the circulating viruses were drifted from the vaccine 
strains during the 2003-2004 influenza season.
In addition, two case-control studies by Hak, Buskens, Nichol et al., (2006) and 
Looijmans-Van den akker, Nichol, Verheij, et al. (2006) have shown that during the 
two influenza seasons (1998-1999 and 1999-2000), first-time influenza vaccination in 
adult persons with high-risk medical conditions was associated with a reduction in 
hospitalisation and mortality from any cause, and these benefits increased with repeat 
vaccination in subsequent the year. This was demonstrated by Looijmans-Van den 
akker, Nichol, Verheij, et al. (2006) in a case-control study assessing clinical 
effectiveness of first and repeat influenza vaccination in patients with diabetes. A 47 
per cent reduction in hospitalisation and deaths was reported in adult diabetic patients 
vaccinated for the first time, and the reduction was 58 per cent in those who received 
vaccination in the subsequent year.
However, benefits associated with influenza vaccination among vaccinated recipients 
in these observational studies should be interpreted with caution because there are 
potentially differences (e.g. health status) between vaccinated and unvaccinated 
groups, thereby affecting the estimate of vaccine effectiveness (Jackson, Jackson,
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Nelson et al., 2006; Simonsen, Taylor, Viboud et al., 2007). More recently, a 
systematic review of eleven randomised controlled trials by Poole et al. (2006) 
indicated that influenza vaccination has been shown to significantly reduce the 
number of exacerbations in patients with COPD. In contrast, a systematic review of 
influenza vaccination among people with asthma by Cates, Jefferson, & Rowe et al. 
(2008) was unable to demonstrate the beneficial effects of influenza vaccination on 
asthma exacerbations in these high-risk individuals.
It has been suggested that the ability of older people to produce protective antibody 
levels in response to influenza vaccine may be reduced due to the decreased number 
of B-lymphocytes (Ershler, 1988; Brydak & Machala, 2000; Hannoun, Megas, & 
Piercy, 2004). Although the influenza vaccine is less effective in preventing illness 
from influenza in elderly people, it is nevertheless effective in reducing 
hospitalisations and deaths attributable to influenza in these high-risk persons 
(Fleming, Watson, Nicholas et al., 1995; Ershler, 1988; Nichol, Wuorenma, & 
Sternberg, 1998; Nichol, Nordin, Nelson, 2007; Nordin, Machala, Poblete et al., 2001; 
Hak, Nordin, Wei et al., 2002; Looijmans-Van den akker, Nichol, Verheij, et al., 
2006; Savulescu, Valenciano, de Mateo et al., 2010).
A randomised, placebo-controlled study conducted in the Netherlands during the 
1991-1992 influenza season in 1,838 healthy adults aged 60 years or older, reported 
that influenza vaccine achieved an 58 per cent (95% Cl = 26 % - 77%) efficacy in 
reduction of laboratory-confirmed influenza (Govaert, Thijs, Masurel et al., 1994). 
Several observational studies that used either cohort or case-control study were 
conducted to evaluate the clinical effectiveness of influenza vaccine in elderly people. 
Non-specific outcomes without laboratory confirmation of influenza virus infection, 
including influenza-like illness, pneumonia, influenza-related hospitalisation and 
death were assessed. A meta-analysis of twenty observational studies evaluating the 
efficacy of influenza vaccine in the elderly by Gross, Hermogenes, Sacks et al. (1995) 
found that influenza vaccination has been shown to prevent 35-45 per cent for 
pneumonia hospitalisations, 31 per cent to 65 per cent for hospital deaths from 
pneumonia and influenza, 43 per cent to 50 per cent for hospital deaths from all 
respiratory conditions, and 27 per cent to 30 per cent for deaths from all causes 
(Gross, Hermogenes, Sacks et al., 1995).
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Likewise, a large cohort study by Nichol (2003) who assessed the effectiveness of 
influenza vaccine in community-dwelling elderly persons during the two influenza 
seasons (1998-1999 and 1999-2000) demonstrated a reduction in the risk of 
hospitalisation among these individuals. Vaccination against influenza reduced the 
risk of hospitalisation for cardiac disease by 19 per cent during both seasons. The risk 
reduction in hospitalisation for pneumonia or influenza was 32 per cent in the first 
season (1998-1999) and 29 per cent in the subsequent influenza season (1999-2000). 
In addition, a 48-50 per cent reduction in the risk of all-cause mortality during the two 
influenza seasons was also observed in this study.
Another study of Nichol, Baken, and Nelson (1999) also addressed the health benefits 
associated with influenza vaccination of elderly people with chronic lung disease over 
three influenza seasons in the urban area of Minneapolis-St. Paul, USA. Influenza 
vaccination resulted in a 52 per cent reduction in hospitalisation for pneumonia and 
influenza and a 70 per cent reduction in death from any cause. Other results included 
fewer outpatient visits for pneumonia and for all respiratory conditions during the 
1993-1994, 1994-1995, and 1995-1996 influenza seasons.
Similar results were obtained in the other studies conducted in the United States; 
vaccination of elderly individuals resulted in the reduction of 19 per cent to 45 per 
cent in hospitalisation (Foster, Talsma, Furumoto-Dawson et al., 1992; Mullooly, 
Bennett, Hombrook et al., 1994; Ohmit & Monto, 1995; Nichol, Wuorenma, & 
Sternberg, 1998; Nordin, Machala, Poblete et al., 2001), and was also associated with 
a 48 per cent to 61 per cent reduction in all causes of death (Nichol, Wuorenma, & 
Sternberg, 1998; Nordin, Machala, Poblete et al., 2001; Hak, Nordin, Wei et al.,
2002). In observational studies from the UK, influenza vaccination was associated 
with a 63 per cent reduction in hospital admissions in 10 Leicestershire hospitals 
during the 1989-1990 influenza season (Ahmed, Nicholson, Nguyen-Van Tam et al., 
1997), and a 75 per cent reduction in death in elderly people during the influenza 
epidemic of 1989-1990 (Fleming, Watson, Nicholas et al., 1995).
More recently, findings in a large cohort of 713,872 community-dwelling elderly 
people across 10 influenza seasons by Nichol, Nordin, Nelson et al. (2007) indicated 
that influenza vaccination had an overall protective effect of 27 per cent (adjusted
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ratio, 0.73; 95% Cl 0.68-0.77) against hospitalisation for pneumonia or influenza and 
48 per cent (adjusted ratio, 0.52; 95% Cl 0.50-0.55) against death in elderly persons. 
Even in two seasons where there was a sub-optimal match between the vaccine 
antigen and the circulating viruses, influenza vaccine was still associated with a 37 
per cent reduction in mortality (adjusted odds ratio, 0.63; 95% Cl, 0.57-0.69).
Among elderly persons in nursing homes, the influenza vaccine has been reported 
to be 23-43 per cent effective in preventing influenza-like illness and clinically 
diagnosed pneumonia (Patriarca, Weber, Parker et al., 1986; Monto, Hombuckle, & 
Ohmit, 2001; Jefferson, Rivetti, Rivetti et al., 2005). A recent systematic review of 
the efficacy and effectiveness of influenza vaccines in elderly persons by Jefferson, 
Rivetti, Rivetti et al. (2005) has found the influenza vaccination was associated with a 
23 per cent (95% Cl, 6-36%) reduction in influenza illness cases, a 46 per cent (95% 
Cl, 30-58%) reduction in pneumonia, and a 45 per cent (95% Cl, 16-64%) reduction 
in hospitalisation in the nursing home populations. Additionally, influenza vaccine 
was 42 per cent (95% Cl, 17 - 59 %) effective in reducing mortality from influenza or 
pneumonia and 60 per cent (95% Cl, 23-79%) in reducing mortality from all causes.
3.4.1.3 Safety of trivalent inactivated influenza vaccines
Trivalent inactivated influenza vaccine has been found to be safe and well- tolerated 
with minor side-effects. The side-effects can include local reactions (e.g. soreness at 
the injection, redness swelling) and systemic reactions (muscle ache, headache, fever, 
and nausea). These side effects are usually mild and last for 1-2 days after vaccination 
and are more common in women than in men. The incidence of local side effects 
within 48 hours, especially arm soreness has been reported by 17.5 per cent to 70 per 
cent in adults (Al-Mazrou, Scheifele, Soong et al., 1991; Aoki, Yassi, Cheang et al., 
1993; Govaert, Dinant, Aretz et al., 1993; Monto, Ohmit, Petrie et al., 2009). Two 
randomised, placebo-controlled trials showed systemic side-effects in 11 per cent to
14.2 per cent of vaccine recipients (Margolis, Nichol, Poland et al., 1990; Govaert, 
Dinant, Aretz et al., 1993). Generalised body aches, muscle soreness, fever, and 
headache have been commonly reported, and these reactions typically begin 6 -1 2  
hours after vaccination (Al-Mazrou, Scheifele, Soong et al., 1991; Govaert, Dinant, 
Aretz et al., 1993; Musana, Yale, Mazza et al., 2004).
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Additionally, two randomised, placebo-controlled trials investigating adverse 
reactions to influenza vaccine in older people indicated that there was no significant 
difference in the rate of systemic reactions between vaccinated and placebo groups 
(Margolis, Nichol, Poland et al., 1990; Govaert, Dinant, Aretz et al., 1993). However, 
previous studies have shown that the systemic side-effects to influenza vaccine are 
more likely to occur among children and young adults, who have had no prior 
exposure to influenza vaccine antigens (Parkman, Galasso, Top et al., 1976; Scheifele, 
Bjomson, & Johnston, 1990). Systemic reactions occurred in 32 per cent of 
individuals aged 18-34 years compared with 7 per cent of those older than 35 years 
old (Wise, Dolin, Mazur et al., 1977). It has also been reported that split-viron 
influenza vaccines have fewer side-effects than the whole-virion influenza vaccines 
(Wise, Dolin, Mazur et al., 1977; Scheifele, Bjomson, & Johnston, 1990). This was 
demonstrated in the study by Al-Mazrou, Scheifele, Soong et al. (1991) who found 
that generalised aching was significantly less prevalent in the split-virion vaccine 
recipients than in the whole-virion vaccines group (13 per cent vs. 26 per cent). Fewer 
local adverse reactions were also observed in the split-virion vaccine recipients.
Serious adverse reactions to inactivated influenza vaccine have been rare. However, 
immediate hypersensitivity reactions (e.g. generalised urticaria, wheezing, swelling 
of the mouth and throat) have been reported among individuals with allergies to eggs 
(Davies & Pepys, 1976). Thus, inactivated influenza vaccines which are produced in 
fertilized chicken eggs are contraindicated for those who have severe anaphylactic 
reactions to egg or egg protein (Davies & Pepys, 1976; Treanor, 2005; CDC, 2009b).
In addition, vaccine-associated Guillan-Barre syndrome (GBS) has also been 
reported, particularly during the 1976-1977 season. In 1976, the national influenza 
immunisation programme against swine influenza has been launched in the United 
States. This programme was designed to provide the A/Swine/New Jersey/76 
influenza vaccine for 45 million persons, including adults and children at high risk 
of serious complications from influenza. In the first 4 to 6 weeks following 
immunisation, the significantly increased incidence of GBS was observed among 
recipients of A/New Jersey influenza vaccine, which the estimated risk of vaccine- 
associated GBS was 1 in 100,000 vaccinations. Subsequent studies have been carried 
out to evaluate the relationship between GBS and influenza vaccines other than the
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A/Swine/New Jersey/76 influenza vaccine, but no causal relationship has been found 
(Schonberger, Bregman, Sullivan-Bolyai et al., 1979; Treanor, 2005).
However, the study of GBS and influenza vaccines (the 1992-1993 and 1993-1994 
seasons) by Lasky, Terracciano, Magder et al. (1998) found that the influenza 
vaccines were associated with 1-2 cases of GBS per million persons vaccinated 
(adjusted relative risk = 1.7; 95% Cl, 1-2.8) during the 6 weeks after vaccination. The 
study investigating trends of GBS after receiving the influenza vaccine in adults from 
1990 to 2003 conducted by Haber, DeStefano, Angulo et al. (2004), found that there 
was significantly decrease in the reporting rates of GBS from 0.17 per 100,000 
vaccinees in 1993-1994 to 0.04 in 2002-2003. Recently, the study by Vellozzi, 
Burwen, Dobardzic et al. (2009) who assessed adverse events after receiving trivalent 
inactivated influenza vaccine in adults aged 18 years or older that reported to the US 
Vaccine Adverse Event Reporting System (VAERS), indicated that pain, fever, 
myalgia and headache were the most common local side-effects after vaccination 
among adults during 1990-2005. Guillan-Barre syndrome was the most common 
reported serious event, and the reporting rate of GBS was 0.70 per million 
vaccinations. The benefits of influenza vaccination clearly outweigh the potential risk 
of acquiring GBS after vaccination (CDC, 2009b).
3.4.2 Live, attenuated influenza vaccine (LAIV)
LAIV consists of live, attenuated influenza viruses. The vaccine is trivalent, with the 
three vaccine component strains used in trivalent inactivated vaccine (cold-adapted 
H1N1, H3N2, and B influenza viruses). The vaccine viruses are generated by 
reassortment between the cold-adapted master donor strains (A/Ann Arbor/6/60 (CA- 
A) and B/Ann Arbor/1/66 (CA-B) and the circulating wild-type viruses. The genetic 
reassortment methods involve a combination of six genes from the cold-adapted 
master donor strains, contributing six internal viral genes and two genes from the 
contemporary wild strain of influenza viruses, encoding the viral surface antigens 
(hemagglutinin and neuraminidase). Thus, the vaccine viruses in LAIV contain six 
genes (PB2, PB1, PA, NP, M, and NS) from a master donor strain that contributes to 
the attenuation and cold-adaptation of live influenza virus, and the HA and NA genes 
from the circulating virus strains recommended by the WHO which confer
62
antigenicity. LAIV is attenuated by cold adaptation, in which the vaccine viruses can 
replicate efficiently and survive at lower temperatures (25 °C) in the mucous 
membrane of the upper respiratory tract; thus LAIV does not produce systemic 
symptoms of influenza in vaccine recipients (Boyce, Gruber, Coleman-Dockery et al., 
2000; Cha, Kao, Zhao et al., 2000; Treanor, Hayden, Vrooman et al., 2000; Nichol, 
2001; Beyer, Palache, de Jong et al., 2002; Belshe, 2004; Belshe, Nichol, Black et al. 
2004; Vesikari, Karvonen, Korhonen et al., 2006; CDC, 2009b).
The LAIV is thimerosal-free vaccine. Each 0.2 ml dose of the 2009-2010 vaccine 
includes three live, attenuated influenza virus strains: A/Brisbane/59/2007 (H1N1), 
A/Brisbane/ 10/2007 (H3N2), and B/Brisbane 60/2008 and is supplied in a prefilled, 
single-use sprayer (CDC, 2009). The vaccine is administered intranasally using 0.1 
mL into each nostril while the recipient is in the upright position. LAIV has been used 
since 2003 and currently approved for immunisation of all healthy, non-pregnant 
persons between the ages of 2 and 49 years. The vaccine should be stored in a 
refrigerator between 2-8 °C (Block, Yogev, Hayden et al., 2008; CDC, 2009b; Wang, 
Tobler, Roayaei et al., 2009). Two 0.2 mL doses of the vaccine are recommended for 
children aged less than nine years in order to produce antibody levels that are 
sufficient for protection against influenza. Those who do not receive two doses in 
their first year of vaccination should have two doses in the following year (CDC, 
2009b).
3.4.2.1 Immune response
As the LAIV is made from live, attenuated viruses and is administered via the 
intranasal route which is the natural route of infection, it is expected that the vaccine 
viruses can induce immune response in human equivalent to those induced by the 
natural influenza infection (Nichol, 2001; Belshe, 2004). A number of studies have 
shown LAIV to induce a broad range of immune response, including a mucosal IgA 
response (influenza-specific IgA nasal antibodies), systemic (serum antibodies) and 
cell mediated immune responses (T cell responses) (Clements, O' Donnell, Levine et 
al., 1983; Clements, Betts, Tierney, 1986; Gorse, Belshe, Munn 1986; Gorse, Belshe, 
& Munn, 1988; Murphy & Clements., 1989; Beyer, Palache, de Jong, et al., 2002). 
Data from a study by Clements and Murphy (1986) demonstrated that LAIV
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stimulated both local and systemic immunity, although it induced lower titres of 
serum antibodies (IgA, IgG, and IgM HA antibody) compared with trivalent 
inactivated influenza A vaccine (TIV). In contrast, LAIV induced a nasal-wash IgA 
response more frequently than TIV (83 per cent vs. 38 per cent), and this antibody 
response reached a peak two weeks after vaccination.
Likewise, a randomised controlled trial investigating efficacy of LAIV and TIV 
against influenza by Edwards, Dupont, Westrich et al (1994) showed that nasal IgA 
antibody was significantly higher in response to LAIV than to TIV. Additionally, the 
study by Clements, Betts, Tierney et al. (1986) found that there was a difference 
between LAIV and TIV in the induction of different levels of antibody in serum or 
nasal wash after experimental challenge with wild-type influenza virus. HAI antibody 
in serum was associated with immune protection against influenza in TIV recipients, 
whereas local HA IgA antibody was responsible for resistance to influenza in LAIV 
recipients after experimental challenge with wild-type influenza virus.
Recently, a meta-analysis of 18 randomised clinical trials comparing LAIV and TIV 
with respect to systemic vaccine reactions, local and systemic antibody response, and 
vaccine efficacy confirmed that LAIV has demonstrated to be more effective than 
TIV in inducing a nasal wash IgA response (Beyer, Palache, de Jong et al., 2002). 
Accordingly, it has been suggested that local antibodies such as IgA HA antibody 
play a more important role in the immune response after immunisation with LAIV 
(Clements, O' Donnell, Levine et al., 1983; Clements, Betts, Tierney et al., 1986; 
Clements & Murphy, 1986; Gorse, Belshe, & Munn et al., 1988; Beyer, Palache, de 
Jong et al., 2002).
Additionally, a 2-year randomised, double-blind placebo-controlled trial assessing the 
safety and efficacy of LAIV in healthy children 15-71 months old by Belshe et al. 
(2000) revealed that serum HAI antibody and nasal wash IgA antibody were 
correlated with protection against H1N1 infection. Interestingly, the results of this 
study also showed that some vaccinated children (16 vaccinees) had neither serum 
HAI antibody nor nasal wash IgA antibody following experimental challenge with 
influenza A H1N1. Despite this, few influenza infections have been reported among 
these children. Thus, other protective mechanisms may be involved in immune
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activation, including T cell responses and interferon (Tomoda, Morita, Kurashige et 
al., 1995; Murphy & Clements, 1989; Belshe, Gruber, Mendelman et al., 2000; 
Boyce, Gruber, Coleman-Dockery et a l, 2000).
In another study, LIAV has been shown to stimulate influenza A virus-specific 
cytotoxic T-cell response in older, chronically ill adults. A higher level of influenza 
virus-specific cytotoxic T lymphocyte activity which has resulted in a cross-reactive 
immune response against different subtypes of influenza A viruses, was observed in 
older adults with chronic medical conditions who received LIAV (Gorse & Belshe, 
1990). Cytotoxic T cells could have contributed to cross-protective immunity against 
influenza A subtypes because they can recognise internal virus antigens (internal 
virion proteins) expressed on the surfaces of infected cell, and these internal virus 
antigens are shared among influenza A viruses (Nichol, Mendelman, Mallon et al., 
1999; Belshe, 2004). Although the mechanisms of LAIV protection have not been 
clearly defined, the vaccine appears to induce a broad immune response, including 
systemic, mucosal, and cell mediated immune responses (Clements, Betts, Tiemey et 
al., 1986; Tomoda, Morita, Kurashige et al., 1995; Nichol, 2001; Belshe, 2004).
3.4.2.2 Virus shedding and transmission after immunisation with LAIV
There has been concern about the potential risk of transmission of the vaccine viruses 
after immunisation with LAIV from vaccine recipients to unvaccinated individuals; 
because LAIV virus strains infect and replicate in nasopharyngeal epithelial cells and 
are shed in the respiratory secretions (Talbot, Crocker, Peters et al., 2005; Vesikari, 
Karvonen, Korhonen et al., 2006; Block, Yogev, Hayden et al., 2008). A study 
conducted by Block, Yogev, Hayden et al. (2008) assessed virus shedding and 
immune response to LAIV in persons aged 5-49 years. The results revealed that the 
incidence of vaccine virus shedding decreased with increasing age; shedding 
incidence ranged from 44 per cent (aged 5-8 years) to 17 per cent (18-49 years). The 
duration of viral shedding was short. The vaccine virus was not recovered from any 
vaccinated person after 11 day post-vaccination. Serum strain-specific hemagglutinin 
inhibition titres had fallen below the limit of detection (<1 logioTCID 50/mL) after day 
10 in children aged less than 9 years and after day 6  in individuals aged 9-49 years.
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Additionally, Talbot, Crocker, Peters et al. (2005) found in their prospective 
surveillance study that viral shedding after LAIV vaccination in 20 adults (aged 18-49 
years) had significantly decreased within one week after immunisation, and it was 
more likely to occur in younger age groups. The viral shedding among LAIV 
vaccinated persons was further demonstrated by Vesikari, Karvonen, Korhonen et al.
(2006) who conducted a randomised controlled study assessing the transmissibility 
and genotypic stability of LAIV virus in 51 day care centres in Finland. This study 
showed that 80 per cent (78 of 98) of LAIV vaccinated children (aged 9-36 months) 
shed one or more vaccine virus strains after vaccination with LAIV. Although the 
shedding incidence was high, only one case of transmission has been reported among 
the placebo recipients (99 subjects), and the transmitted virus maintained its 
attenuated characteristics and did not cause clinical disease to a placebo recipient who 
had been infected inadvertently with vaccine virus. The probability of acquiring 
vaccine virus after close contact with a LAIV vaccinated child was estimated to be 
0.58 per cent (95% Cl, 0-1.7%). However, LAIV recipients have been advised to 
avoid contact with severely immunosuppressed individuals for 7 days after 
immunisation (CDC, 2009b).
3.4.2.3 The efficacy and effectiveness of live, attenuated influenza vaccine (LAIV)
LAIV has been shown to be efficacious in preventing laboratory-confirmed influenza 
and influenza illness in healthy adults. A double-blind, randomised controlled trial 
comparing efficacy of cold-adapted and inactivated influenza vaccines over the five 
influenza seasons (1985-1986 to 1989-1990) by Edwards, Dupont, Westrich et al. 
(1994) demonstrated that the efficacy of cold-adapted influenza vaccine was 85 per 
cent (95% Cl, 70 - 92%) for prevention of culture-proven H1N1 influenza infection 
and 58 per cent (95% Cl, 29 - 75%) for prevention of culture-proven H3N2 influenza 
infection.
The efficacy of LAIV against influenza was further illustrated in a randomised, 
double -blind, placebo-controlled trial conducted in the United States by Nichol, 
Mendelman, Mallon et al (1999) who evaluated the safety and effectiveness of LAIV 
in reducing influenza-like illness without laboratory confirmation, absenteeism, and 
medication use among working adults aged 18-64 years during the 1997-1998 season.
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Despite a mismatch between the vaccine strains and circulating virus (H3N2), results 
showed that immunisation with LAIV has been found to significantly decrease the 
numbers of severe febrile illness by 18.8 per cent (95% Cl, 7.4% - 28.8%) and febrile 
upper respiratory tract illness by 23.6 per cent (95% Cl, 12.7%-33.2%). In addition, 
immunisation with LAIV also resulted in a reduction in the days of work lost 
(reduction by 28.4 per cent, 95% Cl, 16.3% - 38.8%), the days of physician visits 
(reduction by 40.9 per cent, 95% Cl, 30.1%-50.0%), and the days of antibiotic use for 
febrile upper respiratory tract illness (reduction by 45.2 per cent, 95% Cl, 35.2%- 
53.6%). Treanor, Hayden, Vrooman et al. (2000) also found that there was no 
statistically significant difference in efficacy between LAIV and TIV; the efficacy of 
LAIV and TIV in preventing laboratory documented influenza illness was 85 per cent 
and 71 per cent, respectively.
Another study conducted in the US military basic training centres assessing vaccine 
effectiveness against laboratory-confirmed by Strickler, Hawksworth, Myers et al.
(2007) also indicated that LAIV and TIV appeared to have equal efficacy; similar 
levels of protection against laboratory-confirmed among basic trainees were observed 
for LAIV relative to TIV. Additionally, LAIV and TIV have found to be equally or 
more effective in vaccine-nai've persons, including children and young adults who 
have no pre-existing antibodies for the influenza viruses or those who were 
seronegative at baseline. This may be due to the pre-existing immunity in some adults 
which may have resulted from their past infection with antigenically related strains of 
influenza A virus or vaccination; thus, LAIV efficacy has been shown to be similar to 
or better than TIV in vaccine-naive persons (Belshe, Gruber, Mendelman et al., 2000; 
Nichol, 2001; Ohmit, Victor, Rotthoff et al., 2006; Wang, Tobler, Roayaei et al, 
2009).
By contrast, two recent randomised, double-blind, placebo-controlled trials conducted 
in Michigan, comparing the efficacy of TIV and LAIV in healthy adults during the 
2004-2005 (Ohmit, Victor, Rotthoff et al., 2006) and 2007-2008 influenza seasons 
(Monto, Ohmit, Petrie et al., 2009) reported that LAIV was found to be less 
efficacious than TIV for prevention of laboratory confirmed symptomatic influenza A 
in healthy adults. A randomised controlled trial by Ohmit, Victor, Rotthoff et al. 
(2006) showed that LAIV and TIV had an efficacy of 48 per cent and 77 per cent,
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respectively, for preventing culture positive influenza among healthy adults. Monto, 
Ohmit, Petrie et al. (2009) also found an efficacy of 29 per cent (95% Cl, -14 to 55 %) 
for LAIV and of 72 per cent (95% Cl, 49 to 84 %) for TIV.
Similarly, a large cohort study of the US military personnel carried out to assess the 
effectiveness of LAIV and TIV over the three influenza seasons (2004-2005 to 2006- 
2007), revealed that LAIV efficacy was lower compared to TIV in reducing the 
incidence rate of pneumonia and influenza among the US military service members. 
A recent meta-analysis review of the effectiveness of influenza vaccines by 
Demicheli, Pietrantonj, Jefferson et al. (2007) has suggested that LAIV was less 
effective in preventing influenza than TIV among healthy adults.
3.4.2.4 Safety of live, attenuated influenza vaccine
LAIV has been demonstrated to be safe, and well-tolerated in adults. In a randomised 
controlled trial study of healthy, working adults, runny nose (44.3 per cent vs. 26.6 
per cent) or sore throat (26.6 per cent vs. 16.3 per cent) during 7 days after 
vaccination has been reported more frequently in LAIV recipients compared with a 
placebo group. These adverse reactions were short lasting and did not result in 
additional medical treatment such as antibiotics, analgesics/antipyretics, or 
decongestants/ antihistamines. During 28 days after vaccination, there were no 
differences in the frequency of serious adverse events between vaccine and placebo 
recipients (0.18 per cent vs. 0.27 per cent), and none of the nine serious adverse 
events have been associated with this vaccine (Nichol, Mendelman, Mallon et al., 
1999).
A randomised, double-blind, placebo-controlled trial of influenza vaccines assessing 
the efficacy of LAIV and TIV by Ohmit, Victor, Rotthoff et al. (2006) also found that 
runny nose/nasal congestion, cough, headache, and muscle aches were significantly 
more common in LAIV recipients compared with the placebo group. Four serious 
side-effects that occurred within 30 days after vaccination have been reported. Among 
these serious adverse events, one (acute pericarditis with moderate effusion) was 
judged to be probably related to the receipt of LAIV vaccination. The study of serum 
samples collected immediately before and after administration of the vaccine (four
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weeks later) was performed; however, no evidence has been found to indicate that 
vaccine viruses caused acute pericarditis.
In a subset of healthy adults 18-49 years of age from a randomised controlled study 
evaluating the safety, efficacy and effectiveness of LAIV, side-effects following 
vaccination have been reported significantly more often in LAIV recipients than 
placebo group, including runny nose (44.5 per cent vs. 27.1 per cent), sore throat 
(27.8 per cent vs. 17.1 per cent), tiredness/weakness, (25.7 per cent vs. 21.6 per cent), 
cough (13.9 per cent vs. 10.8 per cent), and chills (8 .6  per cent vs. 6 per cent) (Belshe, 
Nichol, Black et al., 2004).
A further and more recent randomised, double-blind, placebo-controlled trial of 
influenza vaccines involving 1952 healthy adults during the 2007-2008 influenza 
season by Monto, Ohmit, Petrie, et al. (2009) showed that runny nose or congestion 
was significantly more common among LAIV recipients than placebo recipients (52.3 
per cent vs. 37.7 per cent). LAIV has also been administered to elderly people with 
chronic medical conditions, although it has not yet been approved for use in persons 
aged 50 years or older. A randomised controlled study evaluating the safety of LAIV 
in simultaneous combination with TIV in the elderly with chronic diseases by 
Jackson, Holmes, Mendelman et al. (1999) indicated that TIV plus LAIV recipients 
were more likely than placebo plus TIV recipients to report sore throat during the 
seven days after vaccination (15 per cent vs. 2 per cent). Other reported symptoms, 
including fever, cough, runny nose, headache, muscle aches, tiredness, and chills did 
not differ between groups. Four serious adverse events were reported during the 28 
days after vaccination. However, none of these adverse effects was considered related 
to the study vaccine.
In addition, a review of adverse events reported following LAIV administration to 
the US Vaccine Adverse Event Reporting System (VERS) during the two influenza 
seasons (2003-2004 to 2004-2005) indicated that a total of 460 adverse event had 
been reported to VERS after approximately 2.5 million doses of LAIV were 
distributed. Of these, forty reports were classified as serious: 15 respiratory events 
(e.g. influenza-like illness, pharyngitis, tracheitis, asthma, and pneumonia), seven 
allergic events (possible anaphylaxis, generalised urticaria, generalised itchy, rash on 
the back and chest), seven neurological events (e.g. Guillan-Barre syndrome, Bell
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palsy, febrile seizures, encephalomyelitis), four constitutional symptoms (weakness/ 
tiredness, fever, headache, dizziness, and arthritis), three cardiovascular events 
(pericarditis, myocardial infarction), one abdominal symptom, one ocular symptom 
(retinal haemorrhage), and three other reports (serious chickenpox, rash/erythema, 
group A streptococcal infection) (Izurieta, Haber, Wise et al., 2005).
3.5 Recommendations for the use of seasonal influenza vaccine
The main objective for the use of influenza vaccine is to reduce the incidence of 
severe illness cases and death in the elderly and high-risk populations, which will, in 
turn, reduce the burden of care and pharmaceutical supplies. Recommendations for 
the use of influenza vaccine are different between countries. This difference is based 
on reliable data on the seasonal occurrence of influenza and its impact, as well as 
knowledge about the effectiveness of influenza control measures and the resources 
for the implementation of a seasonal influenza vaccination programme (WHO, 2000; 
van Essen, Palache, Forleo et al., 2003). However, the influenza vaccine is usually 
recommended in most countries for each of the following groups: (1) elderly residents 
of long-term care facilities or the disabled; (2 ) non-institutionalised elderly with one 
or more chronic disease requiring influenza vaccination; this includes elderly people 
with chronic cardiovascular, pulmonary, metabolic or renal disease, or who are 
immunocompromised; (3) individuals 60 or 65 years of age and older; (4) adults and 
children over 6 months of age who have chronic pulmonary, cardiovascular, 
metabolic or renal disease, or are immunocompromised; and (5) individuals who live 
with or care for people at high risk for severe complications from influenza such as 
health care personnel, household contacts and caregivers of high-risk persons. 
Nevertheless, for a country with limited resources to implement the influenza vaccine 
programme for all groups as listed above, it is recommended that the influenza 
vaccine should be given to residents of institutions for the elderly and disabled as a 
first priority. If more resources become available, the programme should be expanded 
to cover more high-risk individuals (WHO, 2000; van Essen, Palache, Forleo et al., 
2003; Treanor, 2010).
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In addition to the use of influenza vaccine in targeted the elderly and high-risk 
populations, universal mass vaccination of young children against the influenza has 
been implemented in some countries (e.g. Japan, Canada, and the United States) in 
order to disrupt the spread of influenza in the community (Treanor, 2010). In Japan, 
the influenza vaccination programme for schoolchildren was implemented between 
1962 and 1987; most schoolchildren were vaccinated against influenza. Of particular 
note were findings that vaccination of Japanese children resulted in a significant 
reduction in influenza-related deaths among older persons during that period. 
Vaccination of school-aged children prevented about 37,000 to 49,000 deaths per year 
-  or about one death for every 420 children vaccinated (Reichert, Sugaya, Fedson et 
al., 2001). By contrast, an increase in the influenza-related mortality rates among 
older adults has been reported since 1994 as the universal influenza vaccination 
program for school-aged children was discontinued.
Additionally, a single-blind, randomised controlled trial conducted by Hurwitz, 
Haber, Chang et al. (2000) showed that the vaccination of day care children has been 
shown to significantly reduce the incidence of febrile respiratory illness in household 
contacts, especially among school-aged household contacts (aged 5-17 years). As a 
consequence of reduction in febrile respiratory illness, more than 70 per cent 
reduction in physician visits, earaches, antibiotic prescribed, school-days lost and 
parental work-days lost were also reported in this study.
In the present, a major change has been made to guidance on the use of influenza 
vaccine for the 2010-2011 influenza season in the United States. The existing 
guidelines for seasonal influenza vaccination which focus on only certain groups 
(children between the age of 6  months and eighteen years; adults aged fifty years and 
older; those with chronic medical conditions; health care personnel, and household 
contacts and caregivers of high-risk persons) has been changed to include all persons 
aged 6 months or older who do not have contraindications to vaccination. The reasons 
for the expansion of seasonal influenza vaccination in the United States is the 
evidence that seasonal influenza vaccination is safe, and can also potentially provide 
benefits for all age groups. In addition, severe cases of influenza were observed in 
young adults (19-49 years) during the 2009 pandemic influenza A (H1N1) (Gianella,
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Walter, Revollo et al., 2009; Jain, Kamimoto, Bramley, 2010; Kumar, Zarychannski, 
Pinto etal., 2009; CDC, 2010b), and the concerns that 2009 pandemic influenza A 
(HIN 1) viruses will continue to circulate in the coming influenza season 2010-11; 
therefore, these young adults can remain at considerable risk of infection with this 
virus. The recommendations for influenza vaccination for the 2010-2011 influenza 
season are summarised in table 3.5 (CDC, 2010b).
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Table 3.5 Groups recommended for influenza vaccination, 2010
• All individuals aged 6 months or older should be vaccinated annually
• If vaccine supply is limited, the following target groups are proposed as
priority groups for influenza vaccination
Persons at high risk for influenza-related complications
- Children aged 6 months to 4 years (59 months);
- Children aged 6 months to 18 years receiving long-term aspirin therapy and 
therefore would be at increased risk for Reye’s syndrome after influenza 
virus infection;
- Adults aged 50 years or older;
- Adults and children who are residents of nursing home and other chronic 
care facilities;
- Adults and children with chronic pulmonary (including asthma), 
cardiovascular (except hypertension), renal, hepatic, neurologic, 
hematologic, or metabolic disorders (including diabetes mellitus);
- Persons who have immunosuppression (including immunosuppression from 
medication or human immunodeficiency virus: HIV;
- Women who are or will be pregnant during the influenza season;
- Persons who are morbidly obese (body-mass index > 40;
Persons who live with or care for people at high risk for influenza-related
complications
- Health care personnel
- Household contacts and caregivers of children aged five years or less than 
and adults aged fifty years or older, with particular emphasis on vaccination 
of contacts of children aged lass than six months;
- Household contacts and caregivers of persons with medical conditions that 
put them at higher risk for severe complications from influenza
Source: Adapted from CDC, 2010b.
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3.6 Conclusion
The literature related to the influenza vaccine, its effectiveness and side-effects was 
reviewed. Currently, there are two types of vaccine: trivalent inactivated influenza 
vaccine (TIV) and live, attenuated influenza vaccine (LAIV). As two surface 
glycoproteins (HA and NA) of the influenza virus continually change by mutation, the 
components of the vaccine need to be changed every year in order to match the 
circulating virus strains. The protective efficacy of influenza vaccine depends on 
several factors such as the characteristics of the target population, the degree of 
similarity between vaccine viruses and those in circulation, and how the vaccine is 
administered (Demicheli, Jefferson, Rivetti et al., 2000; Hannoun, Megas, & Piercy,
2004). Vaccine effectiveness is estimated to be between 70 and 90 per cent in young, 
healthy adults. Although the vaccine offers less protection against influenza illness for 
high risk populations such as the elderly and persons with chronic medical condition 
(approximately 58 per cent: CDC, 2009), it is effective in reducing hospitalisations for 
acute respiratory disease or cardiopulmonary disease and deaths by 87 and 78 per 
cent, respectively (Hak, Buskens, van Essen et al., 2005).
The inactivated influenza vaccine has been shown to be very safe and well-tolerated 
in older people and those with chronic disease. There have been rare reports of severe 
adverse reactions to the influenza vaccination. Common side-effects from the vaccine 
include soreness, redness, and/or swelling at the injection site, muscles ache, 
headache, and fever. These side effects occur soon after vaccination and are usually 
temporary. Influenza vaccination recommendations vary between countries. 
However, in most countries, annual influenza vaccination is recommended for high- 
risk populations (e.g. the elderly and persons with chronic medical condition) and 
those who live with or care for persons at high risk (e.g. health care workers, 
household contacts and caregivers of children less than six months of age). Despite 
strong recommendations and clear evidence for influenza vaccination efficacy in 
preventing influenza and its complications in high-risk older people, influenza 
vaccination rates remain relatively low in many countries. The following chapter will 
focus on lay beliefs about influenza, the influenza vaccine and the factors that affect 
the decision to be vaccinated against influenza among individuals aged 65 years or 
older and those aged less than 65 with chronic diseases.
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Chapter 4: Understanding lay beliefs about influenza, the 
influenza vaccine and factors influencing influenza vaccination
4.1 Introduction
As described in the previous chapter, influenza vaccine has been shown to be safe and 
effective in reducing the risk of influenza and its disease-related complications such 
as bronchitis, pneumonia, acute exacerbations of chronic bronchitis, asthma, COPD, 
and heart failure (Ahmed, Nicholson, Nguyen-Van Tam et al, 1997; Nichol, Baken, & 
Nelson et al., 1999; CDC, 2010b; Treanor, 2010). Despite this, the rates of influenza 
vaccination in many countries are still below the WHO target for 2010 of vaccinating 
at least 75 per cent of the individuals aged 65 years or older (Kohlhammer, Schnoor, 
Schwartz et al., 2007; Ward & Draper, 2007; Blank, Freiburghaus, Schwenkglenks et 
al., 2008; Lau, Kim, Tsui et al., 2008; Lau, Lau, & Lau 2009; CDC, 2010b). A 
number of factors have been found to affect the decision to accept or decline 
vaccination (Telford & Rogers, 2003; Zimmerman, Nowalk, Raymund et al., 2003; 
Horby, Williams, Burgess et al., 2005; Evans, Prout, Prior et al., 2007; Lyn-cook, 
Halm, & Wisnivesky, 2007; Kohlhammer, Schnoor, Schwartz et al., 2007; Ward & 
Draper, 2007; Payaprom, Bennett, Bumard et al., 2010). This chapter addresses lay 
beliefs about influenza, the influenza vaccine and the factors affecting the decision to 
be immunised against influenza among high-risk adults: those aged 65 years or older 
and those aged less than 65 with chronic medical conditions. These can be grouped 
into six categories.
4.2 Lay beliefs about influenza
Previous studies have highlighted the importance of understanding lay beliefs about 
influenza, its causes, and its symptoms. These beliefs influence people’s attitudes to 
influenza vaccination, and ultimately, their vaccination behaviours (Comford & 
Morgan, 1999; Telford & Rogers, 2003; Adonis-Rizzo & Jett, 2006; Evans, Prout, 
Prior et al., 2007). Adonis-Rizzo and Jett (2006) investigated the health beliefs related 
to influenza prevention in the Haitian Americans. The findings showed that all 
participants thought that influenza was simply a “cold” or “a big cold”. Based on this
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belief, traditional preventive practices such as the use of herbal remedies, dressing 
warmly in cold weather, and eating healthy food were believed to be sufficient to 
prevent influenza. Perceptions regarding the seriousness of influenza were similar to 
those of previous studies which found that older people who refused influenza 
vaccination believed that influenza was not dangerous (e.g. Santibanez, Nowalk, 
Zimmerman et al., 2002; Tabbarah, Zimmerman, Nowalk et al., 2005). The 
interpretation of influenza as a mild infection can contribute to a low acceptance of 
vaccine recommendations. On the contary, perceiving influenza as serious can lead 
older people to comply with the influenza vaccination (Honkanen, Keistinen & 
Kivela, 1996; Rehmet, Ammon, Pfaff et al., 2002).
Few studies have examined what lay persons believe to be the cause of influenza, 
although more studies have explored folk beliefs and practices about the common 
cold. For example, a UK study found that lay people believed that the common cold 
occurred when certain body parts (such as the top of the head, the back of the neck, 
and the feet) were exposed to damp or draughts (Helman, 1978). The folk beliefs that 
exposure to cold weather or wearing wet cothes causes common cold and influenza 
have long been and continue to be influential among the lay persons (Baer, Weller, 
Pachter et al., 1999; CDC, 2003; Baer, Weller, de Alba Garcia, 2008; Prior, Evans, & 
Prout, 2010). These beliefs are, arguably, the descendents of the ancient Greek theory 
of bodily humors.
Hot-Cold imbalance is thought to lead to illness more widely (Harwood, 1971; Baer, 
Weller, de Alba Garcia, 2008). The hot-cold theory of illness influences explanations 
for causality of illness and the ways to treat it. For example, Young and Garro (1994) 
found that among Tarascan Indians, cold or flu was believed to be caused by eating 
“cold” foods, and the illnesses can both be treated by eating “hot” foods. Weller 
(1983) also reported that “flu” was classified by urban Guatemalans as needing “hot” 
remedies, whereas both the “cold” and “flu” were classified as needing “hot” 
remedies among the rural Guatemalans, showing that there is a different perspective, 
possibly culture (Weller, 1983 cited in Baer, Weller, Pachter et al., 1999). A study of 
community beliefs about medico-nutritional practices among Puerto Ricans conducted 
by Lieberman (1979) found that milk which was classified as “cold” should not be 
given to the child during illness. “Hot-cold” beliefs and practices are still prevalent; a
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qualitative study conducted by the United States Centre for Disease Control and 
Prevention (2000, cited in CDC, 2003) revealed that many Hispanic Americans were 
unaware that influenza was a disease caused by a virus; they believed that changes in 
the weather caused influenza, and “not getting wet or chilled when outside in cold 
weather” was proposed as an important strategy for avoiding influenza.
A recent interview study on lay perceptions of symptoms and causes of cold and 
influenza among older British in South Wales, UK, conducted by Prior, Evans, and 
Prout (2010) pointed out that influenza has been associated with a wide range of 
etiological agents, including “viruses, bugs and germs; the environment in general and 
“stuffy” air in particular; being wet wearing damp cloths; the flu jab; and coughs and 
sneezes of other people” (p. 6). Additionally, lay persons believed that catching 
influenza depended not only on being exposed to these factors but, also, on the 
individual’s health and immune system; exposure to viruses, bugs, the air and 
dampness was believed to have very little effect, if the individual’s immune system 
was strong (Prior, Evans & Prout, 2010).
Some differences in the perception of influenza transmission between experts and lay 
people were documented in previous studies (Raude & Setbon, 2009; Prior, Evans & 
Prout, 2010). A national French survey on the public perception of the pandemic 
influenza threat showed that a large percentage of lay people believed that the spread 
of influenza from human to human via direct contacts with saliva or aerosol droplets 
from infected people was believed to be higher than via indirect contacts with 
contaminated fomites. The belief that influenza was not primarily transmitted through 
contact with infected surfaces was also common among older British people in South 
Wales (UK) (Prior, Evans & Prout, 2010). The results from these two recent studies 
suggest that campaigns seeking to promote hand hygiene probably do not work for 
preventing the spread of influenza in all settings (Raude & Setbon, 2009; Prior, Evans 
and Prout, 2010).
Previous studies have shown that lay people make a distinction between the common 
cold and influenza in terms of symptoms experienced (Baer, Weller, Pachter et al., 
1999; Prior, Evans &Prout, 2010). Baer, Weller, Pachter et al. (1999) examined the 
conceptualisation of the common cold and the differences between the common cold
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and influenza from a cross-cultural perspective. In this study, four groups of Latin 
Americans and a group of middle income Americans living in Tampa, Florida were 
studied. The authors found that influenza symptoms reported by the participants who 
lived in Tampa were nausea, stomach ache and diarrheoa, body aches and pains, 
fatigue, and fever, as well as upper respiratory symptoms. The gastrointestinal 
symptoms (nausea, stomach ache and diarrhoea) found in Baer et al. (1999)’s study 
appeared to be the same symptoms as “folk flu” that was identified in the study by 
McCombie (1987). McCombie (1987) noted that, in southern Arizona, lay people 
diagnosed influenza based on symptoms of nausea, vomiting, and diarrhoea. 
Gastrointestinal symptoms with influenza have also been noted among middle-income 
main stream Americans populations, African Americans, and English-speaking 
populations in the United States (Pachter, Niego, & Pelto, 1996; Baer, Weller, Pachter 
et al., 1999). Prior, Evans and Prout (2010) added that some older British people 
associated vomiting with influenza. However, an association between influenza and 
gastrointestinal symptoms did not appear in Latin American populations (Pachter, 
Niego, & Pelto, 1996; Baer, Weller, Pachter et al., 1999). In a study of lay diagnoses 
of common cold and influenza among older British people, Prior, Evans and Prout 
(2010) found that, although most of the influenza symptoms identified by participants 
were consistent with the biomedical understanding of major symptoms of influenza, 
lay people and health professionals used a different frame for the assessment of 
influenza symptoms. For lay people, pain and aching body involved more than just 
the muscles; “it was interpreted as a whole body illness” (p. 6). Influenza was also 
connected to behavioural correlates, for example, people with influenza can be 
bedridden and unable to function in their dialy lives.
In summary, there are agreements and differences between lay people’s beliefs and 
professions’ views regarding influenza, its causes, and symptoms. Most people have 
their own ideas and beliefs about influenza and its consequence, which may or may 
not be relevant to the biomedical theories. Furthermore, these beliefs vary across 
different cultures, and they need to be understood in order to facilitate patients’ 
behaviour change. Previous studies have shown that lay beliefs played an important 
role in determining older people’s acceptance or rejection of influenza vaccination 
(Comford & Morgan, 1999; Telford & Rogers, 2003; Evans, Prout, Prior et al., 2007).
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4.3 Lay beliefs about influenza vaccine and immunisation against 
influenza
Although multiple large-scale, randomised controlled studies have shown that 
the influenza vaccines are safe and efficacious, some lay people believe that the 
influenza vaccine might not be safe (e.g. Govaert, Dinant, Aretz et al., 1993; 
Armstrong, Berlin, Schwartz et al., 2001; Prislin, Dyer, Blakely et al., 1998; Wray, 
Jupka, Ross et al., 2007). In a survey of 659 African-Americans, carried out by 
Armstrong, Berlin, Schwartz et al., (2001), 20 per cent of the respondents were 
concerned that “there may be something they didn’t know about in the flu shot”, and 
this concern has been identified as a deterrent to acceptance of influenza vaccination 
among this low-income population (Armstrong, Berlin, Schwartz et al., 2001). 
Further, Wray, Jupka, Ross et al., (2007) conducted four focus groups (N= 35) and 
eight in-depth interviews with older African Americans. The findings revealed that 
participants were worried about the safety of vaccine components, and they were 
concerned that vaccination would give them the influenza or that the influenza 
vaccine would interact with prescription medications for chronic illness. Similar 
findings were observed among older Haitians; most participants were afraid of 
sickness that was believed to be caused by the vaccination itself and concerned that 
the influenza vaccine would exacerbate other health problems or cause another 
(Adonis-Rizzo & Jett, 2006).
Comford and Morgan (1999) conducted 50 in-depth interviews with elderly people 
with chronic disease (aged over 75 years) regarding their beliefs about influenza 
vaccination. The authors noted that there were different ways of interpreting the 
vaccine side-effects between the elderly, relating to whether they viewed vaccination 
positively or negatively. Those with a negative view of vaccination highlighted the 
side-effects of painful arms, feeling unwell, getting influenza, and catching colds 
more frequently after having influenza vaccine. In contrast, those with positive views 
about vaccination felt that the vaccine side-effects might have been coincidental 
events, and they continued to have themselves vaccinated.
In a study of 54 British people aged 65 years and older, using interviews to explore 
lay beliefs about influenza vaccination, Evans, Prout, Prior et al. (2007) found the
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reason given by refusers and defaulters for not wanting to have the vaccine was that 
the vaccine would make them ill or gave them influenza. Additionally, they also 
believed that the vaccine would not protect them, either because it contained the 
influenza strain that occurred last year or because many different strains were 
included in the vaccine. This suggests that some lay people have some knowledge 
about the influenza vaccine.
Previous studies suggest that the uptake of influenza vaccination among high-risk 
individuals remains low, partly because of mistrust of vaccines and fear of side- 
effects (Comford & Morgan, 1999; Armstrong, Berlin, Schwartz et al., 2001; Telford 
& Rogers, 2003; Evans, Prout, Prior et al., 2007; Wray, Jupka, Ross et al., 2007). For 
example, Armstrong, Berlin, Schwartz et al.’s (2001) survey revealed that participants 
who were concerned about the undisclosed contents of the influenza vaccine were less 
likely to report having had an influenza immunisation. Santibanez, Mootrey, Euler et 
al. (2010) surveyed 8,710 American adults aged 50 years or older, and found that a 
higher chance of being vaccinated was observed among those who did not believe that 
they could get influenza from the vaccine, as compared to those who did believe this 
or who stated that they did not know.
In the United Kingdom, a qualitative study conducted by Comford and Morgan
(1999) found that among British older people aged over 75 years, the decision to 
receive influenza vaccination was based on lay beliefs about whether it could prevent 
or cause morbidity from colds and influenza and the importance of side-effects. A 
further study conducted by Evans, Prout, Prior et al. (2007) also revealed that persons 
who had been offered influenza vaccine but has always refused it and those who had 
been vaccinated but have relapsed, believed that the vaccine was not effective and it 
would give them various side-effects.
Other studies also found that fear of adverse reactions and the belief that the influenza 
vaccine may actually cause illness, were cited as the common reasons by the high-risk 
individuals for declining to vaccination (e.g. CDC, 1999; Pregliasco, Sodano, Mensi 
et al., 1999; Wray, Jupka, Ross et al., 2007).
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In summary, some people’s beliefs about the influenza vaccine and immunisation may 
be different from the medical knowledge. However, misconceptions about the vaccine 
safety must be corrected because vaccination misconceptions have been shown to 
affect markedly the influenza immunisation rates of high-risk older people (e.g. 
Abramson & Cohen-Naor, 2000; Armstrong, Berlin, Schwartz et al., 2001; 
Madhavan, Rosenbluth, Amonkar et al., 2003; Wray, Jupka, Ross et al., 2007). 
It has been suggested that people’s lay beliefs can be changed in the light of new 
experiences and the availability of believable information (Donovan, 1991). Thus, 
health care workers should first acknowledge the patients’concerns and provide 
accurate information about the benefits and risks of the influenza vaccines, as well as 
correcting their misconceptions, to encourage them to take up the immunisation.
4.4 Factors influencing influenza vaccination
4.4.1 Socio-demographic factors
Socio-demographic factors (age, gender, marital status, education level, and socio­
economic status) appeared to influence older adults’ decisions in seeking vaccination, 
although the results of these many studies have been mixed (Russell & Maxwell, 
2000; Bonito, Lenfestey, Eicheldinger et al., 2004; Chi & Neuzil, 2004; Mangtani, 
Breeze, Kovats et al., 2005; Tabbarah, Zimmerman, Nowalk et al., 2005; Bryant, 
Ompad, Sisco et al., 2006; Straits-Troster, Kahwati, Kinsinger et al., 2006; Damiani, 
Federico, Visca et al., 2007; Endrich, Blank, & Szucs et al., 2009; Zimmerman, 
Nowalk, Tabbarah et al., 2009; CDC, 2010; Chiatti, Rosa, Barbadoro et al., 2010; 
Jimenez-Garcia, Hemandez-Barrera, de Andres et al., 2010).
4.4.1.1 Age
Several studies have documented that older age was positively associated with 
influenza vaccine acceptance (Landi, Onder, Carpenter et al., 2005; Tabbarah, 
Zimmerman, Nowalk et al., 2005; de Andres, Carrasco-Garrido, Hemandez-Barrera et 
al., 2006; Lau, Yang, X., & Tsui, et al., 2006; Kohlhammer, Schnoor, Schwartz et al., 
2007; Jimenez-Garcia, Jimenez, Carrasco-Garrido et al., 2008; Jimenez-Garcia, 
Hemandez-Barrera, Carrasco-Garrido, 2009). In the United States, Tabbarah,
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Zimmerman, Nowalk et al. (2005) conducted a longitudinal survey to examine factors 
associated with influenza vaccination over the three influenza seasons (2000-2001,
2001-2002, and 2002-2003) in older Americans, and found that the proportion of 
people who reported having been vaccinated was nearly two times higher in the 
elderly people (62.6 per cent) than in individual aged 50 to 64 years (32.4 per cent) 
for all the three consecutive influenza seasons studied.
de Andres, Carrasco-Garrido, Hemandez-Barrera et al. (2006) analysed influenza 
coverage rates and their determinants among the Spanish elderly using data from five 
surveys of the non-institutionalised Spanish adult population (1993, 1995, 1997, 
2001, and 2003). The results also showed a positive association between age and 
being vaccinated; elderly people (75 years or older) were 2.37 times more likely to 
report being immunised against the influenza than individuals aged 65 to 69 years. 
Although a total of 19,141 records of individuals aged 65 years or over were included 
in this study, the findings were perhaps limited by relying on the validity of self- 
reported data. In addition, this research study included only non-instutionalised people 
aged 65 years or over; therefore, its results cannot be generalized to the entire Spanish 
population.
Similar results were obtained from a survey study assessing influenza coverage in 
Spain by Jimenez-Garcia, Mayo-Montero, Hemandez-Barrera et al (2005). The study 
showed that older age was significantly associated with a greater likelihood of having 
been vaccinated (aged 50-64: OR = 2.28 [95% Cl, 1.82-2.85]; aged 65-74: OR = 5.52 
[95% Cl, 4.36-6.99], and aged > 75: OR = 7.18 [95% Cl, 5.47-9.43]).
Additionally, an international observational study examining prevalence of influenza 
immunisation and factors associated with acceptance of the influenza vaccine among 
frail, elderly people living in the community in eleven European countries, found that 
older age has continued to be a positive predictor of influenza vaccination (OR=1.21, 
95% Cl, 1.01-1.46) in most of countries, except for four countries (Finland, Sweden, 
the Netherlands, and United Kingdom) (Landi, Onder, Carpenter et al., 2005). Similar 
results were obtained by Johansen, Sambel, & Zhao (2006) who analysed trends in 
influenza vaccination coverage rates in Canada in the year 2003. The results showed 
that two-third of people aged 65 to 79 years reported having been vaccinated, and a
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higher percentage of people who received influenza vaccine, was observed in people 
age 80 or older More recently, a survey study that examined influenza vaccination 
uptake levels across two influenza seasons (2006-2007 and 2007-2008) in eleven 
European countries by Blank, Schwenkglenks, & Szucs (2009) demonstrated an 
upward trend in influenza vaccination coverage rates among the elderly (65 years or 
older) in all the countries studied.
The relationship between age and having been vaccinated against the influenza was 
likewise observed among older people with chronic medical conditions. The influenza 
vaccination rate has increased with age. Jimenez-Garcia, Carrasco-Garrido, Maya- 
Montero et al. (2005) explored the influenza vaccination status and its determinants in 
diabetic patients in Spain. The study revealed that the probability of getting 
vaccinated against the influenza in people with diabetes aged 65 year or older was 5.8 
times higher than those under 50 years of age. Additionally, three recent studies 
evaluating influenza vaccination coverage rates and factors associated with influenza 
vaccination in patients with chronic diseases (COPD, chronic bronchitis, and 
cardiovascular disease) in Spain have also found that age was an important predictor 
of influenza vaccination, and the rate of immunisation with influenza vaccine among 
these high-risk individuals has risen with increasing age (Jimenez-Garcia, Mayo- 
Montero, Hemandez-Barrera et al., 2005; Jimenez-Garcia, Hemandez-Barrera, 
Carrasco-Garrido, 2006; Jimenez-Garcia, Hemandez-Barrera, Carrasco-Garrido, 
2009). However, Honkanen, Keistinen, & Kivela (1996) investigating determinants of 
influenza vaccination among the elderly living in three districts in Finland, found no 
influence of age and sex on the acceptance of influenza vaccination in the elderly.
The finding that influenza vaccination coverage rates in older people increase 
significantly with age remains unclear. This may be influenced by government targets 
as routine influenza vaccination has been recommended for people in this age group 
in most countries (van Essen, Palache, Forleo et al., 2003). In addition, there is 
evidence that the prevalence of chronic disease requiring the need for influenza 
vaccination is high in individuals aged 65 or older. The study assessing influenza 
vaccination uptake in eleven European countries by Endrich, Blank, & Szucs (2009) 
indicated that people with chronic medical conditions across all countries studied 
consistently had a significant greater likelihood of being immunised than those who
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reported that they did not have any underlying diseases. Jimenez-Garcia, Carrasco- 
Garrido, Maya-Montero et al. (2005) also found that the number of people who had 
underlying medical conditions rose significantly with increasing age in all the 
surveys. Thus, suffering from underlying diseases may be another explanation for an 
increased probability of being vaccinated in older people. However, it should be noted 
that these two studies have relied on retrospective, self-reported data of vaccination, 
and the information on chronic condition status could not be verified by medical 
records, which may lead to under-reporting or over-reporting by participants and 
thereby affect the validity of results. Nonetheless, several studies that compared self- 
reporting of influenza vaccination status with medical records have shown that the 
agreement between two methods was satisfactory (Mac Donald, Baken, Nelson et al., 
1999; Zimmerman, Raymund, Janosky et al., 2003).
Also, high vaccination coverage levels may have been due to the fact that older 
people with chronic diseases are more frequent use of health care service, thus 
providing more chance to be offered or recommended influenza vaccine, especially in 
countries where general practitioners (GPs) play a key role in delivering influenza 
vaccination such as the UK. The study conducted by Booth, Coppin, Dunleavey et al.
(2000) in central southern England during early 1998 showed that seventy-one per 
cent to eighty-two per cent of GPs reported that they routinely offered influenza 
immunisation to their at risk patients. Another British study revealed that one hundred 
and fifty-two older people reported having been offered vaccination and seventy-one 
percent of these individuals were subsequently vaccinated (Gosney, 2000).
4.4.1.2 Gender
Gender has been reported to be associated with the acceptance of influenza 
vaccination in some studies. However, the effect has varied between studies (Szucs & 
Muller, 2005; Jimenez-Garcia, Hemandez-Barrera, Carrasco-Garrido et al., 2006; 
Jimenez-Garcia, Jimenez, Carrasco-Garrido et al., 2008; Jimenez-Garcia, Hemandez- 
Barrera, Carrasco-Garrido, et al., 2009, Jimenez-Garcia, Hemandez-Barrera, de 
Andres et al., 2010; Kee, Lee, Cheong et al., 2007; Bean-Mayberry, 2009; Endrich, 
Blank, & Szucs, 2009). A population-based study to assess influenza vaccination 
coverage rates in five European countries over two influenza seasons (2001-2002 and
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2002-2003) conducted by Szucs & Muller (2005), indicated that a significant higher 
vaccination rate was found for women in comparison to men.
Similarly, Russell and Maxwell (2000) examined the prevalence and factors relating 
to influenza vaccination in a home care population. The results of this study showed 
that the percentage of people who reported having been vaccinated against influenza 
was higher among women than men (63.1 per cent vs. 54.9 per cent). Recently, in 
South Korea, Kee, Lee, Cheong et al. (2007) also found that women relative to men 
were significantly more likely to be immunised against influenza (OR = 1.41, 95% 
Cl, 0.97-2.06).
In contrast, other studies have shown that the percentage of people who reported 
having been vaccinated was higher in men than in women (Bonito, Lenfestey, 
Eicheldinger et al., 2004; Jimenez-Garcia, Hemandez-Barrera, Carrasco-Garrido, 
2006, Jimenez-Garcia, Hemandez-Barrera, Carrasco-Garrido et al., 2009, Jimenez- 
Garcia, Hemandez-Barrera, de Andres et al., 2010; Endrich, Blank, & Szucs, 2009). 
The study that explored influenza vaccination uptake among non-institutionalised 
Medicare Beneficiaries during 2000-2002, indicated that there was a significant 
difference in vaccination rates between the genders over the study period; a higher 
proportion of vaccinated people was found in men (Bonito, Lenfestey, Eicheldinger et 
al., 2004). A survey study of predictors of influenza vaccination in eleven European 
countries showed that the likelihood of receiving the influenza vaccine was higher 
among men than women in Italy (OR = 1.43), Portugal (OR = 1.41), Spain (OR = 
1.37), Czech Republic (OR = 1.34), Poland (OR = 1.29), France (OR = 1.26), and the 
UK (OR = 1.21), but not in Germany, Austria, Finland, and Ireland (Endrich, Blank, 
& Szucs, 2009).
Likewise, a study of gender influence on the acceptance of influenza vaccination 
among Spanish by Jimenez-Garcia, Hemandez-Barrera, de Andres et al. (2010) has 
also shown that men had better influenza coverage rates than women; the likelihood 
of being vaccinated against influenza was 12 per cent higher in men than in women 
(OR = 1.12, 95% Cl, 1.06 - 1.18). Moreover, three recent studies exploring influenza 
coverage rates and the determinants of influenza vaccine uptake in high-risk people 
with chronic diseases (COPD, cardiovascular, and chronic bronchitis) in Spain,
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indicated that the use of influenza vaccine has been higher in men than in women 
among high-risk individuals with chronic disease (Jimenez-Garcia, Hemandez- 
Barrera, Carrasco-Garrido et al., 2006; Jimenez-Garcia, Hemandez-Barrera, Carrasco- 
Garrido et al., 2009). In addition, Jimenez-Garcia, Jimenez, Carrasco-Garrido et al. 
(2008) examined predictors of influenza immunisation among diabetic adults in 
Spain. The study also showed that the likelihood of being vaccinated was higher 
among men than women (OR = 1.37, 95% Cl, 1.01-1.87). The reasons for the low 
uptake of influenza vaccine among women were unclear. However, the authors 
speculated that less social support, differences in the health status and provider bias 
might be responsible for gender differences in influenza vaccine uptake in Spain 
(Jimenez-Garcia, Hemandez-Barrera, de Andres et al., 2010). The relationship 
between influenza vaccination and gender has also been recently reported in the 
United States; a prospective study of 9,164 older people (65 years or older) using data 
drawn from the Health and Retirement Study (HRS) also revealed that women were 
less likely than men to receive an influenza vaccine and to get a cholesterol screening 
(Cameron, Song, Manheim et al., 2010).
4.4.1.3 Marital status
Being married was found to be a positive predictor of influenza vaccination (Russell 
& Maxwell, 2000; Andrew, McNeil, Merry et al., 2004; Nowalk, Zimmerman, Shen 
et al., 2004). Nowalk, Zimmerman, Shen et al. (2004) conducted a survey study to 
examine barriers to pneumococcal and influenza vaccination among elderly people 
living in the community. The result of this study revealed that married people were 
more likely to report having the influenza vaccination during 2000-2001 influenza 
season than those who were widowed, single, or divorced/ separated (83 per cent 
vs.73 per cent widowed, 66 per cent single, 62 per cent divorced/separated). In 
Canada, the study by Russell and Maxwell (2000) also revealed that influenza 
vaccination was higher among married (56.8 per cent) and widowed (68.9 per cent) 
persons than those who were never married (46 per cent) or divorced (37.5 per cent). 
Similarly, a significant higher rate of influenza immunisation was observed among 
married British aged over 74 years relative to non-married individuals (Mangtani, 
Breeze, Kovats et al., 2005). A positive association between marital status and 
influenza immunisation was further illustrated in a population-based cohort study by
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Andrew, McNeil, Merry et al. (2004) that investigated the factors involved influenza 
vaccine uptake in older people aged 65 or older living in the community. The study 
showed that being married was a strong predictor of influenza vaccination among 
these individuals (OR= 1.29, 95% Cl, 1.14 -1.47). The study determining the 
influenza of gender on influenza vaccination also found that among other factors, 
being married was the predictor of influenza vaccination in Spanish women (Jimenez- 
Garcia, Hemandez-Barrera, de Andres et al., 2010). It was suggested that there was 
more social support from within the family among married persons than those in other 
marital categories; therefore, married people were more likely to receive preventive 
services, including influenza vaccination (Russell & Maxwell, 2000).
4.4.1.4 Living with others
In line with the explanation afforded by Russell and Maxwell (2000), living with 
others has also been associated with an increased probability of being immunised 
(Nexoe, Kraqstrup, & Sogaard, 1999; Lau, Kim, Choi et al. 2007). One study 
exploring factors related to influenza vaccine uptake among the elderly in Denmark 
conducted by Nexoe, Kraqstrup, & Sogaard (1999), for example, showed that living 
together with another person was significantly associated with higher likelihood of 
immunisation (OR = 1.59, 95% Cl, 1.03 -  2.48). Likewise, Lau, Kim, Choi et al. 
(2007) assessed the prevalence and determinants of influenza vaccine uptake in 
people aged 65 years and over. The study has shown that the odds of being 
immunised were significantly greater among the elderly living with family members 
than those living alone (OR = 2.05, 95% Cl, 1.27 -  3.33).
By contrast, living alone appeared to be negatively associated with influenza 
vaccination (Bums, Ring, & Carroll, 2005; Landi, Onder, Carpenter et al., 2005; 
Jimenez-Garcia, Hemandez-Barrera, de Andres et al., 2010). The percentage of 
people who reported having been vaccinated against influenza vaccine, was 
significantly lower in older people who lived alone compared to those who lived with 
others (74 per cent vs. 87 per cent, OR = 2.25, 95% Cl, 1.35 -  3.73) (Bums, Ring, & 
Carroll, 2005). A recent study assessing influenza coverage rates in eleven European 
countries conducted by Landi, Onder, Carpenter et al. (2005) confirmed the negative 
relationship between living alone and influenza vaccination; living alone was
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significantly associated with a lower likelihood of being immunised in eight European 
countries (the Netherlands, Denmark, Norway, Sweden, United Kingdom, Germany, 
Iceland, and Italy) (OR = 0.78, 95% Cl, 0.67 -  0.90).
4.4.1.5 Socio-economic status
Socio-economic status is typically indicated by education attainment, occupational 
status and income. Socio-economic factors have been shown to have significant 
influence on influenza vaccine uptake. However, the findings are inconsistent (Sarria- 
Santamera & Timoner, 2003; Bonito, Lenfestey, Eicheldinger et al., 2004; Nowalk, 
Zimmerman, Shen et al., 2004; Bums, Ring, & Carroll, 2005; Mangtani, Breeze, 
Kovats et al., 2005; Damiani, Federico, Visca et al., 2007; Mayo-Montero, 
Hemandez-Barrera, Carrasco-Garrido et al., 2007; Blank, Schwenkglenks, & Szucs, 
2009; Endrich, Blank, & Szucs, 2009; Chiatti, Rosa, Barbadoro et al., 2010).
The study among people aged 65 or older conducted by Bums, Ring, and Carroll, 
(2005) indicated that the likelihood of being immunised against influenza was 
significantly higher for individuals with a higher occupational status (OR = 1.47, 95% 
Cl = 1.09 - 1.98) than the economically less advantaged. Household income was also 
found to be significantly associated with influenza vaccination among the elderly 
living in community during the 2000-2001 influenza season in the study conducted by 
Nowalk, Zimmerman, Shen et al. (2004); persons with higher incomes were more 
likely to receive influenza vaccine than those with lower incomes. In the UK, the 
study conducted by Mangtani, Breeze, Kovats et al. (2005) yielded similar results; a 
lower vaccination rate of 10 per cent was observed in lower socioeconomic status 
people aged over 74 years (those without central heating or in rented accommodation) 
as compared to those of higher socio-economic status.
Likewise, the study by Landi, Onder, Carpenter et al. (2005) found that economic 
problems were associated with a lower probability of receiving influenza vaccine 
among the elderly (OR = 0.58, 95% Cl, 0.45-0.74). In Italy, the study assessing the 
influence of socioeconomic level on influenza vaccine uptake conducted by Damiani, 
Federico, Visca et al. (2007) showed that significant lower percentages of people who 
reported receiving the vaccine were among lower educated persons and those in lower 
occupational classes than individuals in higher categories, especially among
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individuals under 65 years of age. Recently, a survey study examining factors related 
to influenza vaccination among the elderly by Lau, Kim, Choi et al. (2007), also 
found that perceived financial barriers were associated with influenza vaccination 
among the elderly in Hong Kong; people who did not perceive financial barriers were 
more likely to get vaccinated than those who perceived such barriers (OR = 2.14, 95% 
Cl, 1.48-3.10).
In addition to the influence of income and social class, higher rates of influenza 
immunisation have been found to be associated with higher levels of education. 
Bonito, Lenfestey, Eicheldinger et al. (2004) analysed vaccination coverage rates and 
factors related to disparities in influenza vaccination among elderly Medicare 
Beneficiaries over three years (2000 -  2002). The results of this study also found that 
influenza vaccination rates rose significantly with levels of education. This 
relationship was confirmed in a Canadian study; Andrew, McNeil, Merry et al. 
(2004) have observed that high-level education was significantly associated with 
influenza vaccination among Canadian seniors (OR = 1.05, 95% Cl, 1.03-1.07).
Additionally, a prospective study comparing two cohorts of older adults (vaccinated 
and unvaccinated against influenza and pneumococcal infections) in Stockholm 
County, Sweden by Christenson and Lundbergh (2002) also revealed that vaccination 
rates for both influenza and pneumococcal infections were significantly higher among 
older people (aged 65 or older) with higher education than those with little education. 
Similar results were obtained from the US Behavioural Risk Factor Surveillance 
System (BRFSS); the elderly with higher levels of education were more likely to be 
immunised against influenza than those with less than a high school education (CDC, 
2001).
Nevertheless, a negative influence of socioeconomic level on influenza vaccine 
uptake has been reported (Jimenez, Larrauri, Carrasco-Garrido et al., 2003; Nowalk, 
Zimmerman, Shen et al., 2004; Szucs & Muller, 2005; Blank, Schwenkglenks, & 
Szucs, 2009; Endrich, Blank, & Szucs, 2009; Chiatti, Rosa, Barbadoro et al., 2010). 
The results of a study conducted by Nowalk, Zimmerman, Shen et al. (2004), for 
example, revealed that a significantly higher proportion of people who completed 
vocational or technical school received influenza vaccine during the 2000-2001
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influenza season than that among those with college degrees. Two recent studies 
conducted by Blank, Schwenkglenks, and Szucs (2009) and Endrich, Blank, and 
Szucs (2009) have also found that a higher education level was negatively associated 
with influenza vaccination. Also, Damiani, Federico, Visca et al. (2007) observed a 
greater likelihood of being vaccinated against influenza in persons without any 
qualification relative to those with a university degree among individuals aged 25-44 
years (OR = 2.07, 95% Cl, 1.41 -  3.04).
A survey study analysing trends in influenza vaccination coverage rates in five 
European countries by Blank, Schwenkglenks, and Szucs (2009) also showed that, 
while vaccination rates were lower among individuals with higher education levels 
compared to lower educated person in Italy (OR = 0.6), the reverse effect was found 
for Spain; a greater proportion of persons who reported having been vaccinated was 
found among graduates (OR = 1.4). Likewise, the study among people with chronic 
obstructive pulmonary disease has also shown that individuals who had no formal 
education had the highest likelihood of obtaining the influenza vaccination (OR = 
3.19, 95% Cl, 2.47 -  4.13) (Jimenez-Garcia, Mayo-Montero, Hemandez-Barrera et 
al., 2005).
With regard to a negative effect of household incomes on influenza vaccine uptake, 
Jimenez, Larrauri, Carrasco-Garrido et al. (2003) explored influenza vaccination 
coverage rates and their determinants in individuals aged 50-64 years. The result of 
this study found that low-income people (less than €600 per month) had a higher 
prevalence of influenza vaccination, as compared to those with higher incomes (more 
than €1,200 per month) (OR = 1.71, 95% Cl, 1.14 - 2.56). Szucs and Muller (2005) 
have observed a greater vaccination rate in persons with a monthly income of less 
than €1,000 relative to those with monthly income over € 2,000 per month (29.9 per 
cent vs. 21.0 per cent).
Similar results were obtained in a study examining influenza vaccination coverage 
levels in five European countries (The United Kingdom, Germany, Italy, France, and 
Spain) by Blank, Schwenkglenks, and Szucs (2009). The study also showed that in 
Germany and Spain, people with a lower income (less than € 2,499 per month) were 
significantly more likely to receive influenza vaccine than those with a higher income
90
(> € 2,500 per month). Chiatti, Rosa, Barbadoro et al. (2010) recently reported 
findings that a higher likelihood of being immunised against influenza has been 
observed among individuals in lower social classes as compared to those from upper 
social classes (OR = 1.21, 95% Cl, 1.11-1.33). However, no association was seen 
between educational levels, household incomes and influenza vaccination in the study 
conducted in Spain by Sarria-Santamera and Timoner (2003).
One may predict that higher socioeconomic status would positively influence 
influenza vaccine uptake. Individuals with higher education level and monthly income 
can access more information on influenza and its consequences; therefore they can 
better understand and potentially make the decision to receive influenza vaccine 
(Blank, Schwenkglenks, & Szucs, 2009). However, the impact of socioeconomic 
status on influenza vaccination is controversial. One possible explanation may be that 
other factors such as mistrust of modem medicine and the perception of good health 
may exert influence on the decision to receive influenza vaccine (Conford & Morgan, 
1999; Telford & Rogers, 2003). Additionally, the provision of free vaccination for 
older people in many countries may partially explain why higher socioeconomic 
status did not have a positive influence on influenza vaccine uptake (Mangtani, 
Breeze, Kovats et al., 2005; Blank, Schwenkglenks, & Szucs, 2009; Endrich, Blank, 
& Szucs, 2009).
4.4.2 Health status/conditions
4.4.2.1 Healthy lifestyles
A higher influenza vaccination rate among people with healthy lifestyles (such as 
non-smokers and those who exercise regularly) has been found previously 
(Nicholson, Kent, & Hammersley, 1999; Sarria-Santamera & Timoner, 2003; 
Mangtani, Breeze, Kovats et al., 2005; de Andres, Carrasco-Garrido, Hemandez- 
Barrera et al., 2006; Jimenez-Garcia, Hemandez-Barrera, Carrasco-Garrido et al., 
2006; Nowalk, Zimmerman, Tabbarah et al., 2006; Kee, Lee, Cheong et al., 2007; 
Mayo-Montero, Hemandez-Barrera, Carrasco-Garrido et al., 2007). A survey study 
conducted in South Korea by Kee, Lee, Cheong et al. (2007) revealed that people who 
took regular exercise were more likely to get vaccinated than those who did not 
exercise (OR = 1.49, 95% Cl, 1.09 - 2.03).
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Likewise, the study assessing trends in influenza vaccination coverage rates and 
factors associated with influenza vaccination over five influenza seasons among the 
elderly in Spain by de Andres, Carrasco-Garrido, Hemandez-Barrera et al. (2006) 
found a greater likelihood of being immunised among ex-smokers (OR =1.81 95% 
Cl, 1.35 - 2.41) and those who had never smoked (OR = 1.64, 95% Cl, 1.22 -  2.20), 
as compared to active smokers. Additionally, Nicholson, Kent, and Hammersley 
(1999) indicated a 13 per cent decrease in the odds of being immunised against 
influenza in individuals current smoking status relative to the ex-smokers and non- 
smokers (OR = 0.87, 95% Cl, 0.76 -  0.99). The study among individuals with chronic 
respiratory diseases conducted by Mayo-Montero, Hemandez-Barrera, Carrasco- 
Garrido et al. (2007) found that ex-smokers (OR = 2.62, 95% Cl, 2.04 - 3.37) and 
those who had never smoked (OR = 1.97, 95% Cl, 1.57 -  2.47) were more likely to 
receive influenza vaccine than smokers.
In addition, Sarria-Santamera and Timoner (2003) found that smoking was a negative 
determinant of influenza immunisation (OR = 1.92, 95% Cl, 1.24 -  2.96). More 
recently, the study conducted by Jimenez-Garcia, Hemandez-Barrera, Carrasco- 
Garrido et al. (2009) also found that the higher probability of getting vaccinated 
against influenza was seen in people with healthy lifestyles such as non-smokers (OR 
= 1.80, 95% Cl, 1.23 -  2.62), ex-smokers (OR = 1.73, 95% Cl, 1.20 -  2.50), and those 
who took physical exercise (OR = 1.46, 95% Cl, 1.13-1.88) compared to people with 
less healthy lifestyles (smokers and those who did not exercise). As people with 
healthy lifestyles may be more concerned about their health, and may have more 
interest in the use of preventive services, including influenza vaccination; therefore, 
this may be credited with the higher rate among these individuals (Andrew, McNeil, 
Merry et al., 2004; Kee, Lee, Cheong et al., 2007).
4.4.2.2 Cognitive impairment
Cognitive impairment has been shown to be associated with lower rates of influenza 
vaccination in older adults (Landi, Onder, Carpenter et al., 2005; Mangtani, Breeze, 
Kovats et al., 2005). The study conducted by Landi, Onder, Carpenter et al. (2005) in 
eleven European countries (Czech Republic, Denmark, Finland, France, Germany, 
Iceland, Italy, The Netherlands, Norway, Sweden, and the UK), indicated that the
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odds of being immunised were significantly lower for individuals with cognitive 
impairment in all the countries studied (OR = 0.69, 95% Cl, 0.59 -  0.80). Similarly, 
Mangtani, Breeze, Kovats et al. (2005) also found disparities in influenza vaccination 
uptake between people aged over 74 years who had cognitive impairment and those 
with no cognitive problems.
4.4.2.3 Presence of underlying chronic medical conditions
A number of studies have shown that the existence of co-morbidities was associated 
with influenza vaccination, both for older people (aged 65 years or older) and those 
under 65 years with chronic medical conditions aged (Jimenez, Larrauri, Carrasco- 
Garrido et al., 2003; Jimenez-Garcia, Mayo-Montero, Hemandez-Barrera et al., 2005; 
Jimenez-Garcia, Hemandez-Barrera, Carrasco-Garrido et al., 2006; Horby, Williams, 
Burgess et al., 2005; Landi, Onder, Carpenter et al., 2005; de Andres, Carrasco- 
Garrido, Hemandez-Barrera et al., 2006; Chen, Yi, Wu et al., 2007; Chiatti, Rosa, 
Barbadoro et al., 2010). Although there were consistent findings across theses studies, 
the findings were limited by their cross-sectional designs. In addition, data on 
influenza vaccination uptake and chronic medical conditions were based on self- 
report.
A cross-sectional study that analysed trends in influenza immunisation coverage 
levels (1993-2003) among elderly people in Spain by de Andres, Carrasco-Garrido, 
Hemandez-Barrera et al. (2006) found that there was a 1.58-fold increase in the odds 
of being vaccinated in elderly people who presented with co-morbidity compared to 
those without co-morbidity (OR = 1.58, 95% Cl, 1.34 -  1.86). A population-based 
study that assessed the influenza vaccination coverage levels in eleven countries by 
Landi, Onder, Carpenter et al. (2005) has shown that the presence of co-morbidity 
increased the odds of having influenza vaccination among the elderly in eleven 
European countries (OR = 1.26, 95% Cl, 1.08 -  1.47). In addition, Blank, 
Schwenkglenks, and Szucs (2009) indicated that the presence of chronic diseases and 
being older augmented the adjusted odds ratio of being vaccinated (odds ratios = 20.1, 
95% Cl, 16.6 -  24.4) in all five European countries (the United Kingdom, Germany, 
Italy, France, and Spain) in the 2007-2008 influenza season.
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The association between presence of chronic disease and having influenza vaccination 
in older people was further illustrated in the study conducted in Italy by Chiatti, Rosa, 
Barbadoro et al. (2010). The study demonstrated that the chance of being vaccinated 
in older Italians increased with disease severity (mild disease: OR = 1.43, 95% Cl, 
1.33-1.55; severe disease: OR = 1.97, 95% Cl, 1.82-2.14). In Spain, Jimenez-Garcia, 
Jimenez, Carrasco-Garrido et al. (2008) also found that among the elderly, the 
likelihood of vaccination increased with age and the presence of underlying chronic 
disease.
Several authors have found that having chronic disease was significantly associated 
with a greater probability of getting vaccinated among adults aged less than 65 years 
(Jimenez, Larrauri, Carrasco-Garrido et al., 2003; Jimenez-Garcia, Mayo-Montero, 
Hemandez-Barrera et al., 2005; Jimenez-Garcia, Hemandez-Barrera, Carrasco- 
Garrido et al., 2006; Horby, Williams, Burgess et al., 2005; Chen, Yi, Wu et al., 
2007). In Spain, Jimenez, Larrauri, Carrasco-Garrido et al. (2003) conducted a survey 
study among adults aged 50 to 64 years. The results showed that the probability of 
being vaccinated was three times higher if the person had a chronic disease (OR = 
3.07, 95% Cl, 2.18 -  4.33). A further study describing the evolution of influenza 
vaccination coverage rates in adults from 1993-2001 indicated that the presence of 
chronic medical conditions had an important influence on influenza vaccination; a 
significantly higher number of persons who reported having been vaccinated was seen 
in individuals with chronic diseases (asthma, diabetes, chronic bronchitis, and 
cardiovascular disease) throughout the studied period, regardless of age group, as 
compared to those without such diseases (age < 65 years: 31.24 per cent vs. 9.17 per 
cent; age > 65 years: 61.86 per cent vs. 47.95 per cent) (Jimenez-Garcia, Mayo- 
Montero, Hemandez-Barrera et al., 2005).
Other studies conducted in Australia and Canada, have also found the influence of 
high-risk medical conditions on influenza vaccine uptake. A national survey assessing 
the influenza vaccination coverage rates and factors related to influenza immunisation 
among Australian adults by Horby, Williams, Burgess et al. (2005), found that 
medical risk factor has been shown to be a significant predictor of influenza 
vaccination among individuals aged 40 to 64 years (OR = 4.8, 95% Cl, 3.1- 3.4).
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Despite a large sample size (63,317) in this national survey, the results should be 
interpreted with caution due to the relatively low response rate (30%), indicating that 
this could have resulted in selection bias and limited generalisability of the results.
Additionally, analysis of data drawn from the Canadian Community Health Survey by 
Chen, Yi, Wu et al. (2007) indicated that the higher number of chronic diseases, the 
greater the likelihood of being immunised; there were two to three times greater 
proportion of influenza vaccination among individuals with four chronic conditions 
compared to those with only one chronic condition. Jimenez-Garcia, Hemandez- 
Barrera, Carrasco-Garrido et al. (2006) examined trends in influenza vaccination 
coverage in Spain from 1993 to 2003 among cardiovascular disease (CVD) sufferers. 
The odds of being immunised against influenza among CVD patients who also 
suffered from respiratory chronic diseases was significantly higher, as compared to 
those without a concomitant respiratory disease (OR = 1.97, 95% Cl, 1.46 -  2.67). 
Also, Mayo-Montero, Hemandez-Barrera, Carrasco-Garrido et al. (2007) observed 
that people with chronic respiratory disease who had a concomitant disease were 
significantly more likely than those without concomitant diseases to have received 
influenza vaccination (OR = 1.21, 95% Cl, 1.03 -  1.50). The same results were 
obtained for people with chronic bronchitis; more patients with chronic bronchitis 
who had concomitant asthma or diabetes tended to be immunised than those without 
these concomitant diseases (asthma: OR = 1.45, 95% Cl, 1.11 -  1.90; diabetes: OR = 
1.54, 95% Cl, 1.08-2.19).
An explanation related to the higher rate of influenza vaccination in people with 
chronic medical conditions may be because these high-risk individuals considered 
themselves as being in poor health and more frequently visited physicians; thus 
providing more opportunity to be immunised against influenza (Kohlhammer, 
Schnoor, Schwartz et al., 2007).
4.4.3 Beliefs, knowledge and attitude about influenza and the influenza vaccine
Individual-level factors such as knowledge, attitude towards and beliefs about 
influenza and influenza vaccine have been found to have a significant influence on the 
decision to receive influenza vaccine (Honkanen, Keistinen, & Kivela, 1996; Gosney,
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2000; Santibanez, Nowalk, Zimmerman et al., 2002; Takahashi, Noguchi, Rahman,et 
al., 2003; Zimmerman, Nowalk, Raymund et al., 2003; Chi & Neuzil, 2004; Nowalk, 
Zimmerman, Shen et al., 2004; Brunton, Weir, & Jennings, 2005; Adonis-Rizzo & 
Jett, 2007; Keenan, Campbell, & Evans, 2007; Lyn-cook, Halm, & Wisnivesky, 2007; 
Kwong, Lam, & Chan, 2009). In the United States, Santibanez, Nowalk, Zimmerman 
et al. (2002) examined knowledge and beliefs influencing the decision to get 
vaccinated against influenza and pneumococcal diseases. The study showed that the 
unvaccinated were significantly more likely than vaccinated persons to report that 
they did not know the symptoms of influenza. In addition, a significantly higher 
proportion of those vaccinated mentioned the severity of the influenza as a motivating 
factor for influenza immunisation (i.e. “feel so miserable, never want to get it again”).
A case-control study investigating the determinants of influenza vaccine uptake 
among Japanese people by Takahashi, Noguchi, Rahman et al. (2003) showed that 
knowledge about the influenza vaccine was significantly associated with acceptance 
of influenza immunisation (OR = 3.06, 95% Cl, 1.02 -  9.20). Additionally, a cross- 
sectional study that examined influenza coverage rates in former West Germany in the 
1999-2000 influenza season demonstrated that the decision to be vaccinated against 
influenza was influenced by positive attitude towards vaccination and the belief that 
influenza was a severe disease (OR = 7.8, 95% Cl, 1.9 -  68.9; OR = 3.1, 95% Cl, 0.7 
-28.3, respectively) (Rehmet, Ammon, Pfaff et al., 2002).
Likewise, Brunton, Weir, and Jennings (2005) explored knowledge, attitude and 
beliefs toward influenza immunisation among the elderly (aged 65 and older) in New 
Zealand during the 2001-2002 influenza seasons. The study has found some 
significant differences in knowledge, attitude, and beliefs between the vaccinated and 
unvaccinated persons. These differences included: “an influenza injection will reduce 
your risk of becoming seriously ill from influenza and from the complications of 
influenza” (91 per cent vs. 45 per cent), “healthy older people are at just as much risk 
of getting influenza as older people with chronic illness” (54 per cent vs. 43 per cent), 
“people can get influenza from the flu shot” (21 per cent vs. 54 per cent), “people can 
get sick from the flu shot” (22 per cent vs. 52 per cent), and “I don’t need an influenza 
injection as I rarely get sick” (5 per cent vs. 64 per cent).
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Other studies have also shown that positive beliefs about influenza and influenza 
vaccine significantly increased the likelihood of vaccination among the elderly aged 
65 or older and people with chronic medical conditions aged less than 65 years, 
including “persons who does not get flu shot will probably get the flu” (OR = 5.4, 
95% Cl, 2.4 -  12.0), “flu shots are a good idea (OR = 3.4), “getting the flu shot is 
wise” (OR =13,  95% Cl, 6.2 -  26) “Influenza vaccination gives a good protection 
against the flu” (OR = 2.05, 95% Cl, 1.45 -  2.89), “I would rather have a flu shot 
than get the flu” (OR = 2.7), “If I don’t get vaccinated will probably get the flu” (OR 
= 3.7, 95% Cl, 2.2 -  6.3) (Santibanez, Nowalk, Zimmerman et al., 2002; Zimmerman, 
Nowalk, Raymund et al., 2003; Chi & Neuzil, 2004; Nowalk, Zimmerman, Shen et 
al., 2004; Keenan, Campbell, & Evans, 2007).
In addition, a positive association between the perceived seriousness of influenza and 
influenza vaccine acceptance has been previously documented. For example, a study 
conducted in Finland by Honkanen, Keistinen, and Kivela (1996) found that when 
383 elderly people were asked to express their opinion about the seriousness of 
influenza, 15 per cent of the 383 persons considered that influenza was a mild disease, 
and 33 per cent of these individuals had been immunised. Sixty-six per cent of the 383 
persons felt that it was quite serious, and 52 per cent of these people had been 
vaccinated. Only nineteen per cent of the 383 persons thought that influenza was 
serious; of these, seventy per cent of these individuals reported having been 
immunised against influenza.
People are also more likely to vaccinate if they perceived influenza vaccine to be 
effective in preventing influenza and its complications. A national survey study 
assessing influenza vaccination coverage levels and their determinants conducted by 
Horby, Williams, Burgess et al. (2005) indicated that the belief that influenza vaccine 
was effective strongly predicted influenza immunisation in elderly Australians (aged 
65 years and older) (OR = 13.5, 95% Cl, 10.6 -  17.2). Gosney (2000) revealed that 
ninety-five per cent of vaccinated people thought that the influenza vaccine was 
effective in preventing influenza and its complications, compared with only 30 per 
cent of unvaccinated persons. Similar perceptions have been reported in other studies. 
These include: “vaccination prevents me from catching influenza” (OR = 12.18, 95% 
Cl = 3.61-41.07, “If I get vaccinated, I will decrease the frequency of medical
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consultation” (OR = 8.12, 95% Cl, 2.70 -  24.38), “The flu vaccine can prevent 
influenza” (OR = 10.55, 95% Cl, 3.42-32.49), and “Influenza vaccine was effective 
for the prevention of an asthma attack” (OR = 7.21, 95% Cl, 2.25 -  23.10) 
(Takahashi, Noguchi, Rahman, et al., 2003; Lyn-cook, Halm, & Wisnivesky, 2007; 
Kwong, Lam, & Chan, 2009).
Conversely, a number of studies have shown that a perceived lack of efficacy of 
influenza vaccine, and that “getting a flu shot is more trouble than it is worth” (OR = 
0.12, 95% Cl, 0.03 -  0.45), that “the side-effects of influenza vaccination interfere 
with my usual activities” (OR = 0.04, 95% Cl, 0.01 -  0.13), that “ immunisation is 
inconvenient” (OR = 0.14, 95% Cl, 0.05-0.36), and that “influenza vaccination is 
painful” (OR = 2.73, Cl, 1 .55-4.81) were significantly associated with the likelihood 
of not being vaccinated (Frank, Henderson, & McMurray, 1985; Armstrong, Berlin, 
Schwartz et al., 2001; Takahashi, Noguchi, Rahman et al., 2003; Zimmerman, 
Nowalk, Raymund et al., 2003; Nowalk, Zimmerman, Shen et al., 2004; Kwong, 
Lam, & Chan, 2009).
Additionally, the study evaluating prevalence and determinants of influenza 
vaccination uptake among the elderly living in the community conducted by Lau, 
Kim, Choi, et al. (2007) showed that the likelihood of immunisation was significantly 
lower among those who did not know about the duration of immunity after influenza 
vaccination (OR = 0.54, 95% Cl, 0.30 -  1.00), and those who did not know about the 
place to get vaccination (OR = 0.21, 95% Cl, 0.11 — 0.39). Evans and Watson (2003) 
also found an association between a negative view on the effectiveness and safety of 
the influenza vaccine and non-uptake of influenza vaccination in community-dwelling 
elderly people.
The research reviewed here suggests that beliefs, knowledge, and attitudes about 
influenza and the influenza vaccine undoubted play a significant role in the decision­
making process on influenza vaccination, although other factors such as influence of 
others (i.e. health care providers, family and friends), cost of influenza vaccine, 
convenient access to vaccination services, self-perceived health status, previous 
experience of influenza vaccination, and the use of healthcare services also affect 
such decisions. These factors are discussed in subsequent sections in more detail.
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4.4.4 Influence of others
Health care provider’s recommendation or prompt from family/ friends has been 
identified as a strong predictor of influenza vaccination (CDC, 1988; Honkanen, 
Keistinen, & Kivela 1996; Evans & Watson, 2003; Zimmerman, Nowalk, Raymund et 
al., 2003; Nowalk, Zimmerman, Shen et al., 2004; Sengupta, & Strauss 2004; 
Tabbarah, Zimmerman, Nowalk et al., 2005; Kohlhammer, Schnoor, Schwartz et al., 
2007; Lyn-cook, Halm, & Wisnivesky, 2007; Blank, Freiburghaus, Schwenkglenks et 
al., 2008; Lau, Lau, & Lau, 2009). According to a survey of knowledge, attitudes, and 
practices about influenza and pneumococcal vaccinations among the elderly aged 65 
or older in DeKalb and Fulton counties, Georgia by the CDC, the strongest factor 
associated with influenza immunisation was a provider recommendation for 
vaccination. Advice from health care providers is markedly important, even among 
people who had a negative attitude to vaccination. The result showed that among 
those with negative attitudes towards influenza vaccination (such as influenza vaccine 
was not effective against influenza, and the vaccine was unnecessary), a significantly 
higher vaccination rate was found among those whose health care providers strongly 
recommended the vaccine as compared to those whose health care providers did not 
so recommend (prevalence ratio = 10.8, 95% Cl, 7.3 -  16.0) (CDC, 1988).
Honkanen, Keistinen, and Kivela (1996) has also documented this phenomenon 
among Finnish people; the information received from health visitors contributed to 
increasing influenza vaccine acceptance, even among those with an unfavourable 
attitude to vaccination. A further study exploring the determinants of non-vaccination 
among the elderly aged 65 and older conducted by Nowalk, Zimmerman, Shen et al 
(2004) showed that a belief that “my doctor thinks I should get the flu shot” was 
significantly associated with a greater likelihood of being immunised (OR = 11.4, 
95% Cl, 3.9 -  33.3). Additionally, Zimmerman, Nowalk, Raymund et al. (2003) 
found that a large percentage of the people who reported having been vaccinated were 
influenced by advice or information provided by a health professional (98 per cent vs. 
63 per cent). The results of this study confirmed that a strong association existed 
between the likelihood of vaccination and provider recommendation on influenza 
immunisation (OR = 6.4, 95% Cl, 2.5 -  17).
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Sengupta, and Strauss, (2004) interviewed 28 non-institutionalised elderly aged 65 
and older in North Carolina, and found that a reminder from physician to get 
vaccinated against influenza and the perceived effectiveness of the influenza vaccine 
were identified as important facilitators of influenza vaccination.
Similar results were seen in the study by Tabbarah, Zimmerman, Nowalk et al. (2005) 
that investigated the predictors of influenza vaccination across three influenza seasons 
(2000-2001 to 2002-2003). The study found that the decision about influenza 
immunisation was strongly affected by advice from health care providers, family 
members or friends, together with perceived risk for influenza (OR = 15.03, 95% Cl, 
5.53-40.85).
Other studies have also shown that provider recommendation was found to be 
strongly predictive of influenza vaccination (Evans & Watson, 2003; Kohlhammer, 
Schnoor, Schwartz et al., 2007; Lyn-cook, Halm, & Wisnivesky et al., 2007; Lau, 
Lau, & Lau, 2009). Perenboom and Davidse (1996) demonstrated the value of 
personal invitation by the general practitioner in promoting influenza vaccination 
uptake in the Netherlands, showing that influenza vaccination coverage rates 
increased from 42 per cent to 75.5 per cent. This study confirms that recommendation 
or reminder from the health care provider strongly influences older people's decisions 
to be vaccinated.
On the other hand, a lack (or perceived lack) of recommendations from health care 
providers has been found to correlate with lower acceptance of vaccination against 
influenza (Fiebach &Viscoli, 1991; Nichol & Zimmerman, 2001). Fiebach and 
Viscoli (1991) investigated the factors related to non-acceptance influenza vaccine 
among elderly people aged 65 years or older. The results of this study revealed that 
the likelihood of non-vaccination was 5.8 times higher for people who reported that 
their providers had not recommended influenza vaccine compared with those whose 
health care providers recommended it (OR = 5.8, 95% Cl, 2.5 -  13.2). The study that 
examined factors associated with non-vaccination by Evans and Watson (2003) also 
found that lack of advice from a doctor or nurse predicted the non-uptake of influenza 
vaccination in community-dwelling elderly people.
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Additionally, Evans, Prout, Prior et al. (2007) conducted 54 in-depth interviews with 
people aged 65 and older regarding their lay beliefs about influenza vaccination in 
South Wales, United Kingdom. The authors found that six vaccine defaulters and four 
vaccine refusers would be vaccinated against influenza if the General Practitioners 
(GPs) recommended that they should get influenza vaccine. More recently, a study 
examining influenza vaccination coverage trends 2001-2002 to 2006-2007 in the UK 
also showed that no recommendation from health care providers was cited as the most 
important reason for non-compliance with influenza vaccination (Blank, 
Freiburghaus, Schwenkglenks et al., 2008).
In reviewing the research on determinants of influenza vaccination, several large-and 
medium-scale studies emphasised a health care worker’s recommendation, especially 
the recommendation of a doctor, as a key factor influencing uptake. Thus, doctors and 
other healthcare workers have a substantial opportunity to improve influenza 
vaccination coverage by providing clear information about influenza and the benefit 
of vaccination to their patients and actively promoting influenza vaccination 
programmes.
In addition to the influence of health care professionals, family or friends appeared 
to influence the decision to be vaccinated among older people. The study by 
Takahashi, Noguchi, Rahman et al. (2003) found that the recommendation by a family 
member and /or a close friend was significantly associated with the acceptance of 
influenza vaccination among Japanese patients (OR=17.74, 95% Cl, 1.95-161.7). 
Similarly, the study assessing prevalence and determinants of influenza vaccination 
among non-institutionalised elderly people conducted by Lau, Lau, and Lau (2009) 
indicated that the elderly were more likely to receive influenza vaccine if they receive 
a prompt about influenza vaccination from family members or friends (OR = 3.02, 
95% Cl, 1.61-5.68).
Other studies have also shown that encouragement from family and friends had a 
significant impact on influenza immunisation uptake (Zimmerman, Nowalk, 
Raymund et al., 2003; Tabbarah, Zimmerman, Nowalk et al., 2005; Nowalk, 
Zimmerman, Tabbarah et al., 2006). In contrast, a British study that examined the 
influenza vaccination rates and determinants of non-compliance with influenza
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vaccination among the elderly living in the community by Evans and Watson (2003) 
found that the advice from friends was associated with a lower likelihood of being 
vaccinated; the elderly who had received advice from friends were less likely to 
receive the influenza vaccine than those who reported that they did not receive advice 
from friends (OR = 0.4, 95% Cl, 0.2 -  0.7). Some studies conducted in the US and 
other western countries also found that advice from family and friends was not 
significant predictor of influenza vaccination (Nicholas, Fiebach, Catherine et al., 
1991; Nichol, Mac Donald, & Hauge, 1996; van Essen, Kuyvenhoven, & de melker, 
1997).
The influence of family and friends has been shown to have a positive effect on older 
people’s decisions about whether or not to receive the influenza vaccine in some 
countries, and this effect appears to be strong in Chinese and Japanese culture 
(Takahashi, Noguchi, Rahman et al., 2003; Lau, Lau, & Lau, 2009). Therefore, it is 
reasonable to take this factor into account when developing strategies for promoting 
influenza vaccination.
4.4.5 Accessibility factors
The accessibility factors include the cost of influenza vaccine and convenient access 
to vaccination services. Previous studies have shown the importance of accessibility 
factors in predicting influenza immunisation (Nex0e, Kraqstrup, & Sogaard, 1999; 
Bums, Ring, & Carroll, 2005; Lau, Kim, Choi et al., 2007). In Denmark, the 
likelihood of getting vaccinated against influenza was higher among the elderly who 
lived in Copenhagen where influenza vaccines were offered free-of-charge (OR = 
6.17, 95% Cl, 3.20 -  11.90) (Nexoe, Kraqstrup, & Sogaard, 1999).
The study conducted by Kroneman, Paget, and van Essen (2003) indicated that 
countries that provided free influenza vaccines for the elderly achieved higher rates of 
influenza vaccination than other countries where co-payment systems have been 
implemented. In addition, one study conducted in the United States has shown that 
health insurance was a significant predictor of influenza immunisation, especially 
among adults aged less than 65 years (Figaro & Belue, 2005). A further study that 
explored prevalence and factors associated with influenza vaccination among non­
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institutionalised elderly people in Hong Kong by Lau, Lau, and Lau (2009) also 
showed that “consideration of vaccination if all people aged 65 or above were eligible 
to receive free vaccination” significantly predicted influenza vaccination (OR = 3.02, 
95% Cl, 1.5-6.08).
Convenient access to vaccination service was also found to be associated with 
influenza vaccination (Nichol, Lofgren, & Gapinski, 1992; Bums, Ring, & Carroll,
2005). Bums, Ring, and Carroll (2005) examined factors related to influenza 
vaccination uptake among elderly people living in the community. The results of this 
study showed that having a car or being able to walk to the vaccination clinic 
increased the likelihood of receiving an influenza vaccine (OR = 1.67, 95% Cl, 1.00- 
2.78). On the other hand, a survey study of influenza vaccination among high-risk 
outpatients by Nichol, Lofgren, and Gapinski (1992) revealed a lower probability of 
being vaccinated among people who reported difficult access to services (OR = 0.42, 
95% Cl, 0.31-0.57).
Other studies have found the correlation between size of living residence and 
influenza vaccination rates (Jimenez, Larrauri, Carrasco-Garrido et al., 2003; de 
Andres, Carrasco-Garrido, Hemandez-Barrera et al., 2006). The study investigating 
factors associated with influenza vaccination coverage among individuals aged 50-64 
years conducted by Jimenez, Larrauri, Carrasco-Garrido et al. (2003) has shown that 
persons who lived in small towns with less than 10000 inhabitants were more likely to 
receive influenza vaccination as compared to those living in a town or city with more 
than 100,000 inhabitants (OR = 1.45, 95% Cl, 1.01-2.10).
Two further studies conducted in Spain yielded similar results; a survey study among 
people with chronic obstructive pulmonary disease has shown that living in a small 
town (< 10,000 inhabitants) was significantly associated with the highest likelihood of 
vaccination (OR= 1.65, 95% Cl, 1.42 -  1.92) (Jimenez-Garcia, Mayo-Montero, 
Hemandez-Barrera et al., 2005). The study of trends in influenza vaccination 
coverage rates in Spain from 1993 to 2003 conducted by de Andres, Carrasco- 
Garrido, Hemandez-Barrera et al. (2006) also found that residence in towns with less 
than 10000 increased the odds of receiving influenza vaccination (OR = 1.36, 95% 
Cl, 1.16-1.59).
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In the United States, one study examined the use of preventive health care services 
between rural and urban elderly residents. The study showed that for influenza 
vaccination, a higher vaccination rate was found for rural residents as compared to 
those living in the urban areas, although the difference did not reach statistical 
significance (58 per cent vs. 55 per cent) (Zhang, Tao, & Irwin, 2000). It was 
suggested that the close proximity and convenient access to an immunisation clinic 
might contribute to differences in influenza vaccination rates between sizes of living 
residence (Jimenez, Larrauri, Carrasco-Garrido et al., 2003; de Andres, Carrasco- 
Garrido, Hemandez-Barrera et al., 2006).
4.4.6 Health beliefs and behaviours
4.4.6.1 Self-perceived health status
A number of research studies suggested that the decision to vaccinate has been 
depended on individuals’ perceptions of their own health. Self-perceived health status 
can have a positive or negative influence on the decision about influenza vaccination 
(van Essen, Kuyvenhoven, & de Melker, 1997; Comford & Morgan, 1999; Evans & 
Watson, 2003; de Andres, Carrasco-Garrido, Hemandez-Barrera et al., 2006; Chen, 
Yi, Wu et al., 2007; Evans, Prout, Prior et al., 2007; Chiatti, Rosa, Barbadoro et al., 
2010).
In the Netherlands, the study examining the factors related to non-compliance with 
influenza immunisation among elderly people conducted by van Essen, 
Kuyvenhoven, and de Melker, (1997) showed that those who considered themselves 
to be healthy were less likely to have influenza vaccine compared to those who 
perceived themselves to be in poor health (OR = 57.9, 95% Cl, 4.4 -  770). Evans, 
Prout, Prior et al. (2007) carried out a qualitative study of 54 elderly people aged 65 
years or older. The authors found that both vaccinated and unvaccinated did not 
perceive themselves to be at risk of getting influenza and developing its serious 
complications. They believed that although they got influenza, they were unlikely to 
suffer from any serious consequences. Thus, they did not feel that they needed 
influenza vaccine. In this study, the authors have pointed out that other factors such as 
individual prompts by GPs appeared to be an important motivator to obtain influenza 
vaccination.
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Other studies have also documented this phenomenon. For example, a qualitative 
study using semi-structured interviews with 25 immunised and 25 unimmunised 
individuals aged over 75 years conducted by Comford and Morgan (1999), revealed 
that most older people viewed themselves as healthy and remained active and 
independent despite having a chronic disease. They did not feel at severe risk of 
influenza, and therefore the perceived need for influenza vaccination was low among 
these high-risk individuals. Colley (2008) interviewed 12 older people with a long­
term condition, and found that four unvaccinated people did not consider themselves 
as being in one of the high-risk groups for which influenza vaccination was strongly 
recommended.
A small study to examine health beliefs about influenza immunisation among Chinese 
older people aged 65 years or older conducted by Kwong and Lam (2008), also found 
that most older people (74.3 per cent) felt that they were in good or very good health, 
and eighty-three per cent of the total sample (n = 70) thought that their chances of 
catching influenza were relatively low. In addition, other strategies such as using 
traditional Chinese medicine (herbal tea and soup), staying warm, and avoiding cold 
drinks and food were perceived to be effective in preventing influenza. The study 
concluded that perceived good health and the perceived effectiveness of the 
traditional medicine and other measures adopted for the prevention and cure of 
influenza were the most important reasons for non-compliance with influenza 
vaccination among unvaccinated persons.
Moreover, a survey study to assess trends in influenza vaccination coverage rates in 
Canada by Johansen, Sambel, and Zhao (2006) found that 66 per cent of elderly 
people who had not been vaccinated in the previous year stated that they thought 
influenza vaccine was unnecessary, either because of their own judgment about their 
health or health care provider’s attitudes regarding influenza vaccination for elderly.
Conversely, in the study of Chen, Yi, Wu et al. (2007), adults who reported poor 
general health were 2.5 times more likely to be immunised against influenza, as 
compared with those who reported very good or excellent health (OR = 2.49, 95% Cl, 
2.23 -  2.79). This is supported by the study of de Andres, Carrasco-Garrido, 
Hemandez-Barrera et al. (2006) in which the likelihood of being vaccinated was
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higher in people who had a negative perception of their general health, as compared to 
those with a positive perception of their health (OR = 1.24,95% Cl, 1.07 -  1.46).
Recently, a national survey examining the influenza vaccination coverage levels over 
four influenza seasons and factors associated with influenza vaccination uptake in 
Spain carried out by Mayo-Montero, Hemandez-Barrera, Carrasco-Garrido et al. 
(2007) also found that in persons with chronic respiratory diseases, poor perception of 
health increased the odds of vaccination among these high-risk individuals (OR = 
1.40, 95% Cl, 1.14-1.72).
Similar results were observed by Chiatti, Rosa, Barbadoro et al. (2010) who 
investigated the socio- economic effects on influenza vaccination uptake among older 
Italians aged 65 years and older. The study revealed that lower influenza vaccination 
rates were associated with self-perceived good health; older people who reported 
being in good health were significantly less likely to be immunised than those who 
reported being in fair health (OR = 0.73, 95% Cl, 0.68 -  0.76).
Results from previous research have indicated that perceived “good health” was 
associated with vaccine non-compliance in high-risk older people. Therefore, 
healthcare workers should pay more attention to those people who consider 
themselves to be healthy and provide them with more information about the risk 
of influenza and serious influenza-related complications, emphasising that influenza 
vaccination is recommended for all high-risk individuals, regardless of their general 
health status. This may help to improve influenza vaccination for this particular 
group.
4.4.6.2 Previous experience of influenza-like illness or the influenza vaccination
Apart from self-perceived health status, several studies have shown that previous 
experience of influenza-like illness or influenza vaccination appeared to be a powerful 
predictor of influenza immunisation (Kee, Lee, Cheong et al., 2007: Davis, Fujimoto, 
Chan et al., 2009; Li & Liu, 2009). A survey study exploring barriers and facilitators 
of influenza vaccination conducted by Kee, Lee, Cheong et al. (2007), showed the 
relationship between having been vaccinated in the previous year and the higher odds
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of obtaining the influenza vaccination; older people who had been vaccinated in the 
previous year were significantly more likely to be immunised against influenza in the 
following year than those unvaccinated (OR = 17.94, 95% Cl, 13.21 -  24.37).
This is supported by the study of Li and Liu (2009), which showed that the likelihood 
of getting vaccinated increased if people had been vaccinated in the previous season. 
The elderly who had previously been vaccinated were ten times more likely to be 
immunised than those who were unvaccinated (OR = 10.22, 95% Cl, 9.82-10.64).
Other studies conducted in the United States and Australia, have also found that prior 
immunisation with influenza vaccine led to an increase in the probability of getting 
vaccinated for the next influenza season (odds ratio range 5.9 to 10) (Lewis-Parmar & 
McCann, 2002; Davis, Fujimoto, Chan et al., 2009). One possible explanation for a 
higher rate of influenza vaccination among those who had been repeatedly vaccinated 
may be that having received an influenza vaccination has become part of their healthy 
lifestyle behaviours. These individuals were therefore more willing to get vaccinated 
annually (Gallagher & Povey, 2006).
Telford & Rogers (2003) interviewed 20 people aged 75 or older, and found that 
either personal experience with influenza vaccination or others’ experience with 
influenza or the influenza vaccination could have both positive and negative influence 
on the decision of whether to vaccinate, depending on what experience people have 
had. The authors noted that lay experience and personal perceived risk from influenza 
appeared to have great influence on the likelihood of vaccination.
In addition, a survey study among community dwelling adults in South Korea 
conducted by Kee, Lee, Cheong et al. (2007) has also shown that those who had an 
experience with influenza-like illness were two times more likely to be vaccinated 
against influenza (OR = 2.30, 95% Cl, 1.33 -  3.99). In contrast, a lack of experience 
with influenza vaccination or influenza-like illness, or knowing someone who had had 
a negative experience with influenza immunisation, or listening to people who 
claimed that influenza vaccine gave them an influenza has been found to be 
associated with non-acceptance of influenza vaccine (Telford & Rogers, 2003; 
Sengupta & Strauss, 2004).
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4.4.6.3 Use of healthcare service
Previous studies have shown that the use of healthcare service was positively 
associated with higher rates of influenza vaccination among older people. A 
population-based survey study conducted in Switzerland demonstrated that the higher 
the number of physician visits, the greater the likelihood of being vaccinated; the odds 
ratio for people with at least one physician visit, and those who had seen a physician 
twice or
more were 2.52 (95% Cl, 2.05 -  3.10), and 4.51 (95% Cl, 3.65 -  5.57), respectively 
(Luthi, Mean, Ammon et al., 2002). In former West Germany, a cross-sectional 
survey assessing influenza vaccination coverage levels during the year 1999-2000 
conducted by Rehmet, Ammon, Pfaff et al. (2002) also found that individuals who 
had visited a physician during the autumn were more likely to be immunised than 
those who had not seen a physician (OR = 4.4, 95% Cl, 2.2 -  9.6). Furthermore, in 
this study, physician's advice regarding immunisations during consultation increased 
the probability, 13.5-fold, of people reporting have been immunised (OR = 13.5, 95% 
Cl, 6.7 -  27.9). Other studies have also shown that a visit or a consultation with health 
care professionals increased the likelihood that an older adult would receive the 
influenza immunisation (Stehr-Green et al., 1990; Davis, Fujimoto, Chan et al., 2009; 
Li & Liu, 2009; Jimenez-Garcia, Hemandez-Barrera, de Andres et al., 2010).
Similar results were observed for individuals with chronic medical conditions. The 
study of influenza immunisation among people with chronic obstructive pulmonary 
disease in Spain has also shown that the probability of getting vaccinated increased 
with a greater number of general practitioner (GP) visits in the preceding 12 months; 
those who had visited a physician more than ten times had the highest likelihood of 
receiving the influenza vaccination (OR = 2.78, 95% Cl, 2.26 -  3.43), and the 
adjusted odds ratio of having been vaccinated were 2.15 (95% Cl, 1.83 -  2.52), and 
1.79 (95% Cl, 1.54 -  2.08) for those who had visited their GP six to ten times, and 
three to five times, respectively (Jimenez-Garcia, Mayo-Montero, Hemandez-Barrera 
et al., 2005). A further study of influenza immunisation among diabetic patients has 
also shown that those who reported seeing a physician during the influenza season 
were more likely to have been immunised (OR = 1.46, 95% Cl, 1.12 -  1.96) 
(Jimenez-Garcia, Jimenez, Carrasco-Garrido et al., 2008)
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On the other hand, older people who had less contact with health care providers were 
less likely to obtain an influenza vaccination. In Spain, a survey study conducted by 
Sarria-Santamera and Timoner (2003) has shown that older adults who had not visited 
their health care providers more than six months since the last clinic visit were more 
likely to be associated with non-acceptance of influenza vaccination (OR = 2.13, 95% 
Cl, 1.52 -  2.98). Recently, Bryant, Ompad, Sisco et al. (2006) also found that the 
likelihood of obtaining influenza vaccination was significantly lower among those 
who did not have access to routine medical care (OR = 0.51, 95% Cl, 0.34 -  0.76).
4.5 Conclusion
In summary, researchers have found a number of mismatches between many 
professionals and lay perceptions of influenza, its symptoms and causes, as well as its 
consequences (McCombie, 1987; Baer, Weller, Pachter et al., 1999; Telford & 
Rogers, 2003; Adonis-Rizzo & Jett, 2006; Prior, Evans, & Prout, 2011). Mistrust of 
the vaccine contents, anecdotal stories of previous bad experiences with vaccination, 
fear of adverse reactions, and the belief that influenza vaccination causes other serious 
health problems have also been found to be associated with the low acceptance of 
influenza vaccine (Findlay, Gibbons, Primrose et al., 2000; Armstrong, Berlin, 
Schwartz et al., 2001; Adonis-Rizzo & Jett, 2006; Evans, Prout, Prior et al., 2007; 
Wray, Jupka, Ross, 2007). In addition to lay beliefs about influenza and influenza 
vaccine, the existing literature on determinants of influenza vaccination has 
indentified a variety of individual and social factors that may affect the influenza 
vaccine uptake. Although these studies vary in terms of design quality, data collection 
and analysis methods, the extant body of research literature on this topic provides 
enough information to indicate that decisions whether or not to receive influenza 
vaccination are complex, and influenced by several medical, psychological and social 
factors, including the knowledge, attitude and beliefs about influenza and influenza 
vaccination, perceived risk of contracting influenza, health status, health beliefs, 
concerns about the efficacy and side effects of vaccine, previous experience of 
influenza vaccination, the influence of others (healthcare workers, family members 
and friends), and the costs and convenience of obtaining the vaccination (e.g. Telford
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& Rogers, 2003; Sengupta & Strauss, 2004; Bums, Ring, & Carroll, 2005; Jimenez- 
Garcia, Hemandez-Barrera, Carrasco-Garrido et al., 2006; Evans, Prout, Prior et al., 
2007; Chen, Yi, Wu et al., 2007; Lau, Lau, & Lau, 2009; Payaprom, Bennett, Bumard 
et al., 2010).
These factors provide a number of targets for any public health programme designed 
to increase uptake of influenza vaccine. However, the degree of influence of these 
factors may vary widely between individuals and populations. Identifying factors 
underlying people’s vaccination decisions is an essential first step in the development 
of a tailored intervention to raise influenza vaccination rates among high-risk groups. 
Accordingly, the present study sought to explore Thai older people’s beliefs about 
influenza and influenza vaccination, and other factors that influence their decisions 
whether or not to accept the influenza vaccination (study 1). The study’s findings 
were then used to inform the development of the HAPA-based educational leaflet and 
questionnaire for study two. In the following chapter, the methodology and the results 
of the research will be presented.
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Chapter 5: Understandings of influenza and influenza 
vaccination among high-risk urban dwelling Thai adults
5.1 Introduction
This study employed qualitative methods, drawing on a grounded theory approach to 
explore people’s beliefs about influenza and influenza vaccination, and to examine 
factors influencing urban-dwelling Thai adults’ decisions whether or not to have the 
vaccine. In this chapter, the methodology and procedures used in this study are 
described. This includes an overview of qualitative approach and the rationale. The 
chapter also provides information about the setting, participants, and details on data 
collection and analysis. The findings of the study are reported. Following this, the 
discussion of findings and implications for clinical practice are provided. Finally, a 
conclusion is outlined.
5.2 Qualitative approach
Qualitative research uses an interpretive approach to social reality (Denzin & Lincoln, 
2005; Holloway, 2005; Yin, 2010). A qualitative research method provides an in- 
depth description of a phenomenon being studied. One of the major purposes of 
qualitative research is to understand the phenomenon of interest from the participants’ 
perspectives.
Accordingly, the events or ideas emerging from research findings explore the 
meanings given to real-life events by the participants, not meanings held by the 
researchers (Creswell, 1998; Yin, 2010). The purpose of this study was to explore 
people’s beliefs about influenza and influenza vaccination and to identify factors 
influencing urban-dwelling Thai adults’ decisions whether or not to receive influenza 
vaccine. A qualitative research methodology was chosen for this study because it 
attempts to make sense of, or interpret phenomena from the participant's perspective 
(Denzin & Lincoln, 2005). Thus, it allows for the exploration of participants’ beliefs 
about influenza and influenza vaccine, as well as the influences on their decisions of
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whether to accept or refuse the influenza vaccination. Additionally, Strauss and 
Corbin (1998, p. 11) also pointed out that “qualitative methods can be used to obtain 
the intricate details about phenomenon such as feelings, thought processes, and 
emotions that are difficult to exact or learn about through more conventional research 
methods”. In other words, a qualitative approach may produce greater depth and 
breadth of information on complex issues, rather than conventional research methods. 
Data from a number of studies (e.g. Comford & Morgan, 1999; Telford & Roger, 
2003; Zimmerman, Nowalk, Raymund et al., 2003) conducted in western countries 
indicates that the decisions whether or not to receive influenza vaccine are complex, 
and influenced by many factors. Accordingly, a qualitative approach was used for the 
present study to get an in-depth understanding of the factors underlying people’s 
vaccination decisions to create an effective influenza vaccination programme.
5.3 The rationale for choosing grounded theory method
Within the qualitative paradigm, there are many approaches that could have been used 
to inform the data collection and analysis (Creswell, 1998; Denzin & Lincoln, 2005). 
In this study, in-depth interviews were considered as appropriate methods. In-depth 
interviews permit the researcher to gain access to the participant’s perspective (Patton, 
2002; Charmaz, 2006). Therefore, the interviewer’s questions ask the participants to 
describe their beliefs or express their views in their own words. This involves using a 
flexible technique that allows the important ideas and issues to emerge naturally 
during the interview (Patton, 1987; Kvale, 1996; Charmaz, 2006). In-depth interviews 
can also be useful tool for exploration of complex topics and sensitive experiences, 
which may not be possible through other data collection methods such as survey 
(Taylor, 2005; Charmaz, 2006). According to Jones (1985, p. 46), “To understand 
other persons’ constructions of reality we would do well to ask them (rather than 
assume we know merely by observing their overt behaviour) and ask them in such a 
way that they can tell us in their terms (rather than those imposed rigidly and a priori 
by ourselves)”. Therefore, an in-depth interview was the method used to collect data.
In addition, a grounded theory approach was particularly suitable for exploring and 
gaining insights into a previously unknown area (Glaser & Strauss, 1967). In
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Thailand, to our knowledge, no studies to date have examined people's beliefs about 
influenza and influenza vaccination. Therefore, the focus of this study fitted this 
criterion. Although the main purpose of grounded theory is the generation of theory 
from the data, it can also be used to explore and understand how complex 
phenomenon occurs (Willig, 2001; Corbin & Straus, 2008). According to Glaser 
(1987), grounded theory, unlike other qualitative research methods, not only provides 
meaning, understanding and description of the phenomenon under study, but is also 
theory-generating. Central to this study is the understanding of people’s beliefs about 
influenza and influenza vaccination and identification factors influencing the decision 
whether or not to get the influenza vaccine among high-risk Thai individuals. Thus, a 
grounded theory approach was drawn on the exploration of the complexity of personal 
decision-making in influenza vaccination. The study findings could then inform the 
development of effective interventions to encourage uptake of influenza vaccination 
by such high-risk individuals.
5.4 Methodology
5.4.1 Setting and participants
The study was conducted in the Muang district, an urban community of Chiang Rai 
province with a population of 223, 936. Chiang Rai is the northernmost province of 
Thailand and has an adult literacy rate of 93 per cent (National Statistical Office,
2006). This study was approved by the research ethics committee, Chiang Rai 
Province, Thailand.
The study population was adults who were either (i) aged 65 and over, or (ii) under 65 
years with chronic diseases with clinical indications requiring influenza vaccination 
such as coronary heart disease, chronic pulmonary disease, asthma and diabetes 
mellitus. Potential participants were selected from one health centre’s database. The 
selected participants were determined by the emerging concepts, and evolving data 
analysis informed each subsequent interview. Their medical records were scrutinized 
to confirm the suitability of participants for interview. Those with severe chronic 
conditions (i.e. bed bound or acutely ill), severe mental health problems, or 
communication difficulties were excluded. Letters of introduction were sent to 30 
potential participants: fifteen letters in each group. Twenty potential individuals
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agreed to participate; a response rate of 66.7 per cent. These individuals were 
contacted by the researcher and gave informed consent to participate in the study.
5.4.2 Interviews
In-depth interviews were conducted between February and March 2008, either in 
participants’ homes or at a health centre depending on their preference. On each 
occasion, written consent was obtained before the interview. A semi-structured 
schedule was used to guide the interviews (see Appendix 6). It explored participants’ 
understandings of influenza and influenza vaccination, and factors that may influence 
their decision whether to accept or decline the influenza vaccination in the 
forthcoming vaccination period. Interviews lasted between 30 and 60 minutes, and 
were tape-recorded with the permission of interviewees.
5.4.3 Data analysis
The interviews were fully transcribed in Thai language and analysed following the 
grounded theory approach (Strauss & Corbin, 1998). The data analysis was based on 
the constant comparative method. After data (one interview) were collected and 
transcribed, the first transcript was read thoroughly a number of times and analysed 
line-by-line, closely examined and compared for similarities and differences, then 
code concepts were developed. The coded concepts described the main idea of what 
the participants stated. During coding of data and constant comparative analysis, 
emerging concepts from the data determined what kinds of data would be sought next. 
As more data were examined, the coded concepts were revised and cross-referenced 
with the data as a whole, and similar code concepts were grouped together. The 
analysis process continued, similarities and differences were identified and the cluster 
codes that seem to fit together (similar or related properties) were further grouped into 
categories. At this stage, categories were developed and linked with subcategories 
(Strauss & Corbin, 1998).
In this study, all the transcripts were coded in Thai by two researchers (Y. P. and 
H. T. who is an internist and has social sciences training) to increase reliability, and 
the discrepancies in coding were resolved through discussion; both researchers
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performed open coding separately. Additionally, two participants who could correctly 
verify the texts transcribed from their interviews were asked to validate their 
contribution and provided feedback. The sampling method achieved data saturation 
with respect to our research objectives; the evolving analysis informed the subsequent 
data collection. This process continued until new data did not add to the insights 
already gained (or no new categories emerged) (Corbin, 1986; Strauss & Corbin, 
1998; Charmaz, 2006). After extensive data analysis, the transcripts were translated 
into English and back-translated into Thai language by an independent translator. The 
back-translated transcripts were then compared with the original, and the points of 
divergence were noted and corrected to more closely reflect the meaning of the 
original Thai language. The English translation of transcripts is reported here.
5.5 Findings
In total, 20 community dwelling Thai adults were interviewed: 11 aged > 65 years and 
nine aged < 65 years with chronic diseases. The mean age was 64.9 years, with the 
oldest participant being 75 years old. The study population presented a range of socio­
demographic characteristics, including age, gender, and socio-economic status. There 
were eleven female participants and nine male participants. All men were married, 
whereas the majority of women were widowed. Twelve of participants had completed 
primary school (6 years of schooling), four had completed secondary school, two had 
attainted vocational/technical programmes, and two had no formal education. While 
the majority of older people aged > 65 were unemployed, most individuals aged < 65 
with chronic disease had occupations (such as merchant, farmer, and labourer). All 
participants lived with others. The study also included both takers and non-takers of 
influenza vaccination as well as those who had experienced influenza illness and 
those who had not. As such, the study population may be considered to reflect a 
variety of different views, beliefs and experiences regarding influenza and influenza 
vaccination (see Table 5.5.1).
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Table 5.5.1 Demographic characteristic of participants
Age Sex Marital
status
Educational
Level
Occupation Living
arrangements
Health
problems
Had flu 
in the past
Immunisation
status
72 F Married Primary school None Children and spouse None No never
60 F Widowed Primary school None Children Diabetes No never
58 F Widowed Primary school Merchant Children Asthma Yes never
60 M Married Primary school Farmer Children and spouse COPD No immunised
75 M Married Primary school None Children and spouse None No never
69 F Married Secondary school Merchant Spouse None No immunised
66 M Married Primary school Labourer Children and spouse None No never
56 M Married Primary school Merchant Spouse Diabetes No never
54 M Married Secondary school Labourer Children and spouse Diabetes Yes never
61 M Married Primary school Labourer Children and spouse COPD Yes immunised
65 M Married V  o c a t io n a l /T  e c h n ic a l Labourer Children and spouse None No never
70 F Widowed None None Children None Yes never
52 F Married Primary school Merchant Children and spouse Diabetes No never
72 F Married V  o c a t io n a l /T  e c h n ic a l Pensioner Children and spouse None No immunised
73 M Married Secondary school Pensioner Children and spouse None Yes immunised
61 F Married Secondary school Pensioner Spouse Asthma No immunised
62 F Widowed Primary school None Children Diabetes No never
74 F Widowed None None Children None No never
70 M Married Primary school None Children and spouse None No never
69 F Widowed Primary school None Children None No never
Two major themes emerged from the data (see Table 5.5.2), and under these all of the 
data collected were supported.
Table 5.5.2 Emerged themes and their subcategories
Categories Subcategories
Understanding of influenza and influenza 
vaccination
- Knowledge of influenza and influenza vaccination
- Source of information
Factors affecting decision-making 
in influenza vaccination
- Salience of risk
- Influence of others
- Perception of the need for preventive health care
- Availability
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5.5.1 Understanding of influenza and influenza vaccination
5.5.5.1 Knowledge of influenza and influenza vaccination
Participants were asked to explain what they understood influenza to be. Most of them 
reported that they knew little about influenza, and they did not know how to describe 
it. In terms of its cause, a number of participants thought influenza was associated 
with the changes of weather, particularly from rainy to winter season, while only one 
person stated that influenza was caused by ‘germs’. A few participants aged less than 
65 years with chronic diseases thought that their underlying diseases placed them at 
increased risk for influenza.
“I t’s easy for me to catch the flu  because my resistance is down. I  have lung 
disease also the changing the weather is a contributing factor ” Mr. K. (ID
10), p.2
In addition, some participants reported they did not consider that influenza was a 
communicable disease.
Interviewer: - “I f  one o f  this house members catches flu, do you think you may 
catch it from him?
Mr. N.:- “No, I  have not heard that influenza is a contagious disease...you 
can get ill from other people only in case o f common cold. ”
Mr. N. (ID 7), p.l
With regard to the symptoms of influenza and its seriousness, most participants 
confused the symptoms of the common cold and other respiratory illnesses with 
influenza.
“When you have flu, you have a fever, sneezing, runny nose with watery 
secretions during the first few  days, then these become thick and dark mucus, 
and you also feel headache...flu is more serious than a cold”
Mrs. J.T. (ID 20), p. 2
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Although they considered influenza to be a serious health problem, only few 
participants felt that it could cause death.
“ Haemorrhagic fever can kill you, but not influenza” Mr. N. (ID 7), p 1
and:
“I t ’s possible that flu  can make elderly people very ill and even cause death 
because they have weak immune system. Mr. Y. (ID 4), p.2
and:
“Ifyou are not cured in time, you may die o f  influenza. However, I  haven’t 
heard ofpeople dying o f  it. ” Mr. C. (ID 8), p. 2
Participants were asked how they protected themselves from getting influenza.
Almost all participants proposed general protective measures to avoid influenza.
Few participants mentioned getting influenza vaccine. Others had different strategies:
“ ...I walk around the house for 5 rounds in the evening every day. When the 
weather is cold, I  shower with lukewarm water. I  also drink lukewarm water. ” 
Mrs. V (ID 13) p. 1
and:
“I  work a little at home which to me is an exercise, I  keep myself warm in cold 
weather. On the day I  fee l hot and cold; I  go to bed early, so I  get enough rest, 
and my daughter, she is a nurse, suggested me to get the flu  shot. ”
Mr. M, (ID 15), p. 2
In summary, most participants were not appropriately knowledgeable about influenza; 
influenza was frequently associated with the changes of weather rather than a virus. 
Many participants commonly confused influenza with the common cold or other 
upper respiratory diseases. They generally stated that influenza was more debilitating 
than the common cold. Significantly, the majority of participants did not consider 
influenza to be a potentially deadly disease.
When participants were asked whether they knew about the influenza vaccination, 
most participants reported that they knew little or nothing about it. In other words,
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lack of knowledge about influenza vaccine was clearly evident among our 
participants. A typical comment was:
“/  had heard about the vaccine for children. Is there the influenza vaccine for 
elderly people? Well, I  have not heard o f i t” Mrs. V, (ID 13), p.3
and:
“Nobody probably knows about the vaccine. Only the village health volunteers 
probably know about it. ” Mr. D, (ID 9), p. 3
Participants were also asked “How effective do you think that a flu shot will protect 
you from getting the flu?” The majority of participants reported that they did not 
know how effective the vaccine would be against influenza. However, a few of them 
expressed a positive view toward influenza vaccination. One participant stated that:
“When I  caught influenza, Ife lt so sick, and I  got extremely fatigued. I  could 
not even get up as my muscle was aching. Any pain killer could not help my 
conditions. I  think that getting the flu  shot is necessary for me, and it should 
be 100 percent or nearly 100 percent in preventing the flu. ” Mr. M. (ID 15), 
p.3
Additionally, some participants had misconceptions about influenza vaccination; 
they believed that it could also prevent them from catching a cold. One participant 
mentioned that influenza vaccine would seriously weaken her immune system.
“After received it [influenza vaccination], I  have not been ill. Previously, i f  a 
person who got cold sneezed or coughed toward me, I  would certainly catch a 
cold. ” Mr. K. (ID 10). p.4
and:
“In the elderly, immune systems are not as strong as in younger. I f  I  get a flu  
shot, it may weaken my immune system. ” Mrs. R. (ID 1), p 3.
Interestingly, vaccine side-effects were not a substantial barrier to vaccination for our 
participants. Most felt that these were not a major concern for them. They thought
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that any side-effects would be the same as other vaccines. However, a few 
participants stated that they needed to be reassured that the vaccine was safe.
“I probably will have a fever for a few  days [after vaccination], like when I  
was young”, Mrs. P. (ID 12), p. 3
and:
“I t’s the same as other vaccine injection. I f  the public health staffs give the 
elderly people more information, there should not be any problem ”
Mr. Y, (ID 4), p. 5.
and:
“Few people may have [concerns about side effects of vaccine]. However, i f  
the vaccine comes from the public health staff, and the information is provided 
on vaccine safety, these should help lessen the people’s concerns ”
Mr. S.T. (ID 11), p. 4
5.5.5.2 Source of information
Participants were asked whether they had ever had influenza and how they had 
learned about the condition. A number of participants reported that they had had 
influenza at some time in the past. Other participants had heard about influenza from 
others.
“[I’ve heard] from elderly people. Now, less people catch It [influenza]. I  have 
rarely heard o f someone catching it. ” Mr. N. (ID 7), p. 1
and:
“It has been a long time since I  heard people talking about it [influenza].
Mrs. V. (ID 13), p.l
and:
“They’ve probably heard o f  influenza for a long time, but they do not 
understand it. And I  think no one in this community remembers what the 
disease is. ” Mr. D, (ID 9), p. 2
Additionally, four participants reported that they had received information about 
influenza from public media such as television and radio, but they did not get enough 
information about it. As for the influenza vaccination, most participants stated that
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they had never heard about influenza vaccination from their healthcare providers or 
from public media.
Interviewer: - “Have you ever heard about Influenza vaccine from T. V. ? ”
Mr. Y: - “No, just influenza”
Interviewer:-: “Do you think you have received enough influenza information 
from TV?”
Mr. Y: - “I  did not receive any details from it, just got rough information. ”, 
Mr. Y. (ID 4), p. 3.
and:
Most television programme talks about Haemorrhagic fever, but not much 
about Influenza.” Mr. N. (ID 7), p. 2
and:
“The public health sta ff ...give (s) us a health check-up, but they never mention 
the influenza vaccine. ” Mrs. V. (ID 13), p.3
5.5.2 Factors affecting decision-making in influenza vaccination
5.5.2.1 Salience of risk
Though most participants held generally positive views on influenza vaccination, 
decisions whether to accept or refuse influenza vaccination were also based on their 
perceived risk of contracting influenza. Some participants reported that they would 
only seek influenza vaccine if there was an outbreak of influenza within their 
community or in nearby communities.
“Even it is free. I f  we do not have this kind o f epidemic [influenza epidemic] in 
our community, there is no need to receive the injection ”, Mr. N. (ID 7), p. 5
and:
“I  would receive the vaccine injection for my protection i f  an outbreak 
happens in the community or in the nearby community such as Banpong which 
is 6 Km. from here. ”, Mr. ST (ID1 l),p. 3
and:
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“Yes, I  can wait till there actually is [influenza epidemic]. I  can have the 
injection immediately after the outbreak. That should be in time. The village 
health volunteers will tell us when there is an epidemic o f influenza ”.
Mr. D (ID 9), p. 6
A few participants thought that they had a low risk of contracting of influenza because 
it was not a major health problem in their community. Accordingly, influenza 
vaccination was not necessary for them. One participant commented that:
Why do that? [getting influenza vaccination] I ’m still healthy and this illness is 
not one o f our community’s problems ” Mr. D (ID 9), p. 5
By contrast, those who had previously been vaccinated considered themselves to be at 
risk of developing influenza and that it would affect them seriously:
I have the underlying disease which is lung disease... I  should get a flu  shot 
because I  could get the flu  easily. ” Mr. Y. (ID 4), p. 4.
and:
I ’m afraid o f catching the flu  at old age. People my age, once get sick, will get 
worse and need medical treatment at the hospital. I  have to protect myself. ”
Mrs. S. (ID 14), p. 4.
As mentioned above, some participants perceived themselves as having a low risk of 
contracrting influenza due to a low prevalence of disease in the community, whereas 
others cited their age or their underlying chronic illness as increasing their risk.
5.5.2.2 Influence of others
When asked “Could you make your own decision to get the flu shot?”, a number of 
participants expressed that they could not make decision by themselves and many 
cited reasons why they needed to ask their children or other people in the community.
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“I  have to ask my children before that. I f  they say I  should, I ’ll receive this 
injection. I f  they say no, I  will not receive it... I ’ve to ask them whether or not 
to have a flu  shot, it is necessary” Mrs. V. (ID 13), p. 4
and:
I  will talk with my friends ...people o f  the same age and with the same health 
condition could help us decide whether to get the flu  shot or not. I f  they decide 
against it, I  do not want to do it either. ” Mr. N. (ID 7), p. 5
and:
In this community, we follow each other. Because i f  you do not get the flu shot 
when most people in the community do, you can get blamed i f  anything 
happens.... That’s why you get sick. ” Mrs. JT. (ID 20), p. 6
There was a strong sense that individuals were influenced by their peers and felt a 
need or responsibility to conform. This conveys a sense of responsiblity to the 
community.
In addition, some participants, particularly those who had chronic medical conditions 
reported that their decision about whether to receive the influenza vaccine relied 
heavily on their healthcare providers, regardless of their own views. These 
participants also noted that health care staff were knowledgeable about influenza and 
vaccination, and they were also the people who took care of them when they became 
sick. Therefore, they trusted in the recommendations given by their healthcare 
providers.
“ I ’ve been healthy fo r  about the last 2-3 years, and I ’ve never caught a cold 
once. So I  think it is not necessary to get the flu  shot. But i f  the doctor advised 
me to have the vaccine, I ’ll do it” Mrs. CH. (ID 2), p. 5
and:
“We believe the doctor. I f  the doctor suggests us to get the flu  shot, 
we must follow. ” Mr. C (ID 8), p. 4
and:
“The public health staffs also studied, so we believe them as well. I f  they had 
not studied about it, they would not have told y o u ”, Mr. Y (ID 4), p. 3
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Clearly, the participants’ decisions about whether to accept the influenza vaccination 
were affected by social influences, from sources such as doctors, other health care 
professionals, family members and friends. Where family members are also health 
workers, such as in the case of Mr. M (p. 118) their views might be perceived as 
having added credibility.
5.5.2.3 Availability
Two different issues contributed to the availability of the vaccine: the cost of vaccine 
and having a convenient place for people to get vaccinated. The cost of vaccine was 
considered an important factor that influenced the participants’ decisions concerning 
vaccination. Most participants stated that they would consider having the vaccination 
if it was provided free of charge.
“No, I  do not have any money for a vaccine. I  will only do it, i f  it is free. ”
Mrs. T. (ID 17), p 6.
and:
Vaccine is basically for protection disease. But i f  it costs you money, not many 
people will receive it. I f  it is free, many people will be happy to get the flu  
shot. ” Mrs. JT. (ID 20), p 5.
and:
They should... [get vaccination]. But what would they do? Elderly people 
without any income and support can only live day by day.
Mr. S.T (ID 11), p. 4
By contrast, some participants could afford for influenza vaccination, but they 
nevertheless expected the government to provide them with it free of charge as they 
were now senior citizens.
“I  think that the government will support us. Like when we get free medical 
treatment from the hospital because we are senior citizens. So I  will not get 
the flu  shot until the free vaccine service is launched. ” Mrs. A. (ID 18), p 6
and:
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“Yes, o f course senior citizens should be supported by government, so not 
many people will pay for the vaccine i f  it cost money. I  think that free vaccine 
will be provided to help us. ” Mrs. P. (ID 12), p. 4
The cost of vaccine played an influential part in participants’ decisions about whether 
to get vaccinated. The chance of being immunised seems able to increase if the 
vaccine was made available to high-risk people free of charge. In contrast, when the 
vaccine was not available free of charge, a number of participants commented that 
although they knew about the benefits of vaccine, they would decline the vaccination 
because they were dependent on their children for support. The following comments 
are representative of many participants’ opinions about this issue.
“Most o f elderly people have to rely on their children’s support. I f  you have 
money, the vaccine does not seem so expensive. I f  you don’t, the cost o f 
vaccine [400 baht; £6] is pretty much money ....So you will not get the flu shot. 
Everyone dies at the end anyway.” Mrs. T. (ID 17), p. 4
and:
“The ones without their children’s support must find  it difficult to pay for the 
vaccine. It should be free, same as the medicines. ” Mrs. CH. (ID 2), p. 3
Besides providing free vaccine, most participants proposed that the vaccination 
service should take place at a health or community centre because elderly people 
could easily access such places. Two participants commented that:
“The health centre is fine. I t ’s near our houses, and it’s not crowded. I f  i t’s the 
hospital, you have to spend one day because the hospital service is very slow, 
and my children have to take me there. ” Mrs. A. (ID 18), p. 4
and:
Some elderly people they must pay for the bus fare to travel to the hospital.
I t ’s tough for us [old people] to travel. ” Mr. ST. (ID 11), p. 5
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5.5.2.4 Perception of the need for preventive health care
A perceived need for preventive health care appeared to be another factor influencing 
participants’ immunisation decisions. Some participants believed that getting 
immunised helped to prevent severe illness, including exacerbation of underlying 
conditions. They reported that they would consider getting vaccinated because they 
were concerned that influenza might exacerbate any illness and would make them feel 
a burden on other people.
“I ’m afraid o f getting sick. I  have asthma. I  think that my breathing may 
become difficult. So I  have to protect myself. ” Mrs. W, (ID 16), p.3
and:
“I  have lung disease [asthma]. I  feel tired when I  breathe, my children 
bring me to the hospital and they lose their income for one day. I  think I  will 
get it [influenza vaccine] ” Mrs. SJ. (ID 3), p. 4
By contrast, several participants in the study, especially those who perceived 
themselves as healthy, considered the influenza vaccination to be unnecessary for 
them, even though they could afford to pay for the vaccine. These participants were 
prepared to take the risk of not having the vaccination and developing influenza. 
Consequently, paying for influenza vaccination was ranked behind other expenses.
“I ’ve never caught it so I  am not afraid o f  it. I ’m healthy because I  exercise 
every day. I ’ve a strong immune system. Mr. PS (ID 5), p. 3
and:
Interviewer: - “you are not afraid o f  catching influenza i f  you do not get a flu  
shot? ”
Mrs. V.:- “I  don’t know. I f  I  catch it, I  will receive the treatment at the 
hospital.
Interviewer: - “You mean you want to take the chance? ”
Mrs. V.:- “Yes. ” Mrs. V. (ID 13), p. 4
and:
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“Many people do not want to pay for the vaccine because they say they have 
more important expense. They do not get sick when they are getting the 
vaccine so they think it is not necessary. ” Mr. K. (ID 10), p. 4
5.6 Discussion
Although previous research carried out in developed countries of temperate climate 
has explored high-risk individuals’ understandings influenza and factors associated 
with uptake of the influenza vaccine (e.g. CDC, 2003; Bums, Ring, & Carroll 2005; 
Evans, Prout, Prior et al., 2007; Kroneman, Paget, & van Essen, 2003; Telford & 
Rogers, 2003; Zimmerman, Nowalk, Raymund et al., 2003), to our knowledge, this 
study is the first known to describe these issues in Thailand which has a tropical 
climate.
The results of the study revealed that high-risk community dwelling Thai adults 
had low levels of knowledge regarding influenza and influenza vaccination. Many 
were unsure about its cause and symptoms of influenza, mode of transmission, the 
seriousness of influenza and its complications. Most participants were not aware that 
influenza is caused by a vims. Rather, they associated developing influenza with 
the changes of weather, particularly from rainy to winter season. Exposure to cold 
weather or a change in the weather is a commonly held-belief on the cause of 
common cold and influenza in many other cultures such as British, American, 
Chinese and Malay (CDC, 2003; Chan, 2006; Tan, Lim, Teoh et al., 2007; Prior, 
Evans, Prout, 2010; Sigelman, 2011). This lay belief is inconsistent with published 
scientific data about the cause of influenza (Couch, 2000; Cox & Subbarao, 2000; 
CDC, 2009), and can affect the ways people seek to prevent influenza illness. When 
influenza is considered to be caused by a change in the weather, general protective 
measures such as dressing warmly in cold weather, not getting wet, eating healthy 
food, doing the exercise are perceived to be sufficient in preventing influenza 
(Adonis-Rizzo & Jett, 2006). This can lead many high-risk individuals to be reluctant 
to get vaccinated against influenza.
127
With regard to the influenza symptoms, few participants correctly described the 
symptoms of influenza, while others confused the symptoms of the common cold 
or other respiratory illnesses with influenza. Symptoms of influenza commonly 
recognised by most participants included fever, sneezing, runny nose, and headache; 
other symptoms such as muscle aches and pains, or fatigue were named by few 
participants. However, influenza was considered to be more severe than the common 
cold. These findings may not be specific to this population: one study in the United 
States found that only 44 per cent of their sample was able to describe typical 
influenza symptoms (Santibanez, Nowalk, Zimmerman et al., 2002). Lack of 
knowledge about the symptoms of influenza has also been noted among older people 
in Singapore; Tan, Lim, Teoh et al.’s (2007) study exploring knowledge, attitudes 
and practices about influenza and influenza immunisation among people aged over 
50 years in Singapore found that runny nose (rhinorrhoea) was viewed as a major 
symptom of influenza among most participants. Our results, together with the results 
from previous studies (Santibanez, Nowalk, Zimmerman et al., 2002; Tan, Lim, Teoh 
et al., 2007; Santibanez, Mootrey, Euler et al., 2010), point to the need for public 
information about influenza, its transmission and spread, clinical symptoms, and its 
consequences.
Consistent with previous findings (CDC, 2003; Findlay, Gibbons, Primrose et al., 
2000), most participants regarded influenza as a serious disease. However, many did 
not fully understand how serious influenza can be, considering it to be no worse than 
a “bad cold”. Very few participants thought that it could cause death. These beliefs 
appear to have contributed to a reluctance to seek the vaccine among some individuals 
(see also Sengupta & Strauss, 2004), and may have resulted, at least in part, from the 
lack of information regarding the burden of influenza illness available to our 
participants. An association between lay belief that influenza is not dangerous and a 
low uptake of influenza vaccine has also been found in previous studies (van Essen, 
Kuyvenhoven & de Melker, 1997; Santibanez, Nowalk, Zimmerman et al., 2002; 
Tabbarah, Zimmerman, Nowalk et al., 2005).
Understanding community perceptions of influenza and its severity is essential to 
develop educational materials and design an effective intervention to increase uptake 
of influenza vaccine among individuals at high-risk. In the present study, most
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paricipants believed that influenza was no worse than a “bad cold”. The interpretation 
of influenza as a “bad cold” reduces its perceived potential for being lethal and may 
lead high-risk people to ignore vaccination recommendations. This result suggests 
that, in addition to providing information on the cause of influenza and its symptoms, 
educational materials designed to promote influenza vaccination among high-risk 
Thai adults should emphasise the severity of influenza, the risk of developing 
influenza-related complications and the need for influenza vaccination.
Unlike some previous studies (CDC, 2003; Adonis-Rizzo & Jett, 2006; Kwong & 
Lam, 2008), no respondents reported the use of herbs or other traditional medicines 
for prevention and treatment of influenza. Possible explanations may be related to the 
universal coverage of health insurance in Thailand that has been implemented since 
2001. Additionally, this study was conducted in an urban community among people 
who usually sought care at a health centre or community hospital. Such individuals 
are now most likely to seek care from medical/health professionals, with a minimal 
reliance on traditional healers (Clague, Chamany, Burapat et al., 2006).
Most participants reported that they knew little or nothing about the influenza 
vaccination. This finding is understandable, as the use of influenza vaccine in 
Thailand has, until recently, been limited to a small group of people such as 
healthcare workers and other concerned workers, Thai pilgrims who attend the Hajj, 
and those who are able to afford for the cost of vaccination (Chunsuttiwat, 2002; 
Simmerman, Thawatsupha, Kingnate et al., 2004). It is also interesting to note that 
side-effects following vaccination were not a major concern among our participants, 
in contrast to some studies which have reported that fear of side-effects has been a 
significant factor in decisions not to receive the vaccination (e.g. Comford & Morgan, 
1999; Evans & Watson, 2003; Bums, Ring, & Carroll 2005; Evans, Prout, Prior et al., 
2007; Wray, Jupka, Ross et al., 2007). By contrast, salience of risk did appear to play 
an important role in decision-making in influenza vaccination. A number of 
participants reported that their decisions whether or not to seek vaccination depended 
on there being an outbreak of influenza within their community or in nearby 
communities. Other participants considered their risk of contracting influenza to be 
very low, making the influenza vaccination unnecessary for them. Such beliefs will 
clearly reduce the probability of seeking or accepting the vaccination (van Essen,
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Kuyvenhoven, & de Melker, 1997; Comfom & Morgan, 1999; Gosney, 2000; Telford 
& Rogers, 2003; Brewer, Chapman, Gibbons et al., 2007; Weinstein, Kwitel, McCaul 
et al., 2007).
Participants' vaccination decisions were also influenced by family members and peers. 
In Thai Buddhist culture, taking care and supporting of aged parents have long been 
recognized as virtues and a prime responsibility of adult children. Most older Thais 
live with their children; living in residential care is uncommon in Thailand 
(Choowatanapakom, 1999). Accordingly, it is possible that their decisions concerning 
influenza vaccination will be more influenced by their children than in cultures where 
the generations are more separated. Data here are lacking, although one study by 
Adonis-Rizzo & Jett (2006) found that the children of older Haitian adults, with 
similar patterns of inter-generational care, were also highly involved in such 
decisions. Besides peers and family members, a number of participants reported that 
their vaccination decisions relied heavily on their healthcare providers, regardless of 
their own views. These data add support to similar findings in previous studies (CDC, 
1988; Evans, Prout, Prior et al., 2007; Zimmerman, Nowalk, Raymund et al., 2003). 
Advice from health care professionals was found to be a powerful motivator for high- 
risk people to comply with influenza vaccination, even among those who had a 
negative attitude to vaccination (CDC, 1988; Honkanen, Keistinen & Kivela, 1996). 
The US Center for Disease Control and Prevention (1988) found that among people 
with unfavourable attitudes to influenza vaccine, those whose health care providers 
strongly recommened the vaccine had a significantly higer rate of immunisation than 
those who did not get that advice. This suggests that, if influenza vaccination rates 
are to be improved, healthcare workers should take an active role in educating and 
recommending the influenza vaccination to their patients.
Financial barriers also appear to be another important factor that affected participants’ 
immunisation decisions, particularly those who were unable to support themselves. 
These findings are similar to those of other studies (CDC, 1993; Kroneman, Paget, & 
van Essen, 2003; Nex0e, Kraqstrup, & Sogaard, 1999; Zwar, Hasan, Harris et al.,
2007). Clearly, free vaccination is likely to result in higher levels of vaccination than 
paid for vaccination. Although starting from a higher baselines level (55 per cent), 
Gill, Taylor, and Watson (2007) provided some evidence of the likely benefits of such
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an approach, reporting an increase in vaccination rate of 27 per cent following the 
provision of free influenza vaccination in South Australia.
Apart from these factors, decision-making was affected by the individual’s perception 
of the need for preventive health care. A number of participants with chronic diseases 
stated that they would seek the influenza vaccination, even if it was not provided free 
of charge. These data are consistent with findings reported by the Centers for Disease 
Control and Prevention (2001) and Chen, Yi, Wu et al. (2007), who found that the 
presence of chronic diseases, poor self-reported health and hospital admission 
strongly predicted influenza vaccination in elderly people among other cultures. A 
Similar result was observed in a Spanish study; the likelihood of being immunised 
was higher in people who had a negative perception of their general health, as 
compared to those with a positive perception of their health (de Andres, Carrasco- 
Garrido, Hemandez-Barrera et al., 2006). By contrast, some participants who 
perceived themselves as healthy considered that being vaccinated against influenza 
was unnecessary for them, and were prepared to take the risk of not having the 
vaccination. This is supported by Comford and Morgan’s (1999) study which found 
that most of the participants aged over 75 years perceived themselves as healthy and 
remained active and independent even though they had at least one chronic disease 
that placed them at an increased risk for severe complications or death attributable to 
influenza. Their perception of being in “good health” renders the influenza 
vaccination unnecessary.
5.7 Implications for clinical practice and the proposed intervention
Our findings suggest that in Thailand, as well as in other countries with tropical 
climates where large-scale influenza vaccination programmes have yet to be 
undertaken, the publicising of knowledge on influenza and influenza vaccination to 
the public will be necessary before launching the programme. This educational 
programme should both emphasise the symptoms and severity of influenza as well as 
explaining why the influenza vaccine should be applied to all high-risk groups. The 
educational messages should also clearly explain that the influenza vaccine prevents 
influenza, but not colds or other respiratory illnesses, and should be had before, rather
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than following, the onset of an influenza epidemic. This information should be 
provided in a manner appropriate to the culture and to the level of understanding of 
older people. It may also be targeted at younger people who will not have the 
vaccination themselves, but who may influence the vaccination decisions of their 
parents and others. Maximising uptake also appears to be predicated on the vaccine 
being free and available in local health care centres or community organisations, as 
well as more centralised hospitals. Doctors and other health care workers (including 
out-reach workers) should also be prepared and encouraged to discuss vaccination 
with their patients.
5.8 Strengths and limitations of the study
The strengths were the use of several styles of questions and probing techniques. As 
influenza symptoms can be confounded by symptoms from illness caused by common 
cold as well as other respiratory diseases, and the decision whether or not to vaccinate 
is a complex issue; thus, several styles of questions (essential questions, extra 
questions, and probing questions) that were appropriate for the informants’ 
backgrounds, and probing techniques (silent and echo probes) were used during the 
interview to ensure mutual understanding of the issues. Nevertheless, there were 
limitations to this study. The main limitation is its wider generalisablilty. It was 
conducted in one selected urban community; potentially restricting its implications to 
only high-risk Thai adults living in Muang district, Chiang Rai, Thailand. Another 
limitation is that there were ten potential participants who refused to participate in this 
study: four felt generally unwell, four did not have enough time for interview, and two 
were not interested. Accordingly, while a good response rate for qualitative research 
was obtained, it is possible these individuals might have different views on influenza 
and influenza vaccination from those who participated in the study. Despite these 
cautionary notes, however, our findings provide information relevant to the 
development of public health interventions to promote the use of influenza vaccine 
among high-risk groups in tropical countries such as Thailand where large-scale 
implementation of influenza vaccination programme have yet to be established. 
Nonetheless, further research needs to be done in various settings to provide a 
complete understanding of the knowledge, beliefs regarding influenza and
132
vaccination, as well as the facilitators and barriers to get vaccinated among high-risk 
urban dwelling Thai adults.
5.9 Conclusion
Our study clearly demonstrated that the decision whether or not to vaccinate is a 
complex issue that is influenced by several medical, psychological and social factors. 
This study has important implications for the promotion of influenza vaccination, as 
its findings offer potential insights into how health promotion professionals could 
develop an effective programme to raise influenza vaccination rate of vulnerable 
groups in populations. In the light of study findings, efforts to develop the effective 
influenza vaccination programme should aim to address as far as possible all the 
direct and indirect influences, as well as the knowledge and beliefs about influenza 
and influenza vaccination held by high-risk people. It has been suggested that the 
design of behaviour change interventions should be based on behavioural models, as 
these provide change targets and provide an explanation for an outcome (Dishman & 
Buckworth, 1996; Abraham, Sheeran, & Johnston, 1998; Michie & Abraham, 2004; 
Michie, Johnston, Francis et al., 2008; Michie & Prestwich, 2010). According to the 
behaviour model, it is assumed that when the factors identified as possible causes of 
target behaviour were modified appropriately, this will engender the targeted health 
behaviour change (Michie, Johnston, Francis et al., 2008; Michie & Prestwich, 2010; 
Thomas, Russell, & Lorenzetti, 2010). In study 2, the Health Action Process 
Approach (HAPA) was used as a conceptual framework to guide intervention and 
implementation. Thus, the HAPA model will be the focus of the following chapter.
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Chapter 6: Changing health behaviour: theory and 
application
6.1 Introduction
An individual’s decisions about changing health behaviours is a complex process 
influenced by numerous factors, including personal, social, environmental, and 
economic factors (Abraham, Sheeran, & Johnston, 1998; Conner & Norman, 1998, 
2005). Interventions are therefore needed to address these in order to change a given 
behaviour. In promoting influenza vaccination, for example, some people have 
worked on changing a system of vaccination (e.g. setting up an express vaccination 
clinic, and providing the vaccine free of charge, standing orders and physicians 
consistently offering influenza vaccination to all high-risk patients during the 
influenza season) (Nichol, Korn, Margolis, 1990; Humair, Buchs, & Stalder, 2002; 
Kroneman, Paget, & van Essen, 2003), others have tried to change perceptions and 
motivate high-risk people to get annual influenza vaccination (LaVela, Cameron, 
Priebe et al., 2008; Wray, Buskirk, Jupka et al., 2009). In addition, some people have 
focused on the development of influenza vaccination policies such as lowering the age 
for universal vaccination (WHO, 2000; CDC, 2010). These are all useful approaches, 
but they are based on different conceptual frameworks for promoting change. In this 
study, the intervention to promote influenza vaccination was based on the HAPA 
model which is a psychological model; thus, it focuses on the individual (Schwarzer, 
2001).
Evidence has shown that a theoretical approach to developing an intervention is more 
effective than interventions developed without theoretical guidance (Dishman & 
Buckworth, 1996; Abraham, Sheeran, & Johnston, 1998). In addition, Godin and 
Shephard (1990) pointed out that although an intervention programme without a 
theoretical basis can demonstrate a positive change in health behaviour, the reasons 
which underpin its successful change remain unclear due to the lack of theory to 
support the intervention. This makes it difficult to implement such interventions on a 
large scale or nation-wide. This chapter provides an overview of social cognitive 
models and three commonly used models (Health Belief Model [HBM], Protection
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Motivation Theory [PMT], and Social Cognitive Theory [SCT]), the Health Action 
Process Approach model (HAPA), implementation intentions, and the application of 
the HAPA model to health-related behaviours (Becker, 1974; Rosenstock, 1974; 
Rogers, 1975, 1983; Bandura, 1977, 1986, 1997; Schwarzer, 1992, 1999, 2001; 
Gollwitzer & Brandstatter, 1997; Gollwitzer& Schaal, 1998; Gollwitzer, 1999; 
Conner & Norman, 1998, 2005; Armitage & Conner, 2000; Rutter & Quine, 2002). 
Three social cognitive models (HBM, PMT, and SCT) are reviewed as they are 
historical antecedents to the HAPA.
6.2 Social cognition models
A number of factors have been found to be involved in the decisions to perform 
health-related behaviour, including demographic factors, social factors, emotional 
factors, personality factors, factors associated with access to medical care, and 
cognitive factors (such as knowledge, attitudes, and beliefs) (Conner & Norman, 
2005; Morrison & Bennett, 2006). Among these factors, cognitive factors appear to 
mediate the effects of other factors upon the performance of health behaviours. They 
are also amenable to change, and thus provide targets for interventions designed to 
change health behaviours (Conner & Norman, 1998, 2005; Rutter & Quine, 2002). 
The social-cognitive approach emphasises human cognitions or thoughts. The models 
are derived from expectancy-value theory and subjective expected utility theory, 
which describe individual behaviour as being based intentionally rational judgment 
and aimed at utility maximisation (Edwards, 1954; Conner & Norman, 2005). 
When making a decision to perform a particular behaviour, people are assumed to 
evaluate options by assessing probabilities, weighing up of the potential costs and 
benefits of them, and ranking all of the options in order to make a decision. These 
assessment processes are assumed to be a rational (Edwards, 1954; Conner & 
Norman, 2005). For more than 40 years, various social cognitive models have been 
developed and used to explain and predict health behaviours. Finding the weakness in 
these models has led to the development of new models or refinement of existing ones 
(Rutter & Quine, 2002). In this chapter, three social cognitive models are reviewed: 
Health Belief Model (HBM), Protection Motivation Theory (PMT), and Social 
Cognitive Theory (SCT) (Becker, 1974; Rosenstock, 1974; Rogers, 1975, 1983; 
Bandura, 1977, 1986, 1989, 1997, 2004).
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6.2.1 Health Belief Model
The Health Belief Model (HBM) was originally developed in the 1950s and 1960s by 
a group of the U.S. public health service researchers, including Hochbaum, Kegeles, 
Leventhal, and Rosenstock (Rosenstock, 1974; Becker, 1974), to help explain why 
people did or did not participate in the preventive programme and screening tests such 
as x-ray screening for tuberculosis or accepting immunisation (Becker, 1974; 
Rosenstock, 1974). Subsequently, it has been applied to other health-related 
behaviours, including patients’ responses to symptoms of illness, adherence to 
penicillin prescriptions and compliance with a diet regimen for diabetes mellitus (Janz 
& Becker, 1984). The model has its root in the Lewinian theory of goal setting which 
assumes that individual behaviour is determined by the value placed by individual on 
a particular goal (positive or negative) and the consequences of behaviour related to 
achieving that goal (Maiman & Becker, 1974).
The HBM proposes that the motivation to perform behaviour arises from the 
individual’s perception of a threat to personal health. Threat perception is determined 
by two key beliefs: perceived susceptibility to a disease or health problems and the 
perception of the seriousness of that disease. At the same time, behaviour is evaluated 
from an estimate of the perceived benefits of the recommended treatment or 
preventive behaviours in terms of reduce susceptibility or severity of the health 
problems. The benefits are then weighed against the costs or barriers of performing 
that behaviour; people who perceive more benefits than barriers are more likely to 
take action than those perceiving more barriers than benefits. In addition, the model 
stipulates that a cue to trigger appropriate behaviour is important. The cues may be 
internal (e. g. perceptions of symptoms) or external (e.g. information from health 
education leaflets, receiving a reminder postcard from health care providers). 
Additionally, demographic factors and physiological characteristics are thought to 
influence individual’s perception. Therefore, they indirectly have an effect on health- 
related behaviour (Rosenstock, 1974; Becker, 1974; Janz & Becker, 1984; Mullen, 
Hersey, & Iverson, 1987). The model has been refined over the years. The construct 
“health motivation” to reflect one’s motivation to engage in health behaviour was 
added to the original model (Rosenstock, 1974; Becker, 1974; Rutter & Quine, 2002). 
In addition, the concept of self-efficacy was added to the model by Rosenstock,
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Strecher, & Becker (1988). Generally, these six components are to be treated as 
independent predictors of health behaviour, thus up to six independent variables may 
account for variance in behaviour (Abraham & Sheeran, 2005). A schematic 
description of the Health Belief Model is shown in figure 6.2.1.
Behaviour
Cues to actionHealth motivation
Self-efficacy
Perceived severity
Perceived benefits
Perceived barriers
Perceived susceptibility
D e m o g r a p h ic  v a r ia b le s  
( e .g .  g e n d e r ,  a g e )
Figure 6.2.1 The Health Belief Model (original, plus additions in italics)
The model has been applied to the prediction of a wide variety of health-related 
behaviours, including smoking (Knight & Hay, 1989), exercise (Godin & Shephard, 
1990), attendance at health checks (Norman & Conner, 1993), mammography and 
cervical screening (Fischera & Frank, 1994; Orbell, 1996; Champion & Miller, 1996), 
adherence to safe-sex behaviours (Abraham, Sheeran, Spears et al., 1992; Bakker, 
Buunk, & Siero, 1997), adherence to antipsychotic medication (Hughes, Hill, & 
Budd, 1997; Budd, Hughes, & Smith 1996), breast self-examination (Friedman, 
Hoffman, Nelson et al., 1994; Millar, 1997), and compliance with influenza 
vaccination (Nex0e, Kraqstrup, & Sogaard, 1999; Mok, Yeung, & Chan 2006; Lyn- 
cook, Halm, & Wisnivesky, 2007).
In relation to vaccination behaviour, the HBM predicts that an individual will seek 
the influenza vaccination if they perceive that they are susceptible to the influenza, 
that influenza infection can cause serious complications, that the benefits of obtaining 
influenza vaccine are high, and that the costs/barriers of getting vaccinated are 
comparatively low. In addition, cues to action such as a reminder postcard from health 
care providers or information from the media may prompt them to seek or receive the 
vaccine. Similarly, if one is motivated to stay healthy during the influenza season. 
Finally, the revised model suggests that if he/she has the confidence to either seek or 
cope with the side-effects of vaccination uptake is more likely.
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According to Janz and Becker’s (1984) review of the studies applying the HBM 
published between 1974 and 1984, there were four studies that used the HBM as a 
conceptual framework for explaining swine influenza and influenza vaccination 
uptake. The results of these researches supported the predictions of the HBM; 
perceived susceptibility, perceived efficacy and safety of the vaccine were 
significantly associated with vaccination behaviour. Subsequently, a cross-sectional 
study of factors influencing the decision on influenza immunisation conducted by 
Nexoe, Kraqstrup, & Sogaard (1999) revealed that three major HBM variables: 
perceived barriers, perceived benefits, and perceived severity were significantly 
related to influenza vaccination status among the older people. More recently, Mok, 
Yeung, & Chan (2006) included factors specified in the HBM in the study examining 
correlates of intention to be immunised in Hong Kong Chinese adults aged 65 years 
and older. The results of this study showed that the perception of susceptibility to 
influenza (“I am likely to get the flu if I do not get a yearly flu shot”) appeared as a 
significant predictor of vaccination intention among these individuals. Similar results 
were obtained by Raftopoulos (2007) who explored the knowledge, the beliefs about 
and the attitudes towards influenza and pneumococcal vaccination among 
community-dwelling older people in Greece. This qualitative study found that 
perceived benefits of influenza vaccination emerged as key facilitators of receipt of 
influenza vaccine.
Despite these generally positive findings, a meta analysis of studies of the HBM 
conducted by Harrison, Mullen, and Green (1992) indicated that although the HBM 
has been consistently found to be predictive of health behaviours, the relationship 
between the model’s components and health behaviours across the studies was weak 
(effect sizes ranging from 0.01 to 0.30). Aside from the weak predictive power, the 
model has also been criticised for emphasising individuals and their cognitive 
processing. Other variables that could influence behaviours, including social support 
systems and emotional factors, have not been included. In addition, the operational 
definitions of the variables and the rules for combining variables (such as perceived 
susceptibility and perceived severity) are not clear. Accordingly, different methods 
have been used to measure HBM constructs. For example, susceptibility has been 
used to assess either personal vulnerability to specific disease/threat or general 
vulnerability to disease/ threat compared to others (Simon, Morse, Balson et al., 1993;
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Rutter & Quine, 2002). Also, different combinations of variables have been used in 
the studies applying the HBM model, including adding or multiplying susceptibility 
and severity, or subtracting barriers from benefits (Hill, Gardner, & Rassaby, 1985; 
Rutledge, 1987; Wyper, 1990). Furthermore, the model has not been clearly specified 
any particular relationship among the core set of beliefs, how these beliefs should be 
measured and how they can combine to influence behaviour (Hill, Gardner, & 
Rassaby, 1985; Montano, 1986; Wyper, 1990; Strecher & Rosenstock, 1997; 
Armitage & Comner, 2000; Rutter & Quine, 2002; Abraham & Sheeran, 2005; 
Morrison & Bennett, 2006). Finally, it has been pointed out that the HBM 
conceptualises behaviour change as a static process rather than a dynamic process. 
Various beliefs seem to occur simultaneously, and there is no room in these beliefs for 
change or development (Schwarzer, 1992).
Despite these conceptual flaws, the model has been used extensively to predict a 
range of health-related behaviours. In addition, some of the model’s components 
(susceptibility and severity) have been incorporated into the new models such as 
Health Action Process Approach model and Protection Motivation Theory (Rogers, 
1975, 1983; Schwarzer, 1999; Rutter & Quine, 2002).
6.2.2 Protection Motivation Theory (PMT)
Protection Motivation Theory shares some features with the HBM (Rosenstock, 
1974). It was developed by Rogers (1975), who aimed to provide a framework for 
research on fear appeals and attitude change. According to PMT, an individual’s 
decision whether or not to adopt a particular health behaviour is guided by two 
cognitive processes: threat appraisal and coping appraisal. Threat appraisal refers to 
an individual’s evaluation of risks posed by the threat. This appraisal is based on 
perceived susceptibility, perceived severity, and fear. Fear is labelled as an 
intervening variable between perceived severity and susceptibility and threat 
appraisal; the greater the perceived threat, the more fear will be elicited. Theoretically, 
as perceptions of susceptibility and severity increase, the likelihood of adopting 
unhealthy behaviour decreases. However, there may be a number of intrinsic rewards 
(e.g. pleasure) and extrinsic rewards (e. g. peer approval) that increase the likelihood
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of performing the unhealthy behaviour. As the PMT has been revised in 1983, 
rewards of not adopting the recommended behaviour and self-efficacy have been 
specified and added to the model (Rogers, 1975, 1983; Maddux & Rogers, 1983; 
Maddux, 1993; Armitage & Conner, 2000; Milne, Sheeran, & Orbell 2000; Norman, 
Boer, & Seydel, 2005).
The second appraisal process is coping appraisal which is influenced by response 
efficacy (an individual’s estimation of the effectiveness of the recommended coping 
strategy in reducing appraised threat) and self-efficacy (an individual’s perception of 
his or her ability to perform the behaviour). It is expected that response efficacy and 
self-efficacy increase, the probability of engaging in preventive behaviour increases. 
However, the likelihood of an adaptive response is decreased by the perceived 
response costs or barriers such as the lack of availability of resources. In addition, the 
PMT identifies two types of sources of information: environmental (e.g. verbal 
persuasion, observational learning) and intrapersonal (e.g. prior experience), and this 
information influences susceptibility, severity, fear, response efficacy, and self- 
efficacy, which induce either an adaptive response or a maladaptive response (Rogers, 
1975, 1983; Maddux & Rogers, 1983; Maddux, 1993; Armitage & Conner, 2000; 
Milne, Sheeran, & Orbell 2000; Norman, Boer, & Seydel, 2005).
The PMT describes protection motivation to perform health behaviour as a result of 
the two appraisal processes (threat appraisal and coping appraisal). Protection 
motivation is seen as a proximal predictor of protective behaviour, and it is assumed 
that intention is the most appropriate measure of protection motivation (Prentice- 
Dunn & Rogers, 1986). Protection motivation is an intervening variable that “arouses, 
sustains, and directs activity” (Rogers, 1975, p. 98). According to Rogers (1983), four 
beliefs are assumed to increase protection motivation (a positive linear function) : the 
threat is severe, the individual regards his or herself as susceptible to the threat, the 
recommended behaviour will be beneficial in reducing the threat, and the individual 
has the ability to perform the coping response. Two further beliefs operate in a 
negative linear function: rewards from the maladaptive responses and the perceived 
costs or barriers of the adaptive behaviour (see Figure 6.2.2). Thus, the highest 
amount protective motivation will be elicited if all positive beliefs are high and the 
two negative beliefs are low (Rogers, 1975, 1983; Maddux & Rogers, 1983; Prentice-
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Dunn & Rogers, 1986; Armitage & Conner, 2000; Milne, Sheeran, & Orbell 2000; 
Norman, Boer, & Seydel, 2005).
Source of information Cognitive mediating processes Behaviour
Environmental
Communication
Observational
Learning
+ve +ve
+ve
Intrapersonal —1
personality variables 
Prior experience
+ve
Health
protective
behaviour
Protection
motivation
Maladaptive coping
(e.g. avoiding, denial, 
hopelessness,
Wishful thinking)
Coping appraisal
Perceived response efficacy 
Perceived self-efficacy 
Perceived response costs
Threat appraisal
Perceived vulnerability 
Perceived severity 
Fear
Figure 6.2.2 Schematic representation of protective motivation theory (adapted 
from Rogers, 1983): +ve = positive association; -ve = negative association
Source: Milne, Sheeran, & Orbell, 2000
Floyd, Prentice-Dunn, & Rogers (2000) conducted a meta-analysis of PMT studies. 
The findings of this study provide support for the use of the PMT framework in 
predicting intentions and behaviour; all PMT components were significantly 
associated with intentions, and self-efficacy was the strongest predictor of both 
protection motivation (intention) and behaviour.
In another meta-analysis of PMT studies, carried out by Milne, Sheeran, and Orbell, 
(2000), their analyses also showed that all variables specified by PMT were 
significantly predictive of intentions and concurrent behaviour. With regard to the 
prediction of intention, the effect sizes (r+: sample weighted average correlations) 
were larger for the coping appraisal variables (perceived response efficacy [r+ = 0.29], 
self-efficacy [r+ = 0.33] and response costs [r+ = -0.34]) than the threat appraisal 
variables (perceived severity [r+= 0.10] and susceptibility [r+= 0.16]). In other words, 
coping appraisal variables were stronger in predicting protection motivation or
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intention than threat appraisal variables. This pattern of results was also found in 
measures of association with concurrent behaviour. However, when considering the 
prediction of future behaviour, only four PMT variables proposed in PMT (perceived 
vulnerability, self-efficacy, response costs and protection motivation (intention) have 
been found to be significant predictors of future behaviour. Furthermore, the effect 
sizes for these four variables (susceptibility [r+ = 0.12], self-efficacy [r+ = 0.22], 
response costs [r+= - 0.25], and protection motivation [r+= 0.40]) were in the small to 
medium range according to Cohen’s (1988) guideline, and protection motivation 
(intention) was found to have the largest effect size (r+ = 0.40), followed by self- 
efficacy (r+ = 0.22). However, Milne, Sheeran and Orbell’s (2000) review of PMT 
studies was based on a relatively small number of studies that examined the 
relationship between PMT variables and future behaviour.
In addition, the PMT has been used to predict cancer-preventive intentions and 
behaviours (Seydel, Taal, & Wiegman, 1990). The study showed that the PMT was 
superior to the HBM in the prediction of preventive behaviour related to cancer; self- 
efficacy expectancy and outcome expectancy were found to be predictors of actual 
behaviour -  ordering leaflets (“The seven warning signs” and “Breast self- 
examination) from the national information centre of the Dutch Cancer Society. 
Wurtele and Maddux (1987) also found that perceived vulnerability to heart disease 
and perceived exercise self-efficacy increased intention to adopt an exercise program 
among undergraduate women, but persuasive communications did not have 
significant effects on exercise behaviour.
Unlike the HBM and other social cognitive models (e.g. Theory of Reasoned Action 
[TRA], Theory of Planned Behaviour [TPB] (Ajzen & Fishbein, 1980; Ajzen, 1991; 
Ajzen, 2005), the PMT has been evaluated through the use of a number of 
experimental manipulations (Beck & Lund, 1981; Milne, Sheeran, & Orbell, 2000; 
Milne, Orbell, & Sheeran, 2002; Norman, Boer, & Seydel, 2005). Beck and Lund 
(1981) applied the PMT to oral hygiene behaviour, and found that feelings of fear, 
perceived susceptibility, perceived severity, intention and oral hygiene behaviour 
(flossing) were significantly higher among dental patients exposed to a “high 
seriousness” version of a threat communication designed to change their beliefs about 
periodontal disease than those patients exposed to their “low seriousness” version.
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The study conducted by Wurtele (1988) revealed that perceived vulnerability to 
osteoporosis had a significant influence on adoption intention and recommended 
behaviour for preventing osteoporosis (dietary intake of calcium and picking up a free 
calcium supplement) among female undergraduates. Other studies also found that 
PMT manipulations had positive effect on intentions to adopt the adaptive response 
(Stanley & Maddux, 1986; Rippetoe & Rogers, 1987; Yzer, Fisher, Bakker et al., 
1998).
The PMT differs from the original HBM, in which it includes self-efficacy and 
protection motivation which is generally measured by intention (Prentice-Dunn & 
Rogers, 1986). These two variables (self-efficacy and intention) have been found to 
be positively associated with behaviours in multiple studies (e.g. Beck & Lund, 1981; 
Wurtele, 1988; van der Velde & van der Pligt, 1991; Weinstein, 1993). Also, 
consistent with other models such as the Theory of Planned Behaviour (TPB) (Ajzen, 
1991; Ajzen, 2005), the PMT suggests that protection motivation functions as an 
intervening variable that stimulates, sustains, and directs coping response (Rogers, 
1975, 1983; Prentice-Dunn & Rogers, 1986). Thus, according to the PMT, protection 
motivation is an important predictor of behaviour, and forming protection motivation 
leads to the adoption of precautions or behaviour change (Prentice-Dunn & Rogers, 
1986). This may explain why the PMT has been found useful for explaining and 
predicting health-related behaviours (Prentice-Dunn & Rogers, 1986; Weinstein, 
1993; Floyd, Prentice-Dunn, & Rogers, 2000; Milne, Sheeran, & Orbell, 2000; 
Norman, Boer, & Seydel, 2005).
In contrast to the previous discussion, some studies have found that PMT 
interventions had no effect on actual behaviour (Milne et al., 2002; Wurtele and 
Maddux, 1987). For example, a study that investigated the impact of PMT-based 
intervention on subsequent changes in exercise cognitions, intention and behaviour 
carried out by Milne, Orbell, and Sheeran (2002) found that a motivational 
intervention based on PMT made a significant contribution to changing exercise 
cognitions (threat and coping appraisals) and intention, but had no significant impact 
on subsequent exercise behaviour. The finding that motivational interventions 
grounded in PMT was found to have a strong influence on health-related behavioural 
intentions but not subsequent behaviour may not be specific for the PMT. One
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explanation for these findings is that there is frequently a disjunction between 
intention and behaviour, known as the “intention-behaviour gap” (Armitage & 
Conner, 2000; Sheeran, 2002; Sheeran, Milne, Webb et al., 2005). The intention- 
behaviour relationship may be disrupted by unforeseen barriers or the face of 
temptations; thus, people do not perform a particular behaviour according to their 
intentions (Sheeran, 2002; Sniehotta, Scholz, & Schwarzer, 2005; Schwarzer, 
Luszczynska, Ziegelmann et al., 2008).
Findings from meta-analyses showed that intentions accounted for 20 per cent to 30 
per cent of the variance in health behaviour on average (Sheppard, Hartwick, & 
Warshaw, 1988; Randall & Wolff, 1994; Godin & Kok, 1996; Sheeran & Orbell, 
1998, Sheeran, 2002). This suggests that other predictors of health behaviours (e.g. 
planning and volitional self-efficacy) may be responsible for the intention-behaviour 
gap (Abraham et al., 1998; Armitage & Conner, 2000; Sheeran, 2002; Sheeran, Milne, 
Webb et al., 2005).
Although manipulation of PMT variables tends to have a small impact on subsequent 
behaviour, the model provides useful insights for the design of interventions to enhance 
intention and, perhaps, behaviour. Additionally, it has been suggested that changing 
behaviours may require other volitional strategies such as implementation intentions 
to bridge the gap between intentions and behaviour (Milne, Orbell, & Sheeran, 2002; 
Sheeran, Milne, Webb et al., 2005; Norman, Boer, & Seydel, 2005). In the following 
session, the implementation intentions will be discussed in more detail.
6.2.3 Social Cognitive Theory (SCT)
Social Cognitive Theory (STC) is seen as a comprehensive theory of behaviour 
change. Central to the SCT is the concept of self-efficacy which is now included in 
most of health behaviour models (Bandura, 1977, 1986, 1997; Armitage & Conner, 
2000). The SCT is derived from the Social Learning Theory (SLT) (Bandura, 1986). 
Like other Social Cognition Models, the SCT aims to predict and explain health 
behaviour using a core set of determinants: self-efficacy, outcome expectations, goals, 
facilitators and impediments. In addition, the model also specifies the mechanisms 
involved in the behaviour change. According to the SCT, human behaviour can be
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described in terms of triadic reciprocal causation in which behaviour, personal factors 
(cognitive, affective, and biological factors), and environmental factors all interact 
and influence each other (see figure 6.2.3.1), and health behaviour change lies in these 
interactions (Bandura, 1986; 1989).
P
B *
Figure 6.2.3.1 Schematic representation of triadic reciprocal causation.
Note: B represents behaviour; P the internal personal factors in the form of 
cognitive, affective, and biological events; and E the external environment 
Source: Bandura, 1986
The core constructs of the SCT include goals, self efficacy, outcome expectations, 
facilitators and impediments (Bandura, 2004; Luszczynska & Schwarzer, 2005). 
Social Cognitive Theory suggests that in initiating and maintaining health behaviour, 
individuals first establish a goal, and then they consider the likely consequences of 
performing a given behaviour in relation to that goal (outcome expectations) before 
they decide whether to engage in a given behaviour. Such outcome expectancies can 
be classified into three categories: physical outcome expectations, social outcome 
expectations and self-evaluative outcome expectations. Outcome expectations are 
considered to be important in the initial formulation of the goals. Physical outcome 
expectations are related to the anticipation of physical effects, such as the 
expectations of discomfort or disease symptoms, which might be experienced after 
behaviour change. Social expectancy refers to the consequences of performing a 
particular behaviour that may be determined by others or society. Self-evaluative 
outcome expectations are related to the internal reactions that might expected after 
behaviour change such as being proud of oneself and being ashamed. However, these 
outcome expectancies lose their influence in the phases of action control, and self- 
efficacy appears to have more powerful effect on behaviour. Perceived self-efficacy is
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related to the beliefs about one’s own ability to perform a particular behaviour 
(Bandura, 1977, 1986, 1989, 1997, 2004; Luszczynska& Schwarzer, 2005).
Self-efficacy beliefs are crucial to successful change of health behaviours. They 
have direct impact on personal behaviour, and they can also influence goals, outcome 
expectancies, and perceived facilitators and barriers (Bandura, 2004). Individuals with 
stronger self-efficacy tend to set higher goals for themselves and commit to their 
goals more strongly, which in turn influence actual behaviour (Bandura, 1989; Locke 
& Latham, 1990). Perceived self-efficacy also shapes the outcome expectations of 
an individual. Individuals with high generalised self-efficacy will expect their efforts 
to attain favourable outcomes, whereas those who perceive low self-efficacy tend to 
view poor outcomes (Bandura, 1989, 2004). Behaviours that guarantee valued 
outcomes may not be pursued if the person doubts his or her ability to engage in them 
(Beck & Lund, 1981; Bandura, 1994). A typical study of this phenomenon, conducted 
by Williams and Bond (2002), confirmed the role of self-efficacy in influencing 
health behaviour change; people with diabetes who had less confidence in their self- 
care abilities were unlikely to comply with a diabetic regimen (diet, exercise, and 
blood glucose testing), although they believe that following the regimen would be 
beneficial to their general health.
Additionally, SCT suggests that goal setting is affected by sociostructural factors 
(facilitators and impediments). Social Cognitive Theory proposes that the perceived 
facilitators and barriers could potentially influence behaviour (Bandura, 2004; 
Luszczynska & Schwarzer, 2005). Self-efficacious persons believe that they have the 
capacity to exercise control, even in the face of difficulties or barriers. On the 
contrary, those with low self-efficacy are less likely to persevere in the face of 
obstacles, and are eventually likely to abandon their goal when they encounter 
difficulties and setbacks (Bandura, 1977, 1989, 2004). Bandura (1977) suggested that 
an individual’s persistence and efforts in behaviours as well as the quality of the 
performance are related to his or her level of self-efficacy.
All social cognitive constructs of social cognitive theory are illustrated in figure 
6.2.3.2. However, within social cognitive theory, outcome expectations and self- 
efficacy beliefs are considered as central determinants of behaviour, and are the main
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focus of research attention. According to this perspective, persons are more likely to 
engage in certain health behaviours if they believe that performing them will lead to 
desirable outcomes, and they are confident in their abilities to perform the recommended 
behaviour, even in the face of difficulties or barriers.
BehaviourGoalsSelf-efficacy
Sociostructural factors:
facilitators
Impediments
Outcome expectations: 
Physical 
Social
Self-evaluative
Figure 6.2.3.2 An illustration of social cognitive theory 
Source: Bandura, 2004
One’s self-efficacy can develop through four major sources. These sources include 
performance attainment, vicarious experience, verbal persuasion, and physiological 
state (Bandura, 1977, 1986, 1997). Performance accomplishments are believed to be 
the most potent sources of efficacy information as they provide information about past 
success. Successful experiences boost self-efficacy, whereas failure undermines it 
(Bandura, 1977).
The second source of self-efficacy is vicarious experience, which refers to learning 
through modelled attainment or observing others’ achievements. A trial of vicarious 
experience can be particularly useful for people who are doubtful about their ability to 
perform a particular behaviour. Seeing others perform an activity can help these 
individuals believe that they can possess the ability to perform the recommended 
behaviour (Bandura, 1977, 1986; Parent & Fortin, 2000). However, the effectiveness 
of enhancing self-efficacy through vicarious experience depends on the similarity 
between the model and the observer (Bandura, 1977, 1986; Strecher, DeVellis, 
Becker et al., 1986).
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A third source is verbal persuasion. Persuasive techniques are widely used by health 
educators because of their relative simplicity and ease of use. By using verbal 
persuasion to enhance self-efficacy, individuals are led through suggestion to believe 
that they have the capability to do and to accomplish a particular outcome (Bandura, 
1977, 1997).
Finally, physiological and emotional states can also have an effect on the individual's 
efficacy beliefs. For example, anxiety, and depression can diminish self-efficacy and 
discourage continued efforts to engage in a specific behaviour. People are less likely 
to initiate and continue behavioural efforts if they are tense and viscerally agitated 
(Bandura, 1977, 1989, 1997). Accordingly, reducing emotional arousal is viewed as 
one way of improving an individual self confidence. In addition, for some people who 
are prone to misinterpret their physical state or emotional arousal as symptoms of 
physical illness (e.g. incorrectly interpreting muscle aches and pains after beginning 
an exercise programme as signs of weak physical efficacy), diminishing negative bias 
in interpretation of bodily states may maintain feelings of self-efficacy (Bandura, 
1977, 1986, 1997; Strecher, DeVellis, Becker, 1986; Luszczynska & Schwarzer,
2005).
The SCT has been extensively used to study a variety of health-related behaviours 
such as adherence to antiretroviral therapy, compliance with a diabetic regimen, 
unprotected sexual behaviour, physical exercise, nutrition and weight control, breast 
self-examination, smoking, and substance use (Seydel, Taal, & Wiegman, 1990; 
Ellickson & Hays, 1992; Wulfert & Wan, 1993; Anderson, Winett, & Wojcik, 2000; 
Catz, Kelly, Bogart et al., 2000; Dijkstra & DeVries, 2000; Kremers et al., 2000; 
Schnoll & Zimmerman, 2001; Christiansen et al., 2002; Rodgers, Hall, Blanchard et 
al., 2002; Williams & Bond, 2002). Such studies have shown that outcome 
expectancies and perceived self-efficacy play an influential role in explaining and 
predicting a wide variety of health behaviours, although self-efficacy was found to be 
the most important factor in affecting motivation and subsequent behaviour (Seydel, 
Taal, & Wiegman, 1990; Wulfert & Wan, 1993; Kremers, Mesters, Pladdet et al., 
2000; Christiansen, Vik, & Jarchow 2002; Rodgers, Hall, Blanchard et al., 2002; 
Williams & Bond, 2002). As a consequence of the strong relationship between self- 
efficacy and behaviour in multiple studies, it has been incorporated into several
148
conceptual models of health behaviours, including Health Belief Model, Protection 
Motivation Theory, and Health Action Process Approach (Rosenstock, 1974; Rogers, 
1983; Schwarzer, 1992)
Social Cognitive Theory has also been used as a framework in developing behaviour 
change interventions in several studies (e.g. O'Leary, Shoor, Lorig, & Holman 1988; 
Stanton, Li, Ricardo et al.,1996; Parent & Fortin, 2000; Dijkstra & De Vries, 2001; 
Carson, Gillham, Kirk et al., 2002; Baranowski, Baranowski, Cullen et al., 2003; 
Dishman, Motl, Saunders et al., 2004). For example, an SCT-based intervention 
involving vicarious experience through peer support enhanced self-efficacy following 
coronary artery bypass graft surgery (CABG) more than a standard treatment control 
(Parent & Fortin, 2000). Walking, stair climbing, and ‘general activity’ were also 
more prevalent among patients in the intervention group five days after surgery 
(Parent & Forbin, 2000).
Similar results were obtained by Dishman, Motl, Saunders et al (2004) who 
demonstrated the effects of a comprehensive school-based intervention aimed at 
enhancing physical activity self-efficacy in adolescent girls. The study showed that 
increased self-efficacy led to increased physical activity. In addition, self-efficacy was 
found to partially mediate intervention program effects on physical activity among 
these individuals. Baranowski, Baranowski, Cullen et al. (2003) also showed that a 
psychoeducational, multimedia game based on SCT had positive effects on fruit, juice 
and vegetable consumption among pre-adolescents participating in an intervention 
programme; children in the intervention condition increased intake by 1.0 serving 
more than the children who did not receive the intervention at the end of the 5-week, 
ten-session programme (Baranowski, Baranowski, Cullen et al., 2003).
However, some studies have revealed that interventions designed in line with SCT 
have had limited success in promoting long-term behaviour changes, such as physical 
activity, and condom use (Stanton, Li, Ricardo et al. , 1996; Pinto, Friedman, Marcus 
et al., 2002). In a study conducted by Pinto, Friedman, Marcus et al. (2002), the 
telephone linked communication-physical activity (TLC-PA) was developed to 
promote physical activity in sedentary adults. While the intervention participants were 
asked to call TCL-PA, those in the control group were informed to call TLC-Eat
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(telephone linked communication-healthy eating). The contents regarding physical 
activity for weight loss were not provided to the comparison group (TLC-Eat). The 
intervention was available for six months. The results showed that at three months, 
the higher proportion of participants who met recommendation for moderate-intensity 
or vigorous-intensity physical activity was found in the intervention group, as 
compared with the control group. Also, those in the intervention group reported 
higher daily kilocalorie energy expenditure than the control group. However, after six 
months of intervention, the intervention effects were not maintained. The weak effects 
of the TLC-PA intervention might have been due to a significant decrease in the 
number of users over six months; thirty three per cent of the participants did not 
continue to use the system.
Stanton, Li, Ricardo et al. (1996) found that the HIV-risk-reduction treatment based 
on SCT had positive effects on condom used at six months among African-American 
youths 9-15 years of age, but there was no significant difference in condom use rates 
between the intervention and control groups at 12-month follow-up. In this study, the 
finding that the SCT-based intervention had no long-term effects on condom use 
among early adolescent was unclear. However, similar results have been noted in drug 
prevention study that targeted pre-adolescents (Ellickson, Bell, & McGuigan, 1993).
In summary, all three models have been widely used to predict a wide variety of 
behaviours with a fair degree of success. Intentions or personal goals (as defined 
in social cognitive theory) are regarded as proximal determinants of behaviour 
(Bandura, 2004; Luszczynska & Schwarzer, 2005). However, recent developments in 
social cognition models suggest that intentions alone are not sufficient to drive 
behaviour change (Weinstein, 1993; Abraham, Sheeran, & Johnston, 1998; Armitage 
& Conner, 2000; Sheeran, 2002; Schwarzer & Luszczynska, 2008).
A meta-analysis of 47 experimental studies conducted by Webb and Sheeran (2006), 
for example, found that a medium-to-large change in intention produced a small-to- 
medium change in behaviour. This study confirms that behaviour change is not 
exclusively determined by an individual's intentions. Therefore, in order to better 
understand why and how people change their health behaviour, attention has shifted 
from motivational processes (intention formation) to the post-intentional volition
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processes that are involved in health behaviour change and maintenance behaviour 
change over time (Abraham, Sheeran, & Johnston, 1998; Armitage & Conner, 2000; 
Sniehotta, Scholz, & Schwarzer, 2005; Schwarzer, 1996, 2008). Stages of change 
models such as Transtheoretical Model [TTM] (Prochaska & DiClemente, 1983) and 
Health Action Process Approach [HAPA] (Schwarzer, 1992, 2001) describe the 
processes of health behaviour change, and may be able to overcome some of 
limitations of motivational models.
6.3 The Health Action Process Approach (HAPA) model
The HAPA model was developed by Schwarzer at the Free University of Berlin, 
Germany. It aims to predict health behaviour and provide a better understanding 
of the mechanisms of health behaviour change than motivational models of health 
behaviour (Schwarzer, 1992, 2008). The HAPA integrates the motivational 
components of Social Cognition Models (such as Health Belief Model, and Social 
Cognitive Theory) and Volitional Theories (Heckhausen & Gollwitzer, 1987; 
Schwarzer, 1992, 2001, 2008). The HAPA suggests a distinction between the pre- 
intentional motivation processes that involve the formation of intentions and post- 
intentional volition processes which address the processes in the translation of goal 
intentions into action.
The HAPA can serve as an alternative to other health behaviour change models that 
do not include the post-intentional factors, including the HBM, PMT, TRA, and TPB 
(Luszczynska & Schwarzer, 2005; Sniehotta, Scholz, & Schwarzer 2006; Schwarzer 
& Luszczynska, 2008). These models (also called “continuum models”) assume that 
an individual’s behaviour occurs as the result of a conscious intention, and the 
intention formation is governed by beliefs and attitude (Amitage & Conner, 2000; 
Schwarzer, 2008). Accordingly, many health behaviour change models attempt to 
explain and predict a given health-related behaviour by identifying a set of social 
cognitive factors that influence behaviour (such as personal susceptibility, disease 
severity, perceived costs, perceived self-efficacy, and social norm), and then 
combining these variables into a linear prediction equation. This equation provides us 
information about the likelihood of behaviour which lies somewhere along the
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continuum of action (Weinstein, Rothman, & Sutton., 1998; Schwarzer, 2008). The 
action initiation is supposed to be the same for everyone because the prediction of 
behaviour is based on a single equation (Weinstein, Rothman, & Sutton., 1998). This 
implies that interventions designed to change behaviour based on continuum models 
try to modify all changeable variables in all individuals.
In contrast, stage models posit that health behaviour change passes through a series 
of stages (Weinstein, Rothman, & Sutton., 1998). It is assumed that individuals at the 
same stage experience similar barriers and those in different stages face different 
barriers of translating intentions into action. Additionally, the factors that influence 
the transition from one stage to another are different (Weinstein, Rothman, & Sutton., 
1998). According to this perspective, the optimal intervention can be designed to 
match a person’s stage. The HAPA can be regarded as a stage model because it 
implies the existence between pre-intentional motivation processes and post- 
intentional volition processes (Schwarzer, 2008). The distinction between 
motivational and volitional stages is based on the idea that there is a shift in the 
mindset of a person from the first stage to the second one (Schwarzer, 2008). Within 
the two processes or stages of behaviour change, the role of cognitive variables may 
be different. The motivation phase in which individuals form an intention to act is 
influenced by risk perceptions, outcome expectancy, and self-efficacy (Schwarzer, 
1992, 2001).
Risk perceptions or threat include perceived vulnerability (a person's perception of the 
risk of contracting a disease) and perceived severity (an individual’s perception of the 
seriousness of a disease). Although risk perceptions have found to be a poor predictor 
of health behaviour change, they are a necessary prerequisite for the motivation 
processes; a minimum level of concern about a health threat has to exist in order to 
help a person to deliberate and make a decision about health behaviour change 
(Schwarzer, 1992, 2001, 2008; Schwarzer & Luszcynska, 2008). A person also needs 
to understand the possible consequences of the action before making a decision about 
whether to engage in particular behaviour. Outcome expectancies are a person’s 
beliefs about the positive and negative consequences of performing a specific 
behaviour. It is assumed that the greater perceived positive outcome and the lower 
perceived negative outcome of a behaviour change, the more likely people are to
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develop an intention to change their behaviour. The HAPA suggests that outcome 
expectancies and self-efficacy are considered to be the major predictors of intention. 
Nevertheless, in a situation in which people have no experience with the behaviour 
they are contemplating (and thus no specific efficacy beliefs), outcome expectancy 
may be more powerful in influencing motivation to change (Schwarzer, 1992, 
Bandura, 1997).
In addition to being aware of a health threat and considering the consequences of 
performing a particular behaviour, the HAPA proposes that people also need to 
believe in their ability to perform a desired behaviour {perceived self-efficacy). Self- 
efficacy beliefs influence the individuals’ goals, and reflect how much effort they will 
expend in reaching a goal and how long they will persist in the face of difficulties and 
setbacks (Bandura, 1997, 2004; Schwarzer, 2001). The model also specifies phase- 
specific self-efficacy beliefs: pre-action self-efficacy (or action/task self-efficacy), 
maintenance self-efficacy (or coping self-efficacy), and recovery self-efficacy. Pre­
action self-efficacy is necessary in the motivation phase in which people develop their 
intentions (Schwarzer & Renner, 2000; Schwarzer, 2008; Schwarzer & Luszczynska, 
2008; Schwarzer et al., 2008). There is now convincing evidence that risk perceptions, 
outcome expectancies and self-efficacy significantly contribute to intentions to 
perform specific behaviours (Garcia & Mann, 2003; Sniehotta, Scholz, & Schwarzer, 
2005; Chow & Mullan, 2010; Schwarzer & Luszczynska, 2008). Thereafter, once 
goals have been established, risk perceptions and outcome expectancies exert less 
influence. Only self-efficacy plays a crucial role at all stages in the health behaviour 
change process (Bandura, 1997; Schwarzer, 2001).
After an intention to perform specific behaviour has been formed, people pursue their 
goals in the subsequent volition phase. In order to translate intention into action, the 
intended behaviour is needed to be planned, initiated, maintained, and restarted when 
problem or failure occurs. This involves self-regulatory strategies (Schwarzer, 1992, 
2001; Scholz, Schuz, Ziegelmann et al., 2008).
According to the HAPA, action planning plays an influential role in bridging the gap 
between intentions and behaviour. Action planning is defined as a prospective self- 
regulatory strategy that links behavioural responses to situational cues by specifying
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when, where, and how to perform a behaviour (Gollitwer, 1999; Schwarzer, 2003; 
Sniehotta, Scholz, & Schwarzer, 2005; Scholz, Schuz, Ziegelmann et al., 2008). 
Intentions are most likely to be acted on if the individual develops an action plan 
(Gollwitzer, 1999; Schwarzer, 1992, 2001; Luszczynska & Schwarzer, 2003; 
Schwarzer & Luszczynska, 2008). The action planning specifies about when, where, 
and how to carry out the intended behaviour. By forming a specific plan detailing 
where, when and how to perform the intended behaviour, individuals are more likely 
to recognise their intentions and carry out the desired behaviours when the specified 
situation is entered (Gollwitzer, 1999; Schwarzer, 1992, 2001).
Once a new behaviour has been initiated, it has to be maintained through the 
development of self-regulatory skills and strategies (Schwarzer, 2001; Schwarzer, 
Luszczynska, Ziegelmann et al., 2008). Self-regulation is broadly defined as any effort 
that individuals have undertaken in order to alter their own motivation and 
behaviours, such as setting attainable sub-goals, creating incentives, and mobilising 
support from other people (Carver & Scheier, 1996; Schwarzer, 2001). In the HAPA, 
“action control” refers to the self-regulatory processes that people can use to control 
their actions, including focusing attention on the task at hand, resisting temptations, 
and maintaining emotional balance (Schwarzer, 2001, 2008). The action control is 
strongly influenced by self-efficacy.
Maintenance self-efficacy describes one's perceived capability to act and sustain 
healthy behaviour and to deal with unexpected barriers that arise during the 
maintenance period (Luszczynska & Schwarzer, 2003; Sniehotta et al., 2005; 
Schwarzer, 2008; Schwarzer & Luszczynska, 2008). Once a new behaviour is 
established, people with high maintenance self-efficacy exert more effort and persist 
longer in the face of difficulties and obstacles than those with lower self-efficacy. 
However, it should be noted that a new health behaviour might be difficult to 
maintain over the years without a lapse. Recovery self-efficacy represents one’s 
capability to regain some control over behaviour after a setback or failure 
(Luszczynska & Schwarzer, 2003; Schwarzer, 2008; Schwarzer & Luszczynska, 
2008; Schwarzer, Luszczynska, Ziegelmann et al., 2008). Recover self-efficacy has 
been shown to be important predictor in promoting to long-term maintenance of 
behaviour change (Luszczynska, Mazurkiewicz, Ziegelmann et al., 2007; Schwarzer,
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Luszczynska, Ziegelmann et al., 2008). After the desired behaviour has been 
performed, the individual evaluates it as successful or failing. Many people 
sometimes disengage from their goals (Schwarzer, 1992, 2001). Disengagement from 
the goal implies failure of self-regulation. In the case of health-compromising 
behaviours, effective self-regulation skills are required to improve the maintenance of 
behaviour (Schwarzer, 2001). However, if the goals were set too high or if situations 
have changed and become more difficult than before, disengagement or scaling back 
the goal might be seen as an adaptive strategy because it can have a positive effect 
such as decreased psychological distress (Carver & Scheirer, 1990; Schwarzer, 2001; 
Wrosch, Miller, Scheier et al., 2007; Schwarzer, 2008).
Finally, the HAPA suggests that the perceived and actual environment also affect 
health behaviour change. For example, people may be willing and able to perform the 
recommended behaviour, but situation barriers as well as opportunities may prevent 
them from engaging in such behaviour (Schwarzer, 1992, 2001). A schematic 
representation of Health Action Process Approach model has been shown in figure 
6.3.
Self-efficacy
Outcome
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Figure 6.3 Schematic representation of Health Action Process Approach model 
Source: Schwarzer (1992); http//usepage.fu-berlin.de/~health/hapa.htm 
With regard to the design of health behaviour change interventions, the HAPA 
suggests that there are three distinct stages involved in designing and implementing 
specific-stage interventions: pre-intention, intention, and action stages (Lippke, 
Ziegelmann, & Schwarzer., 2005; Schwarzer, 2008; Wiedemann, Lippke, Reuter et
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al., 2009). Individuals with different mindsets can be identified in order to receive a 
specific intervention/treatment. In a pre-intention stage, individuals are classified as 
non-intenders. At this motivation stage, they are developing their intentions to 
perform a behaviour. After the intentions have been set, people enter the volition 
phase. This volition stage is further subdivided into two sub-stages: intention and 
action stages. While in the intention stage individuals hold an intention to act, but 
they have not yet acted (intenders), people in the action stage already act according to 
their intentions (actors).
A number of studies (e.g. Lippke, Ziegelmann, & Schwarzer., 2005; Schiiz, Sniehotta, 
Mallach et al., 2009) have shown that the specific cognitive factors that move people 
from one stage to the next are different; risk perception is crucial in forming an 
intention for people in the pre-intention stage who have no pre-existing intention, 
whereas self-efficacy has been found to influence the transition through three stages 
of change for all groups: non-intenders, intenders and actors (Lippke, Ziegelmann, & 
Schwarzer., 2005; Schiiz, Sniehotta, Mallach et al., 2009). This implies that effective 
intervention aimed at changing health behaviours should be tailored to their stages of 
change (Lippke, Ziegelmann, & Schwarzer, 2004, 2005; Lippke & Ziegelmann, 2008; 
Schwarzer, 2008). For example, individuals in the pre-intention stage should benefit 
from motivational intervention, whereas people in the intention stage should benefit 
from an action planning intervention to help them translate their intentions into actual 
behaviour. For individuals in the action stage, an intervention designed to promote 
self-efficacy beliefs (coping self-efficacy and recovery self-efficacy) may be useful 
to help them maintain their healthy behaviours (Lippke, Ziegelmann, & Schwarzer, 
2004; Lippke & Ziegelmann, 2008; Schwarzer, 2008).
6.4 The application of the HAPA model: research on health-related 
behaviours using the HAPA model
The HAPA model has shown to predict health behaviours, including dental flossing, 
seat belt use, dietary behaviour, physical activity, breast self-examination, low-risk, 
single-occasion drinking, and smoking (Schwarzer & Renner 2000; Murgraff,
156
McDermott, & Walsh, 2003; Schwarzer & Luszczynska, 2003; Schwarzer, Schuz, 
Ziegelmann et al., 2007; Schwarzer & Luszczynska, 2008; Schwarzer, Luszczynska, 
Ziegelmann et al., 2008; Chow & Mullan, 2010). Moreover, Garcia and Mannn 
(2003) compared the ability of five social-cognitive models, including the HBM, 
revised HBM (including self-efficacy), TRA, TPB, and HAPA in predicting 
intentions to engage in two different health behaviours (resisting dieting and 
performing breast self-examination). The HAPA yielded the greatest predictive 
explanatory power for both behaviours. According to prior studies, the model 
explained between 30 percent and 69 percent of the variance in intentions, and 
between 29 per cent and 73 per cent of the variance in behaviours (Schwarzer & 
Renner 2000; Garcia & Mann, 2003; Luszczynska & Schwarzer, 2003; Murgraff, 
McDermott, & Walsh, 2003; Luszczynska, 2004; Schwarzer, Schuz, Ziegelmann et 
al., 2007; Schwarzer, Luszczynska, Ziegelmann et al., 2008; Schwarzer & 
Luszczynska, 2008; Chow & Mullan, 2010).
6.4.1 The HAPA model: predicting intention and health behaviours
The HAPA model has been used to predict a wide range of health-related behaviours. 
For example, Garcia and Mann (2003) assessed the ability of the HAPA to predict 
intentions to resist dieting. All motivational variables specified by the HAPA (risk 
perception, outcome expectancies, and self-efficacy) were measured. The results of 
this study revealed that risk perception, outcome expectancies, and self-efficacy were 
significantly related to intention to resist dieting.
Likewise, Schwarzer and Renner (2000) applied the HAPA model to predict nutrition 
behaviours (low fat and high-fibre dietary intake) in 524 residents of Berlin. 
Participants completed questionnaires at baseline (time 1) and six months later (time 
2). Risk perception, outcome expectancies, action self-efficacy, and intentions were 
measured at time 1. Coping self-efficacy, low-fat dietary intake, and high-fibre dietary 
intake were measured at time 2. The results of this study revealed that risk perception, 
outcome expectancies, and action self-efficacy significantly predicted intention. 
Nutrition behaviours (low fat and high-fibre dietary intake) were predicted by intentions 
and coping self-efficacy.
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In addition, Murgraff, McDermott, and Walsh (2003) assessed the usefulness of 
HAPA model in predicting drinking behaviour in a sample of 160 female 
undergraduates. Self-efficacy, action planning, action control, intention, social 
barriers, and past drinking frequency were measured at two time points. The first 
questionnaire was completed at recruitment into the research study, and the second 
one was completed two weeks later. Drinking behaviour at follow-up was predicted 
by self-efficacy for action planning and action control (equivalent to coping self- 
efficacy), and past drinking frequency. Intentions did not predict drinking behaviour 
either directly or indirectly.
The HAPA has also been shown to predict detection behaviour such as breast self- 
examination. Luszczynska and Schwarzer (2003) reported an application of the 
HAPA model to breast self-examination (BSE) in 418 young women. Participants 
completed assessments at baseline and twelve to fifteen weeks later. At time 1, all 
HAPA motivational variables (risk perception, outcome expectancies, and action self- 
efficacy) were measured. Action planning, maintenance self-efficacy, recovery self- 
efficacy, and BSE were measured at time 2. Intention to perform BSE was predicted 
by outcome expectancies and action self-efficacy, but not risk perception. Breast self- 
examination was predicted by planning, maintenance self-efficacy and recovery self- 
efficacy.
The model has also proven useful in predicting preventive behaviours. Schwarzer, 
Schuz, Ziegelmann et al. (2007) conducted four studies to investigate the applicability 
of the model across four preventive behaviours (dental flossing, seat belt use, dietary 
behaviour, and physical activity. Three predictors of intention (risk perception, 
outcome expectancies, and self-efficacy) and three proximal predictors of behaviours 
(intention, action planning, and recovery self-efficacy) were included in these studies. 
The findings showed that action planning and recovery self-efficacy emerged as 
significant predictors of all four of the investigated preventive health behaviours.
Sniehotta, Scholz, & Schwarzer (2005) applied the HAPA model to physical exercise 
behaviour in a sample of 307 cardiac rehabilitation patients. Participants were asked 
to complete questionnaires at the rehabilitation centre (time 1), two months after 
discharge (time 2), and four months after discharge (time 3). At time 1, risk
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awareness, outcome expectancies, action self-efficacy, and intentions were measured. 
All of these variables and maintenance self-efficacy, action planning, and action 
control were measured at time 2. Physical exercise was measured at time 3. The study 
showed that intention to exercise in the patients with coronary heart disease was 
predicted by risk perception, outcome expectancy and self-efficacy. Physical exercise 
four months after discharge was predicted by intention, planning, maintenance self- 
efficacy, and action control. The effects of intention on exercise behaviour were lower 
than the direct effects of the three volition constructs. Recently, three longitudinal 
studies examining long-term exercise adherence in rehabilitation patients (cardiac and 
orthopaedic patients) conducted by Schwarzer, Luszczynska, Ziegelmann et al. (2008) 
also showed that planning and recovery self-efficacy were significant predictors of 
exercise adherence across three studies. The authors reported that between 14 per cent 
and 39 per cent of the variance in exercise behaviour was explained by these two 
predictors. In addition, in all three longitudinal studies, risk perception was not 
significantly associated with other variables under study. This may indicate that in the 
context of cardiac and orthopaedic rehabilitation patients, a different strategy (e.g. 
intervention focusing on planning and recovery self-efficacy) may have a significant 
impact on changing physical activity than risk communication (Schwarzer, 
Luszczynska, Ziegelmann et al., 2008).
Scholz, Schuz, Ziegelmann et al. (2008) conducted a 5-week longitudinal study to 
examine whether adding action planning and coping planning would improve the 
overall prediction of exercise behaviour. The study showed that all motivational 
HAPA variables (risk perception, outcome expectancies, and self-efficacy) accounted 
for 17 per cent of variance in exercise activity five weeks later, and only self-efficacy 
was a significant predictor of intention to exercise. However, when adding action 
planning and coping planning into the model, the amounts of variance in Time 2 
exercise behaviour were increased to 23 per cent. In other words, the inclusion of 
action plan and coping plan contributes to the better prediction of exercise behaviour, 
as compared with intentions alone. Additionally, this study showed that only active 
individuals (maintainers) benefited from coping planning (Scholz, Schuz, Ziegelmann 
et al., 2008). Other studies also revealed that coping planning is effective in 
maintaining long-term behavioural change (Sniehotta, Scholz, & Schwarzer, 2005; 
Sniehotta, Schwarzer, Scholz et al., 2005; Ziegelmann, Lippke, & Schwarzer, 2006).
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Finally, Scholz, Nagy, Gohner et al (2009) examined the usefulness of the HAP A in 
predicting two different behaviours (smoking and low-fat diet). It was hypothesized 
that change in HAPA motivational variables would predict change in intentions and 
that change in volitional variables (intentions, self-efficacy, action planning, and 
action control) would predict change in behaviour. In the first study, participants 
viewed a commercial web-based nutrition programme that included an online diet- 
diary, feedback on weight change over time, recipe suggestions and weekly “coaching 
letters”, whereas the participants in study two viewed smoking-related web pages. 
Participants in both studies were asked to fill out the online questionnaires. Data were 
collected at two time points. The results showed that neither change in risk perception 
nor change in outcome expectancies predicted change in intentions. Only change in 
self-efficacy was found to be associated with change in intentions in both behaviours 
(smoking and low-fat diet). For predicting change in behaviours, it was found that 
change in number of daily cigarettes smoked was significantly related to change in 
action control and change in self-efficacy. Change in eating a low-fat diet was 
predicted by change in intentions (marginally significant direct effect), change in 
action planning, and change in action control. The findings from this study suggest 
that action control may be a promising target for designing effective interventions for 
changing repeated behaviours such as smoking and eating low-fat foods because 
change in action control had the strongest effect on change in both investigated 
behaviours (Scholz, Nagy, Gohner et al, 2009).
In summary, a number of studies applying the HAPA have provided support for the 
important role of volitional variables in predicting health-related behaviours. 
Therefore, the volitional factors should be included in the motivational models of 
health behaviour. Schwarzer (1992, 1999, 2001) argued that in the volition phase, 
where individuals plan the details, perform the desired behaviour, persist, possibly 
fail to maintain their health behaviour, and then recover, volitional constructs such as 
action planning, maintenance self-efficacy, recovery self-efficacy, and action control 
help to bridge the gap between intention and behaviour.
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6.4.2 The HAPA model: intervention studies
The HAPA model is increasingly being used to inform the development of behaviour 
change interventions. Recently, three intervention studies have evaluated the effect of 
planning interventions in samples of cardiac and orthopaedic disease patients. Lippke, 
Ziegelmann, & Schwarzer (2004) conducted an experimental randomised prospective 
design to evaluate the effectiveness of planning intervention in 560 orthopaedic 
patients. Participants were randomised to either (1) intervention group (a planning 
intervention) or (2) control group (no-planning). Intervention participants were 
encouraged to form up to three action plans about where, when, and how they would 
exercise after discharge from rehabilitation. In addition, participants were also 
encouraged to think about any difficulties that might hinder the implementation of 
their exercise plans and then formed a coping plan to overcome those difficulties or 
obstacles. The participants were asked to complete three assessments at baseline 
(prior to exercise therapy), two weeks, and four weeks after discharge. The authors 
reported that the planning intervention had no effect on intention in any patient group, 
but resulted in a significant increase in action plans and higher rates of exercise 
behaviour. When the sample was divided into three groups (divided according to their 
intentions to exercise): non-intenders, intenders, and actors, a significantly higher 
exercise adherence rate was found only in intenders.
Similarly, Sniehotta, Scholz, Schwarzer et al. (2005) investigated the effects of two 
interventions (planning intervention and personalised weekly diary intervention) on 
changes in physical exercise in 240 coronary heart patients. Participants were 
randomly assigned to one of three groups: standard care control group, planning 
group, and planning plus diary group. All participants were asked to complete 
questionnaires. The first questionnaire was collected at the rehabilitation centre. 
Follow-up questionnaires were completed two months (time 2), and four months after 
discharge (time 3). Intentions, self-efficacy, and planning were assessed at all three 
times. Action control was measures at time 2 and time 3. Participants in the two 
intervention groups were encouraged to develop a specific plan for their physical 
activity. In addition to forming an action planning, participants in the planning plus 
diary group were encouraged to keep a weekly diary to self-monitor their physical 
activity for six weeks after discharge from the rehabilitation centre. Participants in the
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two intervention groups showed greater adherence to exercise at follow-up than those 
in the standard care group. Those in the planning plus diary group had higher levels of 
action control and more stable intentions. There was also a trend towards higher levels 
of exercise in the planning plus diary group.
Sniehotta, Scholz, and Schwarzer (2006) found similar results in their study that 
assessed the effect of planning interventions designed to promote regular physical 
exercise after discharge from cardiac rehabilitation in 211 cardiac patients. 
Participants were randomly assigned to a standard care control group, action planning 
group, or combined planning group (both action planning and coping planning were 
formed). While patients in the action planning were encouraged to form a specific 
plan about when, where and how they would exercise after discharge, patients in the 
combined planning group were additionally asked to develop up to three coping plans 
regarding strategies for dealing with anticipated difficulties in complying with the 
exercise programme. Data were collected at two time points: the second week of the 
rehabilitation programme (time 1) and two months after discharge (time 2). The 
results of this study showed that participants in the combined planning group had 
significantly higher adherence to exercise after discharge than those in the action 
planning and control groups. Also, a trend towards higher rates of exercise was 
observed in the action planning group.
A more recent intervention study based on the HAPA model (Schiiz, Sniehotta, 
& Schwarzer, 2007) examined stage-specific effects of an action control intervention 
on dental flossing. A total of 151 university students completed questionnaires at 
baseline (timel), two weeks after timel (time 2) and four weeks after time 2 (time 3). 
A dental flossing calendar was designed and used as self-monitoring tools. 
Participants were classified into the motivational and volitional stages. An action 
control intervention resulted in increased action control levels at follow-up in all 
participants. Nevertheless, significantly higher levels of action control were found in 
volitional participants. Additionally, change in dental flossing in volitional 
participants was predicted by change in action control. Intention was not significantly 
related to change in dental flossing among participants in this group. This is consistent 
with the theoretical assumptions, which propose that individuals who are in the 
volition stage profit from self-regulatory efforts (Schwarzer, 2008).
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These studies have provided evidence for the effectiveness of HAPA-based 
interventions in improving or changing health behaviours. Although the HAPA is 
an appealing model in health behaviour research for designing effective health 
behaviour change intervention, a number of criticisms have been brought against it. 
This includes the validity of stage assessment and the lack of specification of the 
factors that influence stage transitions (Sutton, 2005, 2008; Conner, 2008). As the 
stage models will be most useful to design the matching intervention when certain 
groups of individuals in each stage have been correctly identified. Therefore, the 
stage algorithm must identify homogenous group of individuals to stages according 
to their change process (Weinstein, Rothman, & Sutton, 1998; Schwarzer, 2008). 
While in the Transtheoretical Model of behaviour change (TTM), the passage of time 
is used as the main criterion for grouping people in each stage (Prochaska, 
DiClemente, & Norcross, 1992; Weinstein, Rothman, & Sutton, 1998), the HAPA 
uses psychological variables (intention and behaviour) to group people into three 
categories: non-intenders, intenders, and actors (Lippke, Ziegelmann, & Schwarzer 
2004; Schwarzer, 2008).
In the HAPA, the term stage is used as synonymous with phase or process. During 
the behaviour-change process, individuals can cycle and recycle in the motivation 
and volition phases (Schwarzer, 2008). Outcome expectancies, self-efficacy, and 
risk perceptions are expected to be the factors that move individuals from pre­
intenders to intenders (Schwarzer, 2008), whereas action planning, coping planning, 
and self-efficacy are supposed to facilitate in the second transition, from intenders to 
actors (Schwarzer, 2008; Schuz, Sniehotta, Mallach et al., 2009). Although the 
validity of stage assessment poses an interesting debate, recent studies have shown 
that matching treatment to individual in a particular stage is a promising intervention 
and a pragmatic approach (e.g. Lippke, Ziegelmann, & Schwarzer, 2004; Schiiz, 
Sniehotta, & Schwarzer, 2007). However, more research on the stage assessment 
validity and on the potential impact of misclassification of individual at each stage is 
required.
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6.5 The translation o f intention into action: implementation intentions
It has long been argued that individual’s intention to perform a behaviour is the 
most proximal predictor of subsequent behaviour (Locke & Latham, 1990; Ajzen, 
1991, Bandura, 1977, 2004). However, according to a recent meta-analysis of 47 
experimental studies conducted by Webb and Sheeran (2006), a medium-to-large 
change in intention (effect size; d =.66) results in a small-to-medium change in 
behaviour (d = 0.36). This finding suggests that the intention has positive effect on 
behaviour, but the effect size is small to medium only (R2 = .03). In an attempt to 
examine the intention-behaviour gap, Orbell and Sheeran (1998) differentiated 
between people with positive intentions who do not perform behaviour according 
to their intentions (inclined abstainers) and individuals with negative intentions who 
perform behaviour (disinclined actors). The authors found that discrepancies between 
intentions and behaviour were caused by inclined abstainers rather than by disinclined 
actors. In addition, a review of health behaviours (e.g. exercise, condom use, and 
cancer screening) by Sheeran (2002) indicated that individuals with positive 
intentions translated their intentions into action only 53 per cent of the time. This 
indicates that there is a substantial “gap” between individuals’ intentions and their 
subsequent behaviour (Sheeran, 2002; Sheeran, Milne, Webb, et al., 2005; Gollwitzer 
& Sheeran, 2006).
Implementation intentions have been proposed as a powerful tool to bridge the 
intention-behaviour gap. Forming implementation intentions is part of the Model of 
Action Phases (MAP) (Heckhausen & Gollwitzer, 1987; Gollwitzer & Sheeran,
2006). According to the MAP, forming of a goal intention is the first step to goal 
attainment. Intention formation is influenced by individuals’ beliefs about the 
desirability (i.e., expectancy and value) and feasibility of the goal. Following the goal 
setting processes, in order to attain the goal, the person must deal effectively with 
self-regulatory problems (such as failing to get started and getting derailed) in goal 
striving (Heckhausen & Gollwitzer, 1987; Gollwitzer & Sheeran, 2006).
An implementation intention is a specific plan, which specifies exactly when, where, 
and how one will act in order to achieve his or her goal (Gollwitzer, 1999; Gollwitzer
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& Sheeran, 2006). Although both implementation intentions and action planning 
represent a mental “if-then” association that links specified behavioural response to 
specific situational cues, plans in the form of implementation intentions are usually 
provided by the researcher in a pre-worded if-then sentence (Sniehotta, 2009; 
Chapman, Armitage, & Norman, 2009). Implementation intentions are distinct from 
intentions as they specify both the situational context and behaviour that helps to 
realise the desired behaviour. While, a goal intention has a form “I intend to do X” or 
“I will do X”, implementation intentions take on the specific form of “I intend to do X 
in time and place Y” (Gollwitzer, 1999; Sheeran, 2002; Gollwitzer & Sheeran, 2006). 
Implementation intentions are hierarchically subordinate to goal intentions, and they 
are formed in the service of the goal. Forming plans in the form of implementation 
intentions requires an individual to identify a response that will enhance goal 
attainment and anticipate a suitable occasion to initiate that response (Gollwitzer & 
Oettingen, 1998; Gollwitzer & Sheeran, 2006; Sheeran, Milne, Webb, et al., 2005).
Theoretically, implementation intentions facilitate goal attainment through two 
component processes: increasing the activation of the anticipated situational cue 
(specified in the if-component of the plan) and automating the goal-directed response 
to that cue (specified in the then-component of the plan) (Gollwitzer, 1999; 
Gollwitzer & Sheeran, 2006; Parks-Stamm, Gollwitzer, & Oettingen, 2007). An 
individual who forms an implementation intention selects a specific situational cue for 
the if-part of the plan, this means that they decide in advance which of the possible 
opportunities will be used to achieve the intended goal. Therefore, the person is 
“perceptually ready” to encounter that situation, leading to heightened activation of 
the mental representation of the specified situational cues. As a consequence, 
individuals who form implementation intentions are better able to detect, attend to, 
and recall specified cue when that cue is encountered (Gollwitzer, 1999; Gollwitzer & 
Sheeran, 2006).
Forming implementation intentions also involves the selection of an effective goal- 
directed response (specified in the then-component of the plan) upon encountering 
the specified situation. This means that a mental link is created between the chosen 
situational cue and the intended goal-directed response in the form of if-then plans. 
The consequence of this strong link leads to the automatic action initiation once the
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critical situation is encountered. Accordingly, the predetermined responses are 
initiated immediately, efficiently and with less need for conscious intent (Gollwitzer 
& Brandstatter, 1997; Brandstatter, Lengfelder, & Gollwitzer et al., 2001; Gollwitzer 
& Sheeran, 2006; Sheeran, Milne, Webb, et al., 2005; Parks-Stamm, Gollwitzer, & 
Oettingen, 2007; Webb & Sheeran, 2007). Implementation intentions do not affect 
individuals’ motivation or intention (Sheeran & Orbell, 1999; Gollwitz & Sheeran, 
2006; Sniehotta, Soares, & Dombrowski, 2007; Webb & Sheeran, 2007). Rather, by 
forming if-then plans, people pass the control of the behaviour over to anticipated 
critical situational cues (Gollwitzer & Brandstatter, 1997; Gollwitzer, 1999).
There is now significant evidence that encouraging individuals to make 
implementation intentions significantly increases the likelihood of them achieving 
behavioural change (e.g. Sheeran & Orbell, 2000; Milne, Orbell, & Sheeran, 2002; 
Armitage, 2007; Luszczynska, Sobczyk, & Abraham, 2007; Sniehotta, Soares, & 
Dombrowski, 2007; Webb & Sheeran, 2007; Prestwich, Ayres, & Lawton, 2008; van 
Osch, Reubsaet, Lechner et al., 2008). Sheeran and Orbell (1999), for example, 
conducted two experiments to test the effects of implementation intentions in relation 
to vitamin supplement use. Participants were given bottles of vitamin pills and asked 
to fill out the time 1 questionnaire. Follow-up questionnaires were collected ten days 
later (time 2) and three weeks later (time 3). The implementation intention 
intervention was a questionnaire manipulation. Intervention participants were asked to 
write down when and where they would take a vitamin C tablet every day for the next 
three weeks, whereas those in the control group were asked to complete the 
questionnaire without implementation intention manipulation. Behaviour (taking 
vitamin C tablets) was measured by self-report and pill count at time 2 and time 3. 
The results showed that no significant difference was found between the two groups 
in the number of missed pills (both the pill count and self-report) at time 2 (ten days 
into the intervention). However, after three weeks, participants in the intervention 
group missed significantly fewer pills than those in the control group. In the second 
experiment, the results confirmed that there was significant difference in the number 
of missed pills between the two groups at three weeks.
Implementation intentions have been shown to increase attendance for cervical 
screening (Sheeran & Orbell, 2000). Participants were 114 women who registered at a
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medical practice in England. These women received a standard postal reminder from 
their medical practitioner encouraging them to attend for a smear test within the next 
three months. Then, questionnaires based on the Theory of Planned behaviour (TPB) 
with implementation intention manipulation were sent to the participants in the 
intervention group. The following written instructions were included to the postal 
questionnaire for the intervention participants “You are more likely to go for a 
cervical smear if you decide when and where you will go. Please write in below 
when, where, and how you will make an appointment”. Space was included to allow 
participants to write down their implementation intentions. For the control group, the 
questionnaires were identical in all respects apart from this item. The results of this 
study showed that cervical screening attendance rate was significantly higher (92 per 
cent) in participants who formed implementation intentions than those who did not 
form if-then plans (69 per cent).
Armitage (2004) assessed the effectiveness of an implementation intention-based 
intervention for reducing dietary fat intake. Participants were asked to complete 
questionnaire based on the TPB at baseline and one month later. Participants in the 
intervention group (n = 138) received the implementation intention-based intervention 
(questionnaire with implementation manipulation). The same questions were 
administered to the control group (n = 126) but without the implementation intention 
manipulation. Multivariate analysis of variance (MANOVA) indicated that there were 
significant differences between the intervention and control in the total fat intake, 
saturated fat intake, and proportion of energy derived from fat; all the three indexes 
of dietary intake significantly decreased over time in the intervention group but not in 
the control group.
Implementation intentions have also been found to be an effective intervention in 
changing oral self-care behaviour (Sniehotta, Soares, & Dombrowski, 2007). 
Participants were 140 undergraduate students recruited after a lecture. All participants 
completed a questionnaire based on the TPB at baseline and received a coded sample 
of dental floss together with a flossing guide. In addition to TPB variables, intentions 
and perceived behaviour control (PBC) were measured at time 2 in order to assess 
whether the manipulation has effects on participants’ motivation. Participants were 
randomly assigned to either the intervention group or the control group. Intervention
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participants were asked to form an implementation intention specifying when and 
where they would use dental floss. Behaviour was determined from self-report 
flossing and the measurement of residual floss at two weeks and two months after the 
intervention. The results showed that compared with a no-intervention control 
condition, implementation intention-based intervention had no effect on TPB 
motivation variables, but led to a significant increase in flossing by intervention 
participants two weeks and two months after intervention (Sniehotta, Soares, & 
Dombrowski, 2007).
Milne, Orbell, and Sheeran (2002) tested the efficacy of motivational interventions 
augmented by implementation intentions in promoting physical activity. They 
compared the motivational intervention based on the Protection Motivation Theory 
(PMT) with a combined motivational and volitional (implementation intentions) 
intervention. The study was conducted in 248 undergraduate students in the UK. 
Participants were randomly assigned to either the control group or one of two 
intervention groups: PMT-based motivational intervention (experimental group 1) and 
PMT-based motivational intervention plus implementation intentions (experimental 
group 2). Participants were also informed that an exercise session must be at least 20 
minutes long. Data were collected at three points in time. At time 1, the motivational 
intervention was implemented; participants in the two intervention groups were asked 
to read a health educational leaflet regarding coronary heart disease and the benefits 
of exercise, whereas the control group were asked to read the opening three 
paragraphs of a novel.
Following the implementation of the PMT-motivational intervention, PMT variables 
(perceived severity, perceived vulnerability, response efficacy, and self-efficacy) and 
intention were measured. At time 2, one week later, exercise behaviour was measured. 
Then all participants were asked to complete the PMT questionnaire; PMT variables 
and intentions were assessed a second time. In addition to completing the PMT 
questionnaire, participants in the experimental group 2 (PMT-based motivational 
intervention plus implementation intentions) were asked to form implementation 
intentions specifying when and where they would carry out exercise in the following 
week. One week later, at time 3, all the three groups were asked to complete the PMT 
questionnaire again, and exercise behaviour was also measured. The study showed
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that PMT-based motivational intervention had been effective in changing PMT 
cognitions and intention to engage in exercises, but it had no significant effect on 
exercise behaviour. By contrast, the PMT-based motivational intervention plus 
implementation intentions led to significantly increase exercise participation (91 per 
cent) among the experimental group 2. Additionally, this study found that there were 
no significant differences in intention (assessed at time 3) between experimental 
group 1 and experimental group 2 after the implementation of an ‘if-then’ plan 
intervention. Thus, a significant increase in subsequent exercise behaviour could not 
be explained by PMT-based motivational intervention (Milne, Orbell, & Sheeran, 
2002).
Recently, a meta-analysis of 94 studies with participants of different age and gender 
conducted by Gollwitzer and Sheeran (2006) indicated that implementation intentions 
were effective in enhancing people’s achievement of their goals and had overall effect 
size of .65 on goal attainment. Nevertheless, although implementation intentions are 
generally highly effective in translating intention into behaviour, some recent studies 
have failed to show if-then plans intervention effects on behaviour (Michie, 
Dormandy, & Marteau, 2004; Jackson, Lawton, Knapp et al., 2005; Jackson, Lawton, 
Raynor et al., 2006; Rutter, Steadman, & Quine, 2006; De Vet, Oenema, Sheeran et 
al., 2009). It has been argued that the lack of effects of implementation intentions may 
be based on several reasons, including types of health behaviours (single one- 
off/repeated behaviour, simple/complex behaviour), types of goals (difficult/easy 
goals), the study populations (student, clinical population/non-clinical population), the 
setting of the study (clinic/ non-clinic settings), the follow-up time periods, and the 
validity and reliability of the outcome measures used (Dewitte, Verguts, & Lens, 
2003; Michie, Dormandy, & Marteau, 2004; Jackson, Lawton, Knapp et al., 2005; 
Jackson, Lawton, Raynor et al., 2006; Rutter, Steadman, & Quine, 2006; De Vet, 
Oenema, Sheeran et al., 2009).
Michie, Dormandy, and Marteau (2004), for example, tested the efficacy of 
implementation intention intervention in increasing the rates of antenatal screening 
uptake. Women were asked to form a specific plan during their visit for an ultra­
sound dating scan (12 weeks gestation). Participants were also asked to complete the 
questionnaire that measured attitude towards undergoing screening and screening
169
intention. Screening behaviour was assessed from laboratory records. The results of 
this study showed that no statistically significant differences in uptake between the 
intervention and control groups. However, only 63 per cent of women (25/40) in the 
intervention group completed a specific plan in the questionnaire. Within the 
intervention group, the higher screening uptake was observed in woman who formed 
implementation intentions, as compared with those who did not (84 per cent vs. 47 per 
cent, p  = 0.017). Also, there were trends towards positive attitude and stronger 
intentions in the woman who formed if-then plans. The findings suggest that 
implementation intention interventions may be less effective in a clinic setting than in 
the settings used in studies of students (a lecture theatre setting) because in a busy 
place such as an antenatal clinic, women also underwent a medical procedure, were 
referred for counselling, and possibly looked after their children. These activities may 
have contributed to the low rate of compliance for developing implementation 
intentions in these individuals.
Jackson, Lawton, Knapp et al. (2005) found that the formation of implementation 
intentions had no significant effect on promoting adherence to antibiotics. A possible 
explanation may be that participants in this study were sufficiently motivated to take 
the short-term course of antibiotics (7 days). A study examining the effects of 
implementation intentions in relation to vitamin supplement reported by Sheeran and 
Orbell (1999) also found similar results; no significant difference between 
intervention and control groups in the number of missed pills after ten days following 
an implementation intention intervention. For short-term, simple behaviour, strong 
intentions are possibly sufficient to change behaviour without requiring an 
implementation intention. Rather, the formation of implementation intentions may be 
needed in the cases of repeated behaviours (dental flossing, Sniehotta et al., 2007) or 
long-term, complex behaviours such as physical activity, smoking, and a healthy diet 
(e.g. Milne, Orbell, & Sheeran, 2002; Armitage, 2004; Armitage, 2007; Prestwich, 
Ayres, & Lawton, 2008).
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6.6 Conclusion
In summary, this chapter has reviewed the social-cognitive models of behaviour 
change and the application of the theoretical models to health-related behaviours. 
Much consideration has been given to the Health Action Process Approach (HAPA) 
model and the use of implementation intentions to facilitate the translation of 
intentions into behaviour, as they provide a framework for study 2. The HAPA 
identifies both pre-intentional and post-intentional factors relating to behaviour 
change. The existing research literature demonstrates that the HAPA model has been 
successfully applied to the prediction of a wide range of health-related behaviours 
(e.g. Schwarzer & Luszczynska, 2003; Schwarzer, Schuz, Ziegelmann et al., 2007; 
Schwarzer & Luszczynska, 2008; Schwarzer, Luszczynska, Ziegelmann et al., 2008; 
Chow & Mullan, 2010). In the following chapter, the HAPA model, in combination 
with the qualitative data gathered in study 1, will be used to guide an intervention to 
promote influenza vaccination in high-risk Thai adults. The chapter will also present 
the research methodology and the results of a randomised trial investigating the 
effects of a HAPA-based educational leaflet intervention and action planning on 
influenza vaccination, as well as the findings on the applicability of the HAPA model 
in the context of vaccination behaviour.
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Chapter 7: Using the HAPA and implementation intentions 
to increase influenza vaccine uptake
7.1 Introduction
This chapter outlines the research design, description of study population, research 
setting, and the development and implementation of intervention programme to 
increase influenza vaccination rates. It also describes data collection tool, procedures, 
and data analysis. The chapter then presents the results of the study along with the 
discussion. It further considers the strengths and limitations of the study. Finally, a 
conclusion is provided.
7.2 Methodology
7.2.1 Study setting
The study was conducted in the Muang district, an urban community of Chiang Rai 
province with a population of 223,936. Chiang Rai is the northernmost province of 
Thailand and has an adult literacy rate of 93 per cent (National Statistical Office, 
2006). Two geographically separated communities were chosen to limit 
contamination between trial arms. These two areas were similar in overall population 
size, the number of people with chronic diseases requiring influenza vaccination 
within them, and the baseline influenza vaccination rate among high-risk people. The 
two geographically separated communities were assigned randomly to an intervention 
or comparison areas.
7.2.2 Design and participants
A controlled before and after trial was carried out. This study compared the effect of a 
HAPA-based educational leaflet with a standard government information leaflet on 
influenza vaccination behaviours among high-risk urban dwelling Thai adults.
The study was powered to detect between group differences in influenza vaccination 
rates of 22% (between the previous year’s vaccination rate of 38% and a predicted 
rate of 60%). This required a sample size of 177 participants with a power of 0.80 at a 
significance level of 0.05 (Fleiss, Levin, & Paik, 2003).
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The study was confined to people aged 45-65 years with chronic diseases with clinical 
indications requiring influenza vaccination. These included heart disease, chronic 
obstructive pulmonary disease, asthma, chronic renal disease and diabetes mellitus. 
Potential participants were identified from the National Health Security Office list. 
They were excluded from the study if they reported to a research assistant (a local 
health volunteer) any of the following: (1) known or suspected allergy to egg protein; 
(2) hypersensitivity to any component of the vaccine; (3) severe chronic conditions 
(i.e., bed bound or acutely ill); (4) dementia or suspected dementia, or (5) being 
unable to read and write. The research ethics committee, Chiang Rai province, 
Thailand approved the study, and all participants signed informed consent.
Potential participants were identified from the list patients who were offered free 
vaccination from the National Health Security office (NHSO). Of the 594 potential 
participants (two communities), 401 met all the eligibility criteria: (1) people aged 
45-65 years with chronic diseases with clinical indications requiring influenza 
vaccination, and (2) being able to read and write. Of these, 105 were randomly 
selected from one community (comparison area) to participate in the study using a 
lottery method without replacement. The random selection process was repeated. 
One hundred potential participants were randomly selected from another community 
(intervention area). Four participants withdrew before starting the study (before 
completing the baseline questionnaire). Accordingly, a total of 201 high-risk Thai 
adults were included in the study (99 in the intervention group and 102 in the 
comparison group) (see Figure 7.2.2).
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Figure 7.2.2 Flow diagram of participants’ progress through the randomised trial
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7.2.3 Intervention
The interventions were conducted during a 6-week period before the influenza 
vaccines were available for all high-risk people. As data from study 1 showed a wide 
range of perceptions about influenza and influenza vaccination; for example, few 
people believed that influenza was a serious disease and could cause death, whereas 
others considered it to be no worse than a “bad cold”. Some participants with chronic 
diseases viewed influenza vaccination as a mean to prevent exacerbation of their 
underlying conditions. By contrast, several participants in the study, especially those 
who perceived themselves as healthy, considered the influenza vaccination to be 
unnecessary for them. Additionally, the findings showed that salience of risk, 
influence of others, perception of the need for preventive health care, and the 
availability of influenza vaccine emerged as important influences on the decision 
whether to accept or refuse the influenza vaccination.
Based on the responses of our participants, suggestions for focal points to consider in 
the message development for influenza vaccination education materials are the 
emphasis on the seriousness of influenza, risk of developing influenza-related 
complications, the benefits of getting immunised, and the need for influenza 
vaccination. Using a combination of the qualitative data gathered in study 1 and a 
theoretical model of behaviour change (HAPA model), an educational leaflet was 
created to target high-risk Thai adults. As described previously in Chapter 6, the 
HAPA posits two processes involved in changing individual behaviour: motivation 
(the formation of intention) and volition (the translation of intentions into behaviour) 
processes. In the motivational phase, the HAPA suggests that an indiviual’s intention 
to perform a behaviour is influenced by risk perception, outcome expectancy, and 
self-efficacy. After a goal intention has been developed, intended behaviour must be 
planned, initiated, maintained, and restarted when problem occurs (Schwarzer, 1992, 
1999, 2001). Accordingly, the behaviour change techniques used in the leaflet, 
included providing information about the behaviour-health link (Abraham & Michie, 
2008). This involved highlighting the susceptibility to influenza and its complications 
in high-risk people with chronic disease (e.g. “You are at high risk for severe 
complications such as pneumonia, and blood infections. This may put you in the 
hospital, so why risk it?”). These health risk messages focused on increasing
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perceptions of personal risk rather than arousing fear of disease (see Ruiter, Abraham, 
& Kok, 2001).
A second behaviour change technique involved providing information on the benefits 
of vaccination. This involved phrases such as “Taking the flu shot will help you a lot 
through the flu season: Don’t get the flu! Don’t spread the flu! Don’t have serious 
complications, Reduce the risk of going into hospital, and Stay healthy during the 
influenza season”. The leaflet also sought to increase participants’ efficacy in relation 
to their ability to both benefit from and cope with the vaccination by including the 
personal accounts of people who had received the influenza vaccination (e.g. “I have 
asthma, I need to protect myself. At first, I had not agreed to get the flu shot because I 
was afraid of allergies and breathing difficulty, but I was fine after the injection”). 
These accounts also sought to increase normative beliefs favouring vaccination.
Finally, the leaflet encouraged participants to develop a specific plan (Gollwitzer, 
1999, Schwarzer, 2003) detailing where, when and how they would obtain the 
influenza vaccination (prompt specific goal setting). Additionally, participants were 
asked to consider how they would go to the clinic to receive influenza vaccine 
(prompt barrier identification). As action planning (Schwarzer 2001) is analogous 
with implementation intentions (“if-then” plans) (Gollwitzer, 1999). Thus, “if- then” 
statement was used in this study. In order to facilitate the forming of the plans and to 
ensure consistency, examples were also provided by the researcher. The following 
instructions were included in the HAPA-based leaflet for the intervention group.
“Getting a flu vaccination: Plan ahead! You are more likely to go 
for having the flu shot, if you decide now about where, when and 
how you will go. Please write in below when, where and how you 
plan to get a flu vaccine.
“If I get an appointment letter to have the flu vaccine, then I will
.............................. (please write down what you plan to do. e.g. go for
taking the flu shot) at..................................... (please write down
Where, e.g. Chiang Rai hospital, private clinic), and I’m going to get 
there by..................................... (please write down How you go to that
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place, e.g. walking, taking a bus or asking son/daughter/relatives to take 
you to get the flu vaccine)”
A HAPA-based educational leaflet was pretested with five patients with chronic renal 
diseases to assess its content and its format. The patients’ feedback was positive. They 
reported that the leaflet would be useful to high-risk people, and the written content in 
leaflet was clear and easy to understand. They felt that the educational message was 
very persuasive and informative. However, two patients suggested using larger font 
size to improve readability. The leaflet was adapted before being used in the study.
Participants in the comparison group received the standard government information 
leaflet. This was initially used for the people with chronic disease aged 45-65 years in 
the previous year’s (2009) vaccination programme. The leaflet provided general 
information about the symptoms of influenza, brief details about influenza vaccine, 
possible side-effects following vaccination, and the general benefits of influenza 
vaccination, including ‘flu shots help prevent the flu and its serious complications’. 
No details about the complications of influenza and other benefits of influenza 
vaccination were addressed. Accordingly, the key techniques in this leaflet were to 
provide information about the behaviour-health link and the consequences of 
vaccination (Abraham & Michie, 2008). In addition to leaflet distribution, an 
appointment letter detailing the date and time of vaccination was sent to all high-risk 
individuals by the public health staff.
7.2.4 Outcome measures
The outcome measures for this study included the psychosocial determinants of 
influenza vaccination behaviour and immunisation rates among high-risk urban 
dwelling Thai adults. These were measured by questionnaires at baseline (Timel: Tl) 
and two week follow-up (after implementation of the educational leaflet and action 
planning intervention: time 2 [T2]). At T l, risk perception, outcome expectancies, self 
efficacy, and intention to receive influenza vaccine were measured. Additionally, all 
of these variables and action planning were measured at T2, to assess the changes in 
any of HAPA variables and to test for intervention effects. The vaccination rates were 
assessed during the subsequent two months in the intervention and control areas.
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7.2.4.1 Questionnaire
The questionnaire was designed based on the HAPA model. It consisted of items 
assessing risk perceptions, outcome expectancies, self efficacy, action planning, and 
intention to obtain influenza vaccine in the forthcoming vaccination period. Questions 
related to influenza symptoms and side effects following the vaccination were also 
included. In addition, participants were asked to provide the demographic information 
about their age, gender, marital status, level of education and occupation, as well as a 
history of prior influenza immunisation. A draff of questionnaire was pilot tested by 
20 Thai adults and subsequently revised based on analysis of their responses. The 
final version contained 37 questions in three sections: (a) demographic variables and 
history of prior influenza immunisation, (b) knowledge of influenza symptoms 
vaccine side-effects, and (c) the questions on HAPA variables: risk perception, 
outcome expectancies, self-efficacy, action planning, and intention to obtain influenza 
vaccine (the questionnaire is available in Appendix 7 of this thesis). The items were 
assessed as follows:
7.2.4.2 Knowledge
Knowledge of influenza symptoms and vaccine side effects was assessed by 
presenting the participants with a list of 13 symptoms (e.g. fever, muscles ache, 
watery eyes) and eight potential side-effects following vaccination (e.g. pain at the 
vaccination spot, vomiting, feeling generally unwell) (see Appendix 7). There were 
eight correct answers out of 13 for influenza symptoms and four correct answers out 
of eight for vaccine side effects. Participants were asked to tick yes, no, or not sure to 
the symptom and vaccine side effects checklist. The percentage of correct responses 
on knowledge about influenza symptoms and vaccine side effects was calculated.
7.2.4.3 Risk perception
For the measure of risk perception, participants were asked to indicate their level of 
agreement or disagreement with 15 statements referring to (i) the risk of developing 
influenza and (ii) the consequences of influenza to their lives, for instance “If 
someone in my family develops flu, everyone else will”, “I do not think that I am 
personally at risk of contracting the flu”, “Flu can make my existing illness worse”, 
and “If I catch the flu, I may have to go to hospital”. Risk perceptions were measured
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on a five-point Likert scale from one (strongly disagree) to five (strongly agree). Total 
risk perception scores were calculated by summing the scores on all items, ranging 
from 15 to 75. A high score represents higher levels of perceived risk. Cronbach's 
alpha for the risk perception subscales had sufficient internal consistencies at pre- and 
post-intervention (risk of developing influenza a=0.79 and 0.68; severity of influenza 
a  = 0.75 and 0.70, respectively).
7.2.4.4 Outcome expectancies
Outcome expectations after receiving influenza vaccine were assessed with 10 items. 
These items included both positive and negative consequences of influenza 
vaccination such as “If I get the flu shot my chance of getting the flu will be 
decreased, “If I get the flu shot, it can prevent me from getting a more severe case of 
the flu”, and “If I get the flu shot, it will weaken my immune system”. All 10 items 
were rated on a four-point Likert scale from one (not at all true) to four (exactly true). 
These items were summed to provide a total outcome expectancy score. Total scores 
range from 10 to 40. A high score on this ten-item scale reflects more positive 
expectations with receiving influenza vaccine. Cronbach’s alphas were 0.72 and 0.71 
at pre-and post-intervention, indicating sufficient reliability.
7.2.4.5 Self-efficacy
In the present study, the self-efficacy measurement was designed to assess 
participants’ confidence in their ability to obtain vaccination against influenza. Self- 
efficacy was measured by asking participants to rate their level of confidence in 
receiving influenza vaccine in the forthcoming vaccination period with seven items, 
for instance “I am confident that I can cope with side effects after receiving the flu 
vaccine”, “I am confident that I can find the time to get vaccinated against the flu” 
and “I am confident that I can arrange the transportation for myself to get vaccinated”. 
Responses for these items were reported on a four-point Likert scale from one (not at 
all true) to four (exactly true). A total self-efficacy score was computed by summing 
the scores on all items, ranging from seven to 28. A high score indicates higher levels 
of self-efficacy in their confidence in their ability to obtain influenza vaccination. 
Conbach’s alphas for self-efficacy subscales were high at pre- and post-intervention
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(self-efficacy in coping with vaccine side-effects a  = 0.72 and 0.81; self-efficacy in 
arranging time and transportation a  = 0.84 and 0.91, respectively).
7.2.4.6 Intention
To measure behavioural intention, participants were required to indicate their level of 
intention to obtain influenza vaccination with two statements: “I intend to receive a 
flu shot in the forthcoming vaccination period” and “I want to get vaccinated against 
the flu in the next vaccination period”. Answers were given on a 5-point scale from 
one (definitely do not) to five (definitely do). These items were added to form a sum 
score of intention. Total scores range from two to 10, with higher scores representing 
greater intention to obtain influenza vaccine. The Pearson correlation between two 
items was 0.61 at pre-intervention and 0.67 at post-intervention.
7.2.4.1 Action planning
Action planning was measured by responses to three questions: “I have made a plan 
when Pm going to vaccinate during the next vaccination period”, “I have made a plan 
where I’m going to have the flu shot in the next vaccination period”, and “I have 
made a plan how Pm going to get vaccinated against the flu”. The response 
alternatives were “Yes” and “No”. The participants were also required to bring the 
leaflet to the researcher at the time 2 data collection in order to check whether they 
had made an action plan.
7.3 Procedure
The study was conducted between April and August 2009. A briefing meeting was 
held in each community in April in order to provide information about the activities of 
the research project. It was attended by the public health staff, village health 
volunteers and key persons in the community. Additionally, five research assistants 
were trained on data collection and documentation by the principal researcher. The 
training programme included lecture and practice sessions. They were instructed to 
explain the aims of the study to potential participants, to obtain written infored 
consent if these individuals agreed to participate, to answer any questions that 
participants may have, and to administer the questionnaire. In addition, the research
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assistants were accompanied by the principal researcher in the first three cases of data 
gathering in order to enhance their confidence in collecting data.
Potential participants in both the intervention and control areas were approached by 
village health volunteers who gave them an invitation letter together with a reply slip. 
This stated that the study would examine whether an information leaflet would help 
people in two selected communities understand more about the influenza and the 
influenza vaccination, and whether it would influence their decisions related to 
vaccination. Those approached were asked to complete a reply slip, indicating 
whether they were willing to consider participating in the study. For those who agreed 
to consider participation, the volunteers arranged a date, time and venue for them to 
see a research assistant, either in their home or at a health centre. On the meeting day, 
the research assistants provided the participants with an information sheet providing 
details of the study, and answered any questions the participants had. If they were 
willing to participate, a written informed consent was obtained from each participant 
prior to data collection.
Following the informed consent, participants were asked to complete the baseline 
questionnaire. A trained research assistant explained about the questionnaire and how 
to complete it to the participant. For some participants, especially those with limited 
literacy, a trained researcher read the statements or questions out loud and asked 
participants to score their own responses. All participants were unaware of their group 
assignment. After completing the baseline questionnaire, participants were thanked 
and offered a gift (a ceramic coffee mug) for their participation in the study.
After Tl data collection was completed, leaflets were enclosed in a plain brown 
envelope, and were distributed by the village health volunteer of each community to 
participants. The volunteers were blinded to the randomised allocations. Leaflets were 
distributed by the village health volunteer to participants in both groups. The HAPA 
intervention group received a HAPA-based educational leaflet, whereas the 
comparison group received a standard government information leaflet developed by 
the Ministry of Public Health.
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T2 data were collected two weeks after implementing the intervention, using a 
personal identity code to match Tl data with the follow up to maintain anonymity. 
The previous data collection procedure was repeated. Participants in both intervention 
and control groups were asked to complete the questionnaires assessing HAPA 
variables. Although implementation intentions (action planning) have been shown to 
promote health behaviour change, insufficient evidence exists to suggest how long the 
implementation intention effects last (Jackson, Lawton, Knapp et al., 2005). Previous 
studies revealed that the effects of this intervention varied over periods of time 
between one week and one month, depending on the type of behaviour change 
(Sheeran & Orbell, 1999; Armitage, 2004; Prestwich, Ayres, & Lawton, 2008). 
Accordingly, T2 questionnaires were collected within 10 days.
The assessors were blinded to the treatment allocation because the leaflets were 
distributed by the village health volunteer independently. However, the outcome 
assessors were able to identify the trial group when they asked specific questions 
regarding participants' action plans at time 2 because the action plans were verified at 
this stage. Three of the questions regarding action plan were located in the final part 
of the questionnaire. In some cases, participants could not be free to meet with the 
researcher on the appointment date. The village health volunteers arranged a new 
appointment for them; each volunteer was responsible for contacting seven to ten 
participants. In the few cases that volunteers failed to reach the participants, these 
participants were contacted by the public health staff or the principal researcher.
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Finally, influenza vaccination rates were assessed up to two months after the 
intervention by using vaccination clinic records. The process of data collection in both 
intervention and control groups is shown in the flow chart below (Figure 7.3).
Vaccine
available
Vaccine
available
Immunisation rate 
was assessed 
(Time 3)
Immunisation rate 
was assessed 
(Time 3)
A  th eory-b ased  ed u cation al 
lea fle t and  action  p lan n ing  
in tervention
Psychosocial questionnaires 
(HAPA variables) 
were collected (Time 1)
Psychosocial questionnaires 
(HAPA variables) 
were collected (Time 1)
Psychosocial questionnaires 
(HAPA variables, Planning) 
were collected (Time 2)
Psychosocial questionnaires 
(HAPA variables, Planning) 
were collected (Time 2)
Control group
3 weeks
A  stan d ard  govern m en t  
in form ation  lea fle t
2 weeks 10 days 2 months
Intervention group
3 weeks 2 weeks 10 days 2 months
Figure 7.3 The data collection process in two communities.
7.4 Data access/storage
Research data were stored securely in either a locked filing cabinet or on password 
protected files. The completed questionnaires were kept in a locked filing cabinet, 
separately from the identifying data to preserve anonymity. All computerised data 
were stored in a password-protected computer. Additionally, access to these data was 
limited solely to the principal researcher and the head of health centre.
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7.5 Data Analysis
Analyses were performed on an intention-to-treat basis. Baseline characteristics of 
participants in the intervention and control groups were compared using Chi-square 
test for categorical variables and Student’s t-test for continuous variables. McNemar's 
test was used to compare the proportions of correct responses on knowledge about 
influenza symptoms and vaccine side effects at baseline and after intervention within 
groups, Chi-square or Fisher’s exact test where appropriate was used to test for 
differences between groups on categorical data. Means and standard deviations were 
calculated for all HAP A variables at baseline and at T2. In order to assess the changes 
in any of HAPA variables over time and to identify differences between intervention 
and control groups on the outcome measures, a series of one-way ANCOVA was used 
on T2 data. In this analysis the T2 score was the dependent variable and the 
corresponding T1 score was a covariate (Pallant, 2005). The assumptions of 
ANCOVA were tested before performing the analysis.
When multiple testing is performed at set p-values, it increases the chance of a false- 
positive findings (type I errors) due to random variability. Therefore, a number of 
procedures (e.g., Bonferronni correction, Holm correction, and Benjamini and 
Hochberg False Discovery Rate) have been recommended for use in controlling the 
false-positives; the p-value or the significance level needs to be adjusted. However, 
this will also raise the probability of type II errors (false negatives) (Rothman, 1990; 
Feise, 2002). In the present study, statistical advice on multiple comparisons was 
sought. The statistician advised to report actual p-value instead of the adjusted p-value 
in this case because we had an a priori expectation of the direction of change in any 
HAPA variables after the intervention.
Relationships between the hypothesised predictor variables and the outcome measures 
were first tested by Pearson’s product moment correlations. Multivariate analyses 
were then performed to examine the effects of the predictor variables on the outcome 
measures: a linear regression was used to predict the participants' intentions to obtain 
the influenza vaccine at Time 1, and a logistic regression was conducted to examine 
predictors of vaccination behaviour at T2. Finally, Chi-square test was used to
184
compare the differences in influenza vaccine uptake between the intervention and 
comparison groups.
7.6 Results
7.6.1 Data management
The data were checked and cleaned for out-of-range values or non-permitted values 
by running the frequencies of all the variables. Checks were also carried out to ensure 
consistency within questionnaires and to ensure that negative items were inversely 
coded. For the parametric statistical tests, data were checked for assumptions of 
normality and homogeneity of variance. Where appropriate, variables were 
logarithmically transformed to meet a normality assumption. All statistical analyses 
were conducted using SPSS® version 16.0 for Windows.
7.6.2 Sample Characteristics
A total of 201 high-risk Thai adults were included in the study (99 participants in the 
intervention group and 102 participants in the control group). The study population 
had a mean age of 56.24 [SD = 5.86] years, with a range of 45-65 years. The 
demographic characteristics of the sample are presented in Table 7.6.2. Independent- 
sample t-test and Chi-square analyses revealed that participants in the intervention 
and control groups did not differ with regard to age (t=l .7, d f=199; p  = 0.09), gender 
(X2= 1.76; p  = 0.18), marital status (x2= 7.05; p  = 0.07), educational level (x2= 4.96; p  
= 0.17), occupation (x2= 2.24; p  = 0.53) and prior immunisation with influenza 
vaccine (x2 = 3.14; p  = 0.08). These findings indicate that randomisation procedure 
was successful.
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Table 7.6.2 The demographic characteristics of the study sample.
Characteristics Control group 
(N=102)
Intervention group 
(N=99)
Age, Mean (SD) 55.55 [5.98] 56.95 [5.67]
Gender (%) 
Male 
Female
33.33
66.67
42.42
57.58
Marital status (%)
Single
Married
Divorced or Separated 
Widowed
5.88 
88.24
5.88 
0
2.02
86.87
6.06
5.05
Educational Level (%) 
Primary school 
Secondary school 
V ocational/T echnical 
Bachelor’s Degree
94.12
3.92
0
1.96
90.91
7.07
2.02
0
Occupation (%) 
Unemployed 
Farmer 
Labourer 
Merchant
26.47
24.51
18.63
30.39
33.33
19.19
22.22
25.26
Prior immunization with influenza 
vaccine (%)
Yes 0
No 100
3.03
96.97
p -\alue
0.09
0.18
0.07
0.17
0.53
0.08
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7.6.3 Measuring the impact of the intervention
7.6.3.1 Knowledge of influenza symptoms and vaccine side-effects
The percentage of correct responses to symptoms and vaccine side-effects in the 
questionnaire for both groups of participants was computed. “Not sure” responses 
were considered to be incorrect. Additionally, responses of “not sure” or “no” were 
combined into a single percentage score for comparison analysis. The results are 
presented in Table 7.6.3.1-7.6.3.2
Table 7.6.3.1 shows the proportions of participants’ responses to the question 
regarding influenza symptoms. Participants in both groups mistakenly associated 
seizure, common cold symptoms (watery eyes and itching in nose, throat or eyes) and 
gastrointestinal symptoms with influenza at time 1. However, McNemar’s test for 
comparison of paired proportions indicated that there were significant changes in the 
knowledge regarding influenza symptoms at time 2 in the intervention group; a large 
proportion of participants accurately described the main symptoms of influenza, 
including fever (from 79.8 per cent to 100.0 per cent,/? < .001), muscle aches (from
77.8 per cent to 97.0 per cent, p  < .001), extreme tiredness (from 71.7 per cent to
82.8 per cent, p  = 0.05), dry cough (from 45.5 per cent to 76.8 per cent, p  < .001), 
headache (from 76.8 per cent to 90.9 per cent, p  = 0.01), and sore throat (from 65.7 
per cent to 82.8 per cent,/? = .004).
For the control group, McNemar’s test revealed a significant increase in accurately 
describing two typical influenza symptoms: fever (from 72.5 per cent to 98 per cent,/? 
< .001), and muscle aches (from 80.4 per cent to 94.1 per cent, p  = .007) at time 2. 
When comparing knowledge of influenza symptoms between two groups, no 
statistically significant differences were observed at time 1. However, participants in 
the control group were less likely to describe seizure as an influenza symptoms than 
the intervention group at time 2 (47.1 per cent vs. 67.7 per cent, %2 = 6.45; p  = .01), 
whereas intervention participants were more likely to describe two typical symptoms 
of influenza: sneezing (78.8 per cent vs. 65.7 per cent, y2 = 4.29; p  = .03) and dry 
cough (76.8 per cent vs. 60.8 per cent, %2 = 5.96; p  = .01) than those in the control 
group.
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Table 7.6.3.1 Knowledge of participants regarding influenza symptoms at two time
points.
Symptoms Correct
answer
group
Time 1 Time 2
%2 test
P-
value%Yes %No %Not
sure
%Yes %No %Not
sure
Fever (38 C or 
higher)
Yes Control
Intervention
72.5
79.8
4.9
2.0
22.6
18.2
98.0
100.0
1.0
0
1.0
0
.16
Muscle aches and 
pains
Yes Control
Intervention
80.4
77.8
5.9
6.1
13.7
16.1
94.1
97.0
1.0
0
4.9
3.0
.33
Seizure No Control
Intervention
24.5
24.2
40.2
44.4
35.3
31.4
23.5
10.1
47.1
67.7
29.4
22.2
.01
Extreme tiredness Yes Control
Intervention
69.9
71.7
11.8
9.1
18.6
19.2
81.4
82.8
10.8
7.1
7.8
10.1
.79
Diarrhoea No Control
Intervention
20.6
19.2
43.1
45.5
36.3
35.3
13.7
10.1
59.8
70.7
26.5
19.2
.43
Watery eyes No Control
Intervention
38.3
41.4
33.3
30.3
28.4
28.3
44.1
49.5
39.2
41.3
16.7
10.2
.45
Runny or stuffy 
nose
Yes Control
Intervention
72.5
64.6
14.7
17.2
12.8
18.2
74.5
77.8
19.6
17.2
5.9
5.0
.59
Itching in nose, 
throat or eyes
No Control
Intervention
44.1
46.5
24.5
19.2
31.4
34.3
50.0
62.6
33.3
27.9
16.7
9.5
.07
Sneezing Yes Control
Intervention
63.7
72.7
16.7
8.1
19.6
19.2
65.7
78.8
23.1
17.2
11.2
4.0
.03
Nausea No Control
Intervention
25.5
27.3
36.3
43.4
38.2
29.3
30.4
35.4
48.0
48.5
21.6
16.1
.45
Dry cough Yes Control
Intervention
49.0
45.5
27.5
24.2
23.5
30.3
60.8
76.8
29.4
17.2
9.8
6.0
.01
Headache Yes Control
Intervention
75.5
76.8
13.7
11.1
10.8
12.1
84.3
90.9
10.8
6.1
4.9
3.0
.16
Sore throat Yes Control
Intervention
70.6
65.7
11.8
12.1
17.6
22.2
73.5
82.8
20.6
14.1
5.9
3.1
.11
Note * A comparison between groups, using the T2 data
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Participants were asked to identify what they thought were the side-effects of 
influenza vaccine, and table 7.6.3.2 presents the proportions of participant’s responses 
to this question. McNemar’s tests were conducted to assess changes in the proportion 
of participants describing the vaccine side-effects at baseline and follow-up. There 
was a significant increase in accurate description of vaccine side-effects in both 
groups at time 2; the vaccine side-effects, including a low grade fever (intervention 
group: from 66.7 per cent to 94.9 per cent, p  <.001; control group: from 64.7 per cent 
to 88.2 per cent, p  <.001), generally feeling unwell and mild or moderate muscle 
aches for 1-2 days (intervention group: from 75.8 per cent to 92.9 per cent, p  =.001; 
control group: from 78.4 per cent to 94.1 per cent,/> = .002).
There was also a significant increase in identifying pain/soreness at the vaccination 
site by the control group (from 83.3 per cent to 97.1 per cent, p  = .001). There were 
no statistically significant differences in the description of vaccine side-effects 
between the two groups at time 1. However, more participants in the comparison 
group incorrectly identified breathing difficulties or swelling of the face as side- 
effects of vaccination than those in the intervention group at T2 (17.6 per cent vs. 4.0 
per cent, %l = 9.54; p  = .002).
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Table 7.6.3.2 Knowledge of participants regarding side-effects of influenza
vaccination at two time points.
Side-effects Correct
answer
Group Time 1 Time 2 X2 test
P-
value
%Yes %No %Not
sure
%Yes %No %Not
sure
There are no side-effects. No Control
Intervention
0
2.0
93.1
92.9
6.9
5.1
0
0
96.1
100.0
3.9
0
N/A
A slight fever for 8-24 hrs 
after vaccination.
Yes Control
Intervention
64.7
66.7
8.8
3.0
26.5
30.3
88.2
94.9
1.0
1.1
10.8
4.0
.08
Soreness, pain at the 
vaccination spot.
Yes Control
Intervention
83.3
87.9
9.8
4.0
6.9
8.1
97.1
92.9
1.0
4.1
1.9
3.0
.18
Swelling around the 
vaccination spot.
Yes Control
Intervention
62.7
62.6
18.7
17.2
18.6
20.2
69.6
72.7
11.8
18.2
18.6
9.1
.63
Vomiting, diarrhoea, and 
being nauseous.
No Control
Intervention
13.7
13.1
56.9
51.5
29.4
35.4
12.7
6.1
62.7
69.7
24.6
24.2
.10
A fever, runny nose with 
dark and thick secretions.
No Control
Intervention
39.2
39.4
29.4
34.3
31.4
26.3
31.4
29.3
53.9
54.5
14.7
16.2
.75
Feeling generally unwell 
and mild or moderate 
muscle aches for 1-2 days.
Yes Control
Intervention
78.4
75.8
9.8
8.0
11.8
16.2
94.1
92.9
1.0
5.1
4.9
2.0
.73
Difficult breathing or 
swelling of the face
No Control
Intervention
16.7
11.1
50.0
63.6
33.3
25.3
17.6
4.0
65.7
77.8
16.7
18.2
.002
Note * A comparison between groups, using the T2 data
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7.6.3.2 Changes in HAPA variables following the intervention
To understand how the intervention impacted on potential mediators of behavioural 
change, changes in risk perceptions, outcome expectancies, self-efficacy, and 
behavioural intention over time between intervention and control groups were 
analysed. The results are reported in Figure 7.6.3.2. Participants in the intervention 
group showed a greater increase in the mean scores of all variables compared with the 
control group between T1 and T2. This was evidenced by series of analyses of 
covariance (ANCOVA) with baseline score on each variable as a covariate. The 
results indicated significant differences between the groups at T2 in risk perception 
[F (1, 198) = 20.07, p< .001, partial eta squared (r|p2 ) = .09], outcome expectancy 
[F (1,198) =18.65, p< .001, r|p2 = .08], self-efficacy [F (1, 198) = 58.8, p  < .001, 
rjp2 = .23], and intention scores [F (1, 198) = 33.56, p  <.001, r|p2 = .15]. In addition, 
there was a relationship between the baseline (Tl) and follow-up (T2) scores on all 
variables, with effect sizes (partial eta squared) ranged from .10 to .25
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Figure 7.6.3.2 Changes in risk perception, outcome expectancies, self-efficacy, 
and behavioural intention following the intervention
1 9 2
In Table 7.6.3.2.1 the scores for risk perception, outcome expectancies, and self- 
efficacy are broken down into sub-scores in order to examine whether differences 
exist between the two groups. ANCOVA with baseline sub-score as a covariate 
revealed that there were highly significant differences between the two groups on all 
sub-scales: perceived risk of developing influenza [F (1, 198) = 26.54,/? < .001, r|p = 
.12], perceived severity of influenza [F (1, 198) = 8.44,/? = .004, r|p2= .04] perceived 
benefits from influenza vaccination [F ( l ,  198) = 14.04,/? < .001, r|p2= .07], perceived 
costs of vaccination [F (1, 198) = 6.95, p  = .009, r|p2 = .03], perceived self-efficacy in 
coping with vaccine side-effects [F (1, 198) = 16.93, p  < .001, r|p2 = .08], and 
perceived self-efficacy in arranging time and transportation to get vaccinated 
[F (1, 198) = 27.0,/? < .001, rjp2 = .12]. Additionally, there was a relationship between 
the baseline (Tl) and follow-up (T2) scores on all subscales, with effect sizes ranging 
from .07- .14 except for the perceived costs of vaccination [F (1,198) = 2.68,/? = .10,
%2=-oi ]
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Table 7.6 .3.2.1 Mean [and Standard Deviation] for subscales of risk perception, 
outcome expectancies, self- efficacy, and intention to obtain influenza vaccine at two 
time points (n = 2 0 1 ).
Variables Total possible 
score
Group
Timel 
Mean [SD]
Time 2 
Mean [SD]
/7-value
Threat perception:
- Risk of developing influenza 35 Control
Intervention
24.51 [3.01] 
24.09 [3.06]
27.93 [3.63] 
30.12 [3.33]
< .0 0 1
- Severity of influenza 
Outcome expectancies:
40 Control
Intervention
28.51 [3.68] 
28.27 [3.41]
32.98 [4.56] 
34.59 [4.14]
.004
- Perceived costs of vaccination
- Perceived benefits from
12 Control
Intervention
10.32 [1.86] 
10.35 [1.59]
11.17 [1.36] 
11.59 [0.82]
.009
influenza vaccination 
Self-efficacy:
28 Control
Intervention
21.25 [3.71] 
21.13 [3.81]
23.17 [2.93] 
24.61 [2.97]
< .0 0 1
- Coping with vaccine side 
effects
12 Control
Intervention
6.35 [1.63] 
6.17 [1.38]
7.15 [1.12] 
7.66 [0.88]
< .0 0 1
- Arranging time and 
transportation
16 Control
Intervention
13.43 [2.75] 
12.74 [2.58]
14.42 [1.96] 
15.48 [1.25]
< .0 0 1
Intention 10 Control
Intervention
7.34 [1.51] 
7.21 [1.52]
8.38 [1.36] 
9.24 [1.20]
< .0 0 1
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A mean score for each question on the HAPA variables of before and two weeks after 
the intervention in both groups was analysed. ANCOVA with baseline scores as a 
covariate was conducted to determine whether there were differences in mean scores 
for each question between groups at Time 2.
Table 1.63.2.2 shows mean scores for each question on risk perception in both
groups. The results of ANCOVA with baseline score as a covariate illustrated that
there were significant differences between the two groups in the mean scores on the
following statements: “influenza spreads between people very easily” [F (1,198) = 
2 .
6.3, p  = .01, rjp = .03], “I am likely to catch the flu if other people in my district 
develop it” [F (1,198) = 4.8, p  = .03, rjp2 = .02], “If someone in my family develops 
flu, everyone else will” [F (1,198) = 4.5, p  = .03, r|p2 = .02], “I have a good health, so 
I don’t need to get a flu vaccine” [F (1,198) = 17.5, p  < .0005, rjp2 = .08], “I do not 
think that I am personally at risk of contracting the flu” \F (1,198) = 7.1,/? = .008, rjp2 
= .04], and “my body could fight off the flu because I have a strong immune system” 
[F (1,198) =10.2,p  = .002, t|p2= .05].
This indicates a higher perceived risk of developing influenza among intervention 
participants. Additionally, the results of ANCOVA demonstrated a significant 
difference in perceived severity of influenza between the two groups. The participants 
in the intervention group were more likely to believe that “Flu can kill people in poor 
health” [F (1,198) = 5.9, p  = .02, rjp2 = .03], and they were more inclined to disagree 
with the statements, “Flu is not serious enough to interfere with my daily activities” 
[F (1,198) =7.0, p  = .009, r|p2 = .03] and “Flu is a very minor health problem” 
[F (1,198) =8.7,p  = .003, riP2= .04].
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Table 1.63.22  Mean [and Standard Deviation] for risk perception in the intervention
and control groups at two time points (the total possible score for each item = 5)
Item Group Time 1 
Mean [SD]
Time 2 
Mean [SD]
p-value
Risk of developing influenza
1. Flu spreads between people very easily. Control
Intervention
3.97 [.75] 
3.83 [.61]
4.46 [.61] 
4.65 [.50]
.01
2 .1 am likely to catch the flu if other people 
in my District develop it.
Control
Intervention
3.36 [.94] 
3.34 [.72]
4.22 [.86] 
4.44 [.66]
.03
3. If someone in my family develops influenza, 
everyone else will.
Control
Intervention
4.06 [.54] 
4.03 [.59]
4.41 [.76] 
4.61 [.57]
.03
4. Compared to other people, the likelihood 
that I will get the flu is very large.
Control
Intervention
3.46 [.94] 
3.41 [.77]
4.26 [.82] 
4.40 [.73]
.16
5. I do not think that I am personally at risk 
of contracting the flu.a
Control
Intervention
3.09 [.93] 
3.04 [.81]
3.59 [1.21] 
3.98 [.95]
.008
6. My body could fight off the flu because 
I have a strong immune system.a
Control
Intervention
2.99 [.87] 
2.80 [.83]
3.05 [1.16] 
3.54 [1.13]
.002
7. I have a good health, so I don’t need to 
get a flu vaccine.a
Control
Intervention
3.58 [.91] 
3.64 [.75]
3.94 [1.17] 
4.51 [.68]
<.001
Severity of influenza
1. Influenza is a serious disease.
Control
Intervention
3.84 [.82] 
3.69 [.66]
4.43 [.76] 
4.42 [.81]
.84
2. If I get the flu I will become very sick Control
Intervention
3.74 [.79] 
3.56 [.63]
4.29 [.79] 
4.37 [.68]
.39
3. Flu is a very minor health problem.a Control
Intervention
3.25 [.94] 
3.28 [.83]
3.87 [1.11] 
4.27 [.77]
.003
4. Flu is not serious enough to interfere with 
my daily activities.a
Control
Intervention
2.88 [1.02] 
2.93 [.86]
3.20 [1.23] 
3.65 [1.16]
.009
5. Flu can make my existing illness worse. Control
Intervention
3.80 [.84] 
3.62 [.71]
4.25 [.91] 
4.35 [.79]
.15
6. If I catch the flu, I may have to go 
to hospital.
Control
Intervention
3.64 [.78] 
3.67 [.73]
4.32 [.82] 
4.48 [.72]
.15
7. Flu can be very serious for people with 
poor health.
Control
Intervention
3.92 [.77] 
3.84 [.65]
4.48 [.71] 
4.58 [.66]
.24
8. Flu can kill people in poor health. Control
Intervention
3.43 [.83] 
3.70 [.711
4.14 [.91] 
4.45 [.631
.02
Note: a Negative items
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Table 1.63.23  presents the mean scores of participants in the intervention and control 
groups on vaccine outcome expectancy scales. The results of ANCOVA indicated that 
participants in the intervention group held more positive beliefs about the influenza 
vaccine and its effectiveness in preventing influenza and influenza-related 
complications than those in the control group at T2 after controlling for baseline 
scores.
Significant between group differences were found for measures of “If I get the flu 
shot, it can prevent me from getting a more severe case of the flu [F (1,198) =11.74, p  
= .001, T|p2 = .06], “If I get the flu shot, I will feel more confident about not having the 
flu” [F (1,198) =11.44, p  = .001, rjp2 = .06], “If I get the flu shot, I could protect my 
family and friends from flu” [F (1,198) =5.68, p  = .02, rjp2 = .03], and “If I get the flu 
shot, I will be less of a burden to my family” [F (1,198) = 9.42,^ = .002, r|p2 = .05]. It 
also revealed that the participants in the intervention group were more inclined to 
disagree with the statements; “If I get the flu shot, I will be more likely to get other 
illnesses” [F(l,198) = 4.8, p  = .03, rjp2= .02], and “If I get the flu shot, It will weaken 
my immune system” [F (1,198) = 4.5,p  = .04, r\p2 = .02].
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Table 7.6.3.2.3 Mean [and Standard Deviation] for outcome expectation after getting
influenza vaccine in the intervention and control groups at two time points (the total
possible score for each item = 4)
Item Group
Time 1 
Mean [SD]
Time 2 
Mean[SD]
j9-value
If I get the flu shot.....................................
1. My chance of getting the flu will be 
decreased.
Control
Intervention
3.06 [.75] 
2.95 [.67]
3.36 [.66 ] 
3.46 [.61]
.20
2. It can prevent me from getting a more severe 
case of the flu.
Control
Intervention
3.18 [.76] 
3.05 [.67]
3.34 [.62] 
3.62 [.55]
.001
3 .1 will feel more confident about not having 
the flu.
Control
Intervention
3.16 [.67] 
3.21 [.73]
3.41 [.62] 
3.69 [.51]
.001
4 .1 will be more likely to get other illnesses.a Control
Intervention
3.28 [.92] 
3.37 [.85]
3.66 [.69] 
3.85 [.46]
.03
5 .1 could protect my family and friends from flu. Control
Intervention
2.67 [1.06] 
2.58 [1.04]
2.92 [1.09] 
3.23 [.96]
.02
6 . It will weaken my immune system.a Control
Intervention
3.49 [.83] 
3.40 [.8 6 ]
3.69 [.6 6 ] 
3.85 [.41]
.04
7. I will be less of a burden to my family. Control
Intervention
3.04 [.79] 
3.10 [.73]
3.29 [.71] 
3.58 [.55]
.002
8 . My family won’t worry about my chances 
of getting a serious case of the flu.
Control
Intervention
3.08 [.84]
3.09 [.79]
3.33 [.69] 
3.48 [.61]
.10
9. I will get sick with the flu .a Control
Intervention
3.55 [.77] 
3.58 [.72]
3.82 [.57] 
3.89 [.35]
.34
10. It will help me stay healthy during the flu 
season.
Control
Intervention
3.07 [.76] 
3.15 [.75]
3.50 [.59] 
3.55 [.61]
.74
Note. a Negative items
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The mean scores of perceived self-efficacy in obtaining influenza vaccination are 
reported in Table 7.6 .3.2.4. At T2, participants in the intervention group were more 
confident in their ability to receive influenza vaccine in the next vaccination period 
than those in the control group. In support this, the ANCOVA with baseline score as a 
covariate indicated that there was a significant effect for group in the perceived self- 
efficacy in relation to getting vaccinated against influenza, with intervention 
participants reporting greater confidence in their ability to receive the influenza 
vaccine in the forthcoming vaccination period compared to the control group [F 
(1,198) = 10.59, p  = .001, rjp = .05]. In addition, there was a significant main effect 
for group with respect to self-efficacy related to coping with vaccine side effects; 
participant in the intervention group reported significantly high levels of confidence 
in coping with side-effects after receiving influenza vaccine relative to the control 
group [F (l, 198) = 26.31, p < .  001, riP2 = .12],
Similarly, there were statistically significant main effects for group on the self- 
efficacy for arranging time and transportation subscales; intervention participants 
reported greater levels of confidence in their ability to find the time to get vaccinated 
against influenza [F (1,198) =13.37,p  < .001, r|p2= .06], obtain the influenza vaccine 
even though they were quite busy [F (1,198) = 20.63, p  < .001, rjp2 = .09], and 
receiving an influenza vaccine would not interfere with they daily routine [F (1,198) = 
17.23, p  < .001, riP2 = .08]. Moreover, the participants in the intervention group 
reported greater levels of confidence in their ability to arrange the transportation to go 
for the influenza vaccination [F (1,198) = 9.88, p  = .002, r|p2 = .05]. No significant 
between-group differences were observed for dealing with a fear of needles or shot 
[F (1,198) =1.24,p  = .27, r|p2= .006].
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Table 7.6.3.2.4 Mean [and Standard Deviation] for self-efficacy to receive vaccination
against influenza in the intervention and control groups at two time points (the total
possible score for each item = 4)
Item Group Time 1 
Mean[SD]
Time 2 
Mean[SD]
p-value
I am confident that....................
1 . 1 will get the flu shot in the forthcoming 
vaccination period.
Control
Intervention
3.43 [.76] 
3.24 [.73]
3.76 [.53] 
3.92 [.34]
.001
2 . 1 can cope with side effects after 
receiving the flu vaccine.
Control
Intervention
2.97 [.97] 
2.89 [.79]
3.44 [.76] 
3.87 [.39]
<.001
3 .1 can deal with a fear of needles or shot. Control
Intervention
3.38 [.84] 
3.28 [.81]
3.72 [.57] 
3.79 [.59]
.27
4 .1 can find the time to get vaccinated 
against the flu.
Control
Intervention
3.46 [.74] 
3.31 [.6 6 ]
3.75 [.53] 
3.94 [.28]
< .001
5. Receiving a flu shot will not interfere 
with my daily routine.
Control
Intervention
3.35 [.79] 
3.12 [.72]
3.62 [.59] 
3.90 [.42]
<.001
6 . 1 will get a flu shot even though I am 
quite busy during the vaccination period.
Control
Intervention
3.10 [.89] 
2.91 [.83]
3.35 [.77] 
3.74 [.55]
<.001
7 .1 can arrange the transportation for 
myself to get vaccinated.
Control
Intervention
3.52 [.64] 
3.39 [.71]
3.70 [.63] 
3.91 [.32]
.05
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Table 7.6 .3.2.5 shows mean scores on the behavioural intention scale at two time 
points. The results of the ANCOVA found statistically significant differences between 
groups for intention scores on the following statements: “I intend to receive a flu shot 
in the forthcoming vaccination period” [F (1,198) =23.10, p<.001, r|p2 = .10], and “I 
want to get vaccinated against influenza in the next vaccination period” [F (1,198) = 
27.55, p< .001, rjp = .12]. Additionally, there was a strong relationship between the 
baseline (Tl) and follow-up (T2) scores on the behavioural intention for both items, 
with an effect size o f . 17 and . 16, respectively.
Table 7.6 .3.2.5 Mean [and Standard Deviation] for intention to obtain influenza 
vaccine in the intervention and control groups at two time points (the total possible 
score for each item = 5)
Item Group Time 1 
Mean [SD]
Time 2 
Mean [SD]
p-value
1 . 1 intend to receive a flu shot in the 
forthcoming vaccination period.
Control
Intervention
3.79 [.8 8 ] 
3.81 [.83]
4.31 [.76] 
4.74 [.58]
<.001
2 . 1 want to get vaccinated against the 
flu in the next vaccination period.
Control
Intervention
3.55 [.83] 
3.40 [.83]
4.13 [.73] 
4.57 [.70]
<.001
1.63.3 Vaccination behaviour
In addition to the measurement of changes in any of HAPA variables over time, the 
present study examined the difference in the rate of influenza vaccine uptake between 
the intervention and control groups. Eighty nine participants (89.90 per cent) in the 
intervention group were vaccinated compared with 8 6  (84.31 per cent) in the control 
group; this difference was not significant (x2 = 1.39, df = 1 ,p  = .23) (Table 7.6.33).
201
Table 7.6.3.3 Effects of the intervention on influenza vaccination rate
Group Vaccinated Non-Vaccinated x2 p  value
n % n %
Intervention (N=99) 89 89.90 10 10.10 1.39 0.23
Control (N=102) 86 84.31 16 15.69
7.7 Testing the predictive utility of the HAPA model
As well as investigating the intervention effect, the current study also provides an 
opportunity to determine the predictive utility of the HAPA model in relation to both 
intention and subsequent vaccination behaviour among high-risk urban dwelling Thai 
adults. In a test of HAPA model, it was hypothesised that risk perception, self- 
efficacy, outcome expectancies, would predict strength of intention to receive the 
influenza vaccine, and that action planning, self-efficacy, and intention would 
significantly associated with influenza vaccination behaviour of high-risk Thai adults.
In order to examine the relationship between hypothesised predictor variables and 
intention to obtain influenza vaccine, Pearson correlations were computed between all 
variables measured at T1 and T2. The results of these analyses are reported in Table 
(Table 7.7.1-7.7.2). Results indicated that risk perceptions (susceptibility and 
severity), outcome expectancies (perceived benefit and perceived cost of vaccination), 
and self-efficacy (self-efficacy for coping with vaccine side-effects and self-efficacy 
in arranging time and transportation) were all significantly correlated with intention to 
obtain influenza vaccine at both T1 and T 2 (r =.29 to .6 6 , p  — .01).
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Table 7.7.1 Pearson’s correlation matrix of HAPA variables at Time 1
Variables 1 2 3 4 5 6 7 8
1. Age 1 .00 .03 .41 .09 .10 -.06 -.03 - .02
2. Perceived risk of developing 
influenza
.03 1 .0 0 .59**
A *
.58 .33**
3k 3k
.43 .39”
3k 3k
.47
3. Perceived severity of influenza .04
*  *
.59 1 .00
3k 3k
.62 .26** * *.45 .44** -  ** .49
4. Perceived benefits from 
influenza vaccination
.09 .58 .62** 1.00 .08
3fc3|C
.53 .49**
**.58
5. Perceived costs of vaccination .10 .33 .26** .08 1.00 .12 .15*
* *
.29
6 . Self-efficacy for coping with 
vaccine side effects
-.05
♦  ♦
.43 .45**
3k 3k
.53 .12 1.00
**00 .62**
7. Self-efficacy in arranging time 
and transportation
- .0 2 .39** .44** .49 .15* ~  -  ** .84 1.00 .6 6 **
8 Intention -.01 .47** .49** 00
* * .29** .62 .6 6 ** 1.00
-------------------- 9     9  9----------------------------
Note p  = 0.05, p  = .01
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Table 7.7.2 Pearson’s correlation matrix of HAPA variables at Time 2
Variables 1 2 3 4 5 6 7 8
1. Age 1 .00 .07 .12 .06 -.01 .05 .13 .12
2. Perceived risk of developing 
influenza
.07 1 .00 / ' A * *.64 .39" .08 .36" .32 .29"
3. Perceived severity of influenza .11 .64" 1.00 .44" .11 .35" .32 .33"
4. Perceived benefits from 
influenza vaccination
.06 .39" A A * *.44 1.00 .12 .54" _ _  * *  .33 .56"
5. Perceived costs of vaccination -.01 .08 .11 .12 1.00 .02 .12 .33"
6. Self-efficacy for coping with 
vaccine side effects
.05
*  *
.36 .35"
* *.54 .02 1.00 .62- .61"
7. Self-efficacy in arranging time 
and transportation
.13 .32 .32"
* *
.33 .12 .62" LOO .62"
8. Intention .12
_ _  * *  
.29 .33"
$  ♦.56
* ♦
.33 .61" .62" 1.00
Note "/? = 0.01
In addition, a linear regression was used to assess for independent association 
between the various independent variables measured at time 1 and intention. The 
results of this analysis revealed that overall the model had an adequate fit to the data 
(Adj. R2 = .55, F = 42.83, p  < .001). The HAPA variables were able to explain 55 per 
cent of the variance of intentions to vaccinate against influenza among our 
participants. Perceived benefits from influenza vaccination (Beta =. 29, p  < .001), 
perceived costs of vaccination (Beta =.18,/? = .001) and self-efficacy (Beta =. 39,/? < 
.001) were significantly associated with intentions at T1 (Table 7.7.3).
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Table 7.7.3 Prediction of intention to obtain influenza vaccine from risk perception,
outcome expectancies, and self-efficacy at time 1.
Predictor variable Beta t p  value
Perceived risk of developing influenza .015 .35 .73
Perceived severity of influenza .061 .61 .54
Perceived benefits from influenza 
vaccination
.29 4.26 <.001
Perceived costs of vaccination .18 3.5 .001
Self-efficacy for coping with vaccine side 
effects
.94 1.05 .29
Self-efficacy in arranging time and 
transportation
.39 4.41 <.001
Adj. R2= .55, F  = 42.83, p  < .001
The change score in T1 and T2 variables was also assessed by subtracting the baseline 
scores (Tl) from follow-up scores (T2) on each variable. Pearson correlations were 
then used to identify the association between the change in each of the independent 
variables and intentions. Results indicated that changes in risk perceptions 
(susceptibility and severity), outcome expectancies (perceived benefit and cost of 
vaccination), and self-efficacy (self-efficacy for coping with vaccine side-effects and 
self-efficacy in arranging time and transportation) were significantly associated with 
changes in intentions (Table 7.7.4).
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Table 7.7.4 Pearson product moment correlations between change scores in risk 
perception, outcome expectancies, self-efficacy subscales, and intention
Variable 1 2 3 4 5 6 7 8
1. Age 1.00 -.03 .14 -.04 - .10 .08 .09 .13
2. Change in perceived risk of 
developing influenza
-.03 1.00 .48** .31** .13 .18* .16* .17*
3. Change in perceived severity 
of influenza
.14 .48** 1.00 2 7 ** .15* .26** .27** .2 0 **
4. Change in perceived benefits 
from influenza vaccination
-.04 .31** 2 7 ** 1.00 .07 .45** .33** .54**
5. Change in perceived cost of 
influenza vaccination
- .1 0 .13 .15* .07 1.00 .00 .05 .17*
6 . Self-efficacy in coping with 
vaccine side-effects
.08 .18* .26** .45** .00 1.00 72** .51**
7. Self-efficacy for arranging 
time and transportation
.09 .16* .27** .33** .05 72** 1.00 .54**
8. Intention .13 .17* .2 0 ** .54** 17** .51** .54** 1.00
Note: ** p = 0.01 (two-tailed); * p = 0.05 (two-tailed)
Subsequently, a linear regression analysis was conducted with change in intention 
score as the outcome variable and change in perceived risk of developing influenza, 
perceived severity of influenza, perceived benefits from influenza vaccination, 
perceived costs of vaccination, self-efficacy for coping with vaccine side-effects, and 
self-efficacy in arranging time and transportation scores as the independent variables. 
Results from the linear regression analysis showed that the change in all independent 
variables accounted for 43  per cent of the variance in change in intentions, and 
changes in three variables: perceived benefit from influenza vaccination (Beta =. 38,/? 
c.001), perceived costs of vaccination (Beta=. 13, p  = .01), and perceived self-efficacy 
in arranging time and transportation (Beta =.34,/? <.001), were significantly related to 
the change in intentions (Table 7.7.5).
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Table 7.7.5 Prediction of change in intentions from the changes in the risk perception,
outcome expectancies, and self-efficacy subscales
Predictor variable Beta t p value
Change in perceived risk of 
developing influenza
-.03 -.42 0.68
Change in perceived severity of influenza -.03 -.47 0.64
Change in perceived benefits from influenza 
vaccination
.38 6.23 <.001
Change in perceived costs of vaccination .13 2.45 .01
Change in self-efficacy for coping with 
vaccine side effects
.11 1.33 .184
Change in self-efficacy in arranging time 
and transportation
.34 4.41 <.001
Adj. R2= .43, f  =27.0, p < .001
Finally, a logistic regression was conducted to test whether the risk perception, 
outcome expectations, self-efficacy, intention, and action planning at T2 would be 
able to predict actual vaccination behaviour. Overall, the model had an adequate fit to 
the data; the model yielded a nagelkerke R2 of 0.49 and the Hosmer and Lemeshow 
was not significant (%2 =.38, df = 8, p  = 0.87). The results revealed that self-efficacy 
for arranging time and transportation and behavioural intention was significantly 
correlated with vaccination behaviour (Odds ratio= 1.51,/? = .028; Odds ratio = 3.47, 
p = .001, respectively) (Table 7.7.6).
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Table 7.7.6 Summary of logistic regression analysis predicting actual vaccination 
behaviour among high-risk Thai adults (n = 201)
Predictor Variable B S.E. Wald
statistic
p  value Odds ratio 
(95%CI)
Perceived risk of influenza .11 .10 1.14 .27 1.1 (.91-1.36)
Perceived severe of 
influenza
-.06 .09 .45 .50 0.94 (.78-1.13)
Perceived benefit of 
influenza vaccination
-.08 .12 .41 .52 0.93 (.73-1.17)
Perceived cost of 
vaccination
-.14 .42 .12 .73 .86 (.38-1.97)
Self-efficacy in coping 
with vaccine side-effects
.05 .32 .03 .87 1.05 (.57-1.96)
Self-efficacy for arranging 
time and transportation
.54 .23 5.61 .028 1.51 (1.1-2.67)
Intention 1.24 .36 11.85 .001 3.47(1.71-7.06)
Planning -.51 .66 .61 .43 0.59 (0.16-2.17)
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7.8 Discussion
This randomised-controlled pilot study had two objectives: (1) to determine the 
effects of a HAPA-based educational leaflet intervention on influenza vaccination 
behaviours in a sample of high-risk Thai adults; and (2) to test the utility of the HAP A 
model in predicting both intention and subsequence vaccination behaviour among this 
high-risk group. In relation to the first objective, the intervention based on the HAPA 
model showed significant differences between groups in changes over time in key 
mediator variables such as knowledge, risk perception, self-efficacy, outcome 
expectancies, and intention in obtaining influenza vaccination. This was evidenced by 
series of analyses of covariance (ANCOVA) with baseline score on each variable as a 
covariate, indicating that there was a significant main effect for both time and group 
on any of the HAPA variables. Accordingly, the leaflet achieved its first goal; to 
increase the strength of intentions to seek influenza vaccination. Unfortunately, its 
second goal, to translate these motivational differences into behavioural differences 
was not achieved. Between conditions vaccination rates did not differ.
7.8.1 Measuring the impact of the intervention: changes in key mediators
In this study, knowledge of influenza symptoms and vaccine side-effects was assessed 
by presenting participants with a list o f 13 symptoms and eight potential vaccine side- 
effects. At time 1, participants in both groups mistakenly associated seizure, common 
cold symptoms (watery eyes and itching in nose, throat or eyes) and gastrointestinal 
symptoms with influenza. These results confirm the finding of our previous 
qualitative study regarding insufficient knowledge about influenza symptoms among 
high-risk Thai people. In Thai, common cold is referred to as khai wat, while 
influenza is referred to as khai wat yai. This suggests an explicit indication that 
“influenza” is more serious than “a cold”. This may partly explain why the fever and 
upper respiratory infection symptoms were seen as major symptoms of influenza 
among our participants, at T l. Interestingly, approximately one fifth of participants 
included diarrhoea and nausea as symptoms of the influenza. Elsewhere, researchers 
have also found that lay people recognised gastrointestinal symptoms (nausea, 
diarrhea, and stomach ache) as a characteristic of influenza (McCombie, 1987; 
Pachter, Niego, & Pelto, 1996; Baer, Weller, Pachter et al., 1999). For example, in
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Tampa, the symptoms of influenza recognised by the participants included nausea, 
diarrheoa, stomach ache (gastrointestinal symptoms), body aches and pains, fatigue, 
fever, and upper respiratory symptoms (Baer, Weller, Pachter et a l, 1999). 
Gastrointestinal symptoms reported by the Americans living in Tampa appear to be 
the same symptoms as “folk flu” identified by McCombie (1987) in southern Arizona, 
as mentioned in Chapter 4. According to McCombie (1987), “folk flu” was 
characterised by nausea, vomiting and diarrhoea. The concept of “folk flu” does not 
accord with the biomedical knowledge about the clinical symptoms of influenza; 
influenza illness in adults is typically characterised by abrupt onset of fever, 
headache, muscles ache and pain, fatigue, sore throat, and a dry cough (Jennings & 
Read, 2002; Cunha, 2004; Eccles, 2005; Treanor, 2005).
A lack of knowledge of influenza symptoms may not be specific to our samples. The 
study conducted in the US. by Santibanez, Nowalk, Zimmerman et al. (2002) found 
that although there was no difference in accurately describing the symptoms of 
influenza between vaccinated and unvaccinated older people, overall only 44 per cent 
(448/1007) of the participants correctly described one or more of the typical influenza 
symptoms, including headache, myalgia, cough, sore throat, and fever. Furthermore, a 
significantly greater proportion of those who had not been vaccinated reported that 
they did not know the symptoms of influenza than those who received vaccination (17 
per cent vs. 7 per cent). The lack of knowledge and misinformation among high-risk 
older people about the symptoms of influenza underscores the need for education 
efforts about the influenza symptoms to these individuals because lack of this 
information may lead to confusion about the effectiveness of influenza vaccine; older 
people might think that the influenza vaccine did not work if they got influenza-like 
symptoms despite being vaccinated against influenza (Santibanez, Nowalk, 
Zimmerman et al., 2002; Zimmerman, Nowalk, Raymund et al., 2003). However, in 
this study, following the implementation of intervention, participants in the 
intervention group had greater improvements in knowledge about influenza 
symptoms; a significant increase in accurately describing the typical influenza 
symptoms (fever, muscle aches, extreme tiredness, dry cough, headache, and sore 
throat), whereas a significant increase in accurately describing only two typical 
influenza symptoms (fever and muscle aches) was observed among those in the 
control group.
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Additionally, the results of this study showed that participants in the intervention 
group were less likely to describe difficult breathing or swelling of the face as side- 
effects after taking the influenza vaccine than those in the control group. These 
findings support the contention that our educational leaflet provided some 
clarification with regard to influenza symptoms and vaccine side-effects. This is 
consistent with the previous studies that have demonstrated the effectiveness -  and 
specific effect - of tailored messages in changing knowledge, beliefs related to 
severity of influenza, vaccine safety and its effectiveness among high-risk groups 
(LaVela, Cameron, Priebe et al., 2008; Wray, Buskirk, Jupka et al., 2009). Wray, 
Buskirk, Jupka et al. (2009), for example, carried out a randomised controlled trial 
comparing the effectiveness of two influenza vaccine leaflets (vaccine safety 
messages [VSM] based on the Health Belief Model ( Becker, 1974) and vaccine 
information statement [VIS]) in 111 African Americans aged 50 years or older. The 
study showed that the participants in the VSM group had a higher level of beliefs 
related to the safety and efficacy of influenza vaccine than those exposed to the 
vaccine information statement [VIS]. However, the VSM had no effects on changing 
intentions to obtain the influenza vaccination among people in this group. Similar 
results were obtained in a pre-and post-intervention study conducted by LaVela, 
Cameron, Priebe et al. (2008) who found that individuals with spinal cord injuries and 
disorders had greater improvements in knowledge and beliefs related severity of 
influenza after viewing an educational message based on the Theory of Planned 
Behaviour (TPB: Ajzen, 1991; Ajzen, 2005) and the Extended Parallel Process Model 
(EPPM: Witte, 1992), although no change in perceptions of susceptibility to influenza 
infection was observed.
In the present study, intervention participants were more likely to believe that “Flu 
can kill people in poor health”, and they disagreed with the belief that “Flu is not 
serious enough to interfere with my daily activities, and “Flu is a very minor health 
problem”. Other significant differences in risk perceptions of influenza between the 
intervention and control groups included: “I have a good health, so I don’t need to get 
a flu shot”, and “My body could fight off the flu because I have a strong immune 
system”. Results also revealed that there were more statistically significant changes in 
beliefs about the consequences (outcome expectancies) related to influenza vaccine 
among intervention participants compared to those in the control group. In particular,
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significant positive changes in mean scores between T1 and T2 were shown in beliefs 
that “If I get the flu shot, it can prevent me from getting a more severe case of flu”, I 
could protect my family and friends from flu”. This study also found some significant 
differences in negative perception of the influenza vaccine between the two groups, 
including “If I get the flu shot, I will be more likely to get other illnesses”, and that “If 
I get the flu shot, it will weaken my immune system”.
Knowledge, attitude towards, and beliefs about influenza and the influenza vaccine 
have been shown to have a significant influence on the decision to receive the 
influenza vaccine. Previous studies revealed that negative perceptions of influenza 
and influenza vaccination were found to be associated with low vaccination 
acceptance (Zimmerman, Nowalk, Raymund et al., 2003; Takahashi, Noguchi, 
Rahman et al., 2003; Chi & Neuzil, 2004; Brunton, Weir, & Jennings, 2005). A 
survey study conducted by Chi and Neuzil (2004) showed that thirty-six per cent of 
the 324 respondents had at least one negative attitude towards influenza vaccination, 
and 61 per cent of these individuals had been immunised against influenza, compared 
with 93 per cent of those who did not have the negative beliefs.
Additionally, the result of the present study also showed that significant positive 
changes in perceived self-efficacy in obtaining influenza vaccination were found 
between the two groups such as “I can cope with side-effects after receiving the flu 
vaccine”, “I can find the time to get vaccinated against the flu”, “Receiving a flu shot 
will not interfere with my daily routine”, and “I will get a flu shot even though I am 
quite busy during the vaccination period”. Furthermore, intervention participants held 
more positive intentions in receiving influenza vaccine in the forthcoming vaccination 
period than those in the control group at T2.
One explanation for the positive changes in cognitive-motivational variables in the 
present study is the specific content of the HAPA-based educational leaflet. It was 
designed primarily to target people with chronic diseases requiring influenza 
vaccination and to motivate them to obtain vaccination against influenza by using 
tailored educational message. In addition, the leaflet sought to enhance confidence in 
obtaining the influenza vaccination. The content of the educational leaflet highlighted 
the susceptibility and severity of influenza, modes of transmission, the symptoms and
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complications, the positive and negative consequences (outcome expectancies) of 
receiving influenza vaccine, potential side-effects, the effectiveness of influenza 
vaccine, and self-efficacy to get vaccinated against influenza.
A major difference between the HAPA-based educational leaflet and the standard 
government information leaflet was that the HAPA-based leaflet more fully addressed 
the risk of developing a severe case of influenza in high-risk people with chronic 
medical conditions, the benefits of influenza vaccination in preventing hospitalisation 
or serious influenza-related complications (such as pneumonia, bloodstream 
infections) among these individuals and more discussion about common 
misperceptions regarding influenza vaccination (e.g. the flu vaccine does not contain 
any live virus, so it will NOT give you the flu). In addition, the personal accounts of 
people who had been injected with influenza vaccine was added in this educational 
leaflet to increase in participants’ efficacy in their ability to both benefit from and 
cope with the vaccination.
While behaviour change techniques such as providing information about the 
behaviour-health link, providing information on the consequences of a recommended 
behaviour, prompt specific goal setting, and prompt barrier identification (Abraham 
& Michie, 2008), as well as the inclusion of personal accounts attempting to raise 
normative beliefs favouring vaccination were addressed in the HAPA-based leaflet, 
the standard government information leaflet provided the reader general information 
about influenza and general benefits of influenza vaccination; there was no specific 
detail regarding the complications of influenza in high-risk individuals and other 
benefits of influenza vaccination. These differences may have contributed to the 
significant gains in knowledge, risk perception, outcome expectancies, self-efficacy 
and intention to be immunised against influenza by the intervention group over the 
control group. Also, the HAPA-based leaflet was pretested with patients with chronic 
renal disease. The patients’ feedback was positive; these patients felt the massage was 
clear and easy to understand. Furthermore, these patients felt that it was very 
persuasive and informative, and they reported that the leaflet would be useful to high- 
risk people.
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Our findings are also in line with the theoretical assumptions of the HAPA model 
(Schwarzer, 1992, 2001, 2008), showing that providing participants about their 
personal risk and the consequence of receiving the influenza vaccine, as well as 
increasing their perceived self-efficacy in getting vaccinated against influenza can 
enhance their intentions to receive influenza vaccine in the next vaccination period. 
The fact that changes in key HAPA variables of outcome expectancies and self- 
efficacy were independently associated with changes in strength of intentions suggests 
that these variables are both susceptible to change following relatively brief and 
simple interventions and have a critical and mediating role in shaping intentions.
A possible explanation for these observations may be that the present study targeted 
middle-aged and older people with chronic disease. These individuals experienced a 
major health crisis; thus, they may be more likely to be motivated to adopt preventive 
health behaviour than younger individuals. It is expected that motivation to change 
will be high in the context of major life events (Schwarzer & Lusczcnska, 2008). 
Other studies applying the HAPA to older patients in orthopaedic rehabilitation and 
cardiac rehabilitation have shown the usefulness of the model in explaining behaviour 
and in the design of interventions for the sample of middle-aged and older individuals 
(Ziegelmann, Lippke, & Schwarzer, 2006; Renner, Spivak, Kwon et al., 2007; Scholz, 
Sniehotta, Dipl-Psych et al., 2007).
However, it should be noted that the HAPA, like many social cognitive models, 
focuses on intra-individual factors without taking into consideration other factors, 
such as social, environmental and economic factors, that may affect influenza 
vaccination. In addition, the model does not incorporate the effects of social norms 
and peer influences on an individual’s decision-making about health behaviours. In 
the previous qualitative study, we found that participants' vaccination decisions were 
influenced by family members and peers, healthcare providers’ recommendations and 
the availability of free vaccine. Others studies have also shown that the decision to 
vaccinate or not was significantly affected by the influence of healthcare providers, 
family members and friends (e.g. CDC, 1988; Zimmerman, Santibanez, Janosky, 
2003; Evans, Prout, Prior et al., 2007), and the costs and convenience of obtaining the 
vaccination (e.g. Kroneman, Paget, & van Essen, 2003; Bums, Ring, & Carroll, 
2005). This suggests the presence of other factors (e.g. social and economic factors), 
in addition to those included in this study (psychological factors), influences influenza
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vaccination behaviour. Thus, in future study, those factors should also be taken into 
consideration when designing interventions to increase influenza vaccine uptake.
7.8.2 Measuring the impact of the intervention: vaccination behaviour
In addition to testing the effectiveness of a HAPA-based leaflet on changing in key 
mediator variables, this study also investigated the efficacy of a HAPA-based leaflet 
on influenza vaccination behaviour. Taking into consideration the importance of post- 
intentional phase of behaviour change in which an intention is translated into 
behaviour, action planning (implementation intentions) manipulation was included in 
the leaflet used in this study. Forming implementation intentions facilitate goal 
attainment through increasing the activation of the anticipated situational cue and 
automating the goal-directed response to that cue (Gollwitzer, 1999; Gollwitzer & 
Sheeran, 2006). Thus, individuals who form action planning are more likely to 
recognise their intentions and perform the recommended behaviour when the 
specified situation is encountered (Gollwitzer, 1999, Schwarzer, 1992, 2001).
In contrast to the findings in relation to intentions, this study was unable to show a 
significant effect of the HAPA leaflet on influenza vaccination behaviour. Although 
the number of participants who received influenza vaccine in the intervention group 
appeared higher than the comparison group, there was no significant difference in 
vaccination rates between the two groups.
Unfortunately, a number of factors may have limited the effects of our intervention on 
influenza vaccination rate. Firstly, the rates of vaccination were unprecedentedly high 
even in the standard intervention condition, making gains in vaccination rates 
particularly difficult to achieve. Previous vaccination rates were as low as 38 per cent 
(Sriwongpan P., personal communication, March 6, 2009), in comparison to the 84 
per cent found in the standard condition of the study. Clearly, factors other than the 
planned interventions may have affected these rates. The most obvious confounding 
factor was that the vaccination period coincided with a global outbreak of H1N1 
influenza. Although the standard influenza vaccination did not immunise against this 
disease (information which was given in the leaflet), the high levels of awareness and 
concern related to this outbreak may have led to the spontaneous and unplanned
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behaviours (in this case, vaccination) that can be triggered by high-risk situations 
(Gollwitzer & Brandstatter, 1997). Thus, the global outbreak of H1N1 influenza may 
partly account for increasing in influenza vaccine uptake among high-risk Thai adults. 
Evidence in support of this hypothesis can be found in two recent studies conducted in 
Hong Kong which found that beliefs that ‘influenza vaccine was efficacious in 
preventing bird-to-human avian influenza transmission’, and that ‘there is a need to 
receive influenza vaccination following the Severe Acute Respiratory Syndrome 
(SARS) and avian influenza’ were strongly associated with influenza vaccination 
behaviour (Lau, Kim, Tsui et al., 2008; Lau, Lau, & Lau, 2009).
A second explanation for the relatively weak behavioural effects of our intervention 
may involve confounding as a result of all participants, regardless of condition, 
receiving an appointment letter from the public health staff, detailing when and where 
they could get the influenza vaccination. Participants had to take this letter to the 
clinic in order to identify themselves as in a “high-risk group” and to receive a free 
vaccine at the hospital. This may have triggered some goal planning among 
participants in the comparison condition.
A third possible explanation for the lack of difference between the groups is that all 
participants in this study had relatively strong intentions to obtain the influenza 
vaccine, and were being asked to engage in a relatively simple behaviour. In this 
context, it is possible that action planning added little to the likelihood of them taking 
up the influenza vaccine (see, for example, Sheeran & Orbell, 1999; Sheeran & 
Orbell, 2000; Sniehotta, Soares, & Dombrowski, 2007). The only variable we found 
to predict vaccination in addition to intention was self-efficacy in relation to transport 
to the clinic to receive the vaccination, and this relationship was relatively modest. 
Thus, while this variable may be affected by planning, the key driver to vaccination 
appears to have been the individual’s intention to the attend vaccination clinic. This 
may not provide a full explanation for the lack of between group differences in 
vaccination rates, as intentions were stronger in the HAPA condition than the standard 
one. However, it is possible that there is a threshold of intention above which higher 
levels of intention add little to the likelihood of engagement in a particular behaviour. 
Thus, it is possible that both groups were sufficiently motivated to seek vaccination,
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and differences in relatively high intention scores had only a marginal impact on 
behaviour.
Despite these potential confounds, a 5 per cent difference in vaccination rates between 
the HAPA and standard leaflet groups was found. While this was not significant in 
our sample (arguably due to the study being underpowered to detect differences of 
this low magnitude), if this finding were to generalise to a wider population, then the 
HAPA leaflet could result in significantly more people seeking vaccination despite 
this behavioural prompt. This conclusion is clearly speculative, and requires further 
large scale research to verify. However, given the potential no cost benefit of using a 
HAPA-based leaflet, this would seem the leaflet of choice, even before more 
definitive data is obtained.
7.8.3 Testing the predictive utility of the HAPA model: predicting intention to 
receive the influenza vaccine
In relation to the second objective (to evaluate theoretical links proposed by the 
HAPA), however, the HAPA variables provided good predictions of intention to get 
vaccinated against influenza and of subsequent influenza vaccination behaviour. Risk 
perceptions, outcome expectancies, and self-efficacy accounted for 56 per cent of the 
variance in intention at T1.
Prediction of change in intention provided a similar pattern of results. A linear 
regression analysis indicated that approximately 46 per cent of the variance in the 
change in intentions could be explained by the change in risk perception, outcome 
expectancies, and self-efficacy. This is comparable with previous research using the 
HAPA model in other health behaviours, which found that the model was able to 
explain between 30-69 per cent of the variance in intentions (e.g. Schwarzer & 
Renner, 2000; Garcia & Mann, 2003; Luszczynska & Schwarzer, 2003; Sniehotta, 
Scholz, & Schwarzer, 2005; Chow & Mann, 2010). Outcome expectancies and self- 
efficacy were significantly correlated with intention to obtain influenza vaccine. A 
similar pattern of results was seen for the change in intention scores, a linear 
regression analysis indicated that only outcome expectancy change and self-efficacy 
change were found to be an independent predictor of change in intentions.
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Our findings lend support to the HAPA, suggesting an important role for outcome 
expectancies and self-efficacy in the formation of behavioral intentions (Luszczynska 
& Schwarzer, 2003; Schwarzer & Luszczynska, 2008). This study also showed the 
predictive superiority of self-efficacy over outcome expectancies in the motivation 
phase. The HAPA suggests that outcome expectancies can be seen as precursors of 
self-efficacy. While people need to know the possible consequences of a particular 
behaviour, they also need to feel confident in their ability to perform a desired 
behaviour. Self-efficacy is therefore considered to be the most powerful predictor of 
behavioural intentions (Lippke, Ziegelmann, & Schwarzer, 2005; Luszczynska & 
Schwarzer, 2003; Schwarzer, Luszczynska, Ziegelmann et al., 2008).
The finding that risk perception was not a significant predictor of vaccination 
intention is consistent with those of previous studies applying the HAPA model 
(e.g. Schwarzer, Schiiz, Ziegelmann et al., 2007; Schwarzer & Luszczynska, 2008). 
Luszczynska and Schwarzer (2003) found that intention to perform breast self- 
examination was predicted by outcome expectancies and action self-efficacy, but not 
risk perception. Similarly, Schwarzer, Schiiz, Ziegelmann et al. (2007) conducted four 
studies to investigate the applicability of the model across four preventive behaviours 
(dental flossing, seat belt use, dietary behaviour, and physical activity. The findings 
showed that action planning and recovery self-efficacy significantly predicted all four 
of the investigated preventive health behaviours. By contrast, risk perception was not 
significantly associated with any of the variables under study.
Our findings are also in line with the HAPA model (e.g. Schwarzer & Renner, 2000; 
Luszczynska & Schwarzer 2003; Schwarzer, Schiiz, Ziegelmann et al., 2007), which 
states that risk perception is a relatively weak predictor of behaviour, as its key role is 
to lead people to deliberate about changing high-risk behaviours and thereby stepping 
them into the stage of awareness of a health threat (Weinstein, 2000; Schwarzer, 
2001; Schwarzer, Schiiz, Ziegelmann et al., 2007; Schwarzer & Luszczynska, 2008). 
Recent study that examined stage-specific predictors of stage transitions between non­
intenders, intenders, and actors in relation to physical activity confirmed that risk 
perceptions were important in forming an intention for people in the pre-intention 
stage who have no pre-existing intention, but did not appear to exert much influence
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on those who already set their goal intentions to start an activity (Lippke, Ziegelmann, 
& Schwarzer, 2005).
7.8.4 Testing the predictive utility o f the HAPA model: predicting 
vaccination behaviour
Influenza vaccination behaviour was predicted by self-efficacy and intention in 
obtaining influenza vaccine in the forthcoming vaccination period (89.6 per cent of 
participants correctly classified into vaccinated and non-vaccinated groups). Self- 
efficacy predicted both intention and subsequent influenza vaccination behaviour. 
These findings are consistent with other studies and provide support the HAPA model 
in that intention and self-efficacy appear to be key factors influencing on behavioural 
change (Schwarzer & Renner, 2000; Luszczynska, Mazurkiewicz, Ziegelmann et al., 
2007; Scholz, Keller, & Perren, 2009). Clearly, these results suggest that individuals 
with strong self-efficacy and intention to get vaccinated are more likely to have had 
influenza vaccination. It has been argued that self-efficacy beliefs were crucial to 
successful change of health behaviours. Self-efficacious persons believed that they 
had the capacity to exercise control, even in the face of difficulties or barriers and 
tended to set higher goals for themselves and committed to their goals more strongly, 
which in turn influenced actual behaviour (Bandura, 1989; Locke & Latham, 1990).
Nevertheless, contrary to our expectations, action planning did not contribute to the 
prediction of influenza vaccination among high-risk Thai adults. In previous studies 
applying the HAPA, action planning was found to mediate the relations between 
intentions and behaviour, implying that individuals with strong intention will be more 
likely to engage in planning, and those who do an action plan will be more likely to 
perform the desired behaviour (Sniehotta, Scholz, & Schwarzer, 2005; Schwarzer, 
2008; Reuter, Ziegelmann, Lippke et al., 2009). Action planning was also found to 
account for more variance in the prediction of health behaviours (Lippke, Dipl-Psych, 
Ziegelmann et al., 2009). The study investigating whether action planning and coping 
plan would improve the prediction of physical exercise conducted by Scholz, Schuz, 
Ziegelmann et al. (2008) showed that the inclusion of action planning and coping 
planning increased the amounts of explained variance in vigorous physical activity 
from 17 per cent to 23 per cent. Other studies have also reported that action planning 
was a good predictor of behaviour change (e.g. Luszczynska & Schwarzer, 2003;
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Sniehotta, Scholz, & Schwarzer, 2005; Schwarzer, Luszczynska, Ziegelmann et al., 
2008).
Our findings are not consistent with those of previous studies; action planning was not 
found to be a predictor of vaccination behaviour. However, it has been suggested that 
behaviour is governed either by intentions or by perceived and actual environment 
(Schwarzer, 2009). In the present study, it is likely that influenza vaccination 
behaviour may not only involve cognitive processes, but was also influenced by 
external situation such as the outbreak of H1N1 influenza during the vaccination 
period. This may have attenuated the effect of action planning on predicting 
vaccination behaviour. In addition, the study was likely underpowered to detect a true 
association between action planning and vaccination behaviour. Further studies with 
larger samples are needed to better elucidate the relationship between these two 
variables.
7.9 Strengths and Limitations
The strengths of this study include its randomised controlled design, and the 
application of theoretical framework. However, potential limitations need to be 
addressed. In this study, the questionnaires were read out loud to some participants 
with limited literacy by a trained researcher. These participants were then asked to 
score their own responses. This method of data collection may positively affect 
participants’ scores. Another limitation is that the study was conducted in two urban 
communities. The findings of this study may not be generalisable to high-risk people 
living in suburban and rural communities. However, this randomised-controlled pilot 
study showed that our intervention was feasible and acceptable to promote influenza 
vaccination to high-risk people with chronic medical conditions. Thus, it can be 
implemented in other settings and may have potential to raise influenza vaccination 
rates among these high-risk individuals.
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7.10 Conclusion
In summary, the study demonstrated the effectiveness of a HAPA-based leaflet in 
enhancing intention to be immunised against influenza among high-risk Thai adults. 
The intervention also improved vaccination rate although the difference in vaccination 
rates between the two groups did not approach statistical significance. Further larger 
trials should test whether action planning (implementation intentions) works in 
increasing influenza vaccination rates among high-risk people, as well as its efficacy 
in enhancing the likelihood of performing other single behaviours such as 
mammography screening and dental check-up visit. Additionally, the results of the 
study provide support for the application of the HAPA model in the context of 
vaccination behaviour and highlight that the HAPA is a useful model in predicting 
intention to obtain influenza vaccine and subsequent influenza vaccination behaviour. 
Self-efficacy and intention were significantly associated with influenza vaccination 
behaviour. Based on these findings, a HAPA-based leaflet may serve as a useful tool 
for motivating a group of people who are at risk for influenza-related complications 
and severe disease to get vaccinated against influenza. It is a cost-and time-effective 
intervention that helps to reduce the workload to the public health staff or health 
promotion practitioners. The findings provide valuable information to public health 
staff for modifying and improving the content of the standard influenza leaflet that is 
currently available for the high-risk people, as well as designing other effective 
interventions in order to achieve a greater impact in increasing vaccination rates of 
high-risk people with chronic diseases.
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Chapter 8: General discussion and Conclusion
8.1 Introduction
The 2004 outbreak of influenza A H5N1 and the WHO’s recommendation for a 
national pandemic plan has led the Thai Ministry of Public Health to develop an 
influenza vaccination programme. Free influenza vaccine for high-risk older people 
was initially provided in 2008. However, the overall immunisation rate in this high- 
risk group for the first year of the project was relatively low, particularly in Chiang 
Rai province. Accordingly, this research aims to addresses these issues and considers 
how to motivate high-risk individuals to get vaccinated against influenza.
As shown in chapter 4, a broad range of factors have been postulated to be associated 
with the uptake of influenza vaccination. These include demographic factors, 
cognitive, psychological, social support, health beliefs, economic, and health system 
factors (e.g. Telford & Rogers, 2003; Zimmerman, Nowalk, Raymund et al., 2003; 
Chi & Neuzil, 2004; Kohlhammer, Schnoor, Schwartz et al., 2007; Evans, Prout, Prior 
et al., 2007; Ward & Draper, 2007; Blank, Freiburghaus, Schwenkglenks et al., 2008). 
In order to increase influenza vaccine uptake among high-risk Thai people, these 
factors need to be addressed. It has been suggested that before initiating a complex 
intervention, pleliminary work (such as qualitative research, surveys, or case study) is 
essential to improve an understanding of the intervention components, and to provide 
the detailed information on the context in which the trial would take place (Campbell, 
Fitzpatrick, Haines et al., 2000; MRC, 2000).
Therefore, in the present reseach, a qualitative study exploring high-risk individual’s 
understandings influenza and factors associated with influenza vaccine uptake was 
conducted first in order to provide crucial information about people’s beliefs 
regarding influenza, the influenza vaccine and factors influencing influenza 
vaccination, as well as information on diverse population characteristics in which the 
trial (study 2) would to be implemented. This contributes to decision making about 
the planning and design of an intervention.
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A number of specific implications were drawn from the first study, and they were 
significant in shaping the educational intervention programme that was implemented 
and evaluated in study two. These include the need for the development of an 
appropriate educational intervention programme and the need for designing a 
questionnaire that is clear and easy to understand for older Thai people. Additionally, 
the qualitative research also helped to identify the potential barriers to influenza 
vaccination among our participants. Apart from this, the personal accounts of people 
who had received the influenza vaccination (study 1) were used as part of the 
intervention materials to increase participants’efficacy in relation to their ability to get 
vaccinated against influenza in study 2.
Findings from an interview study indicated that most participants had insufficient 
knowledge about influenza and influenza vaccination. Salience of risk, influence of 
others, perception of the need for preventive health care, and the availability of 
influenza vaccine played a major role in the decision making about receiving 
influenza vaccine in high-risk Thai adults. These findings provide valuable insight 
into what interventions may be appropriate for promoting influenza vaccine 
acceptance among these individuals.
Having identified the intervention components that should be targeted, the next step 
was to create an appropriate intervention to promote the influenza vaccination uptake 
in this high-risk group. Among several factors, cognitive factors are considered to be 
the important proximal determinants that mediate the effects of others factors upon 
the performance of health behaviours. Furthermore, they are more likely to be 
amenable to change than other factors (Conner & Norman, 1998, 2005), providing an 
impetus to design an intervention to improve influenza vaccination rate in high-risk 
Thai adults. In addition, the current study is designed as a pilot randomised pragmatic 
trial. Accordingly, study 2 focuses only on the intra-individual factors affecting the 
decision making about obtaining influenza vaccine, and the HAPA model was used as 
a theoretical framework for the present study.
Like other social cognitive models, the HAPA emphasises the rationality of human 
action (Schwarzer, 2001). In changing the behaviour, an individual is believed to 
make a deliberate decision to comply, and to weigh up the costs and benefits of the
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likely outcomes of different courses of action (Conner & Norman, 1998, 2005; 
Schwarzer, 2001). The aim of study 2 was to examine the effect of a HAPA-based 
leaflet and action planning intervention on influenza vaccination behaviour among 
high-risk urban dwelling Thai adults. In addition to assessing the effects of 
intervention, this study also provided an opportunity to examine the predictive utility 
of the HAPA model in explaining behavioural intentions and vaccination behaviour in 
a sample of high-risk Thai adults.
As the HAPA model is considered to be an appropriate theoretical approach to 
conceptualise the important factors and their relations for the current study; thus, the 
the choices of study outcome and the selection of constructs to measure were guided 
by the model. In this study, the outcome measures include the psychosocial 
determinants (HAPA variables) of influenza vaccination behaviour and immunisation 
rates. Although no single theoretical model can encompass all the elements for 
behaviour change, it helps to understand factors underlying decisions whether or not 
to engage in a particular behaviour, to identify mechanisms of change and, perhaps 
most importantly, guide us to design effective prevention programme to change 
health-related behaviours (Weinstein, 1993; Abraham, Sheeran, & Johnston., 1998; 
Conner & Norman, 1998; Fishbein & Yzer, 2003; Morrison & Bennett, 2006; Lippke 
& Ziegelmann, 2008; Michie, Johnston, Francis et al., 2008). While the HAPA 
focuses on the proximal psychological influences on behaviour (in this case, 
vaccination), we have to recognise that in the broader social environment, there are a 
number of factors influencing influenza vaccination acceptance among high-risk 
people. In this chapter, a brief summary of the research findings is presented, 
highlighting what the results showed. Following this, the theoretical implications, 
methodological implications, limitations and directions for future research are 
discussed. Finally, implications for clinical practice and a conclusion are provided.
8.2 Summary of major research findings
This section briefly revisits findings from the research project. As indicated in 
Chapter 5, to date there has been limited research on influenza vaccine acceptance 
in high-risk individuals and factors underlying people’s vaccination decision in
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Thailand. Major findings from this research revealed that high-risk Thai adults had 
low levels of knowledge about influenza and influenza vaccination. Many were 
unsure about the cause and symptoms of influenza, mode of transmission, the 
seriousness of influenza and its complications. Moreover, they believed that influenza 
infection was no worse than a “bad cold”, and very few participants thought that it 
could cause death. Most participants reported that they knew little or nothing about 
the influenza vaccination. Unlike other studies (e.g. Bums, Ring, & Carroll, 2005; 
Evans, Prout, Prior et al., 2007), we found that side-effects following vaccination 
were not a major concern among our participants. Their decisions whether or not to 
get vaccinated against influenza were based on a number of factors, including salience 
of risk, influence of others, perception of the need for preventive health care, and the 
availability of influenza vaccine.
Subsequently, a controlled before and after trial was conducted in Muang district, an 
urban community of Chiang Rai province, Thailand. Two geographically separated 
communities were chosen to limit contamination between trial arms. The intervention 
participants received a HAPA-based leaflet (Schwarzer, 1992, 2001) which was 
designed to motivate them to get vaccinated against seasonal influenza. Additionally, 
they were asked to form a specific plan (Gollwitzer, 1999) detailing where, when and 
how they would obtain the influenza vaccination. Those in the control group received 
a standard government information leaflet. The study showed that there were 
significant changes in knowledge regarding influenza symptoms at T2 in the 
intervention group. Also, participants in the intervention group were less likely to 
describe difficult breathing or swelling of the face as side-effects of influenza 
vaccination than the control group; thus, demonstrating significantly greater gains in 
knowledge of vaccine side-effects. Additionally, the intervention had positive effects 
in changing risk perceptions, outcome expectancies, self-efficacy, and intentions 
relative to the comparison condition. Stronger intentions to become vaccinated against 
influenza in the intervention group than the comparison group were explained by 
change in outcome expectancies (perceived benefits of vaccination and perceived 
costs of vaccination) and self-efficacy in arranging time and transportation. No 
significant difference in vaccination rates was observed between two groups. In 
addition, influenza vaccination was predicted by self-efficacy and intention.
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Overall, study 2 provided evidence that an intervention based on the HAPA model 
is feasible and acceptable to promote influenza vaccination to high-risk Thai adults. 
A HAPA-based leaflet may be a useful and resource-effective tool to enhance 
individual’s vaccination intention, but larger trials are required to confirm these 
findings and to examine further the impact of similar interventions on influenza 
vaccination rates.
8.3 Theoretical implications
8.3.1 The HAPA model: predicting intention and vaccination behaviour
Results from the qualitative data analyses revealed that perceived risk of contracting 
influenza and participants’ beliefs about costs, risks, and benefits of influenza 
vaccination did appear to play an important role in determining the acceptance or 
rejection of influenza vaccination. These findings attest to the important role of risk 
perception and outcome expectancies in shaping an individual’s vaccination intention, 
and this is consistent with the assumption of the HAPA model, which proposes that 
risk perceptions and outcome expectancy are important in forming an intention to 
perform a behaviour (Schwarzer, 1992, 2001).
Previous studies have focused on using social cognition models to predict intention to 
receive influenza vaccine, including Health Belief Model (Lau, Yang, & Tsui et al., 
2006; Mok, Yeung, & Chan, 2006; Lyn-cook, Halm, & Wisnivesky, 2007), Health 
Belief Model and the Multidimensional Locus of Control Theory (Nexoe, Kraqstrup, 
& Sogaard, 1999), Theory of Reasoned Action (Bosompra, Ashikaga, & Ruby, 2004), 
and Theory of Planned Behaviour (Gallagher & Povey, 2006). Thus, in those studies, 
change in health behaviour is focused on motivational factors. In contrast, the present 
research has taken one step forward by assessing both motivational and post- 
intentional predictors (action planning). This is because the recent developments in 
social cognition models suggest that intentions alone are not sufficient to drive 
behaviour change (Weinstein, 1993; Abraham, Sheeran, & Johnston, 1998; Sheeran, 
2002).
The HAPA model which proposes both motivation and volition processes of 
behaviour change was chosen as the theoretical framework. This model allows for a
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test of both the predictors of intentions and actual behaviour within the same 
framework. The HAPA has been shown to predict intention and behaviour in a range 
of behaviours (Schwarzer & Renner, 2000; Schwarzer & Luszczynska, 2003; 
Schwarzer, Schiiz, Ziegelmann et al., 2007; Schwarzer, 2008, Chow & Mullan, 2010). 
This is the first time that the model has been used in the context of vaccination 
behaviour. The HAPA represents a parsimonious modelling style, and the model fits 
the data well overall; HAPA variables were able to explain 56 per cent of the variance 
of intentions to get vaccinated against influenza among our participants. In other 
words, the HAPA appears to be an appropriate theoretical model for predicting 
intention to obtain influenza vaccination and subsequent vaccination behaviour. In the 
formation of intention, risk perception was found to make a minor contribution as 
compared with outcome expectancies and self-efficacy. This finding is consistent with 
the assumption of the model, which posits that the role of cognitive variables may be 
different within the two processes of behaviour change; risk perceptions generally 
play a crucial role in the fist step on the road to behaviour change; they encourage 
people to consider behavioural change (Schwarzer, 1992, 2001, 2008).
Additionally, this research has examined the role of outcome expectancies and self- 
efficacy in predicting intentions to receive influenza vaccine and subsequent 
vaccination behaviour, which have not been fully explored by previous studies (e.g. 
Nexoe, Kraqstrup, & Sogaard, 1999; Lau, Yang, & Tsui et al., 2006; Mok, Yeung, & 
Chan, 2006; Lyn-cook, Halm, & Wisnivesky, 2007). The results of study 2, as 
described in Chapter 7, provided evidence that outcome expectancies and self- 
efficacy were stronger in predicting intentions than risk perceptions. Also, self- 
efficacy was found to predict both intentions and vaccination behaviour. For 
predicting actual behaviour, the findings showed that perceived self-efficacy and 
intentions emerged as predictors of influenza vaccination behaviour. The important 
role played by self-efficacy and intentions in predicting health behaviours have been 
shown by several previous studies (e.g. Sniehotta, Scholz, & Schwarzer, 2005; 
Luszczynska, Mazurkiewicz, Ziegelmann et al., 2007; Scholz, Keller, & Perren, 
2009). Thus, the findings from this research lend support to existing evidence, and 
add evidence of the predictive efficacy of the HAPA model in the domain of 
vaccination behaviour. In addition, the present research extends previous research by 
providing the evidence to support the applicability of the HAPA in non-western
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sample. However, it is difficult to draw definitive conclusions on the universal 
applicability of the HAPA model based on only one high-risk Thai sample and one 
target behaviour. Thus, further studies are required to explore the validity of the 
theory under other cultural settings.
8.3.2 The HAPA model: designing intervention to promote influenza 
vaccination
There is evidence that theoretical models have been useful in designing effective 
behaviour change interventions, including those aimed at increasing the uptake of 
influenza vaccine (e.g. LaVela, Cameron, Priebe et al., 2008; Wray, Buskirk, Jupka, 
et al., 2009). To design effective behaviour change interventions, this research takes 
into consideration the importance of the volitional process through which individuals 
translated their intentions into action; thus, the HAPA model was chosen as the 
theoretical framework for study two because it suggests both pre-intentional and post- 
intentional factors relating to behaviour change (Schwarzer, 1992, 2001, 2008). 
Accordingly, the interventions described in Chapter 7 were based on this model. A 
HAPA-based leaflet highlighted the key details about susceptibility and severity of 
influenza, the benefits of influenza vaccination, and participants’ efficacy in relation 
to their ability to both benefit from and cope with the vaccination. In addition to the 
basic constructs of the HAPA, the leaflet included a specific plan template and 
encouraged participants to plan in advance how they were going to obtain the 
influenza vaccination. The results of this research showed that, following the 
intervention, changes in outcome expectancies and self-efficacy were significantly 
related to changes in strength of intentions to obtain influenza vaccination. This 
suggests that brief and simple interventions used in this study had positive effects in 
enhancing individual’s vaccination intention. However, this research was unable to 
show a significant effect of a HAPA-based leaflet on vaccination behaviour. A 
number of factors may have contributed to the non-significant effect of our 
interventions, as discussed in chapter 7. Although the results showed that there was a 
trend towards higher rates of influenza vaccination in the intervention group (a 5 per 
cent difference in vaccination rates between the HAPA and standard leaflet groups 
was observed following the intervention), the present thesis brings the research 
forward by attempting to use both motivational and volitional interventions to
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improve the uptake of influenza vaccine in high-risk individuals, and future research 
may reveal more positive results.
8.4 Methodological implications
In terms of the study design and methodology, the present research builds on previous 
studies (Nexoe, Kraqstrup, & Sogaard, 1999; Lau, Yang, & Tsui et al., 2006; Mok, 
Yeung, & Chan, 2006; Gallagher & Povey, 2006; Lyn-cook, Halm, & Wisnivesky, 
2007). Firstly, for predicting intention and subsequent vaccination behaviour, study 2 
was the longitudinal study with two measurement points assessed key components of 
HAPA variables (risk perceptions, outcome expectancies, and self-efficacy). Most 
previous studies have used cross-sectional designs (Nexoe, Kraqstrup, & Sogaard, 
1999; Armstrong, Berlin, Schwartz et al., 2001; Gallagher & Povey, 2006; Lau, Yang, 
& Tsui et al., 2006; Mok, Yeung, & Chan, 2006; Kwong, Lam, & Chan, 2009); thus, 
the results of those of previous studies do not reflect changes over time.
Secondly, the important point in terms of the methodology is that this research used a 
controlled before and after trial to investigate behaviour change, which is 
advantageous in establishing cause-and-effect relationships between an intervention 
programme and outcome. There are no known prior studies assessing volitional 
interventions by using a controlled before and after trial in the context of vaccination 
promotion. Despite the lack of significant effects of intervention on influenza 
vaccination behaviour (89.90 per cent vs. 84.31 per cent), the author regards this 
study as encouraging the development of a larger trial to test the efficacy of a HAPA- 
based leaflet. The intervention is relatively simple, inexpensive to implement, and 
requiring no assistance once the leaflet is distributed to the target group. Moreover, 
this intervention can reach large populations. The findings of this research suggest 
that the overall intervention is at least effective in enhancing individual’s vaccination 
intentions, and has the potential to change behaviour.
The non-significant effects of our intervention may have been confounded by the 
global outbreak of a new strain of H INI influenza A virus, as discussed in chapter 7. 
Although it is expected that another influenza pandemic will occur, this is difficult to
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predict when it will appear (Taubenberger, Morens, & Fauci, 2007). Alternatively, in 
future research, monitoring trends in immunisation coverage over time can be used to 
assess the effect of our intervention on vaccination behaviour among high-risk 
individuals.
8.5 Limitations of the research and future directions
While the present thesis provides a number of interesting findings, it also has certain 
limitations. For the qualitative study, the findings are limited to the participants 
involved in the study. Since this study focused only on high-risk adults living in urban 
community of Chiang Rai province, a further study with a different and larger sample 
size is necessary to better understand the beliefs and perceptions about influenza and 
influenza vaccination in Thailand, where large-scale influenza vaccination 
programmes have yet to be undertaken. Another limitation is that the participants in 
this qualitative study were selected from one health centre’s database. These 
participants were health service users, and therefore their views might not reflect the 
views of non-users. In any future study, increasing the diversity of the participants 
(both health service users and non-users) can add the depth and accuracy of the 
findings regarding beliefs and perceptions about influenza and influenza vaccination 
among high-risk individuals.
In study 2, some limitations also need to be addressed. First, as a pilot trial 
investigating the effects of a HAPA-based educational leaflet on influenza 
vaccination, only two communities (intervention and comparison areas) were 
involved in the study; thus, this restriction clearly limits the generalisability of the 
results. In future study, testing the intervention in a larger population of communities 
will provide more confident interpretation of the findings and possibly greater 
generalisability. Second, since there was no intervention group which implemented 
only motivational intervention (a HAPA-based leaflet without action planning 
manipulation); therefore it can not be investigated whether the marginal effects of our 
interventions are the result of motivational intervention or the result of the interaction 
of forming an action plan (volitional intervention) and a motivational intervention.
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Future research should seek to replicate and extend this research by investigating 
action planning intervention independent from a HAPA-based educational leaflet.
In addition, matching intervention to the HAPA stages of change has been found to be 
effective in changing health behaviours (e.g. Lippke, Ziegelmann, & Schwarzer, 
2004; Schiiz, Sniehotta, & Schwarzer, 2007; Schwarzer, 2008). Therefore, further 
investigation should also focus on designing and testing stage-matched intervention in 
the context of vaccination promotion. Third, it should be noted that in this trial, 
outcome assessors were not fully blinded to the treatment assignment during follow- 
up assessment. Because blinding of outcome assessors can prevent bias; therefore, for 
further studies, assessor blinding should be maintained throughout the trial.
With regard to the predictive utility of the HAPA model, although the results of this 
research provide support for the HAPA model in predicting intention and subsequent 
vaccination behaviour in high-risk Thai adults, larger studies need to be carried out in 
different settings with different samples. Also, more research is required to continue 
investigating its applicability to other health behaviours and to other cultural settings. 
In particular, the results of this research showed that action planning did not 
contribute to the prediction of influenza vaccination among high-risk Thai adults. This 
finding is inconsistent with previous studies applying the HAPA model (e.g. 
Luszcznska & Schwarzer, 2003; Sniehotta, Scholz, & Schwarzer, 2005; Schwarzer, 
Schiiz, Ziegelmann et al., 2007). However, in the present research, it is likely that 
vaccination behaviour is influenced by the global outbreak of H1N1 influenza during 
the vaccination period. This may have attenuated the effects of action planning on 
predicting vaccination behaviour. Also, our study was likely underpowered to detect 
expected associations between these two variables. Thus, future studies are warranted 
to clarify the lack of predictive power of action planning in predicting vaccination 
behaviour.
8.6 Implications for clinical practice
Vaccination for seasonal influenza remains the best preventive measure available 
(WHO, 2005). It has been suggested that increasing influenza vaccination rates to 
more than 90 per cent in all recommended groups should substantially reduce the
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impact of annual influenza epidemic (Couch, 2000). In this respect, all health care 
workers need to take every opportunity to encourage influenza vaccination among 
individuals in high risk groups. To achieve this goal, and develop more effective 
vaccination programmes, there needs to be a better understanding of the factors 
underlying people’s vaccination decisions. The results of current research showed that 
most participants had insufficient knowledge about influenza and influenza 
vaccination (study 1). This clearly underlines the need for providing information 
on influenza and influenza vaccine to the public before and during any vaccination 
programme.
Previous studies have shown that knowledge and attitude towards and beliefs about 
influenza and influenza vaccine have a significant influence on the decision to obtain 
influenza vaccination (Honkanen, Keistinen, & Kivela, 1996; Gosney, 2000; 
Santibanez, Nowalk, Zimmerman et al., 2002; Chi & Neuzil, 2004; Brunton, Weir, & 
Jennings, 2005). Education efforts need to address the need for influenza vaccination 
in all high-risk persons, regardless of their general health status and the severity of 
their underlying disease, in order to counter perceptions that only seriously ill person 
requires to obtain influenza vaccination. Recently, one study evaluating the 
effectiveness of influenza vaccine in persons aged 18-64 years with high-risk medical 
conditions showed that influenza vaccination prevented 87 per cent of hospitalisation 
among this high-risk group (Hak, Buskens, van Essen et al., 2005). Based on the 
results of this research (study 2), key beliefs that need to be encouraged include: (1) 
high-risk individuals are susceptible to get a more severe case of influenza, (2) 
influenza infection can cause severe complications, (3) getting vaccinated against 
influenza can reduce its severity if contracted, (4) vaccination against influenza also 
protects family and friends from influenza.
Health care workers should also be prepared and encouraged to discuss vaccination 
with their patients. According to this suggestion, they need to supply solid 
information about influenza and its complications, as well as discuss the safety and 
efficacy of influenza vaccine. Also, most participants in this research (study 1) stated 
that they had never heard about influenza vaccination from their healthcare providers. 
Armed with solid information about influenza and influenza vaccine, healthcare 
workers will be able to provide clear information regarding influenza vaccination to
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the high-risk target individuals. This will lead to increased acceptance of influenza 
vaccine among these groups. A number of studies have shown that advice from health 
care workers was strongly associated with influenza immunisation (e.g. CDC, 1988; 
Honkanen, Keistinen, & Kivela, 1996; Perenboom & Davidse, 1996; Zimmerman, 
Nowalk, Raymund et al., 2003; Nowalk, Zimmerman, Shen et al., 2004; Tabbarah, 
Zimmerman, Nowalk et al., 2005). The information received from health care workers 
can help to increase vaccination rate, even among those with a negative attitude 
toward vaccination. Chi and Neuzil (2004) found that among people with negative 
attitudes towards influenza vaccination, the vaccination rate was 75 per cent among 
those whose healthcare providers recommended the vaccine, whereas vaccination rate 
of 20 per cent was observed among those whose healthcare providers did not 
recommend it. The results of the present research also suggest that improving 
vaccination uptake may be more successful if influenza vaccine is recommended by 
healthcare workers. Efforts to improve influenza vaccination uptake should broaden 
its focus to include not only high-risk older people but also younger people as the 
opinion of them plays a dominant role in encouraging older people to receive the 
annual vaccine. Other strategies include offering free influenza vaccine and 
improving access.
In the current research, the findings that a HAPA-based leaflet had positive effects 
on changing knowledge, risk perception, self-efficacy, outcome expectancies, and 
intentions in obtaining influenza vaccination among intervention participants, have 
practical significance. This research suggests that the theory-based educational leaflet 
may serve as a useful tool to encourage high-risk people to be immunised against 
influenza. A HAPA-based leaflet can be available in waiting rooms in healthcare 
settings. High-risk older people can gainfully spend their time reading the leaflet 
while waiting for their healthcare providers. Furthermore, if these individuals can 
discuss with their healthcare providers (such as nurses) about the contents of the 
leaflet and influenza vaccination, this may increase the rate of vaccination among this 
high-risk group. Clearly, it is very important that people’ beliefs about vaccination 
need to be taken into consideration in that discussion. In particular, for those who do 
not consider themselves to be at high risk for serious complications of influenza, 
healthcare workers will need more time with these individuals to explore their beliefs;
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this will help them fully understand their susceptibility to influenza and their risk for 
serious influenza-related complications.
Additionally, a HAPA-based leaflet can also be sent to high-risk older individuals 
living in the community, together with a reminder letter from healthcare workers. 
In this way, healthcare workers can convey their recommendations and provide 
information about the risks of influenza and the benefits of the influenza vaccine, as 
well as encourage their patients to form an action plan to obtain influenza vaccination. 
It is a cost-and time-effective intervention that helps reduce the workload of 
healthcare workers. Although in the current research, a HAPA-based leaflet is aimed 
at high-risk older persons living in urban community, the same approach may also be 
applied to older people who are residents of nursing homes and other chronic care 
facilities. In addition, public health authorities may consider recommending the 
use of a HAPA-based leaflet for promoting influenza vaccination on a large scale. 
Although there are a number of intervention studies that have been carried out to 
improve influenza vaccination, many of the interventions were atheoretical (Molloy, 
2010; Thomas, Russell, & Lorenzetti, 2010). For such interventions, the specific 
components (key active ingredients) of an intervention programme have not been 
identified. This makes them difficult to design and to determine why interventions are 
effective or ineffective. By contrast, the intervention programme used in the current 
research is based on the HAPA model, and identifies the variables that cause a change 
in intentions (outcome expectancy and self-efficacy), and vaccination behaviour (self- 
efficacy and intention). Thus, the study findings offer an understanding of factors that 
influence behavioural intentions and actual vaccination behaviour. Public health staff 
and other healthcare professionals can gain insight from these findings in creating 
effective strategies to promote influenza vaccination to high-risk individuals.
8.7 Conclusions
The findings of this research have provided valuable information regarding beliefs 
about influenza and influenza vaccination and factors that influence urban-dwelling 
Thai adults’ decisions whether or not to receive influenza vaccine. The results of this
234
research suggest that it is essential to provide information on influenza and influenza 
vaccination to the public before the vaccination programme will be implemented in a 
large scale or nation-wide. Salience of risk, influence of others, perception of the need 
for preventive health care and the availability of influenza vaccine emerged as an 
influential factors in the decision whether or not to obtain influenza vaccination 
among high-risk people. These factors provide a number of targets for any health 
programme designed to promote influenza vaccination. However, such programmes 
are more likely to be successful if individuals’ beliefs about influenza and influenza 
vaccination are taken into account in developing interventions to increase influenza 
vaccination of high-risk people.
Theoretical models also provide target variables to be addressed within any behaviour 
change intervention. They help determine the focus and content of any educational 
programme, and can be utilised to explain how intervention works to promote 
behaviour change (Fishbein & Yzer, 2003). The HAPA (Schwarzer, 1992, 2001) 
provides one such explanatory model. Thus, the model has been used as a theoretical 
background of the intervention content in study 2. The study demonstrated the 
efficacy of a HAPA-based educational leaflet in enhancing intention to obtain the 
influenza vaccination among high-risk Thai adults. Also, the results of this research 
showed that there was a trend towards higher influenza vaccination rate in the 
intervention group. However, further studies are needed to determine the actual 
effects of a HAPA-based leaflet in raising the rate of influenza immunisation among 
this high-risk group.
Additionally, the findings highlight that the HAPA appears to be an appropriate 
theoretical model in predicting intention to receive the influenza vaccine and 
subsequent vaccination behaviour. Self-efficacy and intention were found to predict 
vaccination behaviour. However, the use of HAPA constructs that provide a clear 
theoretical framework for predicting influenza vaccination may lead to overlooking of 
other variables such as social, environmental, and economic factors; these factors are 
not incorporated as a variable in the model, but may play an important role in the 
prediction of vaccination behaviour, as indicated by previous studies (e.g. Nichol, 
Korn, Margolis, 1990; Humair, Buchs, & Stalder, 2002; Luthi, Mean, Ammon et al., 
2002; Kroneman, Paget, & van Essen, 2003; Tabbarah, Zimmerman, Nowalk et al.,
235
2005; Damiani, Federico, Visca et al., 2007; Endrich, Blank, & Szucs, 2009). There is 
no single approach to predict or change health behaviour. Despite the limitations of 
the HAPA, the findings offer valuable information for the public health staff or health 
promotion practitioners for modifying and improving the content of the currently 
available influenza leaflet, as well as designing of other effective interventions in 
order to achieve a greater impact on uptake rates. The HAPA-based leaflet can be 
integrated into routine practice. It is inexpensive to reproduce and disseminate. There 
is no difference in the cost, length, and complexity of printing process between a 
HAPA-based leaflet and a standard government information leaflet. Nevertheless, the 
findings suggest that a HAPA-based leaflet goes further than a standard one in 
changing cognitive-motivational variables. Considering these findings and the 
interventions used in this study, psychological interventions may be one useful means 
for encouraging older people to seek influenza vaccination, and perhaps increasing the 
use of influenza vaccine among these high-risk individuals.
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Appendix
Appendix 1: Consent Form
Version 1: 16/2/2009 
Study Number:
Participant Identification Number:
The uptake of Influenza vaccination among high-risk urban dwelling 
Thai adults: a controlled before and after study
CONSENT FORM
Instructions: Please read each section carefully before you complete this consent 
form, if you wish to give consent, please tick the box provided and sign this consent 
form, and return the signed and completed form to the research assistant.
1. I confirm that I have read and understand the information sheet for 
the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered 
satisfactorily.
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without 
my medical care or legal rights being affected.
3. I understand that relevant sections of any of my medical notes and 
data collected during the study may be looked at by responsible 
individuals from the Health Centre or from Chiang Rai Hospital, 
where it is relevant
to my taking part in this research. I give permission for these 
individuals
to have access to my records.
4. I agree to take part in the above study
Name of Participant Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
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Appendix 2: Participant Inform ation Sheet
Version 1 16 Feb 2009
PARTICIPANT INFORMATION SHEET 
The uptake of Influenza vaccination among high-risk urban dwelling Thai adults 
: a controlled before and after study
You are being invited to take part in a research project. This study will examine 
whether an information leaflet will help people understand more about the flu and the 
flu vaccination, and whether they are more likely to have the vaccine if they have read 
the leaflet.
Before deciding whether to take part, it is important that you understand why the 
research is being done and what it will involve. So please read the following 
information carefully and discuss the study with your family, friends, and the public 
health staff if you want to.
Why have I been asked to take part?
You have been chosen to take part because we are recruiting from people aged 
45- 65 years with chronic diseases like asthma, heart disease, chronic lung diseases, 
chronic kidney diseases, and diabetes mellitus; this because current evidence suggests 
that these people will benefit greatly from receiving the flu vaccine.
Do I have to take part?
No! It is u p  to you to decide whether or not you want to take part.
If you decided to take part,
• the research assistant will ask you to sign a form giving your consent
• you will be given a copy of this information sheet and your signed form 
to keep.
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What if I change my mind and want to stop my participation?
Your decisions will be treated with respect, so you are free to withdraw from the 
study at any time without giving a reason, and this will not affect your medical care or 
treatment that is received now or in the future.
What will happen to me if I take part?
If you agree to take part in the study, the Village Health Volunteers will arrange 
date and time for you to meet with a research assistant, either in your home or at a 
health centre depending on your preference. The study will involve filling in two 
questionnaires (at the start o f the project and two weeks after the first time), and this 
will last for approximately 45 minutes to 1 hour of each questionnaire.
After filling out the first questionnaire, you will receive an educational leaflet. It will 
be sent to you by post. This leaflet provides important information influenza and the 
flu vaccine.
What will I have to do?
We hope that you will be willing to fill out two questionnaires, and we also hope the 
leaflet will answer the questions you have about influenza and the flu vaccine and 
help you to make the decision about getting the flu vaccine.
What are the possible disadvantages and risks of taking part?
There are no risks involved in taking part but it is possible that you may consider 
the time spent filling questionnaires is one disadvantage of taking part in the study.
In total, the study will require approximately 2 hours of your time.
What are the possible benefits of taking part?
There are no direct benefits for the individuals who take part in the study but we hope 
the results will provide useful information for the public health staff in developing an 
effective influenza vaccination programme for people with chronic diseases who 
would benefit most from the flu vaccination.
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What if there is a problem?
If you have a concern about any aspect of the study, you should ask to speak with the 
principal researcher who will do her best to answer any questions you may have. 
Telephone Yupares Payaprom on 08-61623326 or 053-718745. You can also contact 
the head of the health centre on 08-38608624.
Will my taking part in this study be kept confidential?
Yes. All information that is collected about you during the course of this study will be 
kept strictly confidential. We will not include your name or any other information that 
might identify you, so you cannot be recognised from it.
What will happen to the results of the research study?
The results of the study may be published in scientific papers. The findings will also 
be shared with the public health staff and other healthcare professionals through 
workshops and conferences. No individual who took part in this study will be 
identifiable.
Who has reviewed the study?
The study has been reviewed and approved by the Research Review and Ethics 
Screening Committee (School of Nursing and Midwifery Studies, Cardiff University) 
and the Local Research Ethics Committee in Chiang Rai province.
***Thank you for taking the time to read this information and/or
choosing to participate****
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Appendix 3: Ethical Approval
Ref. no. CR 0027.102/c|% f a
The Internal Ethical Committee for Research in Human Subject 
Chiang Rai Regional Hospital
Title o f Project: The uptake o f Influenza vaccination among high-risk urban dwelling
Thai adults
Principle Investigator: Yupares Payaprom 
Institute: CARDIFF UNIVERSITY
Reviewed Document:
Protocol “The uptake o f Influenza vaccination among high-risk urban dwelling Thai adults : 
A pilot randomesed controlled study”
The Internal Ethical Committee for Research in Human Subject, Chiang Rai Regional 
Hospital in ethical concern, review ed the protocol and approved for implementation of 
the research m entioned above. Therefore Thai version o f the protocol will be mainly 
conducted.
Issued date: March 20, 2009
Expiration date: March 19, 2010
(SUPUK PITIPAKORN, MD.) 
Chairman, Internal Ethical Committee
(SUPUK PITIPAKORN, MD.)
Director in charge, Chiang Rai Region Hospital
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Is there anyone who should not be vaccinated?
Some people should not be vaccinated. They include:
- People who are allergic to egg or egg products.
- Individuals who have had an allergic reaction to an 
influenza vaccination in the past.
- People who have a fever should wait to get vaccinated 
until their symptoms lessen.
W hen should I have the flu shot?
The best time to have the 
vaccine is between June and 
July before the main flu season.
Don’t wait until there’s a flu 
epidemic. The vaccine will be 
free, if you have at least one chronic disease — asthma, diabetes, 
heart disease, chronic lung disease, and kidney disease.
W here do I get vaccinated against the flu?  ^ V
The public health staff will send a letter 
to inform you of the appointment date 
and place where you can get the flu shot.
Are you going to get the influenza shot this year?
If you are still in two minds, here are some people’s experiences 
of their vaccination.
"When I  caught flu, Ife lt so weak and so painful that I  
can barely get up. I  had fever and muscle pain. It was serious. 
After I  got the shot, I  have not caught Influenza. I  have a running 
nose and catch a cold some time though” (M r. Tongdee Somrat)
"I have underlying disease, which is asthma. I  have to protect
myself. At first I  had not agreed to get the flu  shot because I  was
afraid o f allergies and breathing difficulty, but I  was fine after
the injection. (M rs. Sangjun  B oonm ee) ^  Don^ )#t
the flu cateh
<^YOUp>
.¥
"I felt little pain where I was injected. It was the same as 
common injection, and my muscles ached on the first 
night, but not much. I  only felt fo r a day. Then I  was 
okay. After the vaccination, I have not been ill with 
influenza. ” (M r. A m aroj Na L am pang)
G etting a influenza vaccination: Plan Ahead!
You are more likely to go for having the flu shot, 
If you decide now about where, when and how 
you will go. Please write in below when, 
where and how you plan to get a flu vaccine.
“If I get an appointment letter to have the flu vaccine, then
I will........................(please write down w h a t y o u  p lan  to
do. e.g. go for taking the flu vaccine)
at................................ (please write down Where, e.g.
Chiang Rai hospital, private clinic), and I’m going to get
there by...............................................(please write down
H o w  you go to that place, e.g. walking, taking a bus or 
asking son/daughter/ relatives to take you to get the flu 
vaccine/ ”
The FLU & YOU
Don’t let Flu knock you out -  
make sure you’re getting the 
flu vaccine this year!
Flu im m unisation Inform ation
Chiang Rai Regional Hospital, 
Ministry o f Public Health
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W hy do I need to worry about the flu?
Influenza is commonly called “the flu”. It is a very 
contagious illness caused by a virus. This virus is 
different from a cold virus. Having flu is much worse 
than a cold particularly if you have a chronic disease.
You are at high risk for severe complications such as bronchitis, 
pneumonia, blood infections and ear infections.
This may put you in hospital.
Unfortunately, some people 
with chronic disease die from 
influenza complications 
every year, so w h y r isk  it?
How do I catch the flu?
The flu is easily passed from one person to another by 
the coughs and sneezes of people who are already 
infected. Anyone living in or visiting a home where someone has 
influenza can become infected. Sometimes you can get the flu by 
touching something that has the flu virus on it (door knobs, table, 
telephone receivers), and then touching your mouth or nose.
What are the flu symptoms?
The flu usually starts sudd en ly  
and severely  w ith  som e or all
of these symptoms: * Fever * Headache 
* Severe muscle aches * Tiredness/extreme fatigue 
Dry cough * Sore throat * Runny or stuffy nose
Can the flu be prevented?
Y es! The best way to prevent the flu is to get the flu vaccine each 
year to protect yourself. You will also be protecting your beloved 
ones, especially any children, by not spreading the flu.
However, the seasonal flu vaccine cannot prevent 
the bird flu and swine flu.
What are the benefits of influenza 
vaccination?
The flu vaccine can be very useful to people 
with chronic diseases like asthma, diabetes, heart disease, 
chronic lung disease, and kidney disease. Catching the flu can 
worsen chronic medical conditions or cause serious 
complications in these individuals. Most people who have been 
vaccinated will not get the flu. But if you do catch flu, it’s most 
likely to be milder than if you had not been vaccinated. Taking 
the influenza shot will help you a lot through the flu season:
Don’t get flu! Don’t spread Flu!,
Don't have serious complications,
Reduce the risk of going into hospital, and 
Stay Healthy during the Flu season!
What are the side effects from the flu vaccine?
The flu vaccine is very safe. It does not contain 
any live virus, so it will N O T  give you the flu.
The most common side effect of the flu vaccine is 
soreness where you were injected. Occasionally, 
some people experience a mild fever and aching 
muscles. This usually goes away after a day or two. 
Any other reactions are very rare.
I’ve never had the flu. Do I need to be vaccinated?
You may look and feel healthy, but anyone can get sick 
with the flu. It spreads easily from person to person, and 
most hospitalisations and deaths affect people with chronic 
diseases. Getting vaccinated is the best protection against 
the flu.
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Appendix 5: A standard Government Leaflet
Precautions: people who should seek 
medical advice before getting tlie flu shot
Adverse reactions after 
influenza vaccination
Seasonal Influenza vaccination service 
for
people with chronic disease- Anyone with a serious allergy to any of the 
components in the vaccine such as eggs, egg 
products, neomycin and formaldehyde.
People can have alow-gade fever, soreness at 
injection site after receiving the flu vaccine. 
These symptoms are usually mild and last 1 - 2 
days. Severe allergic reactions to the flu 
vaccine are very rare.
Departm ent o f  D isease Control,
M in istiy  o f  Public Health, Thailand  
&  National Health Security Office
Department of Disease Control, 
Ministry of Public Health, Thailand 
National Health Security Office
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Seasonal Influenza vaccination service 
for people with chronic disease
What’s the flu vaccine?
 -------------------------------------
Influenza symptoms
The Ministry of Public Health in cooperation 
with the National Health Security Office 
provides flu vaccine free of charge in the year 
2009 to people with chronic disease.
These include those with chronic obstructive 
pulmonary disease, asthma, 
disease, chronic renal disease, cancer patients 
receiving chemotherapy, and diabetes mellitus
People who get the flu have a wide-range of 
symptoms, including fever, cough, headache, 
sore throat, muscle aches, chill, and weakness; 
These symptoms generally last 2 to 4 days.
A flu shot is made from killed influenza virus. 
The vaccine stimulates the immune system to 
produce antibodies that protect against 
influenza viruses. However, the seasonal 
influenza vaccine cannot prevent the bird flu.
After vaccination, it takes about two weeks for 
antibodies to develop in the body and provide 
protection. The immunity from the vaccine 
lasts for a period of about 1 year. However, 
people who have been vaccinated against 
influenza can still get the flu, but they will
usually get a milder case than people who have 
not received the vaccine.
Tlie benefits of influenza vaccination
The flu vaccine will help to prevent seasonal 
influenza and its complications. In particular, 
the vaccine will help to reduce the chances 
of developing severe case of influenza in the 
people with chronic disease which can result 
in the death.
In Thailand, the studies were conducted 
to evaluate the effectiveness of influenza 
vaccination among elderly persons living 
in the community and among patients with 
chronic obstructive pulmonary disease.
The results showed a 2-fold decrease in the 
incidence of influenza in elderly people and 
greater than a four fold decrease in the patients 
with chronic obstructive pulmonary disease.
Appendix 6: Interview schedule
Interview schedule
1 .How would you describe the flu?
Probes:
a. How do you catch flu?
b. What are the signs and symptoms of the flu?
c. Is the “flu” the same as a “cold”?
d. How serious do you think flu is?
e. Do you consider influenza to be a serious illness?
(Why or why not)
f. Can influenza cause death?
2. How have you learned about flu?
Probes:
a. Family/friends/ health professionals/TV/newspaper?
b. Have you or any of your family ever had flu?
3. What you do if you get sick from the flu?
4. How do you protect yourself from getting the flu?
5. Have you ever heard about the influenza vaccination or Flu shot?
Probes:
a. What have you heard about it (benefits and drawbacks)?
b. Where did you hear about it?
c. Do you feel you know enough about the flu shot?
d. Who is recommended to have influenza vaccine?
(Do you know who should get a Flu shot?)
2. How effective do you think that a flu shot will protect you from getting the flu?
3. What sort of side effects would occur to people after getting a flu shot?
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4. Do you believe that people would have had the flu after getting a flu shot?
5. Do you think you really need a flu shot?
Probes:
a. Why or Why not?
b. Have you or your family ever received a flu shot?
6. Could you make your own decision to get a flu shot?
7. Has anyone encouraged you to get a flu shot?
8. Who would influence you to get a flu shot?
Probes: Would it be a physician, your family/ friends, a religious leader?
9. Which will help you decide whether you will get a flu shot?
10. Will you get the flu shot this year?
11. What sorts of things would make you decide to get a flu shot?
Probes:
a. Could you afford for a flu shot?
b. Where can you get a flu shot? and Is this convenient?
12. In your opinion, what would make elderly people more willing to get a flu shot?
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Appendix 7: Questionnaire
ID Number
Influenza and Influenza Vaccination Questionnaire 
Instructions
Please read the following questions carefully and answ er each one. I f  you have any difficulties 
in completing the questionnaire, you can ask the research assistant for help. W e will treat 
information you give us as confidential.
General information
1. Age...........yrs
2. Sex □ Male □ Female
3. Marital status
□ Single □ Married □ Divorced or Separated
□ Widowed □ Living with partner
4. Educational Level
□ Primary school
□ Secondary school □ Vocational/ Technical
□ Other (specify)..........................................................
5. Occupation
□ None □ Farmer □ Labourer
□ Merchant □ Pensioner
□ Other (specify)....................................................................
6. Have you ever had a flu shot?
□ Yes □ No
If yes, when.....................................................................................
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7. What are symptoms of flu? (Please tick the box which corresponds with your answer.)
Symptoms of the flu Definitely
Yes
Definitely
No
Not sure
Fever (usually high) and chills
Muscle aches and pains
Seizure
Extreme tiredness
Diarrhoea
Watery eyes
Runny or stuffy nose
Itching in nose, throat or eyes
Sneezing
Nausea
Dry cough
Headache
Sore throat
8. What can be the side effects of flu vaccination? (Please tick the box which corresponds
with your answer.)
Side effects of the flu vaccine Definitely
Yes
Definitely
No
Not sure
There are no side-effects
A slight fever for 8-24 hours after vaccination.
Soreness, pain at the vaccination spot.
Swelling around the vaccination spot.
Vomiting, diarrhea, and being nauseous.
A fever, runny nose with dark and thick secretions.
Feeling generally unwell and mild or moderate muscle aches for 
a couple days.
Difficult breathing or swelling of the face.
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3S E C T I O N  O N E
P l e a s e  in d ic a t e  how much you agree or disagree with the following statements by choosing 
the face that best matches how you feel. T h e r e  a r e  n o  r ig h t  o r  w r o n g  a n s w e r s .
®
Strongly
disagree
®
Disagree
©'
Not sure
(§)
Agree Strongly
agree
1. I n f lu e n z a  i s  a  s e r i o u s  d i s e a s e . (^ ) (S) (2)' (2) ©
2. I f  I g e t  t h e  f lu  I w i l l  b e c o m e  v e r y  s i c k . (S) 0 (M)
3. F lu  s p r e a d s  b e t w e e n  p e o p l e  v e r y  e a s i l y . ® d~) (J) ©
4. I a m  l i k e l y  t o  c a t c h  t h e  f lu  i f  o t h e r  p e o p l e  
in  m y  D i s t r i c t  d e v e l o p  it .
® (¥) (2) <D ©
5 F lu  i s  a  v e r y  m in o r  h e a l t h  p r o b le m . ® (5) (M) (§) ©
6. I f  s o m e o n e  in  m y  f a m i l y  d e v e l o p s  f lu ,  
e v e r y o n e  e l s e  w i l l .
X / ^ N / @ d~) (2) ®
7 F lu  i s  n o t  s e r i o u s  e n o u g h  t o  in t e r f e r e  w i t h  
m y  d a i ly  a c t i v i t i e s .
(5) (H) (2) ©
8. C o m p a r e d  t o  o t h e r  p e o p l e ,  t h e  l i k e l i h o o d  
th a t  I  w i l l  g e t  t h e  f lu  i s  v e r y  la r g e .
® (5) (2) (D ©
9. F lu  c a n  m a k e  m y  e x i s t i n g  i l l n e s s  w o r s e .
W V © (2) (2) ©
10. I f  I  c a t c h  t h e  f lu ,  I  m a y  h a v e  t o  g o  t o  h o s p i t a l . ® (2) (2) (2) ©
11. F lu  c a n  b e  v e r y  s e r i o u s  f o r  p e o p l e  w i t h  
p o o r  h e a lth .
® © (2) ©
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4®
Strongly
disagree
®
Disagree Not sure
(S)
Agree
(g)
Strongly
agree
12. I do not think that I am personally at risk 
o f  contracting the flu. ® (~) <D
13. M y body could fight o f f  the flu  because  
I have a strong im m une system .
(®) (5) (D
14. Flu can kill people in poor health. wv (S) (D
15. I have a good health, so  I d on ’t need to 
get a flu vaccine.
® (¥) (§) (§)
SE C T IO N  T W O
In this section, w e w ould like  to know  about your expectations after getting the flu shot. P lease tick  
the appropriate box . There are no right or wrong answers.
not at all 
true
a little 
true
Mostly
true
Exactly
true
16.
If  I get the flu  sh o t ................
M y chance o f  getting the flu w ill be decreased.
17. It can prevent m e from getting a m ore 
severe case o f  the flu (influenza com plications).
18. I w ill feel m ore confident about not having the flu.
19. I w ill be m ore lik ely  to get other illnesses.
20 I could protect m y fam ily  and friends from flu
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5not at all 
true
a little  
true
M ostly
true
Exactly
true
21.
If I g e t the flu  sh o t ....................................
It w ill w eaken m y im m une system .
22 I w ill be le s s  o f  a burden to m y fam ily.
23 My fam ily w o n ’t worry about m y chances o f  
getting a serious case o f  the flu.
24. I w ill get sick  with the flu.
25. It w ill help m e stay healthy during the flu  
season.
S E C T IO N  T H R E E
The fo llow in g  statem ents look  at how  m uch confidence you w ould get the flu  shot. P lease tick  
the ap p rop ria te  box. There are no right or wrong answers.
not at all 
true
a litd e
true
m ostly
true
Exactly
true
26.
I am  con fid en t th a t...................................
I w ill get the flu  shot in the forthcom ing vaccination  
period.
27. I can cope with side e ffects after receiving the flu vaccine  
(fever, aches, soreness, redness at the injection site).
28. I can deal with a fear o f  needles or sh o t
29. I can find the tim e to get vaccinated against the flu.
30. Receiving a flu  shot w ill not interfere w ith m y daily  
routine.
31. I w ill get a flu shot even  though I am  quite busy during 
the vaccination period.
32. I can arrange the transportation for m y se lf to get 
vaccinated.
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6SE C T IO N  F O U R
W e are interested in your plan to seek  flu vaccine in the next vaccination period. P lease tick the box
w hich co rresp on d s w ith  y o u r  answ er.
Y es N o
33. I have m ade a plan when I’m  eo in e  to vaccinate  
during the next vaccination period.
34. I have m ade a plan where I’m  eoine to have the 
flu shot in the next vaccination period.
35. I have m ade a plan how I’m  going  to get vaccinated  
against the flu.
The follow ing statem ent lo o k s at how  m uch confidence you could use your plan to get the flu vaccine. 
Please tick  th e  a p p ro p ria te  box.
not at all 
true
a little  
true
mostly
true
Exactly
true
36. I am  confident that I can use this plan.
SE T IO N  FIV E
W e would like to know  about your intention to receive the flu shot. P lease tick the num ber that best 
corresponds to y o u r  an sw er. There are no correct answers.
Definitely  
do not
Definitely
do
37. I intend to receive a flu  shot in the 
forthcoming vaccination period.
□  1 □ 2 □ 3 □ 4  □  5
38. I want to get vaccinated against the flu  in the 
forthcoming vaccination period.
□  1 □  2 □ 3
□■^r□
****Thank y 0 U  for taking part in this study and for your time. ****
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Understandings of influenza and influenza vaccination 
among high-risk urban dwelling Thai adults: 
a qualitative study
Y. Payaprom 12, R B e n n e tt2, P. Burnard3, E. A lab aster3, H. T antipong4
'Department o f  Nursing, Chiang Rai Hospital, Chiang Rai, Thailand
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A B S T R A C T
Background The 2004 outbreak of influenza A H5N1 and the WHO's recommendation for national pandemic plans has led the Thai Ministry 
of Public Health to develop an influenza vaccination programme for high-risk adults. To date there is no available information to guide this 
intervention, and how to maximize the uptake of the vaccine by the Thai population. To address this knowledge gap, this study explored 
factors influencing urban-dwelling Thai adults' decisions whether or not to have the vaccine. It explored their beliefs about influenza and 
influenza vaccination, and other influences on their decisions.
Methods In-depth interviews were conducted among 20 high-risk individuals who were aged 65 and over or under 65 years with chronic 
diseases requiring influenza vaccination. Interviews were tape recorded and analysed following using grounded theory.
Results Most participants had insufficient knowledge about influenza and influenza vaccination. Their decisions in relation to vaccination 
were based on a number of factors, including salience of risk, influence of others, perception of the need for preventive health care and the 
availability of influenza vaccine.
Conclusion These findings underscore the need to consider and understand factors underlying people's vaccination decisions to create an 
effective influenza vaccination programme.
Keywords health promotion, influenza immunization
In troduction
In response to the WHO1 recommendation that all 
countries develop influenza preparedness plans and a recent 
outbreak of influenza resulting in 17 deaths, the Thai gov­
ernment is planning an influenza prevention programme tar­
geting people aged over 65 years with chronic diseases,2 and 
extending to those under 65 years in the next following 
years. Data from studies conducted in western countries 
indicate that decisions whether or not to receive influenza 
vaccination are complex, and influenced by several medical 
and psychosocial factors, including its salience and perceived 
severity,3 the influence of healthcare providers, family 
members and friends4-6 and the costs and convenience of
obtaining the vaccination.7-9 By contrast, factors influencing 
vaccine uptake in tropical countries such as Thailand, 
Vietnam and Indonesia have not been studied. Yet, under­
standing these issues is critical to the development of effec­
tive interventions. In order to begin this process, the present 
study explored beliefs about influenza and influenza
Y  Payaprom, Registered Nurse, PhD Student 
P. B ennett, Professor o f  Nursing Research 
P. Burnard, Professor o f  Nursing Research 
E . Alabaster, Senior Lecturer in Adult Nursing
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vaccination, and other factors likely to influence decisions 
whether or not to accept the influenza vaccination in a 
sample o f  urban-dwelling Thai individuals aged 65 years and 
over or under 65 years with serious chronic health problems. 
The findings will inform  the developm ent o f  interventions 
to encourage uptake o f  influenza vaccination by such  
individuals.
Methods
Setting and participants
This study was approved by the research ethics com m ittee, 
Chiang Rai province, Thailand. It was conducted in the 
Muang district, an urban com m unity o f  Chiang Rai province 
with a population o f  223 936. Chiang Rai is the northern 
most province o f  Thailand and has an adult literacy rate o f  
93%. It, and the northeast province o f  Thailand, has similar 
levels o f  income (around U S$1396 per capita per year, com ­
pared to Thailand average incom e o f  US$3720) and consti­
tutes about 53% o f  the total Thai population.10 A s such, 
the population o f  Muang district may be considered repre­
sentative o f  the poorer half o f  the Thai population, and they 
had typical education. The study population were adults 
who were either aged 65 and over, or under 65 years with  
chronic diseases, which indicated that they w ould benefit 
from the influenza vaccination (e.g. coronary heart or 
chronic obstructive pulmonary disease). Potential partici­
pants were randomly selected from one health centre’s data­
base. Their medical records were scrutinized to  confirm  the 
suitability o f  participants for interview. T hose with severe 
chronic conditions (i.e. bed bound or acutely ill), severe 
mental health problems, or com m unication difficulties were 
excluded. Letters o f  introduction were sent to 30 potential 
participants: 15 letters in each group.
Interviews
In-depth interviews were conducted between February and 
March 2008 in participants’ hom es or at a health centre. 
Written consent was obtained before the interview. A  
semi-structured schedule guided the interviews. It explored  
participants’ understandings o f  influenza and influenza vac­
cination and factors that may influence their decision  
whether to accept or decline the influenza vaccination in the 
forthcoming vaccination period. Interviews lasted between  
30 and 60 min, and were tape recorded.
Date analysis
The interviews were transcribed in Thai and analysed fol­
lowing grounded theory tradition.11 All transcripts were
coded by two researchers to increase reliability, with discre­
pancies resolved through discussion. After extensive data 
analysis, the transcripts were translated into English and 
back translated into Thai by an independent translator. The 
English version o f  the transcripts is reported here.
Findings
Twenty individuals agreed to participate and were inter­
viewed: 11 aged > 6 5  years and 9 aged < 6 5  years with 
chronic diseases. Their mean age was 64.9 years, with the 
oldest participant being 75 years old. Participants were pre­
dominantly female and m ost o f  them had completed 
primary school, and were therefore typical o f  old people in 
Thailand. All participants lived with others. Five participants 
reported having had influenza diagnosed by a doctor in the 
past; there were no laboratory-confirmed cases o f  influenza. 
Additionally, six participants reported having had one influ­
enza vaccination: four had been offered the vaccine by their 
physicians and two reported that their daughters, who were 
nurses, had advised them to be immunized. All paid for the 
vaccine and its administration (Table 1). In view o f  these 
different vaccine histories, the analysis examined any differ­
ences between the transcripts o f  those who had or had not 
previously sought or received flu vaccination. They only dif­
fered in their perception o f  the salience o f  risk for influenza 
and its severity.
Understanding of influenza and influenza 
vaccination
Knowledge o f influenza and influenza vaccination
M ost participants stated they knew little about influenza and 
did not know how to describe it. A  number thought it was 
associated with the changes o f  weather, particularly from the 
rainy to winter season, while only one person stated that 
influenza was caused by ‘germ s’. A  few participants with 
chronic diseases thought that these placed them at increased 
risk o f  infection.
I t’s easy fo r me to catch the flu because my resistance is down. I have 
lung disease also the changing the weather is a contributing factor. 
(ID 10)
M ost participants confused the symptoms with those o f  
the com m on cold and other respiratory illnesses.
When you have flu, you have a fever, sneevyng, runny nose with watery 
secretions during the first few days, then these become thick and dark 
mucus, and you also feel a headache. ..f lu  is more serious than a cold. 
(ID  20)
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T a b le  1 Demographic characteristic of participants
ID  A g e  Sex M a r i t a l  s t a t u s  E d u c a t i o n a l  l e v e l  O c c u p a t i o n  L iv in g  a r r a n g e m e n t s  H e a l th  p r o b l e m s  H a d  f lu  in  t h e  p a s t  I m m u n i z a t i o n  s t a t u s
1 72 F Married Primary school None Children and spouse None No Never
2 60 F Widowed Primary school None Children Diabetes No Never
3 58 F Widowed Primary school Merchant Children Asthma Yes Never
4 60 M Married Primary school Farmer Children and spouse COPD No Immunized
5 75 M Married Primary school None Children and spouse None No Never
6 69 F Married Secondary school Merchant Spouse None No Immunized
7 66 M Married Primary school Labourer Children and spouse None No Never
8 56 M Married Primary school Merchant Spouse Diabetes No Never
9 54 M Married Secondary school Labourer Children and spouse Diabetes Yes Never
10 61 M Married Primary school Labourer Children and spouse COPD Yes Immunized
11 65 M Married Vocational/technical Labourer Children and spouse None No Never
12 70 F Widowed None None Children None Yes Never
13 52 F Married Primary school Merchant Children and spouse Diabetes No Never
14 72 F Married Vocational/technical Pensioner Children and spouse None No Immunized
15 73 M Married Secondary school Pensioner Children and spouse None Yes Immunized
16 61 F Married Secondary school Pensioner Spouse Asthma No Immunized
17 62 F Widowed Primary school None Children Diabetes No Never
18 74 F Widowed None None Children None No Never
19 70 M Married Primary school None Children and spouse None No Never
20 69 F Widowed Primary school None Children None No Never
Although they considered influenza to be a serious health 
problem, only a few participants felt that it could cause 
death.
I t’s possible that Influenza can make elderly people very ill and even 
cause death because thy have weak immune systems. (ID 4)
I f you are not cured in time, you may die o f influenza. However, 
I haven’t heard ofpeople dying of it. (ID 8)
Most participants reported that they knew little or 
nothing about the flu vaccine. A typical comment was:
I  had heard about the vaccine fo r children. Is there the influenza 
vaccine for elderly people? Well, I  have not heard o f it. (ID 13)
Additionally, some participants had misconceptions about 
influenza vaccination, believing that it could either prevent 
them from catching a cold or may weaken their immune 
system.
A fter receiving it [Influenza vaccine], I  have not been ill. 
Previously, if  a person who got cold sneered or coughed toward me, 
I  would certainly catch a cold. (ED 10)
In the elderly, immune ystems are not as strong as in younger. I f  I  get 
a flu shot, it may weaken my immune system. (ID 1)
Most participants were not particularly concerned about 
any vaccine side effects. They thought that these would be 
the same as for other vaccines. However, a few felt the need 
to be reassured that the vaccine was safe.
A  few people may have [concerns about side effects of vaccine]. 
However, i f  the vaccine comes from the public health staff, and the 
information is provided on vaccine safety, these should help lessen the 
people’s concerns. (ID 11)
Source o f  in form ation
A number of participants reported they had developed influ­
enza at some time in the past. A few others had heard 
about influenza from others. However, most participants 
had not been informed about the vaccination by healthcare 
workers, and only four participants had learned about the 
vaccine from the mass media,
[I’ve heard] from elderly people. Noni less people catch it [influ­
enza]. I  have rarely heard of someone catching it. (ID 7)
Thy've probably heard o f influenza fo r a long time, but thy don’t 
understand it. A nd I  think no one in this community remembers what 
the disease is. (ID 9)
Interviewer: Have you ever heard about Influenza vaccine from
TV?
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Mr. Y: No, ju s t influenza
Interviewer: Do you think you've received enough influenza
information from  T V ?
Mr. Y: No, I  did not receive any details from  it, ju s t got
rough information. (ID  4)
The public health staff.. .  -gjve(s) us a health check-up, but they never 
mention the influenza vaccine. (ID  13)
Dcadsion-making in influenza vaccination
Salience of risk
Though most participants held generally positive views on  
influenza vaccination, decisions about the influenza vacci­
nation were based on their perceived risk o f  contracting 
influenza. Some reported they w ould only seek influenza 
vaccine if  there was a local outbreak o f  influenza.
Even it is free. I f  m  do not have this kind of epidemic [influenza 
epidemic] in our community, there is no need to receive the injection. 
(ID 7)
Yes, I can wait till there actually is [an influenza epidemic]. I  can 
have the injection immediately after the outbreak. (ID  9)
By contrast, those who had previously been vaccinated con­
sidered themselves to be at risk o f  developing influenza and 
that it would affect them seriously:
I have the underlying disease which is lung disease.. .  I  should get a flu 
shot because I  could get the flu easily. (ID  4)
I ’m afraid of catching the flu a t old age. People my age, once get sick, 
will get worse and need medical treatment a t the hospital I  have to 
protect myself. (ID 14)
Influence of others
A  number o f  participants stated that they would ask their 
children or other people in the com m unity about whether to 
have die vaccination.
I have to ask my children before that. I f  thty scty I  should, I ’ll receive 
this injection. I f they scry no, I  w ill not receive i t . . .  I ’ve to ask them 
whether or not to have a flu shot, it is necessary. (ID  13)
I will talk with my friends.. .people of the same age and with the 
same health condition could help us decide whether to get the flu shot 
or not. I f th y  decide against it, I  do not want to do it either. (ID  7)
In addition, a number o f  participants with chronic medical 
conditions reported that their decision w ould rely heavily on  
their healthcare providers, regardless o f  their own views.
I ’ve been healthy fo r about the last 2 —3 years, and I ’ve never caught a 
cold once. So I think it is not necessary to get the flu shot, hut if the 
doctor advised me to have the vaccine, I ’ll do it. (ID 2)
Availability
M ost participants would consider having the vaccination if  it 
was provided free o f  charge, and preferred to receive it 
locally.
N o, I  do not have any money fo r  a vaccine. I  will only do it, if  it is 
free. (ID 17)
T h y should... [get vaccination], hu t what would thty do? 
Elderly people without any income support can only live day by day. 
(ID 11)
The health centre is fine. I t’s near our houses, and it’s not crowded If 
i t ’s the hospital, you have to spend one day because the hospital service 
is very slow, and try children have to take me there. (ID 18)
Perception of the need for preventive healthcare
Som e participants with chronic medical conditions reported 
they would consider getting vaccinated because they were 
concerned that influenza might exacerbate any illness and 
would make them feel a burden on other people.
I ’m efraid of getting sick. I  have asthma. I  think that my breathing 
may become difficult. So I  have to protect myself. (ID 16)
I  have lung disease. I  feel tired when I  breathe, my children bring me 
to the hospital and thty lose their income fo r one day. I  think I  will 
get it  [influenza vaccine] (ID 3)
By contrast, several participants who considered themselves 
to be healthy stated that they would not consider getting vacci­
nated even though they could afford to pay for it.
I ’ve never caught it, so I am not efraid of it. I ’m healthy because 
I  exercise every day. I ’ve a strong immune ystem. (ID 5)
Interviewer: A re you efraid of catching influences fyo u  do not get
a flu shot?
Mrs. V: I don’t  know. I f  I  catch it, I  w ill receive the treatment
at the hospital.
Interviewer: You mean you want to take the chance?
Mrs. V: Yes. (ID 13).
Discussion 
Main findings
Overall, the study revealed that high-risk Thai adults had 
low levels o f  knowledge about influenza and influenza vacci­
nation. Many were unsure about its cause and symptoms,
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mode o f  transmission, seriousness and com plications. Few  
correctly described the sym ptom s o f  influen2a, while others 
confused them with the sym ptom s o f  the co m m on  cold or 
other respiratory illnesses. T hese findings may not be 
specific to this population: only 44%  o f  a U S  sam ple was 
able to describe typical influenza sym ptom s.12 Consistent 
with previous findings,13’14 m ost participants regarded 
influenza as a relatively serious disease. H owever, som e  
considered it to be no worse than a *bad cold, while very 
few thought that it could cause death. T h ese  beliefs appear 
to have contributed to a reluctance to  seek the vaccine  
among some individuals.
Most participants knew litde or nothing about the influenza 
vaccination, perhaps because the use o f  influenza vaccine in 
Thailand has, until recently, been limited to  a restricted group 
o f  people such as healthcare workers, pilgrims w h o  attend the 
Hajj and those who are able to afford for it.15-16 O f  note  
was that side effects following vaccination were not a major 
concern among our participants, in contrast to  som e studies 
that have reported fear o f  side effects as a significant contri­
butor to decisions not to receive the vaccination.6’8 By con­
trast, salience o f  risk did appear to  play an important role in 
decision-making. Many considered were reluctant to  be vacci­
nated as they considered themselves to be healthy and the risk 
o f  developing influenza to be low, or stated they would only 
seek vaccination if  there was a local outbreak o f  influenza. 
However, m ost individuals with pre-existing health conditions 
were likely to seek vaccination to prevent further health com ­
plications. Participants’ decisions were also strongly influenced  
by family members, peers and healthcare providers. This 
strong social influence is likely to be the result o f  the close  
intergenerational ties within Thai families17 and participants’ 
willingness to accede health decisions to  doctors regardless o f  
their own views. Financial barriers also appeared to be an 
important influence on healthy individuals’ immunization 
decisions, although participants in poor health were more 
willing to purchase the vaccine.
Our study clearly demonstrated the com plexity o f  per­
sonal decision-making in influenza vaccination, particularly 
in a culture in which there are significant intergenerational 
influences on such decisions. T h e results o f  this study 
suggest that national and local flu vaccination programmes 
should be preceded and accom panied by public educational 
programmes that emphasize the seriousness o f  influenza, its 
complications and the specific merits o f  vaccination for key 
target groups (such as high-risk individuals). In Thailand 
such programmes need to be targeted at both  potential reci­
pients and significant others, including younger family 
members, as these individuals appear to  be key social facili­
tators in encouraging high-risk older people  to  accept
vaccination. Finally, the free provision o f  vaccination is likely 
to have a marked impact on  uptake.
What is already known on this topic
Previous research6,8,9’13 has shown uptake o f  influenza 
vaccine to  be influenced by factors including its salience and 
perceived severity3 the influence o f  healthcare providers, 
family members and friends,4-6 and the costs and conven­
ience o f  obtaining the vaccination.7,9 However, these find­
ings are restricted to western countries, and data is lacking 
from  tropical countries such as Thailand.
What this study adds
O ur data clearly indicate that providing information on  
influenza and influenza vaccination to the public will be 
necessary before and during any vaccination programme. 
Such a programme should both emphasize the symptoms 
and the severity o f  influenza as well as explain why the 
vaccine should be applied to all high-risk groups. It should 
also be targeted at younger people w ho will not have the 
vaccination themselves, but w ho may influence the vacci­
nation decisions o f  their parents and others. Maximizing 
uptake also appears to be predicated on the vaccine being 
free and available in local healthcare centres or community 
organizations as well as more centralized hospitals. Doctors 
and other healthcare workers should also be prepared and 
encouraged to discuss vaccination with their patients. 
A lthough these suggestions are made in application to high- 
risk urban-dwelling Thai adults, they could be applied to 
other countries with tropical climates where large-scale influ­
enza vaccination programmes have yet to be undertaken, 
with further adjustment for differences am ong countries.
Limitations of this study
T he main limitation o f  this study is its specificity to the 
population under study. It was conducted in one selected 
urban community; potentially restricting its implications to 
high-risk Thai adults living in the M uang district, Chiang 
Rai, Thailand. Another limitation is that there were 10 poten­
tial participants w ho refused to  participate in this study, four 
felt generally unwell, four did not have enough time for 
interview and two were not interested. Accordingly, while a 
good  response rate for qualitative research was obtained, it 
is possible these individuals might have different views on  
influenza and influenza vaccination from those w ho partici­
pated in the study. Larger, quantitative, studies on represen­
tative populations are still necessary to ensure the 
generalizability o f  these findings. D espite these cautionary 
notes, however, our findings provide information relevant to
330
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the development o f  public health interventions to  prom ote  
the use o f  influenza vaccine am ong high-risk Thai adults.
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Using the Health Action Process Approach and Implementation Intentions 
to Increase Flu Vaccine Uptake in High Risk Thai Individuals: 
A Controlled Before-After Trial
Yupares Payaprom Paul Bennett
Cardiff University University o f Swansea
Erica Alabaster Hutsaya Tantipong
Cardiff University Chiang Rai Hospital, Chiang Rai, Thailand
Objective: In flu e n za  v accination  rates rem ain  suboptim al in m any countries, inc lud ing  Thailand . This 
study co m p ared  the effec t o f  a  theory-based  educational leaflet, based  on the H ealth  A ction  Process 
A pproach  (H A P A ), and  ac tion  p lann ing  in terven tion  w ith a standard governm ent inform ation leaflet 
designed  to  in c rease  in flu en za  vaccination  up take am ong h igh-risk  Thai adults. Design: A  controlled 
before and  a fte r trial w as conduc ted . P artic ipan ts  in the in tervention  (n =  99) received  a  leaflet based on 
the H A PA  and  a sk ing  them  to fo rm  an ac tion  p lan  identify ing  w here, w hen, and how  they  w ould  seek 
vaccination . T h o se  in the com p ariso n  cond ition  (n =  102) received  a standard  governm ent inform ation 
leaflet. Main Outcomes Measures: T h e re  are  2  sets o f  outcom e m easures: (a) process m easures o f  H A PA  
related variab les  tak en  a t T1 an d  T 2 , and  (b) vaccination  rates during  the subsequent 2  m onths. Results:
The H A PA  in terven tion  resu lted  in g rea ter changes on m easures o f  risk perception , ou tcom e expectan­
cies, se lf-efficacy , and  in ten tion  than  th e  com parison  condition . S tronger inten tions to  obtain  vaccination 
w ere exp la ined  by  changes  in o u tcom e expectanc ies, perce ived  self-efficacy  fo r arrang ing  tim e and 
transportation , and  p lann ing . N o sign ifican t d iffe rence  in vaccination rates w as observed  betw een tw o 
groups. In fluenza  v acc ina tion  w as d irec tly  p red ic ted  by self-efficacy  and intention. Conclusion: Results 
dem onstrate  tha t a  H A P A -b ased  leafle t m ay be a  useful tool to  enhance ind iv id u a l's  vaccination 
intention, but la rg e r tria ls  a re  requ ired  to  confirm  these findings.
Keywords: b efo re -a fte r  s tudy , in flu en za  vaccination , H ealth  A ction  P rocess A pproach
Each year, influenza epidem ics are estimated to cause 3 -5  
million cases o f severe illness, and between 2 5 0 ,0 0 0 -5 0 0 ,0 0 0  
deaths throughout the world (World Health Organization [WHO], 
2003). In Thailand, an outbreak o f the influenza A (H 5N 1) virus in 
2004 resulted in 17 confirmed cases and 12 deaths, while 8.4  
million people were infected and 191 died in the 2009 influenza A 
(H1N1) pandemic (Ministry o f  Public Health [MOPH], 2009). 
Together, these highlight the need for the developm ent o f an 
influenza prevention and control program in Thailand. The pro­
gram has so far made free vaccination available to all health care
Yupares Payaprom and Erica A labaster, C a rd iff  S choo l o f  N ursing  and 
M idwifery Studies, C ard iff U niversity . C ard iff, U n ited  K ingdom ; Paul 
Bennett, D epartm ent o f  P sychology, S w an sea  U n iv ers ity , S w ansea, U nited 
Kingdom; H utsaya Tantipong, D epartm en t o f  M ed ic in e , C h iang  Rai H os­
pital, Chiang Rai, Thailand.
W e thank all the study partic ipants fo r th e ir  co o p e ra tio n  in  fo llow ing  all 
requirements o f  the study. This research  p ro jec t w as partia lly  supported  by 
funds to Yupares Payaprom  from  the T hai governm en t.
Correspondence concerning th is  a rtic le  shou ld  b e  ad d ressed  to  Y upares 
Payaprom, N ursing, H ealth, and  S ocia l C are  R esea rch  C entre, C ard iff 
University, Eastgate H ouse, 4 th  floor, 35 -43  N ew p o rt R oad , C ard iff, C F  24 
0AB, U nited K ingdom . E-m ail: P ay ap ro m Y l@ C ard iff .a c .u k
workers involved in direct patient care and those who have at least 
one chronic disease (Ministry o f  Public Health, 2008). Unfortu­
nately, the vaccination rate during the program’s first year was rela­
tively low (37.7% in Chiang Rai Province, P. Sriwongpan, personal 
communication, March 6, 2009): insufficient to provide population 
protection against the vims.
Factors that influence decisions in relation to vaccination are 
complex. They include knowledge and beliefs about influenza and 
the flu vaccine, perceived risk for influenza, health status, concerns 
about the efficacy and side effects o f  vaccine, health care provid­
ers’ recommendations, social influences such as family and 
friends, and the availability o f  the vaccine (e.g.. Bums, Ring, & 
Carroll, 2005; Evan, Prout, Prior, Tapper-Jones, and Butler, 2007). 
These factors provide a number o f targets for any public health 
program designed to increase uptake o f  influenza vaccine. Theo­
retical models also help determine the content o f any program, and 
can be utilized to explain how it promotes any behavioral change 
(Fishbein & Yzer, 2003). The Health Action Process Approach 
(HAPA; Schwarzer, 2001) provides one such explanatory model, 
and has been shown to have good predictive utility in relation to a 
number o f  health-related intentions and behaviors including diet 
(Schwarzer & Renner, 2000), alcohol consumption (Murgraff, 
McDermott, & Walsh, 2003), breast self-examination (Luszczyn- 
ska & Schwarzer, 2003), physical exercise (Schwarzer, Luszczyn-
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ska, Z ie g e lm a n n , S c h o lz ,  an d  L ip p k e , 2 0 0 8 ) ,  a n d  fo o d  h y g ie n e  
(C h o w  &  M u lla n , 2 0 1 0 ) .
A cco rd in g  to  th e  H A P A , c h a n g in g  h e a lth  b e h a v io r s  in v o lv e s  
tw o  in teractin g  p h a se s . T h e  motivation phase  i s  in f lu e n c e d  b y  r isk  
p ercep tion , o u tc o m e  e x p e c ta n c ie s ,  a n d  p e r c e iv e d  s e l f - e f f i c a c y .  
T ogeth er , th ese  v a r ia b le s  in f lu e n c e  in t e n t io n s  t o  p e r fo r m  s p e c i f ic  
b eh av iors  ( e .g .,  L u s z c z y n s k a  &  S c h w a r z e r ,  2 0 0 3 ;  S c h w a r z e r ,  
2 0 0 1 ) . A fter  a g o a l in te n tio n  h a s  b e e n  e s t a b l is h e d , th e  in d iv id u a l  
en ters the volition phase. In th is , a c t io n  p la n n in g  (S c h w a r z e r ,  
2 0 0 1 )  or th e a n a lo g o u s  p r o c e s s  o f  d e v e lo p in g  im p le m e n ta t io n  
in ten tion s (G o llw itzer , 1 9 9 9 )  p la y  a n  im p o r ta n t  r o le  in  b r id g in g  th e  
in ten tio n -b eh a v io r  ga p . In te n t io n s  are  m o s t  l ik e ly  to  b e  a c te d  o n  i f  
th e  in d iv id u al d e v e lo p s  an a c t io n  p la n /im p le m e n ta t io n  in te n tio n  
(G o llw itzer , 1999; P e s tw ic h , A y r e s ,  &  L a w to n , 2 0 0 8 ;  S n ie h o tta ,  
S o a res , &  D o m b r o w sk i, 2 0 0 7 ) .  S u m m a r iz in g  th e  a v a ila b le  d a ta , a 
m eta -a n a ly sis  o f  9 4  s tu d ie s  c o n d u c t e d  b y  G o l lw it z e r  a n d  S h e e r a n  
(2 0 0 6 )  in d icated  that a c t io n  p la n s / im p le m e n ta t io n  in te n t io n s  h ad  
an ov era ll e f fe c t  s iz e  o f  .6 5  o n  g o a l  a t ta in m e n t .
T h e  p resent stud y  in v e s t ig a te d  w h e th e r  a  l e a f le t  a d d r e s s in g  
variab les id en tified  a s r e le v a n t b y  th e  H A P A  a n d  in c o r p o r a t in g  
action  p lan n in g  w o u ld  re su lt  in  h ig h e r  in te n t io n s  to  s e e k  in f lu e n z a  
v a cc in a tion  and  v a cc in a tio n  ra te s  th a n  a  s ta n d a rd  g o v e r n m e n t  
le a fle t  am o n g  h ig h -r isk  T h a i in d iv id u a ls .  T h e  s tu d y  a ls o  in v e s t i ­
g a ted  th e  exp lan a tory  p o w e r  o f  th e  H A P A  in  r e la t io n  to  in f lu e n z a  
v a cc in a tio n . It w a s h y p o th e s iz e d  that: ( i )  im p le m e n ta t io n  o f  a  
th eory -b ased  le a f le t  and  a c t io n  p la n n in g  in te r v e n t io n  w o u ld  le a d  to  
greater ch a n g es  in  k ey  m e d ia to r  v a r ia b le s  ( k n o w le d g e ,  r isk  p er­
c e p tio n , s e lf -e f f ic a c y , o u tc o m e  e x p e c ta n c ie s ,  in te n t io n  to  s e e k  
vacc in a tio n ) and h ig h er  ra tes  o f  in f lu e n z a  v a c c in a t io n  th an  a 
com p arison  in terven tion ; ( i i )  c h a n g e s  in  r isk  p e r c e p t io n s ,  o u tc o m e  
e x p ec ta n c ie s , s e lf - e f f ic a c y , an d  e s ta b l is h in g  an  a c t io n  p la n  w o u ld  
b e  a sso c ia ted  w ith  c h a n g e s  in  in te n t io n s  to  v a c c in a te  o v e r  tim e ;  
and, ( ii i)  e s ta b lish in g  an a c tio n  p la n , s e l f - e f f i c a c y ,  a n d  in te n t io n s  
w o u ld  p red ict v a cc in a tio n  u p ta k e .
Method 
Study Setting
T h e stu d y  w a s  c o n d u c te d  in  th e  M u a n g  d is tr ic t ,  an  u rb an  c o m ­
m u nity  in C h ia n g  R ai p r o v in c e , th e  n o r th e r n m o s t  p r o v in c e  o f  
T h ailan d , w ith  an ad ult li te r a c y  ra te  o f  9 3 .8 %  ( N a t io n a l  S ta t is t ic a l  
O ffic e , 2 0 0 6 ) . T h e  C h ia n g  R a i p r o v in c e  r e se a r c h  e t h ic s  c o m m itt e e  
ap proved  the stu d y . T h e  s tu d y  w a s  c o n d u c t e d  in  t w o  g e o g r a p h i­
ca lly  separated c o m m u n it ie s  to  l im it  c o n ta m in a t io n  b e tw e e n  trial 
arm s. T h ese  tw o  areas w e r e  s im ila r  in  o v e r a ll  p o p u la t io n  s iz e ,  th e  
n um b er o f  p e o p le  w ith  c h r o n ic  d is e a s e s  r e q u ir in g  in f lu e n z a  v a c ­
c in a tion  w ith in  th em , an d  th e  b a s e l in e  in f lu e n z a  v a c c in a t io n  rate  
am on g  h igh -risk  p e o p le .
Design and Participants
A  con tro lled  b e fo re  an d  a fter  tria l w a s  c a r r ie d  o u t  c o m p a r in g  th e  
e f fe c t  o f  a H A P A -b a se d  le a f le t  w ith  a s ta n d a rd  g o v e r n m e n t  in fo r ­
m ation  le a f le t  on  in f lu e n z a  v a c c in a t io n  u p ta k e  a m o n g  h ig h -r is k  
urban d w e llin g  T h ai a d u lts. P a r tic ip a n ts  w e r e  r a n d o m ly  s e le c te d  
from  p o o ls  o f  e l ig ib le  p a r tic ip a n ts  in  t w o  g e o g r a p h ic a l ly  sep a ra te  
co m m u n itie s  w ith in  th e  M u a n g  d is tr ic t . P a r t ic ip a n ts  in  o n e  area  
rece iv ed  a H A P A -b a se d  le a f le t ;  t h o s e  in  th e  o th e r  r e c e iv e d  a
stan d ard  g o v e r n m e n t  le a f le t .  T h e  s tu d y  h ad  tw o  se ts  o f  o u tco m e  
m e a su res: ( i )  p r o c e ss  m e a s u r e s  o f  H A P A  re la ted  v ariab les  taken at 
T im e  1 (T 1 ) an d  2  w e e k s  a fter  th e  in ter v en tio n  (T im e  2: T 2 ); and  
( i i )  v a c c in a t io n  ra tes  d u r in g  th e  s u b se q u e n t 2  m o n th s. T h e  stud y  
w a s  p o w e r e d  to  d e te c t  b e tw e e n  g ro u p  d if fe r e n c e s  in  v a cc in a tio n  
ra tes  o f  2 2 %  (b e tw e e n  th e  p r e v io u s  y e a r ’s v a c c in a tio n  rate o f  38%  
a n d  a p red ic te d  rate o f  6 0 % ). T h is  req u ired  a sa m p le  s iz e  o f  177 
p a r tic ip a n ts  w ith  a  p o w e r  o f  0 .8 0  at a  s ig n if ic a n c e  le v e l o f  0 .0 5  
( F le is s ,  L e v in , &  P a ik , 2 0 0 3 ) .  T h e  s tu d y  w a s  c o n f in e d  to  p e o p le  
a g e d  4 5 - 6 5  y e a r s  w ith  o n e  o r  m o re  ch r o n ic  d is e a s e s  ( in c lu d in g  
h eart d is e a s e , d ia b e te s , an d  a s th m a ) in d ic a tin g  th e  n eed  fo r  a flu  
v a c c in a t io n . E x c lu s io n  cr iter ia  w ere : ( 1 )  h a v in g  a k n o w n  or s u s ­
p e c te d  e g g  p ro te in  a lle r g y ;  ( 2 )  h y p e r s e n s it iv ity  to  an y  co m p o n e n t  
o f  th e  v a c c in e ;  (3 )  s e v e r e  c h r o n ic  c o n d it io n s  ( i .e . ,  b ed  b o u n d  or  
a c u te ly  il l) ;  (4 )  d e m e n t ia  o r  s u s p e c te d  d e m e n t ia , or  (5 )  an  in a b ility  
to  read  an d  w r ite .
P o te n tia l p a r tic ip a n ts  in  e a c h  area  w ere  id e n tif ie d  from  the  
N a tio n a l H e a lth  S e c u r ity  O f f ic e  lis t . O f  th e  5 9 4  p o ten tia l p artic i­
p a n ts , 4 0 1  m e t a ll th e  e l ig ib i l i t y  cr iter ia . O f  th ese , 2 0 5  w ere  
r a n d o m ly  s e le c te d  to  p a r tic ip a te  in  th e  s tu d y  u s in g  a lo ttery  m eth od  
w ith o u t  r e p la c e m e n t. F o u r  p a r tic ip a n ts  w ith d r e w  b e fo re  c o m p le t­
in g  th e  b a s e lin e  q u e s t io n n a ir e . A c c o r d in g ly , 20 1  p artic ip ants w ere  
in c lu d e d  in  th e  s tu d y  (9 9  in  th e  in ter v en tio n  g rou p  and 10 2  in  the  
c o m p a r iso n  gro u p ; s e e  F ig u r e  1). T h e  s tu d y  p o p u la tio n  h ad  a m ean  
a g e  o f  5 6 .2 4  [S D  =  5 .8 6 ]  y e a r s , w ith  a  ran ge  o f  4 5 - 6 5  y ears. T h e  
m a jo r ity  o f  p a r tic ip a n ts  ( 6 6 .6 7 % ) w e r e  fe m a le , m o s t  (9 4 .1 2 % ) had  
c o m p le te d  p r im ary  s c h o o l  ( 6  y e a r s  o f  s c h o o lin g ) ,  an d  8 8 .2 4 %  w ere  
m arried . P a r tic ip a n ts  in  e a c h  g ro u p  d id  n o t d if fe r  w ith  regard  to  
a g e  (t =  1 .7 , d f  =  199; p  =  .0 9 ) , g e n d e r  ( x 2 =  1 .76; p  -  .1 8 ) , 
m arita l s ta tu s  ( x 2 =  7 .0 5 ;  p  =  .0 7 ) ,  e d u c a tio n a l le v e l ( x 2 =  4 .9 6 ;  
p  =  .1 7 ) ,  o c c u p a t io n  ( x 2 =  2 .2 4 ;  p  =  .5 3 ) , an d  prior flu  im m u ­
n iz a t io n  ( x 2 =  3 .1 4 ;  p  =  .0 8 ) .  O n ly  th ree  p e o p le , a ll o f  w h o m  w e r e  
in  th e  H A P A  c o n d it io n , h a d  r e c e iv e d  o n e  f lu  v a cc in a tio n  prior to  
th e  in te r v e n tio n .
Intervention
P a r tic ip a n ts  in  th e  H A P A  c o n d it io n  r e c e iv e d  a le a f le t  ad d ressin g  
fa c to r s  k n o w n  to  in f lu e n c e  b e h a v io r : r isk  p ercep tio n , o u tc o m e  
e x p e c t a n c i e s ,  s e l f - e f f i c a c y ,  in t e n t io n s ,  a n d  a c t io n  p la n n in g  
(S c h w a r z e r , 2 0 0 1 ) .  T h e  b e h a v io r  c h a n g e  tech n iq u es  u se d  in  th e  
le a f le t  in c lu d e d  p r o v id in g  in fo r m a tio n  a b o u t th e  b eh a v io r-h ea lth  
lin k  (A b r a h a m  &  M ic h ie ,  2 0 0 8 ) .  T h is  in v o lv e d  h ig h lig h tin g  h ig h  
r isk  in d iv id u a ls ’ s u s c e p t ib i lity  to  in f lu e n z a  an d  its  c o m p lic a t io n s  
( e .g . ,  “ Y o u  are a t h ig h  r isk  fo r  s e v e r e  c o m p lic a t io n s  su ch  as  
p n e u m o n ia , an d  b lo o d  in fe c t io n s . T h is  m a y  p ut y o u  in  th e  h o sp ita l,  
s o  w h y  risk  it? ” ). T h e  m e s s a g e s  fo c u s e d  o n  in cr ea s in g  p ercep tio n s  
o f  p erso n a l r isk  rath er th an  a r o u s in g  fea r  o f  d is e a s e  ( s e e  R uiter, 
A b r a h a m , &  K o k , 2 0 0 1 ) .
A  s e c o n d  b e h a v io r  c h a n g e  te c h n iq u e  in v o lv e d  p ro v id in g  in fo r ­
m a tio n  o n  th e  b e n e f it s  o f  v a c c in a t io n . T h is  in v o lv e d  p h rases  in ­
c lu d in g  ‘T a k in g  th e  f lu  s h o t  w il l  h e lp  y o u  a  lo t  th rou gh  th e  flu  
se a s o n :  D o n ’t g e t  th e  f lu ! ,” “D o n ’t h a v e  se r io u s  c o m p lic a t io n s ,” 
an d  “ R e d u c e  th e  r isk  o f  g o in g  in to  h o sp ita l .” T h e  le a f le t  a lso  
s o u g h t  to  in c r e a s e  p a r tic ip a n ts ’ e f f ic a c y  in  re la tio n  to  th eir  ab ility  
to  c o p e  w ith  th e  v a c c in a t io n  b y  in c lu d in g  th e  p erso n a l a cc o u n ts  o f  
p e o p le  w h o  h ad  r e c e iv e d  th e  in f lu e n z a  v a c c in a tio n  (e .g . ,  “I h a v e  
a s th m a , I n e e d  to  p ro tec t  m y s e lf .  A t  f ir st , I h ad  n o t a g reed  to  g e t  
th e  f lu  sh o t  b e c a u s e  I w a s  a fra id  o f  a lle r g ie s  an d  b rea th in g  d if f i ­
333
INCREASING FLU VACCINATION UPTAKE 3
100 randomly selected105 randomly selected
Eligible individuals n=190Eligible individuals n=211
Randomised allocation
Lost to follow-up (n=0) 
(Assessm ent of vaccination rate)
Lost to follow-up (n=0) 
(A ssessm ent of vaccination rate)
Lost to follow-up (n=0) 
(completed T2 questionnaire, n=i
Lost to follow-up (n=0) 
(completed T2 questionnaire, n=102)
Control group: 1 community 
(A ssessed  for eligibility; n=320)
Analysed Time 2 (n=99) 
Analysed Time 3 (n=99)
Intervention group: 1 community 
(A ssessed for eligibility; n=274)
Analysed Time 2 (n=102) 
Analysed Time 3 (n=102)
Excluded (n*84)
• Not meeting inclusion 
criteria (n= 80)
- Could not be contacted (n=2)
- Refused to participate (n=2)
Excluded (n»109)
- Not meeting inclusion 
criteria (n*101)
- Could not b e  contacted (n=5)
- Refused to participate (n=3)
Baseline assessm ent 
A ssessed  for eligibility (n=594) 
Two urban communities
Intervention group (n=100)
- Received allocated intervention 
(n=99)
- Did not receive allocated intervention 
(n=1)
Give reasons: time constraints 
(completed T1 questionnaire, n=99)
Control group (n=105)
- Received allocated intervention 
(n=102)
- Did not receive allocated intervention 
(n=3)
Give reasons: time constraints 
(completed Ttquestionnaire, n=102)
Figure 1. Flow diagram of participants’ progress through the trial.
cu lty , but I w a s  f in e  a fter  th e  in j e c t io n .” ). T h e s e  a c c o u n ts  a ls o  
so u g h t to  in crea se  n o rm a tiv e  b e l ie f s  f a v o r in g  v a c c in a t io n . F o l lo w ­
in g  standard “if- th en ” p r o to c o ls  (G o l lw it z e r ,  1 9 9 9 ) ,  th e  le a f le t  a ls o  
ask ed  p artic ip ants to d e v e lo p  a  s p e c i f i c  p la n  d e ta i l in g  w h e r e ,  w h e n  
and h o w  th ey  w o u ld  o b ta in  th e  v a c c in a t io n  (p r o m p t  s p e c i f i c  g o a l  
se ttin g ). A d d it io n a lly , th ey  w e r e  a s k e d  to  c o n s id e r  h o w  th e y  w o u ld  
g e t  to the c lin ic  to  ob ta in  th e  f lu  v a c c in e  (p r o m p t  b a rr ier  id e n t if i ­
ca tio n ). T h e  fo llo w in g  in s tr u c tio n s  w e r e  in c lu d e d  in  th e  le a f le t  fo r  
the in terven tion  grou p .
“G ettin g  a f lu  v a cc in a tio n :  P la n  a h e a d !  Y o u  are  m o r e  l ik e ly  to  
g o  for h a v in g  th e  flu  sh o t , i f  y o u  d e c id e  n o w  a b o u t  w h e r e , w h e n ,
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an d  h o w  y o u  w i l l  g o .  P le a s e  w r ite  in  b e lo w  w h e n , w h e re , and  h o w  
y o u  p lan  to  g e t  a  f lu  v a c c in e ."
“I f  I g e t  an  a p p o in tm e n t le tte r  to  h a v e  th e  f lu  v a c c in e , th en  I
w i l l ........................................................... (p le a s e  w r ite  d o w n  w h a t y o u  p lan  to
d o , e .g .,  g o  fo r  tak in g th e  flu  sh o t) a t ....................................................................
(p le a s e  w rite  d o w n  w h ere , e .g .,  C h ia n g  R ai H osp ita l, P rivate c lin ic ),
an d  I ’m  g o in g  to  g e t  th ere b y ...................................................................... (p lease
w rite  d o w n  h o w  y o u  g o  to  that p la ce , e .g .  w a lk in g , tak in g a b u s or  
a sk in g  son /d au gh ter/re la tives  to  tak e y o u  to  g e t  the flu  va cc in e).”
P a r tic ip a n ts  in  th e  c o m p a r iso n  g r o u p  r e c e iv e d  th e  standard  
g o v e r n m e n t  in fo rm a tio n  le a f le t . T h is  w a s  u se d  in  th e  p rev io u s
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year’s (2 0 0 9 )  v a c c in a t io n  p r o g r a m , a n d  p r o v id e d  in fo r m a tio n  
about the sy m p to m s o f  in f lu e n z a , b r ie f  d e ta ils  a b o u t  th e  f lu  v a c ­
c in e , p o ss ib le  s id e  e f fe c t s  f o l lo w in g  v a c c in a t io n , an d  th e  g e n e r a l  
b en efits  o f  in flu e n z a  v a c c in a t io n , in c lu d in g  “f lu  s h o ts  h e lp  p r e v e n t  
the flu  and its  ser io u s  c o m p lic a t io n s .” N o  d e ta i ls  a b o u t  th e  c o m ­
p lica tio n s o f  the flu  and  o th e r  b e n e f it s  o f  in f lu e n z a  v a c c in a t io n  
w ere ad dressed . A c c o r d in g ly , th e  k e y  te c h n iq u e s  in  th is  le a f le t  
w ere to  p rov id e  in fo rm a tio n  a b o u t th e  b e h a v io r -h e a lth  lin k  an d  th e  
co n seq u e n c es  o f  v a cc in a tio n  (A b r a h a m  &  M ic h ie ,  2 0 0 8 ) .  A n  a p ­
p o in tm en t letter d e ta ilin g  a  d a te  an d  t im e  o f  v a c c in a t io n  w a s  a ls o  
sen t to a ll h igh -r isk  in d iv id u a ls .
Questionnaires
T h e  q u estion n a ires  a s se ss e d  c h a n g e s  o n  k e y  H A P A  v a r ia b le s . In  
ad d ition , a s  in form ation  ab o u t in f lu e n z a  a n d  th e  in f lu e n z a  v a c c in e  
form ed  an im portant e le m e n t  o f  th e  le a f le t ,  q u e s t io n s  re la ted  to  
in flu en za  sy m p to m s and v a c c in e  s id e  e f f e c t s  w e r e  a ls o  in c lu d e d .  
W ith  the ex c ep tio n  o f  th ree q u e s t io n s  a d d r e s s in g  p la n n in g , a s k e d  
o n ly  at T 2 , the sam e q u e st io n n a ir e  w a s  g iv e n  to  p a r tic ip a n ts  at T 1  
and T 2 . A  draft q u e stio n n a ire  w a s  p i lo t  te s te d  b y  2 0  T h a i a d u lts .
Knowledge
K n o w led g e  o f  in flu en za  s y m p to m s  an d  v a c c in e  s id e  e f f e c t s  
w ere  a s se sse d  b y p resen tin g  p a r tic ip a n ts  w it h  a l i s t  o f  13  s y m p ­
to m s (e .g .,  fev er , w atery  e y e s )  a n d  e ig h t  p o te n t ia l v a c c in e  s id e  
e f fe c ts  (e .g .,  pain  at th e  v a c c in a t io n  s p o t , v o m it in g ) .  T h e r e  w e r e  
e ig h t  correct in flu en za  sy m p to m s  a n d  fo u r  c o r r e c t  v a c c in e  s id e  
e f fe c ts . P articipants w ere  a sk e d  to  t ic k  y e s ,  n o ,  o r  n o t  su r e , to  
the sy m p to m  and v a cc in e  s id e  e f f e c t s  c h e c k l is t .
Risk Perception
For the m easu re o f  risk  p e r c e p tio n , p a r t ic ip a n ts  w e r e  a s k e d  to  
in d icate  their le v e l o f  a g re em en t o r  d is a g r e e m e n t  w ith  15 s ta te ­
m en ts  referring to  ( i)  th e r isk  o f  d e v e lo p in g  in f lu e n z a  a n d  ( i i )  th e  
c o n seq u e n c es  o f  in flu en za  to  th e ir  l i v e s  ( e .g . ,  “ I f  s o m e o n e  in  m y  
fa m ily  d ev e lo p s  f lu , e v e r y o n e  e l s e  w i l l ,”  a n d  “ F lu  c a n  m a k e  m y  
e x is t in g  il ln e ss  w o r se ” ). I tem s w e r e  m e a s u r e d  u s in g  a 5 -p o in t  
L ikert sca le  from  1 (strongly disagree) to  5  (strongly agree). T o ta l  
risk  percep tion  sco res , ra n g in g  fr o m  15 to  7 5 ,  w e r e  c a lc u la te d  b y  
su m m in g  the item  sco res . In a d d it io n , s e p a r a te  r isk  (C r o n b a c h ’s a  
T1 =  0 .7 9 ; T 2  =  0 .6 8 )  an d  c o n s e q u e n c e  s u b s c a le s  (C r o n b a c h ’s a  
T1 =  0 .7 5 ;  T 2  =  0 .7 0 )  w ere  d e r iv e d .
Outcome Expectancies
O u tco m e ex p ec ta tio n s  a fter  r e c e iv in g  th e  v a c c in e  w e r e  a s s e s s e d  
w ith  sev en  item s, in c lu d in g  “ I f  I g e t  th e  f lu  s h o t  it  c a n  p r e v e n t  m e  
from  gettin g  a m ore s e v e r e  c a s e  o f  th e  f lu ,” a n d  “ I f  I g e t  th e  f lu  
sh o t it w ill h elp  m e stay  h e a lth y  d u r in g  th e  f lu  s e a s o n .” A l l  it e m s  
w ere rated on  a 4 -p o in t L ik er t s c a le  fr o m  1 (not at a ll true) to  4  
(exactly true). Item  s co res  w e r e  s u m m e d  to  p r o v id e  a  to ta l o u t ­
c o m e  ex p ec ta n cy  sco re , ra n g in g  fr o m  7  to  2 8  (C r o n b a c h 's  a lp h a  
T1 =  .72; T 2  =  0 .8 1 ) .
Self-Efficacy
S e lf -e ff ic a c y  w a s m ea su red  b y  a s k in g  p a r t ic ip a n ts  to  rate  th e ir  
le v e l o f  co n fid e n c e  in  th eir  a b ili ty  to  o b ta in  a n d  c o p e  w ith  th e
in f lu e n z a  v a c c in e  in  th e  n e x t  v a c c in a t io n  p er io d . T h e  s c a le  c o m ­
p r is e d  s e v e n  it e m s , in c lu d in g  “ I a m  c o n f id e n t  that I ca n  c o p e  w ith  
s id e  e f f e c t s  a fter  r e c e iv in g  th e  f lu  v a c c in e ,” and  “ I am  c o n fid e n t  
th a t I c a n  f in d  th e  t im e  to  g e t  v a c c in a te d  a g a in st th e  f lu .” R e ­
s p o n s e s  w e r e  re p o r te d  o n  a  4 -p o in t  L ik er t s c a le  fro m  1 (not at all 
true) to  4  (exactly true). T w o  s e l f - e f f i c a c y  s u b s c a le s  w ere  d erived :  
s e l f - e f f i c a c y  in  c o p in g  w ith  v a c c in e  s id e  e f f e c t s  (C ro n b a ch ’s a  
T 1 =  0 .7 2 ;  T 2  =  0 .8 1 )  a n d  s e l f - e f f ic a c y  fo r  arran gin g  t im e  and  
tra n sp o r ta tio n  (C r o n b a c h ’s  a lp h a  T 1  =  0 .8 4 ;  T 2  =  0 .9 1 ) .
Intention
P a r tic ip a n ts  in d ic a te d  th e ir  l e v e l  o f  in te n tio n  to  o b ta in  in flu en za  
v a c c in a t io n  w ith  tw o  s ta te m e n ts :  “ I in te n d  to  r e c e iv e  a f lu  sh o t  in  
th e  fo r th c o m in g  v a c c in a t io n  p e r io d ,” an d  “I w a n t to  g e t  v a cc in a ted  
a g a in s t  th e  f lu  in  th e  n e x t  v a c c in a t io n  p e r io d .” A n s w e r s  w e r e  g iv e n  
o n  a 5 -p o in t  s c a le  fro m  1 (definitely do not) to  5  (definitely do). 
T h e s e  ite m s  w e r e  a d d e d  to  fo r m  a s u m  s c o r e  o f  in ten tio n , w ith  tota l 
s c o r e s  ra n g in g  fr o m  2  to  10  (P e a r s o n ’ s r T1 =  0 .6 1 ;  T 2  =  0 .6 7 ) .
Action Planning (T2 Only)
A c t io n  p la n n in g  w a s  m e a s u r e d  b y  r e sp o n se s  to  th ree q u estio n s:  
“I h a v e  m a d e  a p la n  w h e n  I ’m  g o in g  to  v a c c in a te  d u r in g  th e  n ex t  
v a c c in a t io n  p e r io d ,” “ I h a v e  m a d e  a  p la n  w h e r e  I ’m  g o in g  to  h a v e  
th e  f lu  s h o t  in  th e  n e x t  v a c c in a t io n  p e r io d ,” an d  “ I h a v e  m a d e  a 
p la n  h o w  I ’m  g o in g  to  g e t  v a c c in a te d  a g a in s t  th e  f lu .” T h e  re­
s p o n s e  a lte r n a tiv e s  w e r e  “ Y e s ” a n d  “N o .” P ar tic ip an ts  in  th e  
H A P A  in te r v e n tio n  w e r e  a ls o  re q u ir ed  to  b r in g  th e  le a f le t  to  th e  
re se a r c h e r  a t th e  T 2  d a ta  c o l le c t io n  in  o rd er  to  v e r ify  w h e th e r  th ey  
h a d  m a d e  an  a c t io n  p la n . P a r tic ip a n ts  w e r e  s c o r e d  a s  e ith e r  c o m ­
p le t in g  th e  p la n n in g  p r o c e s s  (a ll  th ree  i s s u e s  w e r e  a d d r esse d ) or  
n o t c o m p le t in g  th e  p r o c e s s  ( tw o  o r  le s s  is s u e s  w e r e  a d d ressed ).
Procedure
P o te n tia l p a r tic ip a n ts  in  b o th  th e  in te r v e n tio n  and  co m p a r iso n  
area s  w e r e  a p p r o a c h e d  b y  v i l la g e  h ea lth  v o lu n te e r s  w h o  g a v e  th em  
an  in v ita t io n  le tte r  to g e th e r  w ith  a  re p ly  s l ip ,  in d ica tin g  th eir  
w il l in g n e s s  to  c o n s id e r  p a r tic ip a tin g  in  th e  stu d y . T h o se  w h o  
a g re ed  to  c o n s id e r  p a r tic ip a tio n  w e r e  th en  v is ite d  b y  a research  
a ss is ta n t , e ith e r  in  th e ir  h o m e  o r  at a  h ea lth  ce n ter . A t th is  m ee tin g , 
p a rtic ip a n ts  w e r e  g iv e n  m o r e  in fo r m a tio n  ab o u t th e  s tu d y  and  
s ig n e d  a c o n s e n t  fo r m  b e fo r e  c o m p le t in g  th e  b a se lin e  q u e st io n ­
n a ire . I f  p a r tic ip a n ts  h a d  lim ite d  li te r a c y , th e  re search er read the  
s ta te m e n ts  o r  q u e s t io n s  o u t  lo u d  an d  a s k e d  p artic ip an ts  to  sco re  
th e ir  o w n  r e sp o n se s .
A f te r  T 1  d ata  c o l le c t io n  w a s  c o m p le te d , le a f le t s  e n c lo se d  in a  
p la in  b ro w n  e n v e lo p e  w e r e  d is tr ib u te d  to  p a rtic ip a n ts  b y  th e  v i l­
la g e  h ea lth  v o lu n te e r s . T h e  H A P A  in te r v e n tio n  p artic ip an ts  re ­
c e iv e d  a H A P A -b a s e d  e d u c a t io n a l le a f le t .  T h e  co m p a r iso n  g rou p  
r e c e iv e d  a stan d ard  in f lu e n z a  le a f le t  d e v e lo p e d  b y  th e  M in istry  o f  
P u b lic  H e a lth . T w o  w e e k s  la ter , p a r tic ip a n ts  w e r e  a g a in  ap ­
p r o a c h e d  b y  re sea rch  a s s is ta n t , an d  a s k e d  to  c o m p le te  th e  T 2  
q u e st io n n a ir e s  an d  to  s h o w  th e ir  le a f le t s  v e r ify in g  th eir  u se  th e  
im p le m e n ta t io n  in te n tio n  in te r v e n tio n .
Data Analysis
A n a ly s e s  w e r e  p e r fo r m e d  o n  an  in te n tio n -to -tr e a t  b a s is . B a s e ­
lin e  c h a r a c te r is t ic s  o f  p a r tic ip a n ts  in  th e  in ter v en tio n  an d  co m p a r­
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ison  grou p s w ere  co m p a red  u s in g  c h i-s q u a r e  te s t  fo r  c a te g o r ic a l  
variab les and S tu d en t’s  t te s t  fo r  c o n t in u o u s  v a r ia b le s . W ith in  
group  a n a ly ses  in v o lv e d  th e  M c N e m a r ’s te s t , c o m p a r in g  th e  p ro ­
p ortion s o f  correct r e sp o n se s  o n  k n o w le d g e  o f  in f lu e n z a  s y m p to m s  
and v a cc in e  s id e  e f f e c t s  at b a s e l in e  a n d  a fter  th e  in te r v e n tio n . A  
series  o f  o n e -w a y  a n a ly s e s  o f  c o v a r ia n c e  ( A N C O V A s ;  w ith  b a s e ­
lin e  sco res  as c o v a r ia te s )  w a s  c o n d u c te d  o n  T 2  d a ta  t o  id e n t ify  a n y  
s ig n ifica n t b e tw een  g ro u p  d if fe r e n c e s  o n  th e  o u t c o m e  m e a s u r e s  at 
th is tim e . R e la tio n sh ip s  b e tw e e n  th e  h y p o th e s iz e d  p r e d ic to r  an d  
o u tco m e  m easu res w ere  fir st  a n a ly z e d  b y  P e a r s o n ’s p ro d u c t  m o ­
m en t co rrela tion s. A  lin e a r  r e g r e s s io n  w a s  th e n  u s e d  to  p red ic t  
p artic ip an ts’ in ten tio n s, an d  a lo g is t ic  r e g r e s s io n  w a s  c o n d u c te d  to  
ex a m in e  p red ictors o f  v a c c in a t io n  b e h a v io r . M e d ia t io n  e f f e c t s  
w ere  tested  u sin g  a b o o tstr a p p in g  p r o c e d u r e  fo r  m u lt ip le  m e d ia to r  
m o d e ls  d escrib ed  b y  P rea ch er  a n d  H a y e s  ( 2 0 0 8 )  an d  u s in g  th e  
m acros for both lin ear  an d  d ic h o t o m o u s  v a r ia b le s  a v a ila b le  fro m  
their w eb site  (h ttp : / /w w w .q u a n tp s y .o r g ). T h e  9 5 %  b ia s -c o r r e c te d  
c o n fid en ce  in terva ls o f  th e  e s t im a te s  o f  th e  in d ir e c t  e f f e c t s  ( fo r  
both lin ear  and d ic h o to m o u s  o u tc o m e  v a r ia b le s )  w e r e  d e r iv e d  w ith  
5 ,0 0 0  bootstrap  re sa m p le s , w ith  in d ir e c t  e f f e c t s  in ter p r e ted  a s  
s ta tistica lly  s ig n if ic a n t  i f  th e  9 5 %  c o n f id e n c e  in te r v a l d id  n o t  
over lap  zero .
Results 
Measuring the Impact of the Intervention
A d h eren ce  to the p lan n in g  e le m e n t  o f  th e  in te r v e n t io n  ( i .e . ,  fu ll  
co m p le tio n  o f  a ll three p la n n in g  e l e m e n t s )  w a s  h ig h  in  th e  in ter ­
ven tion  grou p  (9 5 /9 9 :  9 6 % ) an d  z e r o  in  th e  c o n tr o l c o n d it io n .
Knowledge of Influenza Symptoms and Vaccine Side 
Effects
M c N em a r tests  in d ica te d  s ig n if ic a n t  in c r e a s e s  in  to ta l s y m p to m  
k n o w le d g e  sco res  in b o th  H A P A  a n d  s ta n d a rd  le a f le t  g r o u p s  
b etw een  T1 and T 2  (H A P A  le a f le t:  fr o m  2 5 .2 5 %  to  5 6 .5 6 % , p  <  
.001 ; standard le a f le t  fro m  2 1 .5 6 %  to  3 7 .2 5 % , p  =  .0 0 2 ) .  C h i-
sq u a re  te s ts  fo u n d  n o  s ig n if ic a n t  d if fe r e n c e s  b e tw e e n  g ro u p s  at T l ,  
b u t s ig n if ic a n t ly  h ig h e r  k n o w le d g e  o f  in f lu e n z a  sy m p to m s  in  th e  
in te r v e n t io n  g r o u p  at T 2  ( 5 6 .5 6 %  v s . 3 7 .2 5 % , x 2 =  7 .5 3 ,  d f  =  1, 
P ~  0 0 6 ) .  C h i-sq u a r e  te s ts  r e v e a le d  n o  s ta t is t ica lly  s ig n if ic a n t  
d if f e r e n c e s  in  th e  d e s c r ip t io n  o f  v a c c in e  s id e  e f fe c t s  b e tw e e n  the  
tw o  g r o u p s  a t T l . T h e r e  w e r e  s ig n if ic a n t  in c r e a s e s  in  k n o w le d g e  o f  
v a c c in e  s id e  e f f e c t s  in  b o th  H A P A  le a f le t  an d  standard  le a f le t  
g r o u p s  b e tw e e n  T l  an d  T 2  (H A P A  le a f le t  grou p : fro m  5 2 .0 %  to  
8 6 .3 % , p  <  .0 0 1 ;  sta n d a rd  le a f le t  g r o u p  fr o m  5 1 .5 %  to  8 4 .4 % , p  <  
.0 0 1 ) .  A t  T im e  2 ,  n o  s ig n if ic a n t  d if fe r e n c e  in  tota l k n o w le d g e  o f  
v a c c in e  s id e  e f f e c t s  w a s  o b s e r v e d  b e tw e e n  th e  tw o  g ro u p s  (8 6 .3 %  
v s . 8 4 .8 % , x 2 =  .0 8 ;  p  =  .7 7 ) .  H o w e v e r ,  m o r e  p artic ip an ts  in  th e  
c o m p a r iso n  g r o u p  in c o r r e c t ly  id e n t if ie d  b rea th in g  d if f ic u lt ie s  or  
s w e l l in g  o f  th e  fa c e  a s  s id e  e f f e c t s  o f  v a c c in a t io n  than th o se  in  the  
in te r v e n tio n  g r o u p  at T 2  (1 7 %  v s . 4 % , x 2 =  9 .5 4 ;  p  =  .0 0 2 ) .
Changes in HAPA Variables Following the 
Intervention
T h e  m e a n  s c o r e s  o f  a ll v a r ia b le s  (r isk  p erc ep tio n , o u tc o m e  
e x p e c ta n c y , s e l f - e f f i c a c y ,  a n d  in te n t io n s )  in c r e a se d  s ig n if ic a n t ly  in  
b o th  g r o u p s  b e tw e e n  T l  an d  T 2 . H o w e v e r ,  p artic ip an ts  in th e  
in te r v e n tio n  g r o u p  s h o w e d  a  g re a te r  in c r e a s e  than  th e  co m p a r iso n  
g r o u p  o n  a ll v a r ia b le s . A N C O V A s  in d ic a te d  s ig n if ic a n t  d iffe r ­
e n c e s  b e tw e e n  th e  g r o u p s  at T 2  o n  m e a s u r e s  o f  p e r c e iv e d  r isk  o f  
d e v e lo p in g  in f lu e n z a  [ F ( l ,  1 9 8 )  =  2 6 .5 4 ,  p  <  .0 0 1 ,  t |*  =  .12 ];  
p e r c e iv e d  s e v e r ity  o f  in f lu e n z a  [ F ( l ,  1 9 8 )  =  8 .4 4 ,  p  -  .0 0 4 , -rip =  
.0 4 ] ;  p e rc e iv ed  b e n e fits  fro m  in flu e n z a  vacc in a tion  [F (I , 198) =  
1 4 .0 4 , p <  .0 0 1 , rip =  .0 7 ];  p e r c e iv e d  se lf -e f f ic a c y  in co p in g  w ith  
v a c c in e  s id e  e f fe c ts  [ F ( l ,  19 8 ) =  1 1 .8 0 , p  -  .0 0 1 , -rip =  .05]; 
p erc e iv ed  s e lf -e f f ic a c y  in  arranging  tim e  and transportation to  get  
v a cc in a ted  sco res  [ F ( l ,  1 9 8 )  =  2 7 .0 ,  p  <  .0 0 1 , =  .12]; and
in ten tion  s c o r e s  [ F ( l ,  1 9 8 ) =  33.56, p  <  .0 0 1 , =  .15; se e  T ab le  1].
Vaccination Behavior
E ig h ty -n in e  p a r tic ip a n ts  o f  9 9  in  th e  in ter v en tio n  g rou p  w ere  
v a c c in a te d  c o m p a r e d  w ith  8 6  o f  1 0 2  in  th e  c o m p a r iso n  grou p . T h is
T a b le  1
Mean (SD) for Subscales o f  Risk Perception, Outcome Expectancies, Self-Efficacy, and Intention to Obtain the Flu Vaccine at Two 
Time Points (n =  201)
Variables Total possible score Group Time 1 Mean (SD) Time 2 Mean (SD)
p-value of 
ANCOVA
Risk perception:
Risk of developing influenza 35 Comparison 24.51 (3.01) 27.93 (3.63) <.001
Intervention 24.09 (3.06) 30.12(3.33)
Severity of influenza 40 Comparison 28.51 (3.68) 32.98 (4.56) .004
Intervention 28.27 (3.41) 34.59 (4.14)
Outcome expectancies:
Perceived benefits from influenza vaccination 28 Comparison 21.25(3.71) 23.17(2.93) <.001
Intervention 21.13(3.81) 24.61 (2.97)
Self-efficacy:
Coping with vaccine side-effects 12 Comparison 9.78 (2.28) 10.84(1.50) .001
Intervention 9.41 (1.89) 11.36(1.18)
Arranging time and transportation 16 Comparison 13.43 (2.75) 14.42(1.96) <.001
Intervention 12.74 (2.58) 15.48(1.25)
Intention 10 Comparison 7.34(1.51) 8.38(1.36) <.001
Intervention 7.21 (1.52) 9.24(1.20)
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d iffer en ce  w a s n o t s ig n if ic a n t  ( 8 9 .9 0 %  v s . 8 4 .3 1 % , r e s p e c t iv e ly ;  
X2 =  1 .39 , df =  1 , p =  .2 3 ) .
Predicting Intentions to Obtain the Flu Vaccine
In order to  e v a lu a te  th e  a b ility  o f  th e  H A P A  m o d e l  to  p r e d ic t  th e  
en d -p o in t o f  the m o tiv a tio n a l p r o c e s s e s  ( in t e n t io n s ) ,  c h a n g e  s c o r e s  
b etw een  T l  and T 2  w e r e  c r e a te d  fo r  e a c h  th e o r e t ic a l p re d ic to r  
variable (r isk  p ercep tio n , o u tc o m e  e x p e c ta n c y , s e l f - e f f i c a c y ) ,  fo r  
all partic ipants. P earson  c o r r e la t io n s  w e r e  th en  u s e d  to  id e n t ify  th e  
a sso c ia tio n  b etw een  ch a n g e  in  e a c h  o f  th e  in d e p e n d e n t  v a r ia b le s  
(and a g e ) and ch a n g es  in  in te n t io n s . C h a n g e s  in  r isk  p e r c e p tio n s , 
o u tco m e  ex p e c ta n c ie s , an d  s e l f - e f f i c a c y  w e r e  s ig n if ic a n t ly  a s s o c i ­
a ted  w ith  ch a n g es  in  in ten tio n s  ( s e e  T a b le  2 ) .  T o  e x a m in e  w h e th e r  
p lan n in g  w a s  a sso c ia ted  w ith  c h a n g e s  in  th e s e  m e d ia to r  v a r ia b le s , 
a ser ies  o f  t tests  w a s  co n d u c te d  c o m p a r in g  c h a n g e  s c o r e s  o n  e a c h  
variab le accord in g  to w h e th e r  o r  n o t  p a r t ic ip a n ts  h a d  e n g a g e d  in  
plan n in g . T h ese  s h o w ed  p la n n in g  to  b e  a s s o c ia t e d  w ith  s ig n i f i ­
ca n tly  greater ch a n g es  o v e r  t im e  o n  a ll th e  v a r ia b le s  ( s e e  T a b le  2 ) .
A  lin ear  regression  a n a ly s is  w a s  th e n  c o n d u c te d  in c lu d in g  th e s e  
v ariab les. T ogeth er  th ey  e x p la in e d  4 6 %  o f  th e  v a r ia n c e  in  in te n ­
tion s (ad justed  R2 ~  .4 6 , F =  2 7 .8 2 3 ,  p  <  .0 0 1 ) .  H o w e v e r ,  o n ly  
p lan n in g  ( 3  =  0 .1 7 , p  =  .0 0 3 ) , o u t c o m e  e x p e c ta n c y  c h a n g e  ( 3  =  
0 .4 0 , p  <  .0 0 1 ) , and s e lf -e f f ic a c y  c h a n g e  in  r e la t io n  to  a r r a n g in g  
t im e  and transportation , p  =  0 .3 1 ,  p  <  .0 0 1 )  m a d e  s ig n if ic a n t  
con trib u tion s to  th e fin a l eq u a tio n  ( s e e  T a b le  3 ) .  P la n n in g  m a y  
h a v e  con tribu ted  to  ch a n g es  in  in te n t io n s  b o th  d ir e c t ly  a n d  th ro u g h  
its  in flu en ce  on  o th er  var ia b les , a n d  in  p a r tic u la r  s e l f - e f f i c a c y  in  
arranging tim e and transport to  v a c c in a t io n . T o  te s t  th is  h y p o th e ­
s is , a  test o f  m ed ia tion  w a s  c o n d u c te d  u s in g  th e  b o o ts tr a p  p r o c e ­
dure, w ith  in ten tion s a s th e  d e p e n d e n t  v a r ia b le , p la n n in g  a s  th e  
in d ep en d en t variab le , and s e lf - e f f i c a c y  in  a r r a n g in g  t im e  an d  tra n s­
port to  vacc in a tio n  as th e  m e d ia t in g  v a r ia b le . A s  p r e d ic te d , th e  
d irect e ffe c t  o f  p lan n in g  on  in te n tio n s  r e m a in e d  s ig n if ic a n t  ((3 =  
0 .4 8 3 , SE =  .1 7 6 , t =  2 .7 5 , p  =  .0 0 6 ) .  H o w e v e r ,  a  s ig n if ic a n t
T a b le  3
Prediction o f Change in Intentions (n =  201)
Variable B SE Beta t P
Planning .52 .17 .17 2.96 .003
Change in:
Perceived severity of influenza - .0 0 .02 -.01 -.1 5 .878
Outcome expectancy .15 .02 .40 6.45 <.001
Self-efficacy in coping with vaccine 
side-effects .06 .06 .08 1.03 .304
Self-efficacy for arranging time and 
transportation .16 .04 .31 3.995 <.001
Note. Adj. R2 =  .46, F =  27.823, p  <  .001.
m e d ia t io n  e f f e c t  w a s  fo u n d  (p o in t  e s t im a te  =  .2 8 0 , 95%  b ia s  
c o r r e c te d  C l =  0 .1 2 6 - 0 . 5 1 0 ) .
Predicting Influenza Vaccination Behavior
A  s e c o n d  ( lo g i s t i c )  r e g r e s s io n , in v o lv in g  a ll H A P A  v a r ia b les  
m e a s u r e d  at T 2  (p e r c e iv e d  r isk , p e r c e iv e d  se v e r ity  o f  in f lu e n z a , 
o u tc o m e  e x p e c ta n c ie s ,  s e l f - e f f i c a c y  in  c o p in g  w ith  v a c c in e  s id e  
e f f e c t s ,  s e l f - e f f i c a c y  fo r  a rr a n g in g  t im e  an d  tran sp or ta tion , in ten ­
t io n , an d  a c t io n  p la n n in g )  e x p lo r e d  th e  a b ili ty  o f  th e  H A P A  to  
p r e d ic t  b e h a v io r a l o u tc o m e s .  R e s u lt s  s u m m a r iz e d  in  T a b le  4  
s h o w e d  th at o v e r a ll ,  th e  m o d e l  h ad  an  a d e q u a te  f it  to  th e  data; th e  
m o d e l y ie ld e d  a  N a g e lk e r k e  R2 o f  0 .5 2  an d  th e  H o sm e r  and  
L e m e s h o w  w a s  n o t  s ig n if ic a n t  ( x 2 =  1 5 .1 2 , d f  =  8 , p  =  .0 7 ) . T h e  
r e su lts  r e v e a le d  a  s tr o n g  a s s o c ia t io n  b e tw e e n  v a c c in a tio n  o u tc o m e  
a n d  in te n tio n  (o d d s  ra tio  =  3 .8 9 , /?  <  .0 0 1 )  an d  a sm a lle r , but still 
s ig n if ic a n t ,  a s s o c ia t io n  w ith  s e l f - e f f i c a c y  fo r  arran g in g  t im e  and  
tra n sp o r ta tio n  (o d d s  ra tio  =  1 .7 0 , p  =  .0 1 6 ) .  N o  in d ep en d en t  
a s s o c ia t io n  b e t w e e n  p la n n in g  an d  v a c c in a t io n  w a s  fo u n d . M e d ia ­
t io n  a n a ly s is  in d ic a te d  th at s e l f - e f f i c a c y  fo r  arran g in g  t im e  an d
T a b le  2
Pearson’s Correlation Matrix o f  Change Scores o f  Social-Cognitive Variables and Between Group T-Tests o f  Mean Differences
According to Use of Planning
Variables 1 2 3 4 5 6 7
Age 1.00 .03 .11 .04 .07 .10 .13
Changes in:
.23**Perceived risk of developing influenza .03 1.00 .49** .34*’ .16* .29**
Perceived severity of influenza .11 .49** 1.00 .35** .21** .27** .32**
Outcome expectancies - .0 4 .34** .35** 1.00 .43** .33** .54**
Self-efficacy in coping with vaccine side-effects .07 .23** .21** .43** 1.00 .66** .49**
Self-efficacy for arranging time and transportation .100 .16* .27** .33** .66** 1.00 .54**
Intention .13 .29** .32** .54** .49** .54** 1.00
Mean (SD) change T1-T2
No plan Plan t P
Perceived risk of developing influenza 1.06 (1.45) 2.05 0 .37 ) 4.98 <0.001
Perceived severity of influenza 4.48 (4-9) 6.37 (4.35) 2.88 <0.01
Outcome expectancies 2.03 (3.99) 3.41 (3.83) 2.48 0.014
Self-efficacy in coping with vaccine side-effects 1.10 (2.31) 2.24(1.76) 3.896 <0.001
Self-efficacy for arranging time and transportation 1.00 (2.96) 2.81 (2.45) 4.69 <0.001
Intention 1.06 (1.45) 2.05(1.37) 4.98 <0.001
* p  = .05 (two-tailed). ** p  = .01 (two-tailed).
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T ab le  4
Summary o f Logistic Regression Analysis Predicting Actual Vaccination Behavior at Time 2 (n =  201)
Predictor variable B SE Wald statistic p  value Odds ratio (95% Cl)
Perceived risk of influenza .13 .11 1.62 .203 1.14 (.93-1.39)
Perceived severity of influenza - .0 7 .10 .58 .445 .93 (.77-1.12)
Outcome expectancies - .0 8 .12 .51 A l l .92 (.72-1.16)
Self-efficacy in coping with vaccine side-effects .06 .32 .031 .860 1.06 (.57-1.95)
Self-efficacy for arranging time and transportation .53 .22 5.80 .016 1.70(1.10-2.62)
Intention 1.36 .35 14.96 <.001 3.89(1.96-7.76)
Planning - .9 4 .65 2.08 .149 .39 (.11-1.40)
transportation  to  r e c e iv e  th e  f lu  v a c c in a t io n  a c te d  a s  m e d ia to r  
b etw een  in ten tion s and v a c c in a tio n  (p o in t  e s t im a te  =  .3 5 ,  9 5 %  
b ia s  corrected  C l =  0 .0 7 7  to  0 .6 2 9 ) ,  a lth o u g h  th e  m e d ia t io n  e f f e c t  
w a s on ly  partial, w ith  in ten tio n  a ls o  s t i l l  h a v in g  a s tr o n g  d ir e c t  
e ffe c t  on  v a cc in a tion  b eh a v io r  ( 3  =  1 .3 1 , SE =  .3 4 3 ,  W a ld  =  
14 .5 3 , p  <  .0 0 1 ).
Discussion
T h is  ra n d o m ized -co n tro lled  s tu d y  h ad  t w o  o b je c t iv e s :  ( 1 )  to  
ex a m in e  w hether an in terven tion  b a se d  o n  th e  H A P A  m o d e l  w o u ld  
b e  m ore e f fe c t iv e  in  ch a n g in g  f lu  v a c c in a t io n  u p ta k e  an d  re la ted  
in ten tion s than a standard, a th eo retica l in te r v e n t io n  a m o n g  h ig h -  
risk  T h ai adults; and (2 )  to  test th e  u t il i ty  o f  th e  H A P A  in  
p red ic tin g  both  in ten tion  and su b seq u en t v a c c in a t io n  b e h a v io r . In  
re la tion  to  the first o b jec t iv e , the in ter v en tio n  s h o w e d  s ig n if ic a n t  
p ostin terven tion  d iffe r e n c e s  b e tw e e n  th e  in te r v e n t io n  g r o u p s  o n  
k ey  m ed iator v ariab les  su ch  as k n o w le d g e , r isk  p e r c e p t io n , s e lf -  
e ff ic a c y , o u tco m e  e x p e c ta n c ie s , and  in te n tio n  to  o b ta in  in f lu e n z a  
vacc in a tion . A cco r d in g ly , th e le a f le t  a c h ie v e d  its  f ir st  g o a l;  to  
in crease the strength  o f  in ten tio n s to  s e e k  f lu  v a c c in a t io n  r e la t iv e  
to  a standard in terven tion . U n fo r tu n a te ly , its  s e c o n d  g o a l ,  to  tran s­
la te  th ese  m o tiva tion a l d iffe r e n c e s  in to  b e h a v io r a l d if f e r e n c e s  w a s  
not ach iev ed . B e tw e e n -c o n d it io n s  v a c c in a t io n  ra tes  d id  n o t  d iffe r .
T h ese  fin d in g s  are co n s is ten t  w ith  p r e v io u s  s tu d ie s  th at h a v e  
dem on strated  the e f fe c t iv e n e s s  o f  ta rg eted  m e s s a g e s  in  c h a n g in g  
b e lie fs  related  to  sev er ity  o f  in f lu e n z a , v a c c in e  s a fe ty  a n d  its  
e ffe c t iv e n e s s , s e lf  e f f ic a c y , and r e sp o n se  e f f ic a c y  a m o n g  h ig h -r is k  
grou p s (L a V ela , C am eron , P r ieb e, &  W e a v e r , 2 0 0 8 ;  W r a y  e t  a l.,  
2 0 0 9 ) . T h e  fact that ch a n g es  in  k e y  H A P A  v a r ia b le s  o f  o u tc o m e  
e x p ec ta n c ie s  and s e lf -e f f ic a c y  w ere  in d e p e n d e n t ly  a s s o c ia t e d  w ith  
ch a n g es  in strength o f  in ten tio n s s u g g e s t s  th at th e s e  v a r ia b le s  are  
both  su scep tib le  to  ch a n g e  fo l lo w in g  r e la t iv e ly  b r ie f  an d  s im p le  
in terven tion s and h a v e  a cr itica l ro le  in  s h a p in g  in te n t io n s .
In contrast to  th e  fin d in g s  in  re la tion  to  in te n t io n s , th is  s tu d y  w a s  
u nab le to  sh o w  a s ig n ific a n t e f fe c t  o f  th e  H A P A  le a f le t  o n  in f lu ­
en za  v acc in a tion  b eh av ior . A  n u m b er o f  fa c to r s  m a y  h a v e  a tten u ­
ated  th e e ffe c ts  o f  ou r in terven tion  on  in f lu e n z a  v a c c in a t io n  rates. 
First, the v a cc in a tion  rates w ere  u n p r e c e d e n te d ly  h ig h  e v e n  in  th e  
standard in terven tion  co n d itio n , m a k in g  g a in s  in  v a c c in a t io n  rates  
particularly d iffic u lt  to  a ch ie v e . P r e v io u s  v a c c in a t io n  ra tes  w e r e  as  
lo w  as 38%  (P . S riw o n g p a n , p erso n a l c o m m u n ic a t io n , M a r ch  6 ,  
2 0 0 9 )  in the p rev io u s year  in  co m p a r iso n  to  th e  84 %  fo u n d  in  the  
standard co n d itio n  o f  the stu d y . C le a r ly , fa c to r s  o th e r  th an  the  
plan n ed  in terven tion s m ay  h a v e  a f fe c te d  th e s e  ra tes . T h e  m o st  
o b v io u s  co n fo u n d in g  factor  w a s  th at th e  v a c c in a t io n  p er io d  c o in ­
c id ed  w ith  a g lo b a l ou tbreak  o f  H 1 N 1  in flu e n z a . A lth o u g h  the
stan d ard  f lu  v a c c in a t io n  d id  n o t  im m u n iz e  a g a in s t  th is  d is e a s e  
( in fo r m a tio n  g iv e n  in  th e  le a f le t ) ,  th e  h ig h  le v e ls  o f  a w a r e n e ss  and  
c o n c e r n  re la ted  to  th is  o u tb r ea k  m a y  h a v e  le d  to  th e  s p o n ta n eo u s  
an d  r e la t iv e ly  u n p la n n e d  b e h a v io r s  ( in  th is  c a s e ,  v a c c in a t io n )  that 
ca n  b e  tr ig g e r e d  b y  h ig h -r is k  s itu a t io n s  ( G o l lw it z e r  &  B ran d statter, 
1 9 9 7 ) . E v id e n c e  in  su p p o r t  o f  th is  h y p o th e s is  c a n  b e  fo u n d  in  tw o  
re c e n t  s tu d ie s  c o n d u c te d  in  H o n g  K o n g  th at fo u n d  b e lie f s  that  
“ in f lu e n z a  v a c c in e  w a s  e f f i c a c io u s  in  p r e v e n t in g  b ird -to -h u m a n  
a v ia n  in f lu e n z a  tr a n s m is s io n ,” an d  th a t “th ere  is  a  n e e d  to  r e c e iv e  
in f lu e n z a  v a c c in a t io n  f o l lo w in g  th e  S e v e r e  A c u te  R esp ira to ry  S y n ­
d r o m e  ( S A R S )  an d  a v ia n  in f lu e n z a ” w e r e  s tr o n g ly  a s so c ia te d  w ith  
in f lu e n z a  v a c c in a t io n  u p ta k e  (L a u , K im , T s u i , &  G r iff ith s , 2 0 0 8 ;  
L a u , L a u , &  L a u , 2 0 0 9 ) .
A  s e c o n d  e x p la n a t io n  fo r  th e  la c k  o f  b eh a v io r a l im p a ct o f  ou r  
in te r v e n tio n  m a y  in v o lv e  c o n fo u n d in g  a s  a  re su lt  o f  a ll p a rtic i­
p a n ts , r e g a r d le s s  o f  c o n d it io n , r e c e iv in g  an a p p o in tm e n t le tter  
fr o m  th e  p u b lic  h ea lth  s ta f f ,  d e ta il in g  w h e n  an d  w h e r e  th e y  co u ld  
g e t  th e  in f lu e n z a  v a c c in a t io n . P a r tic ip a n ts  h a d  to  ta k e  th is  le tter  to  
th e  c l in ic  in  o rd er  to  id e n t ify  th e m s e lv e s  a s in  a  “h ig h -r isk  g ro u p ” 
an d  to  r e c e iv e  a fr e e  v a c c in e  at th e  h o sp ita l .  T h is  m a y  h a v e  
tr ig g e r e d  s o m e  g o a l p la n n in g  a m o n g  p a r tic ip a n ts  in  th e  c o m p a r i­
so n  c o n d it io n . A  th ird  p o s s ib le  e x p la n a t io n  fo r  th e  la c k  o f  d iffe r ­
e n c e  b e tw e e n  th e  g r o u p s  is  th a t a ll p a r tic ip a n ts  in  th is  s tu d y  had  
r e la t iv e ly  stro n g  in te n t io n s  to  o b ta in  th e  f lu  v a c c in e ,  an d  w ere  
b e in g  a sk e d  to  e n g a g e  in  a r e la t iv e ly  s im p le  b e h a v io r . In th is  
c o n te x t , it  is  p o s s ib le  th a t a c t io n  p la n n in g  a d d e d  lit t le  to  the  
l ik e l ih o o d  o f  th em  ta k in g  u p  th e  f lu  v a c c in e  ( s e e ,  e .g . ,  P c s tw ic h  e t  
a l.,  2 0 0 8 ;  S h e era n  &  O r b e ll, 1 9 9 9 ; S h e e r a n  &  O r b e ll, 2 0 0 0 ;  
S n ie h o tta  e t  a l., 2 0 0 7 ) :  a lth o u g h  as n o ted  b e lo w , p la n n in g  m a y  
h a v e  in f lu e n c e d  le v e ls  o f  in te n tio n  to  o b ta in  v a c c in a tio n .
D e s p ite  th e s e  p o te n tia l c o n fo u n d s , a  5%  d if fe r e n c e  in  v a c c in a ­
t io n  ra tes  b e tw e e n  th e  H A P A  an d  stan d ard  le a f le t  g r o u p s  w a s  
fo u n d . W h ile  th is  w a s  n o t  s ig n if ic a n t ,  i f  th is  f in d in g  w e r e  to  
g e n e r a liz e  to  a  w id e r  p o p u la t io n , th en  th e  H A P A  le a f le t  c o u ld  
r e su lt  in  s ig n if ic a n t ly  m o r e  p e o p le  s e e k in g  v a c c in a t io n  d e s p ite  th is  
b eh a v io ra l p rom p t. T h is  c o n c lu s io n  is  c le a r ly  sp e c u la t iv e , and  
req u ires  fu rth er la r g e  s c a le  r e sea r ch  to  v e r ify . H o w e v e r , g iv e n  th e  
p o ten tia l n o  c o s t  b e n e f it  o f  u s in g  a  H A P A -b a s e d  le a f le t , th is  w o u ld  
s e e m  th e  le a f le t  o f  c h o ic e ,  e v e n  b e fo r e  m o r e  d e f in it iv e  d ata  are  
o b ta in ed .
In re la tio n  to  th e  s e c o n d  o b je c t iv e  ( to  e v a lu a te  th eo r e tic a l lin k s  
p ro p o se d  b y  th e  H A P A ) , c h a n g e s  in  r isk  p e r c e p tio n s , o u tc o m e  
e x p e c ta n c ie s , an d  s e l f - e f f i c a c y  (a s  w e ll  a s  p la n n in g )  a c c o u n te d  fo r  
4 6 %  o f  th e  v a r ia n c e  in th e  c h a n g e  in  in te n t io n s . T h is  is  c o m p a r a b le  
w ith  p r e v io u s  re sea rch  u s in g  th e  H A P A  m o d e l in  o th er  h ea lth  
b e h a v io r s , w h ic h  h a v e  fo u n d  th at th e  m o d e l to  e x p la in  b e tw e e n  3 0
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and 69%  o f  th e va r ia n ce  in  in te n t io n s  (C h o w  &  M u lla n , 2 0 1 0 ;  
G arcia  &  M an n , 2 0 0 3 ;  L u s z c z y n s k a  &  S c h w a r z e r , 2 0 0 3 ;  S c h w a r ­
zer  &  R en ner, 2 0 0 0 ;  S n ieh o tta , S c h o lz ,  &  S c h w a r z e r , 2 0 0 5 ) .  T h e  
present resu lts p ro v id e  fu rth er su p p o r t fo r  th e  H A P A  m o d e l ,  s u g ­
g estin g  an im p ortan t ro le  fo r  o u t c o m e  e x p e c ta n c ie s  an d  s e lf -  
e ff ic a c y  in th e  form a tio n  o f  in te n t io n s  ( e .g . ,  C h o w  &  M u lla n ,  
2 0 1 0 ; G arcia  &  M an n , 2 0 0 3 ;  S c h w a r z e r  &  L u s z c z y n s k a , 2 0 0 8 ) .  
In contrast, n eith er  th e  ch a n g e  in  p e r c e iv e d  r isk  n o r  th e  c h a n g e  in  
p erce ived  sev er ity  o f  in f lu e n z a  w a s  a s s o c ia t e d  w ith  c h a n g e  in  
in ten tion  to  g e t  v a cc in a ted  a g a in s t  th e  f lu . T h e  f in d in g  th a t r isk  
p ercep tion  w a s n o t a  s ig n if ic a n t  p r e d ic to r  o f  v a c c in a t io n  in te n tio n  
is  co n s is ten t w ith  th e H A P A  m o d e l ( e .g . ,  L u s z c z y n s k a  &  S c h w a r ­
zer, 2 0 0 3 ; S ch w arzer  &  R en n er , 2 0 0 0 ) ,  w h ic h  s ta te s  th a t r isk  
p ercep tion  is  a re la tiv e ly  w e a k  p red ic to r  o f  b e h a v io r ,  a s  its  k e y  ro le  
is  to  in itiate d elib era tion  ab ou t th e  n e e d  to  c h a n g e , w ith  o th e r  th e  
variab les b eco m in g  m o re  im p ortan t s u b s e q u e n t ly  ( e .g . ,  S c h w a r z e r , 
2 0 0 1 ; W ein ste in , 2 0 0 0 ) . O f  n o te  a ls o  is  th a t w h i le  th e  H A P A  
co n s id ers  p lan n in g  to b e  a d r iv er  o f  b e h a v io r , it  m a y  a ls o  in f lu e n c e  
in ten tion s, both  d irectly  and  in d ire c tly : th in k in g  th r o u g h  an d  p la n ­
n in g  h o w  to  m ak e tim e  and  tra v e l to  th e  v a c c in a t io n  a p p e a r e d  to  
in crease  partic ip ants' c o n f id e n c e  in  th e ir  a b ili ty  to  d o  s o .  T h is ,  in  
turn, in creased  th e  strength  o f  th e ir  in te n t io n s  to  o b ta in  th e  v a c c i ­
n ation .
In flu en za  vacc in a tio n  w a s  p red ic ted  b y  in te n t io n s  to  o b ta in  
va cc in a tio n , and to a le sse r  e x te n t  b y  s e l f - e f f i c a c y  in  a rr a n g in g  
t im e  and transport to  a c c e ss  th e  v a c c in e  (9 3 %  o f  p a r t ic ip a n ts  w e r e  
correctly  c la ss if ie d  in to  v a cc in a ted  an d  n o n v a c c in a te d  g r o u p s ) .  
T h is  f in d in g  is  co n s is ten t  w ith  p r e v io u s  s t u d ie s  a n d  p r o v id e s  
support for  th e p rop osed  lin k s  in  th e  H A P A  m o d e l  in  th a t in te n t io n  
and se lf -e f f ic a c y  appear to  b e  k e y  fa c to r s  in f lu e n c in g  o n  b e h a v ­
ioral ch an ge (e .g .,  S c h o lz , K e lle r , &  P e rren , 2 0 0 9 ;  S c h w a r z e r  &  
R en ner, 2 0 0 0 ) . H a v in g  sa id  th is , d e s p ite  th ere  b e in g  s ig n if ic a n t  
b etw een  group  d iffe r e n c e s  in  stren g th  o f  in te n t io n  to  o b ta in  v a c ­
c in a tio n , there w ere  n o  d if fe r e n c e s  in  a c tu a l v a c c in a t io n  ra tes  
b etw een  them . T h is  m ay  b e  a ttr ib u tab le  to  o n e  o r  m o r e  o f  th e  
factors d iscu ssed  ab o v e . A n  a lte rn a tiv e  e x p la n a t io n  is  th a t th ere  
m ay b e a th resh o ld  o f  in ten tio n  a b o v e  w h ic h  h ig h e r  l e v e l s  o f  
in ten tion  add litt le  to  th e  lik e lih o o d  o f  e n g a g e m e n t  in  a  p a r tic u la r  
b eh avior . T h u s, it is  p o ss ib le  th at b o th  g r o u p s  w e r e  s u f f ic ie n t ly  
m otiva ted  to s eek  v a cc in a tio n , an d  d if f e r e n c e s  in  r e la t iv e ly  h ig h  
in ten tion  sco res  had o n ly  a  m arg in a l im p a c t  o n  b e h a v io r .
Contrary to  ou r e x p ec ta tio n s, a c tio n  p la n n in g  d id  n o t  c o n tr ib u te  
to  the p red iction  o f  in flu en za  v a c c in a t io n  u p ta k e . T h is  f in d in g  is  
n ot co n s is ten t w ith  the p rev io u s  s tu d ie s  a p p ly in g  th e  H A P A  m o d e l  
that h a v e  repeated ly  reported  that a c t io n  p la n n in g  w a s  a  g o o d  
p red ictor o f  b eh av ior  c h a n g e  (e .g . ,  L u s z c z y n s k a  &  S c h w a r z e r ,  
2 0 0 3 ;  S ch w arzer  e t a l., 2 0 0 8 ;  S n ie h o tta  e t  a l . ,  2 0 0 5 ) .  H o w e v e r ,  
b eh a v io r  is  govern ed  e ith er  b y  in te n t io n s  o r  b y  th e  p e r c e iv e d  an d  
actual en v iron m en t (S ch w a rzer , 2 0 0 9 ) .  In th is  s tu d y , a s  d is c u s s e d  
a b o v e , it is p o ss ib le  that in flu e n z a  v a c c in a t io n  w a s  in f lu e n c e d  b y  
the externa l co n d itio n s  su ch  as th e  o u tb r e a k  o f  H 1 N 1  in f lu e n z a  
d urin g the vacc in a tion  p eriod . T h is  m a y  h a v e  a t te n u a te d  th e  e f f e c t  
o f  action  p lan n in g  on  p red ic tin g  v a c c in a t io n  b e h a v io r . T o  fu rth er  
e lu c id a te  th ese  f in d in g s , larger s tu d ie s  n e e d  to  b e  p e r fo r m e d  in  
d ifferen t se ttin gs  w ith  d ifferen t s a m p le s  an d  d if fe r e n t  b e h a v io r s .
T h e  stren gth s o f  th is stu d y  in c lu d e  its  c o n tr o l le d  d e s ig n , an d  th e  
ap p lication  o f  th eoretica l fra m ew o rk . H o w e v e r ,  p o te n t ia l l im ita ­
tion s n eed  to  b e  ad d ressed . T h e  o u tc o m e  a s s e s s o r s  w e r e  n o t  fu lly  
b lin d ed  to treatm ent g rou p  d u r in g  fo l lo w -u p  a s s e s s m e n t .  T h is
c o u ld  h a v e  in tr o d u c e d  b ia s  to  th e  re su lts :  a lth o u g h  th e  research ers  
w e r e  b lin d  u n til th e y  a d d r e s se d  w h e th e r  o r  n o t p artic ip an ts  h ad  
c o m p le te d  th e  p la n n in g  p r o c e s s .  A lth o u g h  a  f e w  q u e stio n n a ires  
w e r e  read  o u t  lo u d  to  p a r tic ip a n ts  w ith  lim ite d  litera cy  b y  a  trained  
r e se a r c h e r , th e s e  p a r tic ip a n ts  w e r e  a s k e d  to  s c o r e  th eir  o w n  re­
s p o n s e s ,  w ith o u t  d ir e c t  in p u t fr o m  th e  a s s e s s o r s . A n o th er  lim ita ­
t io n  is  th at th e  s tu d y  w a s  c o n d u c te d  in  tw o  urban  c o m m u n it ie s .  
T h e  f in d in g s  o f  th is  s tu d y  m a y  n o t  b e  g e n e r a liz a b le  to  h ig h -r isk  
p e o p le  l iv in g  in  su b u rb a n  an d  ru ral c o m m u n it ie s . H o w e v e r , th is  
c o n tr o l le d  b e fo r e  a n d  a fte r  s tu d y  s h o w e d  th at o u r  in ter v en tio n  w a s  
f e a s ib le  an d  a c c e p ta b le  in  p r o m o tin g  in f lu e n z a  v a c c in a tio n  to 
h ig h -r is k  p e o p le  w ith  c h r o n ic  m e d ic a l  c o n d it io n s .  A c c o r d in g ly , it  
c a n  b e  im p le m e n te d  in  o th e r  s e t t in g s . F in a l ly , th e  s tu d y  w a s  
u n d e r p o w e r e d  to  d e te c t  th e  r e la t iv e ly  s m a ll d if fe r e n c e s  in  v a c c i­
n a tio n  ra tes  e v e n tu a lly  fo u n d . L a rg e r  s tu d ie s  w o u ld  b e  n e e d e d  to  
v e r ify  th e  p o s s ib i l i t y  o f  s ig n if ic a n t  d if f e r e n c e s  in  v a c c in a tio n  rates  
a s  a  c o n s e q u e n c e  o f  th e  H A P A  in te r v e n t io n .
Conclusion
T h e  s tu d y  d e m o n str a te d  th e  e f f e c t iv e n e s s  o f  a  th eo ry -b a sed  
e d u c a t io n a l le a f le t  a n d  a c t io n  p la n n in g  in te r v e n t io n  in  e n h a n c in g  
in te n t io n  to  b e  im m u n iz e d  a g a in s t  th e  f lu  a m o n g  h ig h -r isk  T h a i 
a d u lts . H o w e v e r ,  n o  s ig n if ic a n t  d i f fe r e n c e  in  v a c c in a tio n  rates  
b e tw e e n  th e  tw o  c o n d it io n s  w a s  fo u n d . Furth er , larger , trials  
s h o u ld  te s t  w h e th e r  a c t io n  p la n n in g  w o r k s  c a n  in cr ea se  in f lu e n z a  
v a c c in a t io n  ra tes  a m o n g  h ig h -r is k  p e o p le ,  a s  w e l l  a s  its  e f f ic a c y  in  
e n h a n c in g  th e  l ik e l ih o o d  o f  p e r fo r m in g  o th e r  b e h a v io r s . A d d it io n ­
a lly , th e  r e su lts  h ig h lig h t  th at th e  H A P A  is  a  u se fu l m o d e l in 
p r e d ic t in g  in te n t io n s  to  o b ta in  th e  f lu  v a c c in e  an d  su b seq u en t  
in f lu e n z a  v a c c in a t io n  b e h a v io r . S e l f - e f f i c a c y  an d  in ten tio n  w ere  
fo u n d  to  b e  a  s ig n if ic a n t  p r e d ic to r  o f  in f lu e n z a  v a c c in a tio n  b e h a v ­
io r . T h e  f in d in g s  p r o v id e  v a lu a b le  in fo r m a tio n  to  p u b lic  h e a lth / 
h e a lth  p r o m o tio n  p r o fe s s io n a ls  to  a l lo w  m o d if ic a t io n  an d  im p ro v e  
th e  c o n te n t  o f  in f lu e n z a  le a f le t  th a t are  cu rr en tly  a v a ila b le  fo r  th e  
h ig h -r is k  p e o p le ,  a s  w e l l  a s  d e s ig n in g  o th e r  e f f e c t iv e  in ter v en tio n s  
to  a c h ie v e  a  g re a te r  im p a c t  in  in c r e a s in g  v a c c in a tio n  rates o f  
h ig h -r is k  p e o p le  w ith  c h r o n ic  d is e a s e s .
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